

North American Association of Central Cancer Registries

Standards for Cancer Registries Volume II

Data Standards and Data Dictionary

**Seventh Edition
Record Layout Version 10**

**Edited By
Dianne Hultstrom**

March 2002

Sponsoring Organizations

American Cancer Society
American College of Surgeons
American Joint Committee on Cancer
Canadian Association of Provincial Cancer Agencies
Centers for Disease Control and Prevention
Health Canada
National Cancer Institute
National Cancer Registrars Association
Statistics Canada

Edited By

Dianne Hultstrom, BS, RHIT, CTR
Chair, Volume II Workgroup of the Uniform Data Standards Committee
Manager Education/Northeast District Manager
Impath Information Services
One University Plaza, Suite 501
Hackensack, NJ 07601
Dianne.Hultstrom@impath.com

Comments and suggestions on this and other NAACCR standards documents are welcome. Please send your comments to the Editor or any member of the NAACCR Board of Directors.

The other volumes in the series, Standards for Cancer Registries, are:

❖ **Volume I, *Data Exchange Standards and Record Description***

Intended for programmers, this provides the record layout and specifications for the standard for data exchange, including correction and analysis formats. Released annually as an electronic document and posted on the NAACCR Web Site.

❖ **Volume III, *Standards for Completeness, Quality, Analysis, and Management of Data***

Intended for central registries, this provides detailed standards for many aspects of the operation of a population-based cancer registry.

❖ **Volume IV, *Standard Data Edits***

This documents standard computerized edits for data corresponding to the data standards in Volume II. The standard currently is only made available electronically as program code and a database.

Copies of all standards documents can be viewed or downloaded from NAACCR's Web Site at: <http://www.naacr.org>. For additional paper copies, write to the NAACCR Executive Office.

Suggested citation

Hultstrom D, editor. Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Seventh Edition, Version 10. Springfield, IL: North American Association of Central Cancer Registries, March 2002.

Support for editorial services of this volume was provided in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. N02-PC-05030. Support for production and distribution of this volume was provided in part through a cooperative agreement to NAACCR from the Centers for Disease Control and Prevention, U75/CCU515998. The NAACCR Board of Directors adopted these standards in March 2002.

TABLE OF CONTENTS

NAACCR Board of Directors 2001-2002	vii
Uniform Data Standards Committee 2001-2002	ix
Members of the Volume II Work Group 2001-2002	xi
Addresses of Major Standard-Setting Organizations	xiii
Preface to the Seventh Edition	xv
Chapter I: Problem Statement, Goals, and Scope of This Document	1
Chapter II: Historical Background and Status of U.S. Standards	7
Chapter III: Standards for Case Inclusion and Reportability	15
Chapter IV: Recommended Data Edits and Software Coordination of Standards	19
Chapter V: Unresolved Issues	23
Chapter VI: Pathology Laboratory Electronic Reporting Recommendations	33
Chapter VII: References	91
Chapter VIII: Record Layout Table (Column # Order)	95
Chapter IX: Required Status Table (Item # Order)	107
Chapter X: Data Descriptor Table (Item # Order)	119
Chapter XI: Data Dictionary	137
Appendix A: FIPS Codes for Counties and Equivalent Entities	399
Appendix B: EDITS Tables for Selected Data Items	415
Appendix C: Abbreviations and Acronyms Used	429
Appendix D: Alternate Names	431
Appendix E: Grouped Data Items	439
Appendix F: Tables and Data Dictionary Revisions	441
Index	455

NAACCR BOARD OF DIRECTORS 2001-2002

President:

Vivien W. Chen, PhD
Louisiana Tumor Registry
LSU Health Sciences Center
1600 Canal Street, Suite 900A
New Orleans, LA 70112
Telephone: (504) 568-4716
Fax: (504) 568-2493
E-mail: vchen@lsuhsc.edu

2001-03

Mignon Dryden, CTR
Cancer Registry of Northern California
1560 Humboldt Road, Suite 4
Chico, CA 95928
Telephone: (530) 345-2483
Fax: (530) 345-3214
E-mail: mignond@calif-hlth-collab.org

2001-03

Past President:

Thomas C. Tucker, PhD
Kentucky Cancer Registry, Suite A-230
2365 Harrodsburg Road
Lexington, KY 40504
Telephone: (859) 219-0773, ext. 225
Fax: (859) 219-0557
E-mail: tct@kcr.uky.edu

2001-02

Dale Herman, MSPH
North Carolina Central Cancer Registry
1908 Mail Service Center
Raleigh, NC 27699-1908
Telephone: (919) 715-4558
Fax: (919) 733-8485
E-mail: dale.herman@ncmail.net

2001-03

Treasurer:

Sally A. Bushhouse, DVM, PhD
Minnesota Cancer Surveillance System
Minnesota Department of Health
P.O. Box 9441
717 Delaware, S.E.
Minneapolis, MN 55440-9941
Telephone: (612) 676-5216
Fax: (612) 676-5099
E-mail: sally.bushhouse@health.state.mn.us

2001-03

Jill MacKinnon, CTR
Sylvester Cancer Center
P.O. Box 016960 [D411]
Miami, FL 33101
Telephone: (305) 243-3426
Fax: (305) 243-4871
E-mail: jill_mackinnon@miami.edu

2000-02

Representative, Sponsoring Member Organization:

Connie Blankenship
Administration Manager
American Joint Committee on Cancer
633 N. Saint Clair Street
Chicago, IL 60611-3211
Telephone: (312) 202-5290
Fax: (312) 202-5009
E-mail: cblankenship@facs.org

2000-02

Mary McBride, MSc
Epidemiologist, Cancer Control Research
British Columbia Cancer Registry/Agency
Cancer Control Research Unit
600 W. 10th Avenue
Vancouver BC V5Z 4E6
Canada
Telephone: (604) 877-6122
Fax: (604) 877-0702
E-mail: mmcbride@bccancer.bc.ca

1999-03

Members at Large:

Dennis Deapen, DrPH
Cancer Surveillance Program of Los Angeles
1540 Alcazar Street, CHP 204
Los Angeles, CA 90033
Telephone: (323) 442-1574
Fax: (323) 442-2301
E-mail: ddeapen@hsc.usc.edu

1998-02

Georgia Armenta Yee, BSW, CTR
Arizona Cancer Registry
Arizona Department of Health Services
2700 N. 3rd Street, Suite 4075
Phoenix, AZ 85004
Telephone: (602) 542-7308
Fax: (602) 364-0082
E-mail: geyee@hs.state.az.us

1999-02

Executive Director:

Holly L. Howe, PhD

NAACCR, Inc.

2121 W. White Oaks Drive

Suite C

Springfield, IL 62704-6495

Telephone: (217) 698-0800, ext. 2

Fax: (217) 698-0188

E-mail: hhowe@naaccr.org

UNIFORM DATA STANDARDS COMMITTEE 2001-2002

Steven Peace, CTR*

Chair, 2002

Florida Cancer Data System
Sylvester Comprehensive
Cancer Center
P.O. Box 016960 (D4-11)
Miami, FL 33101
Telephone: (305) 243-4600
Fax: (305) 243-4871
E-mail: Steven_Peace@miami.edu

JoAnne Sylvester, MA*

Chair, 2001

American College of Surgeons
633 N. Saint Clair Street
Chicago, IL 60611
Telephone: (312) 202-5298
Fax: (312) 202-5009
E-mail: jsylvester@facs.org

Dianne Hultstrom, CTR*

Chair, Volume II Work Group

Impath Information Services
16 Robert Road
Acton, MA 01720
Telephone: (978) 897-5330
Fax: (978) 461-2872
E-mail:
Dianne.Hultstrom@impath.com

Toshi Abe, MSW, CTR

New Jersey State Cancer Registry
3635 Quakerbridge Road
P.O. Box 369
Trenton, NJ 08625-0369
Telephone: (609) 588-3500
Fax: (609) 588-3638
E-mail: Toshi.Abe@doh.state.nj.us

Patricia Andrews, MPH, CTR*

Louisiana Tumor Registry
1600 Canal Street, Suite 900A
New Orleans, LA 70112
Telephone: (504) 568-4795
Fax: (504) 568-2493
E-mail: pandre@lsuhsc.edu

Sally Bushhouse, DVM, PhD

Minnesota Cancer Surveillance
System
Minnesota Department of Health
717 Delaware, S.E.
P.O. Box 9441
Minneapolis, MN 55440
Telephone: (612) 676-5216
Fax: (612) 676-5099
E-mail:
sally.bushhouse@health.state.mn.us

Susan Capron

2443 W. Moffat
Chicago, IL 60647
Telephone: (773) 278-6207
Fax: (773) 278-0116
E-mail: scapron@mindspring.com

Cynthia Conant, CTR*

Cancer Surveillance Program, Los
Angeles
1540 Alcazar Street, CHP 204
Los Angeles, CA 90033
Telephone: (323) 442-2333
Fax: (323) 442-2301
E-mail: conant@hsc.usc.edu

April Fritz, ART, CTR

National Cancer Institute
SEER, DCCPS, Cancer Statistics
Branch
6116 Executive Boulevard, Suite 504
Bethesda, MD 20892-8316
Telephone: (301) 402-1625
Fax: (301) 496-9949
E-mail: april.fritz@nih.gov

Ken Gerlach, MPH, CTR*

CDC
NCCDPHP/DCPC/CSB
4770 Buford Highway, N.E., MS K-53
Atlanta, GA 30341-3724
Telephone: (770) 488-3008
Fax: (770) 488-4759
E-mail: kbg4@cdc.gov

Susan Gershman, MPH, PHD, CTR

Massachusetts Cancer Registry
250 Washington Street, Sixth Floor
Boston, MA 02108-4619
Telephone: (617) 624-5646
Fax: (617) 624-5697
E-mail: susan.gershman@state.ma.us

Maria Halama, MD, CTR*

New Jersey State Cancer Registry
3635 Quakerbridge Road
P.O. Box 369
Trenton, NJ 08625-0369
Telephone: (609) 588-3500
Fax: (609) 588-3638
E-mail:
Maria.Halama@doh.state.nj.us

Elaine Hamlyn*

Canadian Cancer Registry
Health Statistics Division
86 Michener Avenue
Mt. Pearl, Newfoundland
Canada A1N 3T8
Telephone: (709) 364-9229
Fax: (709) 364-9228
E-mail:
elaine.hamlyn@roadrunner.nf.net

Lori Havener, CTR*

Illinois State Cancer Registry
605 West Jefferson
Springfield, IL 62761
Telephone: (217) 524-1412
Fax: (217) 524-1770
E-mail: lhavener@idph.state.il.us

Mary Hutton, MPH, CTR

CDC
NCCDPHP/DCPC/CSB
4770 Buford Highway, N.E., MS-K53
Atlanta, GA 30341-3724
Telephone: (770) 488-4869
Fax: (770) 488-5759
E-mail: mdh1@cdc.gov

Nancy Jackson, BS, CTR*

California Cancer Registry
1700 Tribute Road, Suite 100
Sacramento, CA 95815-4402
Telephone: (916) 779-0310
Fax: (916) 779-0264
E-mail: nancy@ccr.ca.gov

Ali Johnson, CTR*

Chief
Vermont Cancer Registry
Vermont Department of Health
P.O. Box 70
Burlington, VT 05402-0070
Telephone: (802) 863-7644
Fax: (802) 651-1787
E-mail: ajohnso@vdh.state.vt.us

Carol Johnson, BS, CTR

National Cancer Institute
SEER, DCCPS, Cancer Statistics
Branch
6116 Executive Boulevard, Suite 504
Bethesda, MD 20892-8316
Telephone: (301) 402-6226
Fax: (301) 496-9949
E-mail: carol.johnson@nih.gov

Amy Kahn, MS, CTR*

New York State Cancer Registry
Corning Tower, Room 536
Empire State Plaza
Albany, NY 12237-0679
Telephone: (518) 474-2255
Fax: (518) 473-6789
E-mail: ark02@health.state.ny.us

Vencine Kelly, BA, CTR*

American Joint Committee on Cancer
Stony Brook University Hospital
Cancer Registry
Stonybrook, NY 11794-9125
Telephone: (631) 444-9844
Fax: (631) 444-9835
E-mail: vkelly@notes.cc.sunysb.edu

David O'Brien, PhD*

Alaska Cancer Registry
Section of Epidemiology, Department
of Health
3601 C Street, Suite 540
P.O. Box 240249
Anchorage, AK 99524-0249
Telephone: (907) 269-8047
Fax: (907) 562-7802
E-mail:
david_obrien@health.state.ak.us

Lynn Ries, MS*

National Cancer Institute
SEER, DCCPS, Cancer Statistics
Branch
6130 Executive Boulevard, Room 343J
Bethesda, MD 20892-8316
Telephone: (301) 402-5259
Fax: (301) 496-9949
E-mail: Lynn_Ries@nih.gov

Winnie Roshala, BA, CTR*

National Cancer Registrars Association
California Cancer Registry
1700 Tribute Road, #100
Sacramento, CA 95815-4402
Telephone: (916) 779-0313
Fax: (916) 779-0264
E-mail: wroshala@ccr.ca.gov

Andrew Stewart, MA*

American College of Surgeons
633 N. Saint Clair Street
Chicago, IL 60611
Telephone: (312) 202-5285
Fax: (312) 202-5009
E-mail: astewart@facs.org

*Voting Member

MEMBERS OF THE VOLUME II WORK GROUP 2001-2002

**Dianne Hultstrom, BS, RHIT,
CTR, Chair**

Impath Information Services
16 Robert Road
Acton, MA 01720
Telephone: (978) 897-5330
Fax: (978) 461-2872
E-mail:
Dianne.Hultstrom@impath.com

Toshi Abe, MSW, CTR

New Jersey State Cancer Registry
P.O. Box 369
3635 Quaker Bridge Road
Trenton, NJ 08625-0369
Telephone: (609) 588-3500
Fax: (609) 588-3638
E-mail: tabe@doh.state.nj.us

Patricia Andrews, MPH, CTR

Louisiana Tumor Registry
1600 Canal Street, Suite 900A
New Orleans, LA 70112-1393
Telephone: (504) 568-4795
Fax: (504) 568-2493
E-mail: pandre@lsuhsc.edu

Sally Bushhouse, DVM, PhD

Minnesota Cancer Surveillance
System
Minnesota Department of Health
P.O. Box 9441
717 Delaware, S.E.
Minneapolis, MN 55440
Telephone: (612) 676-5216
Fax: (612) 676-5099
E-mail:
sally.bushhouse@health.state.mn.us

Susan Capron

2443 W. Moffat Street
Chicago, IL 60647
Telephone: (773) 278-6207
Fax: (773) 278-0116
E-mail: scapron@mindspring.com

Ken Gerlach, MPH, CTR

Cancer Surveillance Branch
Division of Cancer Prevention and
Control
National Center for Chronic
Disease Prevention and Health
Promotion
Centers for Disease Control and
Prevention
MS-K53
4770 Buford Highway, N.E.
Atlanta, GA 30341-3724
Telephone: (770) 488-3008
Fax: (770) 488-4759
E-mail: kbg4@cdc.gov

Carol Hahn Johnson, BS, CTR

Cancer Statistics Branch, SRP,
DCCPS
National Cancer Institute
6116 Executive Blvd, Suite 504
MSC 8316
Bethesda, MD 20892-8316
Rockville, MD 20852 (courier or
overnight delivery)
Telephone: (301) 402-6226
Fax: (301) 496-9949
E-mail: carol.johnson@nih.gov

Vencine Kelly, BA, CTR

American Joint Committee
on Cancer
Stony Brook University Hospital
Cancer Registry 9125 SUNY
Stony Brook, NY 11794-9125
Telephone: (631) 444-9844
Fax: (631) 444-9835
E-mail:
vkelly@notes.cc.sunysb.edu

David O'Brien, PhD

Alaska Cancer Registry
EPI-Cancer
Division of Public Health
Department of Health and Social
Services
P.O. Box 240249
3601 C Street, Suite 540
Anchorage, AK 99524-0249
Telephone: (907) 269-8000
Fax: (907) 562-7802
E-mail: dobrien@health.stat.ak.us

Judy Paradies, CTR

Nebraska Cancer Registry
Health and Human Services
P.O. Box 95007
Lincoln, NE 68509
Telephone: (402) 354-3393
Fax: (402) 354-3387
E-mail: jparadi@nmhs.org

Steven Peace, CTR

Florida Cancer Data System
Sylvester Comprehensive Cancer
Center
P.O. Box 016960 (D4-11)
Miami, FL 33101
Telephone: (305) 243-4600
Fax: (305) 243-4871
E-mail: Steven_Peace@miami.edu

Jerri Linn Phillips, MA, CTR

American College of Surgeons
National Cancer Data Base
1550 Eddy Street, #401
San Francisco, CA 94115
Telephone: (415) 771-0913
Fax: (415) 771-0913
E-mail:
Jerri_Linn@alumni.grinnell.edu

Sue Vest, CTR

Missouri Cancer Registry
Missouri Department of Health
P.O. Box 570
920 Wildwood
Jefferson City, MO 65109
Telephone: (573) 882-7236
Fax: (573) 882-6158
E-mail: vests@health.missouri.edu

Castine Verrill, MS

Epidemiologist
Maine Cancer Registry
11 State House Station
Key Bank Plaza, Fourth Floor
Augusta, ME 04333
Telephone: (207) 287-5190
Fax: (207) 287-4621
E-mail: castine.verrill@state.me.us

ADDRESSES OF MAJOR STANDARD-SETTING ORGANIZATIONS

American Cancer Society

Department of Epidemiology and
Statistics
1599 Clifton Road, N.E.
Atlanta, GA 30329
Telephone: (404) 329-7658
Fax: (404) 325-1467
www.cancer.org

American College of Surgeons

Commission on Cancer
633 St. Clair Street
Chicago, IL 60611
Telephone: (312) 202-5000
Fax: (312) 202-5009
www.facs.org

American Joint Committee on Cancer

Executive Office
633 N. St. Clair Street
Chicago, IL 60611
Telephone: (312) 202-5085
Fax: (312) 202-5009

Centers for Disease Control and Prevention

National Program of Cancer Registries
Division of Cancer Prevention and Control
National Center for Chronic Disease
Prevention and Health Promotion
MS-K53
4770 Buford Highway, N.E.
Atlanta, GA 30341-3724
Telephone: (770) 488-4783
Fax: (770) 488-4759
www.cdc.gov/nccdphp/dpc/npcr

National Cancer Institute SEER Program

Cancer Surveillance Research Program
Division of Cancer Control and Population
Sciences
6116 Executive Boulevard, Suite 504
MSC 8316
Bethesda, MD 20892-8316
Telephone: (301) 496-8510
Fax: (301) 496-9949
www.seer.cancer.gov

National Cancer Registrars Association

1330 Braddock Place, Suite 102
Alexandria, VA 22314
Telephone: (703) 299-6640
Fax: (703) 299-6620
www.ncra-usa.org

North American Association of Central Cancer Registries

2121 W. White Oaks Drive, Suite C
Springfield, IL 62704
Telephone: (217) 698-0800
Fax: (217) 698-0188
www.naccr.org

PREFACE TO THE SEVENTH EDITION

Standardization of cancer registry data is a core component of cancer registration and surveillance. It provides the foundation for developing comparable data among registries that can then be combined for the compilation of national or regional rates. Standardization also allows data from different registries to be used for comparison of variations in cancer rates among different populations and across geographic boundaries.

NAACCR continues its strong commitment to all its members in North America to maintain standardization of cancer registry data, as evidenced in the publication of the Seventh Edition of NAACCR Standards for Cancer Registry Volume II: Data Standards and Data Dictionary. This volume represents a new level of collaboration and commitment among our members to collect timely and accurate uniform data, in response to the needs of changing medical practice and delivery. As in the past, there will be challenges in the implementation of the new and revised standards in this volume. I hope that these revisions will assist our members in achieving the NAACCR mission, namely, providing current, high-quality, and useful data for the cancer surveillance community and cancer control researchers with the ultimate goal of reducing cancer morbidity and mortality in North America. **Please note that black vertical lines in the outside margins highlight revisions from the previous version.**

This volume is the result of the collaboration and cooperation of our sponsoring members, many of which set the standards for the differing needs of their organizations. We are especially grateful to the National Cancer Institute's Surveillance, Epidemiology and End Results Program, the Centers for Disease Control and Prevention's National Program for Cancer Registries, the American College of Surgeons' Commission on Cancer, and the National Cancer Registrars Association for their collaborative spirit and willingness to compromise in the interest of uniformity and achieving common goal. On behalf of the NAACCR Board of Directors, I express our gratitude to these organizations for their support of the work that this volume represents.

This new edition also represents the voluntary contributions of NAACCR Committees, Subcommittees, and Work Groups. I would like to thank the many individuals for their commitment to this project. Special appreciation goes to the members of the Uniform Data Standards Committee and the Volume II Work Group for their diligence, valuable insights, consensus building, and this final document.

The NAACCR Board of Directors would like to extend a special thanks to Dianne Hultstrom, Chair of the Volume II Work Group. Under her leadership, this group reviewed the collaborative stage and other data items for their consistencies with other descriptions published by standard-setters and put countless hours of work into completing this major revision. The Board of Directors also would like to recognize the leadership of JoAnne Sylvester, the former Chair, and Steve Peace, the current Chair of the Uniform Data Standards Committee. We greatly appreciate their efforts in bringing standard-setters together, resolving differences, building consensus, and coordinating all aspects of this project.

Vivien W. Chen, Ph.D.
President

CHAPTER I

PROBLEM STATEMENT, GOALS, AND SCOPE OF THIS DOCUMENT

THE PROBLEM

In the late 1980s, increased efforts to pool data collected by different cancer registries for different purposes drew attention to problems encountered as a result of insufficient data standardization. It became clear to the cancer registry community that the lack of standardization had a substantial cost and limited more widespread use of valuable data. Three examples follow:

Electronic Submission of Hospital Registry Data to State or Other Central Registries

Central registries recognized that data quality and collection efficiency could be improved with electronic data reporting by means of a diskette, modem, or the Internet. Many registries have established systems for receiving electronic data from multiple sources. Often, these data were collected using different software, different data variables, different codes, and different coding rules. Central registries experienced the frustration of mapping submission files into their own data systems. Software providers were frustrated at the need to prepare submissions for multiple state registries that differed from each other and followed different models of electronic data collection.

North American Association of Central Cancer Registries Data Evaluation and Publications Committee Activities

The North American Association of Central Cancer Registries (NAACCR) requested statistical analysis files from its member registries in the standard NAACCR data exchange record layout¹ to prepare descriptive epidemiological data about the participating areas. However, datasets submitted by the participants differed; the original codes, data formats, edits, and coding rules varied; and a significant amount of work was required to produce comparable summary statistics.

National Cancer Data Base

The National Cancer Data Base (NCDB) is a joint project of the American College of Surgeons' (ACoS) Commission on Cancer (COC) and the American Cancer Society (ACS) that pools data submitted by participating hospitals to address questions of clinical interest. Discrepancies in codes, format, and datasets, however, required effort and interpretation before the data could successfully be pooled.

Data items used by different registries or software systems varied in their definition and codes, even when they had the same name and were intended to represent the same information. Other problems encountered in pooling data included the lack of standardization regarding the use of blanks in fields and the inconsistent use of blanks, dashes, and defined codes for "unknown" data. More substantial discrepancies were less easy to detect and correct. Hospitals were faced with conflicting standards when they were both reporting to a central registry and maintaining a database consistent with COC standards, and the requirements were not the same.

THE SOLUTION

Many of NAACCR's sponsoring organizations, including the National Cancer Institute (NCI), the Centers for Disease Control and Prevention (CDC), and COC recognized that increasing standardization is an essential step in decreasing the costs associated with data collection; making more efficient use of increasingly limited human

resources needed for data collection, management, and analysis; and obtaining more useful data that can be compared across registries and geographic areas.

Preparation of a statement of consensus on data standards for cancer registries was proposed by the NCDB and the NAACCR Data Exchange Committee, and prepared by a subcommittee of NAACCR's Uniform Data Standards Committee. At the same time, CDC entered into an agreement with NAACCR—one of the projects to be accomplished under that agreement was the preparation of broader standards for population-based cancer registries. The two efforts were complementary, producing separate but related documents that together specified NAACCR standards. The continued support from CDC has enabled continued development and maintenance of standards. The results of these efforts are the following standards documents published to date:

NAACCR Standards Volume I:

Gordon B, editor. Standards for Cancer Registries, Volume I, Data Exchange Standards and Record Description. Version 3.0. Sacramento (CA): American Association of Central Cancer Registries; February 1994.

Gordon B and Seiffert J, editors. Standards for Cancer Registries, Volume I, Data Exchange Standards and Record Description. Version 5.1. Sacramento (CA): North American Association of Central Cancer Registries; 1997.

North American Association of Central Cancer Registries. Standards for Cancer Registries, Volume I, Data Exchange Standards and Record Description. Version 6. Sacramento (CA): North American Association of Central Cancer Registries; March 20, 1998.

North American Association of Central Cancer Registries. Standards for Cancer Registries, Volume I, Data Exchange Standards and Record Description. Version 7. Sacramento (CA): North American Association of Central Cancer Registries; January 1, 1999.

Abe T and Seiffert J, editors. North American Association of Center Cancer Registries, Standards for Cancer Registries, Volume I, Data Exchange Standards and Record Description. Version 9. Springfield, IL: North American Association of Center Cancer Registries, September 7, 2000. (Electronic version only; available at www.naacr.org.)

NAACCR Standards Volume II:

Menck HR and Seiffert J, editors. Standards for Cancer Registries, Volume II: Data Standards and Data Dictionary. Version 3.0. Sacramento (CA): American Association of Central Cancer Registries; February 14, 1994.

Seiffert J, editor. Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Second Edition. Version 5.1. Sacramento (CA): North American Association of Central Cancer Registries; March 14, 1997.

Seiffert J, editor. Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Third Edition. Version 6. Sacramento (CA): North American Association of Central Cancer Registries; March 20, 1998.

Seiffert J, editor. Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Changed Data Dictionary Entries Only. Sacramento (CA): North American Association of Central Cancer Registries; April 13, 1998.

Johnson CH, editor. Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Fourth Edition. Version 8. Sacramento (CA): North American Association of Central Cancer Registries; March 30, 1999.

Johnson CH, editor. Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Fifth Edition. Version 9. Sacramento (CA): North American Association of Central Cancer Registries; May 15, 2000.

Hultstrom D, editor. Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Sixth Edition. Version 9.1. Springfield (IL): North American Association of Central Cancer Registries; March 4, 2001.

NAACCR Standards Volume III:

Seiffert J, editor. Standards for Cancer Registries Volume III: Standards for Completeness, Quality, Analysis, and Management of Data. Sacramento (CA): American Association of Central Cancer Registries; February 14, 1994.

North American Association of Central Cancer Registries. Standards for Completeness, Quality, Analysis, and Management of Data, Volume III. Springfield (IL): North American Association of Central Cancer Registries; September 2000.

NAACCR Standards Volume IV:

Seiffert J, Capron S, and Tebbel J, editors. Standards for Cancer Registries Volume IV: Standard Data Edits. Sacramento (CA): North American Association of Central Cancer Registries; April 4, 1996.

GOAL OF THIS DOCUMENT

The goal of this document, which describes and publishes continuing, modified, and new data items and codes as well as the specification for transmission of data in record layout Version 10, is to define the NAACCR data standards for cancer registration for use by central registries, hospital-based registries, and other groups in North America as of January 1, 2003. Although the new and modified codes and the layout are available for use on that date, some registries may continue to use compatible earlier versions of the NAACCR record layout.

Objectives of the standardization effort, and of this document, are to:

- ❖ Provide a comprehensive reference to ensure uniform data collection
- ❖ Reduce the need for redundant coding and data recording between agencies
- ❖ Facilitate the collection of comparable data among groups
- ❖ Provide a resource document to help registries that are establishing or revising their databases
- ❖ Encourage the adoption of these standards by all parties.

This document will be used by new and existing facility-based and central cancer registries to ensure that the definitions and codes used within their programs are standard and consistent with those used by regional and national databases. Other potential users include registry software providers and those using registry data,

especially if they are combining data from multiple sources or exchanging data. National standard-setting groups, such as ACoS, CDC, NAACCR, and NCI also will benefit.

The present document uses the same structure and philosophy as NAACCR's data exchange standards. Where a standard exists for an item or type of data, the standard is incorporated by reference. Where a variety of standards are in use, alternate coding schemes are provided, but the different items are kept separate or another data field is used to indicate which coding standard was used.

The NAACCR data exchange layout incorporates several record types that are combinations of standard components, such as demographic information, patient confidential information, and text. Thus, the different purposes and constraints of data exchange can be accommodated without the requirement for separate formats (see Volume I for specifics).

SCOPE OF THIS DOCUMENT: WHAT STANDARDS ARE INCLUDED?

A variety of standards for cancer registries can be specified. Some standards apply to the data themselves, and other standards record activities in the registration process, such as death clearance procedures, follow-up methods, or quality control. Yet another standard might address the completeness of coverage of a population-based central registry, and still another the qualifications and adequacy of staffing.

The present document is limited to standards regarding data rather than procedures. More specifically, it focuses on a subset of possible data standards that NAACCR considers important to establish. These include:

❖ Reportability

Reportability specifies the rules for which cases are to be included in the registry (see Chapter III).

❖ Data Items or Elements To Be Included

Data items or elements consist of required or recommended data items that a registry should collect and include in its database. Chapter XI contains standards for dataset items.

Example: "Sex" is a standard data element on the list in Chapter XI.

❖ Standardized Item Numbers and Item Names

For ease and consistency of reference, all items are assigned both item numbers and names. The item number is intended to be permanent and will not change in future NAACCR standards publications. Assignment of permanent numbers was necessary because standard-setting organizations have changed item names over time or have applied similar names to items with different definitions. Item numbers allow the required precision of reference. Numbers were not assigned consecutively to allow insertion of related items in the future.

Example: The item "Sex" is assigned the item number 220.

The NAACCR item names are assigned to meet the needs of NAACCR and its data standards publications. Where possible, the NAACCR name is the same as that used by the standard-setter for the item. However, the following constraints are placed on the names:

- **Length**

Names are limited to 25 characters because that is the maximum length for item names in the EDITS software system (see Chapter IV). Item names thus can be identical in this data standards volume and the NAACCR Metafile.

- **Consistency**

Consistency was attempted in formatting names and in using special characters. The character "--" is used to distinguish among item names built on the same stem name.

Example: "Sequence Number--Hospital" and "Sequence Number--Central" are the names of two differently defined sequence numbers.

To meet the length restriction, the word "first" always is entered "1st," "treatment" is "RX," and so on. Other limitations will be imposed as needed.

- **Interrelated Items, Fields, and Subfields**

To make the relationship among items more apparent, a constant term was consistently added to the stem of the name.

Example: All of the names of treatment fields related to radiation therapy begin with "Rad," so that in a list of item names they will appear together:

Rad--No of Treatment Vol

Rad--Elapsed RX Days.

- ❖ **Record Layout/Data Exchange**

Record layout/data exchange identifies the position of the data item in a standard flat file data exchange record. These positions are indicated in Chapter VIII. Also, see Volume I¹ in this series for information on the data exchange and other NAACCR standard layouts.

Example: "Sex" is in character position 118 in the NAACCR data exchange record layout Version 10.

- ❖ **Codes**

Codes identify allowable values, their meanings, and data entry formats for data items. Chapters X and XI specify the standard codes for each data item.

Example for the item "Sex":

Codes:

1 Male

2 Female

3 Other (Hermaphrodite)

4 Transsexual

9 Not stated

When it is necessary to collect more specific information than that represented by the standard codes, every effort should be made to ensure that the more specific codes would accurately collapse into the categories represented by the standard codes. This approach permits diversity without compromising inter-registry comparability or meta-analyses.

❖ **Coding Rules**

Coding rules are the rules and interpretations for deciding the correct code for a given case. Coding rules are defined in the documentation of other standard-setting organizations. For each data item, Chapters IX and XI list a “Source of Standard,” and the documentation of this source should be consulted for coding rule standards.

Hypothetical Example: A coding rule might state what code to assign for sex when the medical record states the patient is female and the death certificate states male.

CHAPTER II

HISTORICAL BACKGROUND AND STATUS OF U.S. STANDARDS

STANDARD-SETTING ORGANIZATIONS AND OTHER STANDARDS DOCUMENTS

Several organizations have played a major role in the development of cancer registry standards. They are listed in alphabetical order.

American Cancer Society

ACS historically has supported the development of standardized cancer classification systems, publishing the first code manual for the morphology of neoplasms in 1951. ACS has long supported the standard-setting programs of ACoS, including the Fundamental Tumor Registry Operations Education Program, the Registry Operations and Data Standards, and the American Joint Committee on Cancer (AJCC).

American College of Surgeons

Since the 1950s, ACoS has taken a leading role in establishing standards for hospital-based cancer programs and the cancer registries that are a part of such programs. Through its Approvals Program, COC implements its requirements for case management, registry operation and case inclusion, and dataset specifications as published in:

- ❖ *Cancer Program Standards (Standards of the Commission on Cancer, Volume I),²⁸* which presents standards for the full range of cancer program activities, including the registry.
- ❖ *Facility Oncology Registry Data Standards (FORDS) (Standards of the Commission on Cancer, Volume II),²* which specifies standards for cases to be included in the registry, data items to be collected, and the codes and coding rules for those items.

Beginning with 2003 cases, COC requires approved cancer programs to use the codes published in *FORDS*.

Through NCDB, COC provides data quality feedback to facilities, software providers, and the general cancer registry community. Hospitals in the Approvals Program are required to submit nonconfidential registry data to NCDB, and COC monitors the quality of data submissions in accordance with existing published standards for approved programs.

The NCDB Call for Data announcements, instructions, and technical specifications are available to download at no charge at <http://www.facs.org>. COC maintains an interactive Inquiry and Response Database to field questions about all cancer-related requirements at the same online site.

American Joint Committee on Cancer

AJCC formulates and publishes systems of classification of tumors by their anatomic site and histology through use of the Tumor, Node, Metastasis (TNM) staging system. The TNM staging system is the U.S. standard used by the medical profession to select the most effective treatments and determine prognosis to facilitate the management of cancer care. AJCC is dedicated to the ideal that all cancer cases should be staged, and it publishes the *Cancer Staging Manual*,⁵ now in its Sixth Edition as well as the *Collaborative Staging Manual and Coding Instructions*.¹¹

National Cancer Registrars Association

An organization of cancer data professionals founded as the National Tumor Registrars Association in 1974, the National Cancer Registrars Association (NCRA) has been instrumental in the training and certification of cancer registrars. NCRA has produced a variety of educational materials, including guidelines for a college curriculum in cancer registry management, a planning manual for registry staffing, training materials for staging of cancer, and a publication on using cancer data to promote the services of the cancer registry. A college-level cancer registry methods textbook also was published (*Cancer Registry Management: Principles & Practice*, 1997).⁴¹

Since 1983, NCRA has promoted the certification of cancer registrars through a semi-annual examination. More than 4,000 Certified Tumor Registrars (CTRs) successfully have completed the exam, which evaluates technical knowledge of methods of cancer data collection, management, and quality control, as well as *International Classification of Diseases-Oncology* (ICD-O) topography and morphology coding and AJCC and Surveillance, Epidemiology and End Results (SEER) Program staging systems. In 1995, responsibility for administration of the certification examination was turned over to an independent board, the National Board for the Certification of Registrars (NBCR). To maintain their credentials, CTRs are required to complete 20 hours of continuing education every 2 years, which can be obtained by participating in conferences and teleconferences that NCRA has precertified, and by obtaining a passing score on quizzes in NCRA's *Journal of Registry Management*.

Membership in NCRA is open to anyone interested in cancer data collection. For further information, contact NCRA at the address on page xiii or on the Web at: www.ncra-usa.org.

National Coordinating Council for Cancer Surveillance

Founded in 1995, the National Coordinating Council for Cancer Surveillance (NCCCS) meets biannually to coordinate surveillance activities within the United States through communication and collaboration among major national cancer organizations, ensuring that the needs of cancer patients and the communities in which they live are fully served; that scarce resources are maximally used; and that the burden of cancer in the United States is adequately measured and ultimately reduced. NCCCS includes representatives from ACoS, CDC and its National Center for Health Statistics, NCI, NCRA, NAACCR, and the Armed Forces Institute of Pathology. Current priorities for NCCCS include developing a roadmap between staging systems and establishing a national framework for cancer surveillance.

National Program of Cancer Registries

CDC has worked to improve registry data nationwide since 1992, when Congress authorized the establishment of the National Program of Cancer Registries (NPCR) through the Cancer Registries Amendment Act (Public Law 102-515).³⁶ CDC provides funds to 45 states, 3 territories, and the District of Columbia to assist in planning or enhancing cancer registries, developing model legislation and regulations for programs to increase the viability of registry operations, setting standards for data, providing training for registry personnel, and helping establish computerized reporting and data processing systems.

CDC has contributed substantially to the development of data standards through its financial support of NAACCR, as well as by funding and developing EDITS, a software system that facilitates the coordination of data standards (see Chapter IV). In administering NPCR, CDC requires participating central registries to collect data items that conform to NAACCR's standards. NPCR staff also continue to maintain Registry Plus™, a suite of publicly accessible free software programs made available by CDC to facilitate the implementation of NPCR.

To maximize the benefits of state-based cancer registries, CDC is implementing the NPCR-Cancer Surveillance System (CSS) for receiving, assessing, enhancing, aggregating, and disseminating data from NPCR-funded

registries. This system of cancer statistics will provide valuable feedback to improve the quality and usefulness of registry data and monitor the impact of cancer prevention and control programs.

For additional information on NPCR, visit the CDC/NPCR Web Site at: <http://www.cdc.gov/cancer/npcr/index.htm>.

North American Association of Central Cancer Registries

The American Association of Central Cancer Registries (AACCR) was established in 1987, and with the addition in 1995 of Canadian registries as members, the name was changed to the North American Association of Central Cancer Registries. Members are population-based cancer registries in the United States and Canada, national cancer and vital statistics organizations in both countries, and other organizations and individuals interested in cancer registration and surveillance. NAACCR is a professional organization that develops and promotes uniform data standards for cancer registration; provides education and training; certifies population-based registries for high-quality data; evaluates, aggregates, and publishes data from central cancer registries; and promotes the use of cancer surveillance data and systems for cancer control and epidemiologic research, public health programs, and patient care to reduce the burden of cancer in North America. NAACCR welcomes membership from cancer registries and other organizations or individuals that are concerned with the collection, analysis, and publication of data on cancer incidence.

Surveillance Epidemiology and End Results Program

NCI's SEER Program has collected standardized data to measure progress in cancer prevention and control for more than 25 years. Established by a federal mandate—the National Cancer Act of 1971—the SEER Program is an organizational descendent of the NCI-sponsored End Results Group (1956-72) and the Third National Cancer Survey (1969-71).

Seven population-based registries have provided data continuously since the SEER Program began in 1973: the States of Connecticut, Iowa, New Mexico, Utah, and Hawaii; and the Metropolitan Areas of Detroit and San Francisco-Oakland. In 1974-75, the regions of Seattle-Puget Sound and Metropolitan Atlanta were added. These areas, plus the rural Georgia region added in 1978, cover about 9.5 percent of the U.S. population. In 1992, the SEER Program added two additional regions in California—Los Angeles and San Jose-Monterey—bringing coverage of the U.S. population to 14 percent. These regions were selected for their epidemiologically significant population subgroups and, in fact, oversample minority populations in the United States. In 2001, four states were added—Kentucky, Louisiana, New Jersey, and the remainder of California—resulting in coverage of about 26 percent of the U.S. population.

The purpose of the SEER Program, as stated in the National Cancer Act legislation, is to collect, analyze, and disseminate data useful in the prevention, diagnosis, and treatment of cancer. The goals of the program are to:

- ❖ Monitor annual cancer incidence trends to identify patterns of cancer occurring in population subgroups
- ❖ Provide continuing information on changes over time in the extent of disease (EOD) at diagnosis, trends in therapy, and associated changes in patient survival
- ❖ Promote studies to identify factors that can be studied and applied to achieve cancer prevention and control.

These goals illustrate that the aim of the SEER Program is providing cancer surveillance over time. As a result, changes in standards are carefully considered for their impact both on future data and compatibility with previous data.

Participating registries are required to submit data twice per year in a standard format using standardized definitions and codes (currently the *SEER Program Code Manual*, Third Edition, 1998,³ and *SEER Extent of Disease-1998: Codes and Coding Instructions*, Third Edition).⁶ However, the individual SEER registries have not used standardized data collection methods or data management methods locally, and they differ in the extent to which they impose data requirements on the reporting facilities in their areas.

Standardized edits, developed by SEER and shared with participating registries, are applied to data submissions, and the results are returned to the participating registries.

SEER Program publications relating to data standards include:

- ❖ A series of eight self-instructional manuals for cancer registrars³⁹ covering abstracting, coding, terminology, anatomy, treatment, statistics, and other aspects of cancer registry operations. Book 8 in the series is a comprehensive list of drugs used in treating cancer and is the standard reference for drug-treatment coding rules.
- ❖ *SEER Extent of Disease-1998: Codes and Coding Instructions*, Third Edition.⁶ This document includes site-specific codes and coding guidelines to describe spread of tumor in anatomic terms. EOD is a 10-digit code that includes 3 digits for size of tumor, 2 digits for tumor extension, 1 digit for lymph node involvement, 2 digits for the number of regional lymph nodes examined, and 2 digits for the number of positive regional lymph nodes. SEER always has collected EOD information and collapses this information into different staging schemes.
- ❖ *The SEER Program Code Manual*, Third Edition.³ This manual includes comprehensive codes and coding guidelines for the data elements required by SEER.
- ❖ *Comparative Staging Guide for Cancer*.⁴ This guide illustrates the relationships among EOD codes, the summary staging system, and the Third Edition of the TNM Staging System. A revision updating the comparative stagings to the Fifth Edition of the TNM Staging System is in development.
- ❖ *Summary Staging Guide for the Cancer Surveillance, Epidemiology and End Results Reporting Program*.⁹ Originally published in April 1977, and most recently reprinted in July 1986, this is the standard for localized-regional-distant staging for cases diagnosed between 1977 and 2000.
- ❖ *SEER Summary Staging Manual 2000*.¹⁰ Published in 2001, is the standard for summary stage for cases diagnosed January 1, 2001, and after.

There is no charge for single copies of SEER Program publications. To place an order or to obtain further information, contact SEER at the address on page xiii, or go to the SEER Program Web Site at: <http://seer.cancer.gov/Publications>.

World Health Organization

The World Health Organization (WHO), an agency of the United Nations, is responsible for publishing and maintaining the international standard for diagnosis coding systems. Selected publications include:

- ❖ *International Classification of Diseases* (ICD-9, the Ninth Revision), as modified by the Health Care Financing Administration¹³

- ❖ *International Statistical Classification of Diseases and Related Health Problems (ICD-10, the 10th Revision)*¹²
- ❖ *International Classification of Diseases for Oncology*.^{14, 15}

These publications are world-standard diagnosis coding systems.

ICD-9 was adapted for use in the United States as the Clinical Modification of ICD-9¹³ (ICD-9-CM), and is the current standard for coding medical record diagnoses in health information management departments in U.S. health care facilities. ICD-10 was implemented for coding causes of death on death certificates in the United States effective January 1, 1999.

The Second Edition of ICD-O became the standard for coding cancer diagnoses in the United States in 1992. An extensive revision of the morphology codes, especially the Lymphoma and Leukemia Section, was field-tested for the 1999 and 2000 diagnosis years, and the Third Edition of ICD-O¹⁵ has been implemented for 2001 diagnoses.

WHO publications are sold through the following two agencies in the United States:

Q Corporation
49 Sheridan Avenue
Albany, NY 12210
(518) 436-9686

College of American Pathologists
325 Waukegan Road
Northfield, IL 60076
(800) 323-4040
<http://www.cap.org/index.cfm>

In the United States, the contact for further information on ICD-O is the Expert on Nomenclature and Coding at SEER (see address on page xiii).

HISTORICAL BACKGROUND OF STANDARDS COORDINATION

Because the various standard-setting organizations use their data for different purposes, some data elements had different meanings, depending on the organization using the data. A long history of cooperation has been evident among organizations interested in cancer data to resolve the discrepancies between organizations in their interpretation of data elements.

The earliest standard-setters were COC and SEER. The End Results Group, predecessor of SEER, published coding rules and guidelines as early as the 1950s; COC published its first data collection manual, the *Supplement on the Tumor Registry*, in conjunction with its *Cancer Program Manual 1981*. At that time, hospital-based cancer registries often used COC's recommended codes and coding rules, and SEER central registries used those of the SEER Program. The two systems were not always in agreement. As a result, COC and SEER began working together in the early 1980s to make the codes and definitions in their manuals consistent.

COC and SEER attempted to define one common set of data item definitions, field lengths, and codes for use by both SEER registries and hospital-based registries. By 1988, the collaboration resulted in the publication of both COC's *Data Acquisition Manual* and the *SEER Program Code Manual*, with data items and codes in substantial agreement. Having more congruent datasets allowed for easier data sharing and data comparisons, especially with the advent of personal computers that were sufficiently powerful to analyze large amounts of cancer data. This achievement helped set precedents for cooperation in data management, and maintaining congruence whenever possible has continued to be a top priority for these two groups.

During the same period, the California Cancer Registry was developing a statewide automated system that allows facilities to report electronically to the state registry system. One region in California was a SEER registry at that time, and a large number of hospitals maintained COC-approved programs. To facilitate implementation of standards within its program, the California Cancer Registry requested that SEER and COC establish a formal committee to pursue data standardization and requested membership on this committee.

The function of that committee was transferred to NAACCR's Uniform Data Standards Committee (UDSC) when it was established in 1987. Membership was expanded to include all of the major standard-setting organizations and representation from registry software vendors and central registries. This Committee has made enormous progress toward standardization. A major success occurred when all of the participating groups agreed to implement the Second Edition of ICD-O simultaneously for cancer cases diagnosed in 1992 and later. In 1993, NAACCR convened a multidisciplinary conference to address the issue of collecting data on preinvasive cervical neoplasia, resulting in specific recommendations for member registries to cease collection of cervical carcinoma *in situ*. UDSC provides the national forum to discuss data issues and reach consensus on data standards. Given the extensive effort required to maintain uniform standards, in 2000, a subsidiary of UDSC, the Volume II Work Group, was formed to focus on the annual updates, revisions, and additions to compendiums of national standards. By June of each year, new and revised standards are released for implementation in January of the subsequent year. All standards are published annually in Volume II of the Standards for Cancer Registries.

CDC added another strong voice for standardization. CDC requires that the registries in 45 states, the District of Columbia, and U.S. Territories funded by NPCR use standard data items and codes. CDC is a sponsoring member of NAACCR, and has participated in committee activities of NAACCR. Through its contractor, CDC provides quality control activities for participants in NPCR and has facilitated the setting of standards and encouraged their adoption. The EDITS project described in Chapter IV is an example of the innovative approach CDC has supported.

At the time of this revision to Volume II, the major organizations agree in principle that their data standards will be consistent wherever possible. There are, however, areas where agreement has not been reached. These are discussed in detail in Chapter V. It also must be realized that standardization is not always desirable or feasible. For example, although the NAACCR standard for entry of dates is MM/DD/CCYY, SEER collects only month and year of birth date and date of death. SEER does not want to receive day of birth or death because of potential compromises to patient confidentiality, although individual SEER registries may collect this information.

Despite the progress made toward standardization and the near-universal agreement that standardization is desirable, much remains to be done. Implementation of existing standards is not uniform, and implementation of changes in standards is not always synchronized. SEER and COC will continue to publish separate coding manuals on different update schedules. Coding rules and rule interpretations sometimes are determined informally and documented marginally. Standardized data edits must be updated, maintained, and used by all registries.

In Canada, cancer registries at the provincial and territorial level joined together with Statistics Canada, a national agency, to form the Canadian Council of Cancer Registries. This process started in 1986 and led to the development of common national standards for the Canadian Cancer Registry, which were implemented with a reference date of January 1, 1992. A Data Quality Committee, which reports to the Council, is responsible for making recommendations to set national standards, and will review and monitor data quality and resolve any inconsistencies in procedures, coding, or other activities affecting data comparability.

NAACCR hopes that documenting existing standards, recommending standards where they do not yet exist, and publishing the results in a concise and authoritative form will enable registries and software providers to move forward in achieving comparable data that can be more widely used.

Schedule of Revisions to NAACCR Standards Documents

The NAACCR Board has agreed that the record layout, definitions, and codes will change at most only once each year. Until further notice, all revisions approved during the year will be released at the annual meeting for implementation in January of the following year. Thus, changes effective in January 2003, are being released in June 2002, as Version 10 of the layout.

CHAPTER III

STANDARDS FOR CASE INCLUSION AND REPORTABILITY

Due to recent efforts by standard-setting organizations, facility- and population-based central registries now follow nearly identical standards for determining cases that are reportable and are to be included in the registry; however, some differences remain. For facility-based registries, COC stipulates the cases, which must be included in approved registries, while most population-based registries follow the standards, set by SEER and NPCR. The *Cancer Program Standards*,²⁸ the COC *FORDS Manual*,² SEER code manuals,^{3,6} and the NPCR Program Announcement⁴⁰ should be consulted for more details.

Standards for case reportability are defined by the following criteria:

Reference Date

The reference date is the effective date cancer registration starts in a specified at-risk population or in a specific facility. It is not the date the registry is organized or the date work actually is performed. Cases diagnosed on or after the reference date must be included. The reference date usually should be January 1 of a calendar year, but sometimes it is another date.

Residency

For a population-based registry, it is essential to include all cases occurring in the at-risk population, and rules must be in place for determining the members of that population. The goal is to use the same rules for the cancer cases as those used by the Census Bureau in enumerating the population. The registry must have rules for determining residency of, for example, part-year residents, institutionalized persons, homeless persons, military personnel, and students. See the *SEER Program Code Manual*³ for specific instructions.

NAACCR recommends that population-based registries include in their database case reports of nonresidents from facilities in their catchment area for several reasons in order to:

- ❖ Allow for sharing of cases that otherwise may go unreported with other population-based registries
- ❖ Facilitate death clearance and other record linkages
- ❖ Allow preparation of complete and accurate reports to individual facilities.

Hospital-based registries are less concerned with residency of the patient than the reason for admission, and hospital registries may exclude certain categories of patients that the central registry must include, for example, patients admitted to a hospice unit or transient patients who receive care to avoid interrupting a course of therapy. Also, COC does not require complete abstracting of cases that are “nonanalytic” for the facility. Therefore, for the central registry, clear rules that are well documented, widely distributed, and accepted are essential to prevent missed cases.

Reportable List

COC, NPCR, and SEER have achieved greater consensus on reportable cases in the past few years. For all cancers diagnosed from January 1, 1992, through December 31, 2000, all three standards require the inclusion of all neoplasms in the International Classification of Diseases for Oncology, Second Edition¹⁵ (ICD-O-2) with a behavior code of 2 or 3 (*in situ* or malignant), with the exception of squamous cell and basal cell carcinoma of the skin. For all cancers diagnosed on or after January 1, 2001, all three organizations require the inclusion of

all neoplasms in the International Classification of Diseases for Oncology, Third Edition¹⁴ (ICD-O-3) with a behavior code of 2 or 3 (*in situ* or malignant), with the exception of squamous cell and basal cell carcinoma of the skin, prostatic intraepithelial neoplasia (PIN) III, carcinoma *in situ* (CIS) of the cervix, and cervical intraepithelial neoplasia (CIN) III. Code M9421 (juvenile astrocytoma, pilocytic astrocytoma, or piloid astrocytoma), with a behavior code of 1 (borderline) in ICD-O-3, is reportable. Prior to 2003, COC considered basal and squamous skin cancers that were AJCC stage group II or higher at diagnosis as reportable.

Additionally, all three standards now exclude CIS of the cervix (see Table 1, Comparison of Reportable Cancers: COC, SEER, and NPCR).³³ However, some minor differences persist and are summarized in Table 1 at the end of this chapter. For detailed presentations of the reportability rules, see the *FORDS*,² the *SEER Program Code Manual*,³ and the NPCR Program Announcement.⁴⁰

In Situ/Invasive

Some morphologic and disease descriptive terms that are considered “localized” or invasive in ICD-O-2, ICD-O-3, the SEER *Summary Staging Guide*, or the SEER *Summary Staging Manual 2000* are considered equivalent to *in situ* in the *AJCC Cancer Staging Manual*. These include:

- ❖ Paget’s disease of the nipple (8540/3) (an “invasive” code in ICD-O-2 and ICD-O-3) *with no underlying tumor* is coded Tis.
- ❖ For colon/rectum, “invasion of the lamina propria” (defined by AJCC as intramucosal with no extension through the muscularis mucosae into the submucosa) is coded as *in situ*.

Whether a tumor diagnosis is *in situ* or invasive is important because it affects how the case will be reported in published statistics. Central cancer registries using SEER Summary Stage or SEER EOD codes report some diagnoses as “invasive” and “localized,” but they will end up as *in situ* when EOD codes are converted to AJCC stage. This discrepancy should be considered when data are being compared. For more information on differences in staging classifications and current activities toward improving the situation, see Chapter V.

Multiple Primary Rules

The method used for counting tumors affects the comparability of cancer rates among registries. It is important that identical rules have been used for counting multiple tumors in the patient—whether in the same organ, on opposite sides of paired organs, in different sites or subsites—and whether they were diagnosed at the same or different times. SEER rules are the *de facto* standard in the United States for both central and hospital-based registries. See the *SEER Program Code Manual*³ for details.

SEER rules are not identical to the international standard recommended by the International Agency for Research on Cancer (IARC) and the International Association of Cancer Registries (IACR).³⁷ The IARC rules have the effect of defining fewer cases than do the SEER rules.

The following addition to SEER multiple primary rules was reviewed by UDSC and adopted on April 26, 1994, effective with cases diagnosed in 1995 and later (note: as of March 2002, COC has not adopted this rule):

EXCEPTION: If there is an *in situ* followed by an invasive cancer at the same site more than 2 months apart, report as two primaries even if stated to be a recurrence. The invasive primary should be reported with the date of the *invasive* diagnosis (*SEER Program Code Manual*, Third Edition, page 11).

CARCINOMA *IN SITU* OF THE CERVIX, CIN, AND THE BETHESDA SYSTEM

The term “pre-invasive cervical neoplasia” refers to carcinoma *in situ* of the cervix and conditions viewed as equivalent to it or on a continuum with it. Diagnostic terminology for pre-invasive cervical neoplasia has changed significantly over time, from the four-tiered system of dysplasia and carcinoma *in situ*, to the three-tiered system of CIN, to the two-tiered Bethesda System, with high- and low-grade squamous intraepithelial lesions (SIL). In the past, cancer registries generally considered carcinoma *in situ* of the cervix reportable, but they differed in which of these other terms they considered synonymous with carcinoma *in situ* and hence reportable. Consequently, data were not comparable over time or across registries.

NAACCR convened a multidisciplinary working group in April 1993 to review the problem and make recommendations for its membership. The recommendation was that “population-based registries discontinue routine collection of data on pre-invasive cervical neoplasia unless there is strong local need and interest and sufficient resources are available to collect all [high-grade squamous intraepithelial lesions] and its equivalent terms.”³³ NAACCR and NPCR adopted this recommendation. SEER and COC adopted this recommendation effective January 1, 1996.

Ambiguous Terminology

In most circumstances, the diagnosis of cancer, as recorded in the patient’s medical record, clearly is synonymous with reportable cancer. However, in those situations where the physician is not certain of the diagnosis, the associated terminology in the medical record reflects that uncertainty and is ambiguous. Both COC and SEER are in agreement in regard to the list of terms considered as diagnostic of cancer and a list of terms not considered as cancer. These terms are shown in Table 1.

Table 1. NAACCR Layout Version 10: Comparison of Reportable Cancers: COC, SEER, and NPCR.

	COC	SEER	NPCR
Reportable Diagnoses On or after 1/1/2003	1. Behavior code of 2 or higher as defined in (ICD-0-3) *2. Juvenile astrocytoma, pilocytic astrocytoma, piloid astrocytoma (M9421) 3. Basal and squamous cell cancers originating in muco-epidermoid sites: lip (C00.0-C00.9); anus (C21.0); vulva (C51.0-C51.9); vagina (C52.9); penis (C60.0-60.9); scrotum (C63.2)	1. Behavior code of 2 or 3 in (ICD-0-3) *2. Juvenile astrocytoma, pilocytic astrocytoma, piloid astrocytoma (M9421)	1. <i>In situ</i> and invasive cancers (behavior codes 2 or 3 in ICD-O-3) [includes VINIII, VAIN III, AIN III] *2. Juvenile astrocytoma, pilocytic astrocytoma, piloid astrocytoma (M9421)
Exceptions (not reportable)	1. Skin cancers (C44._) with histology (8000- 8110) and AJCC stage group I 2. CIS of the cervix and CIN III (after 1/1/96) 3. PIN III (after 1/1/96) 4. VIN III (after 1/1/96) 5. VAIN III (after 1/1/96) 6. AIN (after 1/1/96)	1. Skin cancers (C44._) with histologies (8000-8004, 8010-8045, 8050-8082, 8090-8110), other than those listed above 2. CIS of the cervix and CIN III (after 1/1/96) 3. PIN III (after 1/1/2001)	1. Basal and squamous cell carcinoma of the skin (C44._) 2. CIS of the cervix and CIN III 3. PIN III (after 1/1/2001)
Multiple Primary Rules	Follows SEER rules with the following exception: when there is an <i>in situ</i> followed by an invasive cancer at the same site more than 2 months apart, does not report the invasive cancer as a second primary if stated by the physician to be a recurrence.	Follows SEER rules	Follows SEER rules
Ambiguous Terminology Considered as Diagnostic of Cancer	compatible with consistent with most likely probable suspect suspicious Exception: if the cytology is reported as “suspicious” and no positive biopsy or physician’s clinical impression supports the cytology findings, do not consider as diagnosis of cancer.	apparent(ly) appears comparable with compatible with consistent with favors malignant appearing most likely presumed probable suspect(ed) suspicious (for) typical of Exception: if the cytology is reported as “suspicious” and no positive biopsy or physician’s clinical impression supports the cytology findings, do not consider as diagnosis of cancer.	Not addressed
Ambiguous Terminology NOT Considered as Diagnostic of Cancer	equivocal possible questionable suggests worrisome	cannot be ruled out equivocal possible potentially malignant questionable suggests worrisome	Not addressed

* Juvenile astrocytomas should be reported as 9421/3.

CHAPTER IV

RECOMMENDED DATA EDITS AND SOFTWARE COORDINATION OF STANDARDS

Definitions

“Data edits” refer to computer software algorithms that check the content of data fields against an encoded set of acceptable codes and subsequently provide feedback on the quality of the data. Data edits verify that only acceptable values are used for codes and, more importantly, enforce relationships between the codes in related data items. Data edits can apply pass/fail criteria to data, so that a particular code or set of entries is determined to be either correct or incorrect. Incorrect data will have to be corrected to pass subsequent edits. Other types of edits indicate possible (or probable) errors that require human review for resolution. Many of these possible errors are tied to over-ride flags that indicate that the data in a record (or records) have been reviewed and, while unlikely, are correct.

Generally, there are three types of edits:

- ❖ Single-field edits or item edits are those that look at only one data field at a time. For example, an edit of the item “Sex” would verify that only valid values are used in the field.
- ❖ Interfield edits or multifield edits are those that compare the codes of a data item with those in other related data items. For example, a common interfield edit compares the code for “Sex” with the code for “Primary Site,” and identifies female prostate cancer as an error.
- ❖ Interrecord edits or multirecord edits compare data on more than one record, commonly for those situations where a patient has multiple tumors. They compare the code of a data item in one record for a particular tumor with the same data item in another record or tumor. For example, an interrecord edit compares sequence numbers in multiple tumors to ensure that they have been assigned in chronological order for the patient’s cancers.

Challenges

There are at least six challenges to the standardization of data edits across central and hospital-based cancer registries. These include:

- ❖ Registry systems that encode an edit from standard specifications may be written in different computer languages, with possible differences in translation detail.
- ❖ Each implementation of an agreed-upon standard specification may be programmed differently, despite intent to encode a standard meaning.
- ❖ Complete edits are not always performed at the time of data entry.
- ❖ Documentation of the edit algorithms often is difficult for both data analysts and data collectors to obtain and use.
- ❖ Consolidated data collected via different data entry tools may encourage “apples” and “oranges” to be equated, without the users’ knowledge.

- ❖ When standards change, synchronized implementation is difficult, due to the release schedules of software providers and their limited ability to respond to changes at a given time.

Comparable results can only be reasonably expected when identical edits are applied to cancer registry data.

The EDITS Software

The EDITS Software Project began with an informal discussion about promoting and supporting data processing standards after a 1990 meeting of the NAACCR Data Evaluation and Publication Committee. A small group of registry operators, software producers, and data consumers identified a missing element of standard setting: an executable version of a standard that could be applied directly to data in a variety of processing scenarios without reinterpretation by programmers. Producers of cancer registry software who intended to adhere to a published standard had to write their own computer code to implement the edit-checking algorithms. The solution would need to be flexible in many dimensions to accommodate the many technical, operational, scientific, economic, and agency considerations that determine the cancer registry milieu.

Although EDITS handles single-field and interfield type edits routinely and interactively, the software's ability to process interrecord edits is limited. CDC has developed EDITS to accommodate interrecord edits. This edit typically is applied as a freestanding batch program and run at the time of data submission.

The EDITS software consists of three main components: EditWriter, the EDITS Application Program Interface (API), and the Generic EDITS Driver Program (GenEDITS).

❖ EditWriter

The EditWriter is a versatile and complete development environment for defining, testing, documenting, and distributing data standards. It also provides a means of maintaining the definition of a standard as it matures and changes over time. Data checking can be as complete and as complicated as the applications require.

The output of EditWriter is the EDITS Metafile, a compiled database that contains all of the logic, tables, and constant values needed to check fields of data for validity. Single-field and interfield checks are included in the NAACCR Metafile. Although EditWriter is an MS-DOS program, the metafiles that it produces can be copied and used on other operating systems, such as UNIX. The metafiles also can be used on hardware platforms other than the PC.

❖ EDITS Application Program Interface

The EDITS API can be incorporated into programs of many descriptions, including programs for interactive data entry, after-the-fact verification of data, recoding, reformatting, and vertical or horizontal subsetting. Any language product for Windows should be able to use the EDITS API. Additionally, applications written in C and compiled with modern compilers for MS-DOS, UNIX, and VAX/VMS operating systems can include the EDITS engine. The EDITS API is distributed as a Windows Dynamic Link Library and as C source code.

❖ Generic EDITS Driver Program

GenEDITS is a configurable application for editing any data file with any EDITS Metafile. GenEDITS is the fastest way to apply standard edits to data and obtain a report of data errors. Because GenEDITS already incorporates the EDITS API, no programming is required.

The EDITS Language

Using the EDITS language—a simplified programming language designed to validate data—specifies the algorithms that check data. The language includes a collection of powerful and specialized built-in functions that often reduce the complete validation of a data item to a single program statement. When complicated data relationships exist within a record, the EDITS language can express an arbitrarily complex validation schema, including multiple fields, multiple table look-ups, nested control statements, local and global variables, and external functions.

For additional information about EDITS or to download the EDITS software, see CDC's Division of Cancer Prevention and Control Web Site at: <http://www.cdc.gov/cancer/edits/editintr.htm>.

The EDITS Metafile

EDITS Metafiles contain everything needed to edit a data file, except the data. Metafiles provide portability of edits; in that the same edits can be applied to different data formats for different purposes. EDITS Metafiles are created and modified using EditWriter. The key components of a metafile include: agencies, data dictionary, record layouts, edits, edit sets, error messages, and user look-up tables.

SEER*Edits

For many years, the SEER Program has maintained a library of standardized edits written in IBM COBOL,³⁴ which it applied to data submissions from the participating SEER registries. Over the years as experience and expertise increased, SEER has fine-tuned and expanded the edits and has made these edits available to SEER and other registries. In addition, the logic of the SEER edits has been used as the foundation for the EDITS project where SEER is the source of standard for the item or items.

As more and more computer processing moved away from the mainframe environment, the SEER Program decided to reprogram their edits in C++. This change has allowed the SEER edit engine to be ported to and compiled on a variety of hardware platforms. The edit engine includes the entire field, interfield, and interrecord edits in the COBOL edits plus new and revised edits needed because of the introduction of ICD-O-3. The SEER*Edits package replaces the COBOL edits and the COBOL edits are no longer being maintained. The SEER*Edits can be used as a stand-alone package for the SEER areas to use before submission of data to SEER or the edits can be incorporated individually by SEER registries for use in their data entry programs or routine editing of data. Data are input into the stand-alone version of SEER*Edits in NAACCR format. The SEER*Edits package also includes report-generating functions including manipulation of errors to facilitate data correction, a follow-up report, and a surveillance report. Any change made to the SEER*Edits package also is made to the SEER metafile for the EDITS project and vice versa to keep them in sync.

NAACCR Standard Edits and the NAACCR Metafile

NAACCR has made increased standardization of data edits a priority, facilitated by the EDITS software, which provides a mechanism for standardized, transportable, and updateable edits to be provided through a “public library.” The goals are to help limit standards proliferation when there is no compelling need to be different, and to provide comprehensive public documentation in a current and readily accessible form in those instances where standards must differ.

The NAACCR Metafile is a comprehensive database of cancer registry standards and consists of a collection of tables that contain all the information needed to test data fields for validity and acceptability. The NAACCR Metafile specifically includes the following: look-up tables, translation tables, choice lists, data dictionary of standard fields, local field name table, error messages, executable single- and multifield validation logic, text

descriptions of edits, sets of fields defining standard records, standard-setter list, description of local data storage, data-entry help, standards documentation text, EDITS system help, and EDITS language reference.

NAACCR first made standard edits available in 1996. These edits corresponded to its 1995 record layout and data dictionary, as Volume IV in its Standards series.²⁹ Since that time, NAACCR has posted standard edits on the Internet that correspond to the annual record layouts and data dictionaries. For example, “Revised Version 6 Metafile--NAACCR6D” refers to the current standard edits in the NAACCR Version 6 record layout. The “D” notation indicates the fourth revision to the Version 6 record layout standard edits. The hardcopy Volume IV has been discontinued in favor of Internet publication. The EDITS Software with general instructions and various current and previous metafiles containing the most recent and historical public standards for cancer registry data are available on the NAACCR Web Site at: <http://www.naaccr.org/Standards/Edits.html>.

CHAPTER V

UNRESOLVED ISSUES

Despite the progress made toward data standardization, some issues remain unresolved. These issues are described in detail below. UDSC will continue to seek consensus on unresolved issues. Before new standards can be agreed upon, all interested parties must be provided sufficient time to study the proposals. Once UDSC approves new standards, there must be adequate time for implementation. The NAACCR Board has agreed that the layout will change once per year only. All approved revisions occurring during the year will be released in June for implementation in January of the following year.

All members are encouraged to present suggestions or comments on proposed changes to the standards to UDSC. The NAACCR Web Site, <http://www.naacr.org>, provides the name of the Committee Chair and forms for proposing additions or revisions.

Record Layouts:

Nine versions of the NAACCR layout have been released. All registries should begin using Version 10 in January 2003:

- ❖ Version 10 (dated March 2002)
- ❖ Version 9.1 (dated March 2001)
- ❖ Version 9 (dated May 2000)
- ❖ Version 8 (dated April 1999)
- ❖ Version 7 (dated April 13, 1998)
- ❖ Version 6 (dated January 23, 1998, and as slightly revised, dated March 20, 1998)
- ❖ Version 5.1 (dated March 12, 1997)
- ❖ Version 5 (dated April 10, 1996)
- ❖ Version 4 (dated 1994).

Please refer to Table 2 on the following page for more detail.

All versions of the NAACCR layout are compatible, but information is likely to be lost during a conversion. CDC and NAACCR are preparing standardized conversion programs between the versions.

Case Inclusion, Reportability, and Multiple Primary Rules. See Chapter III.

County--Current (item 1840)

County--Current was an item in the COC dataset prior to 2003. Codes used may have varied among facilities for reasons described in the discussion of County at DX, item 90, on the next page. Users of pooled data should ascertain what codes were used for this item.

Table 2. Record Layout Table With References.

NAACCR	Release Date	Effective Date*	Reference Manuals Accommodated	EDITS Version
Version 4	02/14/1994	01/01/1994	COC/ACOS Data Acquisition Manual, 1994 SEER Program Code Manual, 1992 WHO ICD-O-2, 1990 SEER Summary Staging Guide, 1977 AJCC Staging Manual, Fourth Edition, 1992 SEER Extent of Disease Manual, 1992	EDITS Version 4
Version 5	04/10/1996	01/01/1996	COC/ROADS, 1996 SEER Program Code Manual, 1992 WHO ICD-O-2, 1990 SEER Summary Staging Guide, 1977 AJCC Staging Manual, Fourth Edition, 1992 SEER Extent of Disease Manual, 1992	EDITS Version 5
Version 5.1	03/12/1997	01/01/1997	Same as Version 5	EDITS Version 5.1
Version 6	01/23/1998 Rev 3/20/1998	01/01/1998	COC/ROADS, 1996, Rev. 1998 SEER Program Code Manual, 1998 WHO ICD-O-2, 1990 SEER Summary Staging Guide, 1977 AJCC Staging Manual, Fifth Edition, 1997 SEER Extent of Disease Manual, 1998	EDITS Version 6
Version 7	04/13/1998	01/01/1999	Same as Version 6	EDITS Version 7
Version 8	03/30/1999	01/01/2000	Same as Versions 6 and 7	EDITS Version 8
Version 9	05/15/2000	01/01/2001	COC/ROADS, 1996, Rev. 1998 SEER Program Code Manual, 1998 WHO ICD-O-3, 2000 SEER Summary Staging Manual, 2000 AJCC Staging Manual, Fifth Edition, 1997 SEER Extent of Disease Manual, 1998	EDITS Version 9
Version 9.1	03/21/2001	01/01/2002	Same as Version 9	EDITS Version 9.1
Version 10	03/20/2002	01/01/2003	COC FORDS SEER Program Code Manual, 2003 WHO ICD-O-3, 2000 SEER Summary Staging Manual, 2000 AJCC Staging Manual, Sixth Edition, 2002 Collaborative Staging Manual and Coding Instructions, Version 1.0	EDITS Version 10

Bolded text indicates changes from previous version.

* Either the date of diagnosis or year first seen for this cancer may have been used by some standard-setters. Refer to the Data Dictionary or to the standard-setter reference manuals for clarification of date requirements.

County at DX (item 90)

NAACCR has adopted the Federal Information Processing Standards (FIPS) codes for county as the standard in this volume (see Appendix A for codes). However, standards for codes used vary somewhat by standard-setter as follows:

- ❖ The SEER Program requires the use of FIPS codes for counties in the United States, plus the special code 999. Because SEER collects only cases of residents of the reporting areas, no codes are needed for SEER registries other than the codes for the counties in their areas.
- ❖ COC requires the use of FIPS county codes as their standard, plus the special codes 998 and 999. However, the *FORDS Manual* also provides for use of geocodes for countries of residence outside the United States and Canada to be used in this field.
- ❖ NPCR requires the use of FIPS codes for counties in the United States, plus the special code 999, starting with cancers diagnosed on or after January 1, 2002. Prior to 2002, NPCR recommended the use of FIPS county codes.
- ❖ NAACCR recommends the use of FIPS codes.

For cancers diagnosed prior to 2002, the use of FIPS codes was not universally adopted. For this reason, users of data should determine which codes were used for coding County at DX in a particular file, because no field indicating “County at DX Coding System” is included in the NAACCR layout.

Hispanic Ethnicity (items 190-210)

There is agreement on the standard data item “Spanish/Hispanic Origin” and its codes. However, there has been substantial variation among registries in how the Spanish or Hispanic origin is determined. Procedures for determining ethnicity include:

- ❖ Recording ethnicity from information in the medical record.
- ❖ Recording ethnicity based on all information available, including the surname, birthplace, or stated ethnicity.
- ❖ Recording ethnicity based on a manual or computer matching of surname against a list of Spanish surnames that, in most cases, is based on the 1980 Census. Some registries also perform an additional manual or computer match on the maiden name.
- ❖ Recording the ethnicity based on the application of a computer algorithm to surnames to determine ethnicity.

Population-based registries must attempt to categorize their cases using a method that best approximates the method used by the Census Bureau to determine ethnicity of the population denominators, but a standard method has not been determined. NAACCR’s UDSC has discussed the issue extensively, and a subcommittee convened a workshop in Atlanta, GA, in January 1996. A report was prepared and is available on the NAACCR Web Site (<http://www.naacr.org>) under the heading “Epidemiologic Reports.” In 1999, a research group was formed from representatives of NAACCR to address issues of definition and to produce comparable data for Hispanic ethnicities across the United States. The group operates under the auspice of the Data Evaluation and Publications Committee. Results from the survey of registry practices are available on the NAACCR Web Site.

Based on these discussions, NAACCR has added fields for Computed Ethnicity and Computed Ethnicity Source, and has clarified how the code for Spanish/Hispanic Origin is to be determined. Registries continue to use different methods of coding ethnicity, but users of the data should be able to determine how coding was done in a particular file if the standard codes are used. See the descriptions and notes for items 190-210 for details.

Name--Last (item 2230)

The COC *FORDS Manual* allows embedded spaces, hyphens, apostrophes, and punctuation in the last name field. NAACCR standards allow no embedded spaces and punctuation, except hyphens. Neither COC nor NAACCR standards allow the last name field to be blank.

Name--Maiden (item 2390)

The COC *FORDS Manual* allowed embedded spaces, hyphens, apostrophes, and punctuation in the maiden name field. NAACCR standards allow no embedded spaces and punctuation, except hyphens. Both COC and NAACCR standards allow the maiden name field to be blank.

Occupation and Industry (items 270-330)

Most population-based registries have found the collection of usual occupation and industry data to be difficult and of limited utility. Traditionally, no consensus on data items and codes for occupation and industry had been achieved. In 1992, the Cancer Registries Amendment Act required collection of occupation or industry data to the extent available in the medical record by central registries funded by NPCR.³⁶ In response to this mandate, CDC sponsored a meeting of experts in occupational health and cancer epidemiology in 1995. Recommendations from the meeting resulted in the adoption of data items and codes by the NAACCR UDSC in August 1995.²⁵ These agreed-upon standards were included in Versions 6 and later of NAACCR's data standards.

Data on usual occupation and industry are unavailable in an unknown, but significant, proportion of medical records. Additionally, even when available, the quality of the data in the medical record is generally untested and often limited to less useful information such as "retired." Concurrently, this information generally is available in text format on death certificates and, in some states, on the associated state mortality data tapes. Some state mortality data tapes in addition to the text data also contain the associated occupation and industry codes. Software for the automated coding of the text data is available from the Division of Safety Research, National Institute for Occupational Safety and Health, CDC. Regardless, much work remains to be done to improve the availability and capture of this potentially important information.

NAACCR will continue to discuss the quality and completeness of occupation and industry data and will reconsider the inclusion of occupation and industry in its recommended datasets.

RX Summ--Rad to CNS (item 1370)

SEER and COC had different requirements for this item. SEER no longer collects it for cases diagnosed 1998 and later; however, they retain the codes for older years' cases, and also convert the data into an appropriate code in the RX Summ--Radiation field.

Sequence Number (items 380 and 560)

As discussed in Chapter III, SEER, NPCR, and COC have different standards for reportable diagnoses. In addition, some registries collect and assign sequence numbers to nonreportable tumors such as benign brain tumors. Although most registries assign sequence numbers to cancers in the patient's lifetime, others assign sequence numbers to cancers from the reference date of the registry.

The NAACCR layout provides fields for two sequence numbers, one assigned by the reporting facility and one assigned by the central registry. Numerous operational issues result, such as storage of multiple facility-specific sequence numbers, appropriate linkage rules, and feedback of data to hospitals. When identifying patients with only one cancer for analysis, it is important to realize that there is variability in the definitions used to make that determination, and that cases may have been handled inconsistently in data collected using different systems.

Stage, TNM, and EOD (items 760-830, 880-1070)

Currently, five major staging schemes are widely used in cancer registries throughout the United States. The schemes differ in complexity, structure, purpose, definitions, and rules. The five schemes are:

❖ **The American Joint Committee on Cancer's TNM System**

In its Sixth Edition, the *Cancer Staging Manual* includes a clinically oriented, site-specific staging system that consists of a separate category for the tumor, nodes, and metastases. The TNM categories then are grouped by stage, from 0 to IV. COC standards for approved cancer programs require that the medical record contain the AJCC stage assigned/initialed by the managing physician.

❖ **SEER Extent of Disease**

This site-specific 10-digit coding scheme⁶ is required for SEER registries and is used by some other state and central registries as well. EOD was designed to allow collapse of the codes into the stage groupings of several different staging systems, including AJCC stage group.

❖ **SEER Summary Stage**

This site-specific single-digit coding scheme is required for NPCR registries, and is used by some SEER registries as well. In addition, COC requires the coding of SEER Summary Stage when a corresponding AJCC TNM site code scheme is not available. There are two related data items: SEER Summary Stage 1977 [760] and SEER Summary Stage 2000 [759]. Cancers diagnosed on or after January 1, 2001, should be assigned a summary stage according to the *SEER Summary Staging Manual, 2000*,¹⁰ and the code should be reported in the SEER Summary Stage 2000 [759] data item. Cancers diagnosed before January 1, 2001, should be assigned a summary stage according to *Summary Stage Guide, Cancer Surveillance Epidemiology and End Results Reporting, SEER Program, April 1977*,⁹ and the code should be reported in the SEER Summary Stage 1977 [760] data item (see NAACCR Guidelines for Implementation of SEER Summary Stage 2000).

❖ **SEER Historic Stage**

When SEER stage data are published, the stage categories used are derived from categories used by an earlier program, the End Results Group. The categories are not identical to those in the SEER Summary Stage. However, the Historic Stage variable has been defined consistently over time to facilitate trend analyses.

❖ **Collaborative Stage**

The initial focus was to develop a translation between the TNM staging system of the AJCC and the SEER Summary Staging System. The translation would eliminate duplicate data collection by registrars reporting to clinical and epidemiologic registries, address the concerns of clinicians for more clinically relevant data as well as the public health sector's concerns about data reproducibility over time, and provide a higher degree of compatibility between the systems that would expand data-sharing opportunities.

The Collaborative Stage (CS) Data Set is a combination of data items (most of which have traditionally been collected) that include tumor size, extension, lymph node status, metastatic status, evaluation fields that describe the hierarchy of the data collected, and site-specific factors. This unified dataset for cancer reporting has an algorithm that derives three different staging systems and resolves staging rule differences. The three systems are AJCC TNM, SEER Summary Stage (SS) (1977 and 2000), and SEER EOD. AJCC TNM staging provides forward flexibility and clinical utility. SEER EOD provides longitudinal stability for epidemiological studies, and SEER Summary Stage provides a population surveillance staging system.

Collaboration among the participating organizations has resulted in resolution of the timing rule and standardized staging rules for one staging information collection model. The timing rule going into effect on either January 1, 2003, or January 1, 2004, will be: “use all information through the first course of surgery or 4 months, whichever is longer.” This timing rule change will allow the CS Data Set to capture “best stage” combining clinical and pathologic data. SEER currently uses the “4 month rule,” and this collaboration brings both SEER and AJCC to one standard. Other rule modifications have been made and are printed in the “site-specific” chapters.

The CS model will improve the quality of data being collected. Uniform rules and standardized training will make it easier for cancer registry personnel to complete staging tasks.

These schemes were designed for different purposes at different times, and are not easily compared. There have been several editions of the TNM Manual, and implementation has not been synchronized. SEER has published the *Comparative Staging Guide for Cancer*⁴ as an attempt to present comprehensive, site-specific comparisons of the schemes to aid in data collection and interpretation. This guide covers the major cancer sites of colon and rectum, lung and bronchus, breast, female genital, prostate gland, and urinary bladder. According to the guide:

- ❖ Changes over time in methods of cancer screening, diagnosis, staging, and treatment have affected the distribution of stage of disease.
- ❖ Changes over time in the classification schemes themselves can complicate data analysis and obscure the meaning of time trends. Various other staging schemes also are in use. Several oncology subspecialties have developed staging systems applying to a limited number of cancer sites.

For these reasons, comparing cancer registry data by stage over time or across registries, or using pooled data collected by different registries applying different staging schema, is problematic⁴ (page I.3).

The lack of comparability among these systems causes major problems for those collecting the data and for users of the data. For example, hospital cancer registrars often are required to code stage information using more than one scheme to meet requirements of different standard-setting organizations. This increases the training needed for staff and the time needed to code each case. Users of the data may be unaware that the same term may be defined differently in the schemes, and that data cannot be compared easily. For example, the category of *in situ* carcinoma of the colon includes different cases in TNM and SEER historic stage.

For a discussion of staging issues that affect rules for case inclusion and reportability, see Chapter III, especially the paragraphs “*In Situ*/Invasive” and “Multiple Primary Rules.”

Surgery, Radiation, Chemotherapy, and Hormonal Treatment for Years 1996-97, 1998-2002, and 2003 forward (items 1200-1296, 1310-1460, 1510, 1540-1590, 1640-1645, 3200-3280) and corresponding fields for Hospital-Specific Treatment and Subsequent Treatment

❖ **1996-1997**

For the diagnosis years 1996 and 1997, the COC *ROADS*, in preparation for the major revision of the coding of treatment implemented in 1998, separated the concept of noncancer-directed surgery and reconstructive surgery from the field for cancer-directed surgery, while keeping the same basic codes. Additionally, the data item RX Summ--Reconstruct 1st [1330] was redefined to include reconstruction at any time in the patient's course rather than just in the first course of therapy. Three new fields (Reason for No Radiation [1430], Reason for No Chemo [1440], and Reason for No Hormone [1450]) were added, and codes 7 and 8 (Patient or Patient's Guardian Refused Chemotherapy; and Chemotherapy Recommended, Unknown if Administered) were removed from the corresponding code list. These new fields, codes, and related dates were required of COC-approved programs beginning with 1996 cases. NAACCR added all necessary fields to the data exchange record layout for 1996.

SEER continued to collect codes 7 and 8 (Patient or Patient's Guardian Refused [treatment modality] and Recommended Unknown if Given, respectively within the specific fields for radiation, chemotherapy, and hormonal therapy [1360, 1390, 1400],) instead of adding separate fields for "Reason for No [treatment modality]." Thus, there were major differences in the coding of treatment among standard-setting organizations for 1996 and 1997 cases. NAACCR revised the meaning of some codes and added a new code to RX Coding System--Current [1460] that indicates how treatment is coded in the record.

❖ **1998-2002**

Effective with cases diagnosed between January 1, 1998, and December 31, 2002, the completed treatment code revisions were implemented by COC, and the NAACCR layout was modified as needed. New fields were added: RX Summ--Scope Reg LN Sur [1292], RX Summ--Surg Oth Reg/Dis [1294], and RX Summ--Reg LN Examined [1296]. Three data items were renamed: RX Summ--CA Dir Surg [item 1290] became RX Summ--Surg Prim Site; Residual Primary Tumor [1320] became RX Summ--Surgical Margins; and Reconstructive Surgery [1330] became RX Summ--Reconstruct 1st. Another data item, RX Summ--Surgical Approach [1310], was redefined. Analogous changes were made to the corresponding fields of RX Hosp and Subsq RX. COC-approved cancer programs were required to implement all of these changes effective with 1998 cases.

SEER adopted some, but not all, of these fields effective with cancers diagnosed January 1, 1998 through December 31, 2002. SEER implemented the new codes for RX Summ--Surg Prim Site [1290]. They added the new items RX Summ--Scope Reg LN Sur [1292], RX Summ--Surg Oth Reg/Dis [1294], and RX Summ--Reg LN Examined [1296], to their required dataset. They elected, on a trial basis for 1998, to collect RX Summ--Reconstruct 1st [1330] for breast cancers only. SEER continued to collect codes 7 and 8 (Patient or Patient's Guardian Refused [treatment modality] and Recommended Unknown if Given, respectively) within the specific fields for radiation, chemotherapy, and hormonal therapy [1360, 1390, 1400], instead of adding separate fields for "Reason for No [treatment modality]." COC had dropped codes 7 and 8 from each modality for which they had added a "Reason No..." field (see above). UDSC has allowed users to either assign codes 7 and 8 or to use the fields "Reason No..." for radiation, chemotherapy, and hormonal therapy.

Historically, NPCR has required the collection of "date and type of first course of definitive treatment when available in the medical record."³⁰ For the 1996-1997 diagnosis years, NPCR-funded registries

were required to collect and process available treatment information using either the (1995 or 1996) SEER Program treatment dataset or the (1995 or 1996) COC treatment dataset.

For 1998-2000, NPCR had a similar recommendation. NPCR-funded registries were required to adopt either the SEER 1998 or the full COC 1998 treatment dataset. The NAACCR data item “RX Coding System--Current” [1460] also was encouraged to indicate how treatment was coded for a specific record.

❖ **Forward**

Beginning in 2003, the COC *FORDS*² has redefined some treatment fields and added several more. The new and redefined data fields along with dates of treatment are required. New treatment fields include: Rad--Boost RX Modality [3200]; Rad--Boost Dose cGy [3210]; RX Hosp--Palliative Proc [3280]; RX Summ--Palliative Proc [3270]; and RX Summ--Transplnt/Endocr [3250]. The following fields were revised for 2003 data collection: Rad--Regional RX Modality [1570]; Rad--Treatment Volume [1540]; Reason for No Radiation [1430]; Reason for No Surgery [1340]; RX Hosp--BRM [720]; RX Sum--BRM [1410]; RX Hosp--Chemo [700]; RX Summ--Chemo [1390]; RX Hosp--DX/Stg/Proc [740]; RX Summ--DX/Stg/Proc [1350]; RX Hosp--Hormone [710]; RX Summ--Hormone [1400]; RX Hosp--Other [730]; RX Summ--Other [1420]; RX Hosp--Scope Reg LN Sur [672]; RX Summ--Scope Reg LN Sur [1292]; RX Hosp--Surg Oth Reg/Dis [674]; RX Summ--Surg Other Reg/Dis [1294]; RX Hosp--Surg Prim Site [670]; RX Summ--Surg Prim Site [1290]; and RX Summ--Surgical Margins [1320].

In 2003, field width was expanded to 2 characters and codes 82, 85, 86, 87, and 88 were added to the code list for RX Hosp--Chemo [700], Rx Summ--Chemo [1390], RX Hosp--BRM [720], RX Summ--BRM [1410], RX Hosp--Hormone [710]; RX Summ--Hormone [1400]; RX Hosp--Other [730]; and RX Summ--Other [1420] to record the reason if the respective treatment was not provided. The last two codes correspond to the codes 7 and 8 in the former “Reason No...” items for those treatments. Also in 2003, Reason for No Chemo [440] and Reason for No Hormone [1450] fields were discontinued.

SEER will use the same codes as the COC *FORDS* but may not collect all of the fields. For example, SEER areas will not collect Rad--Treatment Volume. See the list of data items (Chapter IX) that SEER areas collect and that SEER requires the SEER registries to transmit to NCI. SEER areas will use the field Rad--Regional RX Modality [1570] from COC hospitals to complete RX Summ--Radiation [1360].

COC Rules for conversion between the various available treatment coding schemes have been developed. It should be emphasized, however, that treatment data collected using pre-1998 treatment coding cannot be completely converted to the 1998 codes without review.

Time Period for First Course of Treatment (items 1260, 1270, 1500)

The NAACCR record layout provides two data items that indicate the date of the start of the first course of treatment: Date of 1st CRS RX--COC [1270] as defined by COC, and Date of Initial RX--SEER [1260] as defined by SEER. The primary difference between these two definitions is that COC defines the date the physician decides not to treat the patient as the date of initial treatment, while SEER considers such a decision to be no treatment and the date is recorded as zeros. The NAACCR record layout contains a data item, First Course Calc Method [1500], to record which definition was used.

The SEER and COC definitions of treatment to be included as “first course” have become increasingly congruent, differing now primarily in their “fall-back” recommendations that apply when no treatment plan is recorded, no standard facility practice applies, no protocol applies, no physician is able to provide assistance, and no record of treatment failure or recurrence of disease is available. In that extreme instance, COC recommends a 4-month cutoff for the beginning of first-course treatment, and SEER applies a 1-year cutoff.

Users of historical treatment data should be aware that the definitions of “first course” have changed over time and have been disjointed in the past. The applicable coding manuals and standard-setting organizations should be consulted for specifics.

Users of treatment data also should be aware that registries differ in the amount of treatment data collected in terms of the types of treatment included, non-hospital treatment locations surveyed, items covered (see the previous section), and the use of all codes provided for each item. Thus, treatment data are likely to be inconsistent among registries and to have varying levels of completeness, especially for treatment given in physicians’ offices or other non-hospital settings.

Tumor Size Rules (item 780)

Both SEER and COC measure the size of the primary tumor (and, for malignant melanomas, the depth of invasion) in millimeters, but SEER defines variations that are not defined by COC:

- ❖ COC sets Tumor Size for all Kaposi sarcoma, Hodgkin lymphoma and non-Hodgkin lymphoma cases to unknown (999); SEER uses the field for these cases to indicate HIV/AIDS status.
- ❖ SEER defines the code 001 for solid tumors as “microscopic focus or foci only,” and 002 as “< 2 mm.” COC applies the code 001 for “microscopic focus,” but also uses the code to indicate 1 mm.

Note: Through 2001, COC used the same scale of measurement for the depth of invasion of malignant melanomas (whole millimeters) as it did for other tumors; SEER has always used a measurement scale 100 times finer, allowing measurements to the tenth and hundredth of a millimeter. Beginning with cases diagnosed January 1, 2002, COC uses the same measurement scale as SEER.

Type of Reporting Source (item 500)

This item is used to identify the source documents used to abstract a cancer case. The existing codes do not distinguish between inpatient and outpatient or clinic records. Many central registries want to keep track in more detail of the types of facilities submitting cases to the registry, especially to monitor shifts in the types of facilities delivering cancer care. UDSC has reviewed suggested enhancements to this item that would provide greater coding detail (e.g., identifying freestanding clinics).

Some central registries have adapted this item to meet changing needs. The California Cancer Registry uses the additional data item Source of Case finding to indicate the type of service or facility where a case was first identified. The NAACCR UDSC may recommend additional data items or codes in the future.

Vital Status (item 1760)

Both SEER and COC use code 1 in this 1-digit field to indicate that the patient is alive. However, these programs use codes 4 and 0, respectively, to indicate that the patient is dead. Both programs have long-standing historical reasons to retain their coding. No agreement has been reached on this data item.

Canadian Data

The NAACCR data standards adopted thus far do not adequately deal with data from places outside the United States. Changes have been made to accommodate postal codes, standard abbreviations for provinces/territories, and other fields in Canadian data. Future versions of this document will review and increasingly incorporate standards established for Canadian cancer registries.

CHAPTER VI

PATHOLOGY LABORATORY ELECTRONIC REPORTING RECOMMENDATIONS

SECTION 1: PREFACE

This chapter documents recommended standards and implementation guidelines for electronic transmission of reports from pathology laboratories to central cancer registries.

It is the hope of the NAACCR Pathology Laboratory Subcommittee that making these consensus standards available to the community will make it easier for pathology laboratories, central cancer registries, and software vendors to adopt a uniform method for report transmission. Ultimately, our goal is to develop resources that will support future initiatives toward standardization through the recommended communication protocol that will assure the collection of those cancer cases that do not reach the traditional hospital setting. The content of this chapter will help central cancer registries develop the infrastructure needed to electronically receive and process reports from pathology laboratories. It is not intended to be the final section, and it will evolve over time as more is learned about laboratory technology, electronic reporting, new information technologies, vocabulary and codes, reporting regulations, and confidentiality.

The current NAACCR Pathology Committee Chairs would like to acknowledge the previous Chairs (Frank Caniglia and Robin Otto of the Pennsylvania Cancer Registry) for their initiative, coordination, and efforts in the production of this chapter. In addition to the Pathology Laboratory Subcommittee, the NAACCR Uniform Data Standards (UDS) Committee as well as the Information and Technology (IT) Committee have extensively reviewed much of the data content of this chapter. A special thanks is warranted to all NAACCR members and committees that collaborated on this effort.

Susan Gershman and Warren Williams

**SECTION 2: MEMBERS OF THE NAACCR PATHOLOGY LABORATORY
SUBCOMMITTEE 1999-2000**

Chairs

Susan Gershman, PhD
Massachusetts Cancer Registry

Barry A. Gordon, PhD
California Cancer Registry

Warren Williams, MPH

Centers for Disease Control and Prevention

Joanne Harris
Michigan Cancer Surveillance System

Johnny Heath
North Carolina Cancer Registry

Subcommittee Members

Toshi Abe, MSW
New Jersey State Cancer Registry

Larry Hebert
Illinois State Cancer Registry

Wendy Aldinger
Pennsylvania Cancer Registry

Gary Hulett
Iowa Cancer Registry

Mayra Alvarez, RHIT, CTR
University of Miami School of Medicine

Kathleen McKeen
State Health Registry of Iowa

Jane Braun, MS, CTR
Minnesota Cancer Surveillance System

Donna Morrell
California Surveillance Program of Los Angeles

Darlene Dale
Ontario Cancer Registry

Robin Otto, RHIA, CPA
Pennsylvania Cancer Registry

Mignon Dryden, CTR
Cancer Registry of Northern California

Mary Potts, RHIA, CPA
The Fred Hutchinson Cancer Research Center

Sarah Evans
South Carolina Central Cancer Registry

Wendy Scharber, RHIA, CTR
Minnesota Cancer Surveillance System

Velma Garza
Texas Cancer Registry

Patricia Wolfgang
New York State Cancer Registry

SECTION 3: PROBLEM STATEMENT, GOALS, AND SCOPE OF THIS CHAPTER

The Problem

One of the major changes in the health care delivery system, and specifically in regards to the cancer patient, is that diagnoses and treatments are occurring in non-hospital settings. This shift from what traditionally has occurred primarily in hospital settings is presenting challenges to central cancer registries in their need for complete case ascertainment. It now is essential that central cancer registries develop mechanisms for ascertaining cases from these non-hospital sources to maintain a complete and accurate count of cancer cases.

One type of non-hospital source necessary for complete cancer data collection is the pathology laboratory. The lack of a standardized system for reporting by pathology laboratories results in each central registry developing its own procedures for capturing these cases. Pathology laboratories must comply with the different specifications from each state or province/territory to which they are required to report.

The Proposed Solution

The Pathology Laboratory Subcommittee of the NAACCR IT Committee was formed to develop a recommended approach for pathology laboratories to report electronically to central cancer registries. The result of this Subcommittee's efforts is the documentation contained in this chapter. The philosophy of the Subcommittee was to incorporate current industry standards and provide additional resources to offer support in areas of connectivity and communication protocols. Health Level 7 (HL-7) or a character-delimited flat file is recommended as the data format for reporting cases. A standard pathology laboratory dataset, data dictionary, and HL-7 transmission format and flat file were developed to enhance the completeness, timeliness, consistency, and efficiency with which cancer data are transmitted by pathology laboratories and received and processed by central cancer registries. These standards are referred to in this section as the Standard Format Documents. They are contained in Section 4 and consist of: *Text of NAACCR Pathology Laboratory Dataset and Record Format for Electronic Reporting to Central Cancer Registries*; *Pathology Laboratory Data Table*; and *HL-7 Addendum*. Implementation guidelines were developed to provide assistance in implementing the recommended standards.

Goals of the Pathology Laboratory Reporting Standards Section

The goal of this chapter is to define the data standards for cancer registration as used by central cancer registries, pathology laboratories, vendors, and other groups, as well as to provide guidelines for the implementation of these standards.

Objectives of the standardization effort include:

- ❖ Providing a resource to help ensure uniform data collection
- ❖ Eliminating the need for each central cancer registry to develop a mechanism for electronic transmission of reports from pathology laboratories
- ❖ Reducing the need for pathology laboratories to maintain separate transmission protocols for each central cancer registry to which they are required to report
- ❖ Reducing the need for redundant coding and data recoding between data exchange parties
- ❖ Providing a resource document to help registries and pathology laboratories that are establishing or revising their method of collection and reporting

- ❖ Serving as a bridge to develop a cost-effective approach to system connectivity through the use of a clinical data interchange standard that will support current and future data standards
- ❖ Encouraging the adoption of these standards by all parties
- ❖ Encouraging consistent reporting formats and standards from laboratories to health department areas.

Scope of This Chapter

The scope of this chapter is limited to standards and guidelines regarding what electronic records should contain when they are used to transmit cancer information from pathology laboratories to central cancer registries. The Standard Format Documents address data items, data item definitions, and transmission specifications. Implementation guidelines and business rules are incorporated to help central registries, pathology laboratories, and vendors within North America respond to the call for cancer cases in a uniform method. In addition, the use of HL-7 as the recommended clinical data interchange standard will provide a cost-effective solution to addressing data exchange in the 21st century.

SECTION 4: STANDARDS AND GUIDELINES FOR ELECTRONIC TRANSMISSION OF REPORTS FROM PATHOLOGY LABORATORIES TO CENTRAL CANCER REGISTRIES

The Standards

The Standard Format Documents included in this volume are the standards recommended by NAACCR for electronic reporting by pathology laboratories to central cancer registries. Use of these standards (found in Section 7) will greatly increase the efficiency and consistency with which laboratories and central registries can meet reporting and data collection requirements.

- ❖ ***Text of NAACCR Pathology Laboratory Dataset and Record Format for Reporting to Central Cancer Registries.*** This section describes the data items reported by pathology laboratories. Standard NAACCR data item names, relative field lengths, and definitions for NAACCR-defined items are included in the Pathology Laboratory Data Description.

The column “Field Requirements” indicates whether the data item is required or recommended. The required data items (Y) comprise the minimum dataset needed to process a report by the central registry. “Field Length” indicates a relative field length for the NAACCR-approved data items. Field lengths for pathology laboratory-specific data items are based on similar NAACCR data items and central registry experience with pathology laboratory data. Although field lengths are somewhat irrelevant for data transmission in HL-7, they are included to indicate limits by the central registry. The column “HL-7 Location Name and Field ID” specifies an HL-7 location that corresponds to the pathology laboratory information (see “File Layout,” Section 7).

The third column of the table maps each pathology laboratory data item to the corresponding NAACCR Item Number. Many of these items are new NAACCR data item numbers as approved by the NAACCR UDS and IT Committees.

- ❖ ***Pathology Laboratory Data Table.*** Section 8 defines each data item in the NAACCR Pathology Laboratory Dataset. NAACCR standard data items are defined according to the *NAACCR Standards for Cancer Registries, Volume II, Data Standards and Data Dictionary*. Many of the items in the pathology reporting documents translate to previously published NAACCR items, for example, the site code for a

pathology report may be coded in a SNOMED code, and there are mapping tables available from the College of American Pathologists to translate to the appropriate ICD-O-3 code.

- ❖ **HL-7 Addendum.** Section 9 is the key to standardization of electronic reporting from pathology laboratories to central cancer registries. It provides instructions and specific HL-7 formatting parameters for pathology laboratory personnel to use when transmitting reports. The documentation also is used by central registry personnel to check initial pathology laboratory transmissions to ensure that fields are correctly populated. Using the HL-7 format will enable pathology laboratories to report electronically to any central registry with minimal effort. Central registries also will be able to receive reports from all pathology laboratories in the same format. System-specific development by central registries for each pathology laboratory and by pathology laboratories for each state or province/territory will be eliminated.

An ASCII flat file also is provided for laboratories and registries that do not have the capability to report data in an HL-7 style message.

SECTION 5: GUIDELINES FOR IMPLEMENTATION OF AN ELECTRONIC PATHOLOGY LABORATORY REPORTING SYSTEM

When designing and implementing procedures for electronic pathology laboratory reporting, the uniqueness of each central registry must be considered. Information in this section is provided for use as a starting point. Although issues requiring discussion are not limited to those presented below, central registries should consider the following in preparing to implement an electronic pathology laboratory reporting system:

- ❖ Investigate several areas within the state infrastructure:
 - **Clinical Laboratory Improvement Act Numbers:** Central registries should identify the regulatory body within the state that certifies clinical laboratories and monitors Clinical Laboratory Improvement Act (CLIA) numbers issued by the Centers for Medicare & Medicaid Services (formerly the Health Care Financing Administration). This unique identifier provides central registries the ability to follow-up with laboratories providing source records.
 - **Other Reportable Diseases:** This electronic reporting system has the potential to serve as the infrastructure for electronic reporting of all diseases reportable to the state or province/territory or to be included in an existing electronic reporting system. Using HL-7, standard vocabularies, and code sets enables laboratories to transmit to one location the necessary data items to comply with many disease-reporting requirements. The HL-7 file header segment enables records to be automatically routed to the appropriate program area.

To prevent duplication of effort, central registries should discuss electronic transmission issues with other program areas receiving reports from laboratories. Efforts to identify corporate and technical contacts with laboratories already could be established. Convening a work group comprised of representation from the cancer registry, communicable disease, lead program, and information services is advantageous to identify opportunities for joint efforts and to reduce time for system deployment. Examples of issues for discussion include:

- Connectivity between laboratories and health departments
- Secured telephone lines for data transmission

- Predetermined format for data transfer (HL-7)
- HL-7 capability within your organization
- HL-7 training needs and availability. Additional information on HL-7 can be found by referring to: <http://www.HL7.org>.
- **Hardware Recommendation:** A recommendation of specific types of hardware requirements is inappropriate because of the many factors to be determined locally before the selection of hardware is addressed, and also because the computer field changes so quickly that recommendations soon are obsolete. The following questions, however, should be considered:
 - What type of operating system would best fit the registry’s situation (i.e., multi-user, single user, network, etc.)?
 - What is the nature of the physical facility where the equipment will be housed, used, and connected?
 - What type of software packages will run on the system?
 - How much training will be required for existing staff?
- ❖ Refer to “Recommended Business Rules for Electronic Transmission of Reports From Pathology Laboratories to Central Cancer Registries,” in Section 6. These rules were developed to identify critical issues requiring discussion between laboratories and central registries.
- ❖ Contact pathology laboratories to discuss electronic reporting and provide laboratories with the Standard Format Documents contained in this volume. Pathology laboratories should use the *HL-7 Addendum* to prepare for electronic transmission of reports.
- ❖ Develop or link with a connectivity system (i.e., file transfer protocol [FTP], the bulletin board system [BBS], or Web-based) that is compatible with laboratory capabilities through which pathology reports can be electronically transmitted.
- ❖ Develop or acquire software to process pathology reports received from the laboratory. The processing software must:
 - Include an HL-7 reader to take the HL-7 transmission and convert it to an appropriate data file or flat file for processing
 - Examine for reportable conditions
 - Include a mechanism to assign ICD-O-3 codes to site and histology based on pathology report text, or map pathology SNOMED codes to ICD-O-3 codes
 - Include a mechanism to identify reports with insufficient demographic information needed for record linkage to follow-up with the ordering client (the physician ordering the analysis of the specimen).

The Pennsylvania Cancer Registry (PCR) has developed software to process reports received electronically from pathology laboratories in HL-7. This software addresses the components mentioned above. The PCR Client Server software was developed using funding provided by the CDC through the NPCR. PCR's HL-7 reader, processing software, code, and user's manual are available at: <http://www.health.state.pa.us/download/cancer>.

- ❖ Develop central registry-specific procedures for accessioning pathology laboratory records to the registry's database. Although procedures developed by each central registry will differ, it is important to remember that pathology reports alone usually do not provide adequate information to confirm a new primary cancer or the date of initial diagnosis. Some specimens may represent metastatic sites or recurrences. Therefore, linkage between pathology reports and existing records on the registry's database must be performed systematically for at least 6 to 9 months following receipt of the pathology report. If no match occurs during this time, the central registry must ascertain sufficient information before the pathology report can be confirmed as a new primary cancer. There are a variety of challenges associated with merging and consolidating patient, tumor, or treatment data. Please see the report by the NAACCR Work Group on Consolidation for appropriate recommendations. A copy of the report can be found on the NAACCR Web Site.

SECTION 6: RECOMMENDED BUSINESS RULES FOR ELECTRONIC TRANSMISSION OF REPORTS FROM PATHOLOGY LABORATORIES TO CENTRAL CANCER REGISTRIES

This section identifies recommendations to address basic issues in establishing electronic transmission of data from pathology laboratories to central cancer registries. These issues reflect a starting point for discussion between laboratories and central registries to assist and simplify data transmission. Both parties may have additional issues to incorporate as business rules.

- ❖ **Record Format:** Use of the "Text of NAACCR Pathology Laboratory Data and Record Format for Electronic Reporting to Central Cancer Registries" in Section 7 and the "Pathology Laboratory Data Table" in Section 8 for pathology laboratories reporting to central cancer registries is strongly encouraged.
- ❖ **Communication Protocol:** To facilitate standardization of electronic transmission, laboratories should submit reports to the requesting central cancer registry using HL-7 communication protocol, and central cancer registries should accept cases transmitted in the HL-7 format as specified in the *HL-7 Addendum*, Section 9. The Subcommittee also specifies a character-delimited format for registries and laboratories to use when HL-7 reporting is not feasible.
- ❖ **Narrative Diagnosis:** All reports transmitted to central cancer registries should contain text to support the coded diagnosis. Text should be segmented as specified in the *Text of NAACCR Pathology Laboratory Data and Record Format for Electronic Reporting to Central Cancer Registries*, *Pathology Laboratory Data Table*, and *HL-7 Addendum*.
- ❖ **File Transfer:** Laboratories and central cancer registries should work together to select the most appropriate method to transfer reports between the laboratories and registries. The most appropriate method of transfer may differ among laboratories, resulting in the need for central registries to be able to accept transmissions in more than one file-transfer method. Available options at this time include, but are not limited to, FTP, BBS, or the World Wide Web.

- ❖ **Report Selection:** Pathology laboratories and registries should negotiate various options for identifying which events or reports will be submitted to the requesting central cancer registry. Some registries will want all events/reports to be submitted, so that the registry can screen them for reportable diagnoses/conditions. In other situations, the registry and laboratory may need to define specific criteria (such as laboratory tests, diagnoses, or conditions) that will be used by the laboratory to select the events/reports to be submitted.
- ❖ **Frequency of Reporting:** Laboratories should submit reports to central cancer registries as often as possible. State reporting laws and regulations also must be considered when establishing frequency of reporting. The following schedule may be used as a guide; however, daily transmissions also are appropriate:
 - **Weekly Transmissions:** Laboratories with a report volume* ≥ 100 reports/week.
 - **Monthly Transmissions:** Laboratories with a report volume* ≤ 99 reports/week.

* Report volume refers to the number of pathology reports a laboratory completes regardless of diagnosis.
- ❖ **Data Security:** Central registries and laboratories should work together to develop security measures to reduce the risk of any breach of confidentiality. In establishing a security plan, specific issues including, but not limited to, the following should be addressed: access control, access to information, backup procedures, encryption of files, passwords, retention, archiving, and destruction of electronic information.
- ❖ **Duplicate Reports:** Laboratories should evaluate the criteria for report transmission to prevent duplicate report submission to central cancer registries.

SECTION 7: TEXT OF NAACCR PATHOLOGY LABORATORY DATASET AND RECORD FORMAT FOR ELECTRONIC REPORTING TO CENTRAL CANCER REGISTRIES

ADDR--CITY

Alternate Name	Item #	Length (Characters)	Source of Standard
City or Town	70	20	HL-7

Description:

Name of city in which the patient resides at the time the specimen was removed/collected. If the patient resides in a rural area, record the name of the city used in their mailing address. If the patient has multiple tumors, the city of residence may be different.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>Somewhere</i>	N	Left justify	Alpha only, no special characters, mixed case, blank filled
No data	Y	Populate to Unknown	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

ADDR--NO & STREET

Alternate Name	Item #	Length (Characters)	Source of Standard
Patient's Street Address	2330	40	HL-7

Description:

The number and street address or the rural address of the patient's residence at the time the specimen was removed/collected.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>1 Main Street</i>	N	Left justify	Alpha-numeric, mixed cases plus spaces, no punctuation
No data	Y	Populate to Unknown	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

ADDR--POSTAL CODE

Alternate Name	Item #	Length (Characters)	Source of Standard
ZIP Code	100	9	USPS

Description:

Postal code for the address of the patient's residence at the time the specimen was removed/collected. If the patient has multiple tumors, the postal code may be different. For U.S. ZIP codes, either the 5-digit or 9-digit extended ZIP code may be used. Blanks follow the 5-digit code. For Canadian residents, use the 6-character alpha-numeric postal code. When available, enter the postal code for other countries.

Special Codes:

999999999 Residence unknown.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>123455555</i>	N	Left justify	Alpha-numeric, no special characters, blank filled, embedded spaces allowed
No data	Y	999999999	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

ADDR--STATE

Alternate Name	Item #	Length (Characters)	Source of Standard
	80	2	HL-7

Description:

USPS abbreviation for the state (including U.S. territories, commonwealths, or possessions) or Canadian province/territory in which the patient resides at the time the specimen was removed/collected. If the patient has multiple tumors, the state of residence may be different.

Special codes:

ZZ Unknown.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>PA</i>	N		Alpha only, upper case
No data	Y	Populate with ZZ	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

BIRTH DATE

Alternate Name	Item #	Length (Characters)	Source of Standard
Date of Birth	240	8	

Description:

Date of birth of the patient.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
CCYYMMDD	Y	MMDDCCYY	
No data	Y	99999999	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

CPT CODES

Alternate Name	Item #	Length (Characters)	Source of Standard
	7380	5	AMA

Description:

Current Procedural Terminology (CPT) codes.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
88309	N		

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

DATE TRANSMITTED

Alternate Name	Item #	Length (Characters)	Source of Standard
	2110	8	NAACCR

Description:

Date the reports are transmitted from the facility to the central cancer registry (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
CCYYMMDD	Y	MMDDCCYY	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

LABORATORY CODES VERSION CONTROL TABLE

Alternate Name	Item #	Length (Characters)	Source of Standard
		5	

Description:

A table indicating the type/version of the code being submitted. The values indicated which SNOMED, ICD, CPT or other code version is being used.

Rationale:

It is anticipated that this list of standard codes may need local modification and additions to adequately capture the version of the codes transmitted from laboratories. Registries and laboratories are encouraged to use this list and make local modification as needed. A value from this table is anticipated to be transmitted with every code to indicate its version.

Note: The Laboratory Codes Version Control Table is not a data item. The table is a reference for all coded data within the pathology laboratory standard.

Allowable Values and Format:

Alpha-numeric.

Codes:

I9	ICD9
I9C	ICD9-CM
ICDO2	ICDO Second Edition
ICDO3	ICDO Third Edition
I10	ICD-10
C4	CPT-4
C5	CPT-5
I8	ICD 8
SNM	SNOMED Second Edition
SNM3	SNOMED International
SNT	SNOMED Topology
LN	LOINC
L	LOCAL Codes

MEDICAL RECORD NUMBER

Alternate Name	Item #	Length (Characters)	Source of Standard
	2300	11	NAACCR

Description:

Records medical record used by the facility to identify the patient.

Rationale:

This number identifies the patient in a facility. It can be used by a central registry to point to the patient record, and it helps identify multiple reports on the same patient.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>KP123456789</i>	N	Right justify	Alpha-numeric, or all blank
No data	Y	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

NAME--FIRST

Alternate Name	Item #	Length (Characters)	Source of Standard
Patient's First Name	2240	14	HL-7

Description:

First name of the patient (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>John</i>	N	Left justify	Alpha only, no embedded spaces, no special characters, blank filled

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

NAME--LAST

Alternate Name	Item #	Length (Characters)	Source of Standard
Patient's Last Name	2230	25	HL-7

Description:

Last name of the patient (required field—part of the minimum dataset).

Allowable Values:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>Smith</i>	N	Left justify	Alpha only, no embedded spaces, no special characters, blank filled, hyphens may be used

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

NAME--MIDDLE

Alternate Name	Item #	Length (Characters)	Source of Standard
Patient's middle name	2250	14	HL-7

Description:

Middle name or initial of the patient.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>Robert</i>	N	Left justify	Alpha
<i>R</i>	N	Left justify	Alpha
No data	N	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

ORDERING CLIENT/PHYSICIAN

Alternate Name	Item #	Length (Characters)	Source of Standard
	7200	50	

Description:

Name of the facility where specimen was removed/collected.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>Elm Cancer Center</i>	N	Left justify	Alpha only, no special characters
No Data	Y	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

ORDERING CLIENT/PHYSICIAN ADDR--CITY

Alternate Name	Item #	Length (Characters)	Source of Standard
	7150	20	

Description:

Name of the city of the physician's practice at the time the specimen was removed/collected. If the physician's practice is in a rural area, record the name of the city used in their mailing address (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>Hometown</i>	N	Left justify	Alpha-numeric, mixed case, blank filled

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

ORDERING CLIENT/PHYSICIAN ADDR--NO & STREET

Alternate Name	Item #	Length (Characters)	Source of Standard
	7140	25	

Description:

The number and street address or the rural or post office box address of the ordering physician's practice at the time the specimen was removed/collected. Also may include street direction (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>214 Center Street</i>	N	Left justify	Alpha-numeric, mixed case

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

ORDERING CLIENT/PHYSICIAN ADDR--POSTAL CODE

Alternate Name	Item #	Length (Characters)	Source of Standard
	7170	9	

Description:

USPS ZIP code for the state and city of the physician's practice at the time the specimen was removed/collected. May use either the 5-digit or 9-digit extended ZIP code. Blanks follow the 5-digit code. Canadian postal code is a 6-digit alpha-numeric format (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>543219999</i>	N	Left justify	Alpha-numeric, no imbedded blanks, blank filled

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

ORDERING CLIENT/PHYSICIAN ADDR--STATE

Alternate Name	Item #	Length (Characters)	Source of Standard
	7160	2	

Description:

USPS abbreviation for the state, commonwealth, or country where the physician's practice was at the time the specimen was removed/collected (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>PA</i>	N		Alpha only, no blanks allowed; use only officially designated abbreviations

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

ORDERING CLIENT/PHYSICIAN--LICENSE NUMBER

Alternate Name	Item #	Length (Characters)	Source of Standard
	7100	8	

Description:

License number of physician ordering analysis of the specimen.

Codes:

99999999 Physician unknown or ID number not assigned

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>D1234567</i>	N	Left justify	Alpha-numeric, no embedded blanks, blank filled
No data	Y	99999999	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

ORDERING CLIENT/PHYSICIAN--NAME

Alternate Name	Item #	Length (Characters)	Source of Standard
		50	

Description:

Last and first name of physician ordering analysis of the specimen (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>Jones</i>	N	Left justify	Alpha only, no special characters, may be initial only, space between names

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

ORDERING CLIENT/PHYSICIAN--TELEPHONE

Alternate Name	Item #	Length (Characters)	Source of Standard
	7180	10	

Description:

Telephone number of ordering physician's practice, including the area code.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>2334444567</i>	N	Left justify	Numeric, no embedded blanks, blank filled
No data	Y	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

ORDERING CLIENT/PHYSICIAN WORK FACILITY ADDR--CITY

Alternate Name	Item #	Length (Characters)	Source of Standard
	7220	20	

Description:

Name of the city of the facility where the specimen was removed/collected.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>Happy Valley</i>	N	Left justify	Alpha only, mixed case
No data	Y	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

ORDERING CLIENT/PHYSICIAN WORK FACILITY ADDR--NO & STREET

Alternate Name	Item #	Length (Characters)	Source of Standard
	7210	25	

Description:

The number and street address or the rural or post office box address of the facility where the specimen was removed/collected.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>2 Pine Street</i>	N	Left justify	Alpha-numeric, mixed case
No data	Y	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

ORDERING CLIENT/PHYSICIAN WORK FACILITY ADDR--POSTAL CODE

Alternate Name	Item #	Length (Characters)	Source of Standard
	7240	9	

Description:

USPS ZIP code for the state and city of the physician's practice at the time the specimen was removed/collected. May use either the 5-digit or 9-digit extended ZIP code. Blanks follow the 5-digit code. Canadian postal code is a 6-digit alpha-numeric format.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>987654444</i>	N	Left justify	Alpha-numeric, no imbedded blanks, blank filled
No Data	N	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

ORDERING CLIENT/PHYSICIAN WORK FACILITY ADDR--STATE

Alternate Name	Item #	Length (Characters)	Source of Standard
	7230	2	

Description:

USPS abbreviation for the state, commonwealth, or country of the facility where the specimen was removed/collected.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>PA</i>	N		Alpha only, no imbedded blanks, blank filled, used only officially designated abbreviations
No data	Y	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

ORDERING CLIENT/PHYSICIAN WORK FACILITY--TELEPHONE

Alternate Name	Item #	Length (Characters)	Source of Standard
	7250	10	

Description:

Telephone number of the facility where the specimen was removed/collected.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
2223334444	N	Left justify	Numeric, no imbedded blanks, blank fill
No Data	N	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

PATH--CLINICAL HISTORY

Alternate Name	Item #	Length (Characters)	Source of Standard
	7410		

Description:

Relevant clinical information, generally stating the patient's past history of cancer, preoperative diagnosis, and/or the reason the specimen was collected (required field—part of the minimum dataset).

Allowable Values and Format:

Alpha-numeric plus spaces, or all blank. No returns or line feeds are allowed within the text.

PATH--COMMENT SECTION

Alternate Name	Item #	Length (Characters)	Source of Standard
	7460		

Description:

Additional comments from the pathologist regarding situations such as the possible source of the metastases, comparison to previous specimens, the need for additional surgery or specimens, and the usefulness of additional stains/examinations, if applicable (required field—part of the minimum dataset).

Allowable Values and Format:

Alpha-numeric plus spaces, or all blank. No returns or line feeds are allowed within the text.

PATH--DATE OF SPECIMEN COLLECTION

Alternate Name	Item #	Length (Characters)	Source of Standard
	7320	8	

Description:

Date of specimen collection for the cancer being reported, not the date read or date the report was typed (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
CCYYMMDD	Y	MMDDCCYY	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

PATH--FINAL DIAGNOSIS

Alternate Name	Item #	Length (Characters)	Source of Standard
	7450		

Description:

Summarizes the microscopic findings for each specimen examined. Confirms or denies gross findings of malignancy, given the histologic type of the cancer and, in some instances, the grade (required field—part of the minimum dataset).

Allowable Values and Format:

Alpha-numeric plus spaces, or all blank. No returns or line feeds are allowed within the text.

PATH--GROSS PATHOLOGY

Alternate Name	Item #	Length (Characters)	Source of Standard
	7430		

Description:

A physical description of the gross appearance of the specimen, including source, size, color, unusual features, location of any lesions visible within the specimen, margins, markings placed by the surgeon, and labeling scheme used by the pathologist for assigning portions of the specimen to blocks or cassettes (required field—part of the minimum dataset).

Allowable Values and Format:

Alpha-numeric plus spaces, or all blank. No returns or line feeds are allowed within the text.

PATH--ICD VERSION NUMBER

Alternate Name	Item #	Length (Characters)	Source of Standard
	7370	5	

Description:

Indicator for the coding scheme used to ICD-CM code the diagnosis being reported.

Codes: See Laboratory Codes Version Control Table.

Allowable Values and Format:

Transmit Values*	Convert†	Registry Values	Description/Comments
I9C	Y	Right justify	Numeric
No Data	N	Blank	

* Used in flat file or HL-7 protocol.

† Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

PATH--ICD-CM CODE

Alternate Name	Item #	Length (Characters)	Source of Standard
	7360	6	

Description:

ICD-CM code for the diagnosis being reported.

Allowable Values and Format:

Transmit Values*	Convert†	Registry Values	Description/Comments
<i>146.0</i>	N	Left justify	Alpha-numeric, including decimal, ICDA-8, ICD-9, or ICD-10 codes
No Data	N	Blank	

* Used in flat file or HL-7 protocol.

† Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

PATH--MICROSCOPIC PATHOLOGY

Alternate Name	Item #	Length (Characters)	Source of Standard
	7440		

Description:

Findings and description of the presence or absence of disease in each section of the specimen(s). Generally include the types of tissues, cells, or mitotic activity observed (required field—part of the minimum dataset).

Allowable Values and Format:

Alpha-numeric plus spaces, or all blank. No returns or line feeds are allowed within the text.

PATH--NATURE OF SPECIMEN

Alternate Name	Item #	Length (Characters)	Source of Standard
	7420		

Description:

Describes the site(s) and laterality of the specimen(s). If there is more than one specimen included on the pathology report, each is generally assigned an identifying letter or numeral, beginning with “A,” “1,” or “I” (required field—part of the minimum dataset).

Allowable Values and Format:

Alpha-numeric plus spaces, or all blank. No returns or line feeds are allowed within the text.

PATH--ORDERING CLIENT/PHYSICIAN

Alternate Name	Item #	Length (Characters)	Source of Standard
	7190	25	

Description:

Facility ID number as defined by the American Hospital Association (AHA).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>230012</i>	N	Left justify	Alpha-numeric, blank filled
No Data	Y	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

PATH--PATHOLOGIST LICENSE NUMBER

Alternate Name	Item #	Length (Characters)	Source of Standard
	7300	8	

Description:

The reporting pathologist's license number for the state, commonwealth, or country for which the pathologist is licensed to practice in the laboratory reporting this cancer case.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
88888888	N	Left justify	Alpha-numeric
No data	N	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

PATH--PATHOLOGIST STATE LICENSURE

Alternate Name	Item #	Length (Characters)	Source of Standard
	7310	2	

Description:

Two-digit USPS abbreviation for the state, commonwealth, or country associated with the pathologist license number in which the reporting pathologist is licensed. If a commonly accepted 2-letter abbreviation does not exist for the country, leave blank.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>PA</i>	N		Alpha only, upper case or all blank
No Data	N	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

PATH--PATIENT AGE AT SPECIMEN

Alternate Name	Item #	Length (Characters)	Source of Standard
	7080	10	

Description:

The age of patient at the time of the specimen sample. Large block is designed to handle unstructured age information.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
75	Y	075	Numeric, right justify zero fill
<i>85 years</i>	Y	085	
<i>24 months</i>	Y	002	
No data	Y	999	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y= Yes, N= No
Italics indicate an example.

PATH--REPORT TYPE

Alternate Name	Item #	Length (Characters)	Source of Standard
	7480	2	

Description:

This variable is a derived (and somewhat arbitrary) classification to be calculated at the cancer registry. It can be derived from several information sources.

Rationale:

This variable is primarily used for administrative and tracking purposes at the cancer registry. Often, laboratories will classify the specimen in the slide or path number; for example, the first digit of the slide number will indicate pathology (P) or cytology (C). Laboratories also may categorize or recycle these slides or path numbers according to a specific year. It also may be derived from a specimen source type code, the institutional number, tag, or laboratory title from which the laboratory results came.

Codes:

- 01 Pathology
- 02 Cytology
- 03 Gyn Cytology
- 04 Bone Marrow
- 05 Autopsy
- 06 Clinical Laboratory Blood Work
- 07 Eye
- 98 Other
- 99 Unknown

PATH--REPORTING PATHOLOGIST LAST NAME

Alternate Name	Item #	Length (Characters)	Source of Standard
	7260	25	

Description:

The reporting pathologist's last name.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>Smith</i>	N	Left justify	Alpha only, no special characters
No data	N	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

PATH--REPORTING PATHOLOGIST FIRST NAME

Alternate Name	Item #	Length (Characters)	Source of Standard
	7270	14	

Description:

The reporting pathologist's first name.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>David</i>	N	Left justify	Alpha only, no special characters
No data	N	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

PATH--REPORTING PATHOLOGIST MIDDLE NAME

Alternate Name	Item #	Length (Characters)	Source of Standard
	7280	14	

Description:

The reporting pathologist's middle initial.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>F</i>	N	Left justify	Alpha only, no special characters
No data	N	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

PATH--REPORTING PATHOLOGIST SUFFIX

Alternate Name	Item #	Length (Characters)	Source of Standard
	7290	3	

Description:

The reporting pathologist's name suffixes (if any).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>Jr</i>	N	Left justify	Alpha only, no special characters
No data	N	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

PATH--SLIDE REPORT NUMBER

Alternate Name	Item #	Length (Characters)	Source of Standard
	7090	20	

Description:

Unique sequential number assigned to a report by a laboratory (required field—part of minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>S98012345</i>	N	Left justify	Alpha-numeric

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

PATH--SNOMED CODE(S)

Alternate Name	Item #	Length (Characters)	Source of Standard
	7340	18	

Description:

The Systematized Nomenclature of Medicine (SNOMED) code(s) for the encounter being reported may include morphology, topography, and procedure codes.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>M-8140</i>	N	Left justify	Alpha-numeric
No Data	N	Blank	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

PATH--STATUS INDIVIDUAL RESULT

Alternate Name	Item #	Length (Characters)	Source of Standard
	7330	1	

Description:

Code reflecting verification to a specific individual reported result (required field—part of the minimum dataset).

Codes:

C	Record coming over is a correction and thus replaces final result
D	Deletes the record
F	Final results; can only be changed with a corrected result
I	Specimen in laboratory; results pending
P	Preliminary results
R	Results entered—not verified
S	Partial results
X	Results cannot be obtained
U	Results status change to Final, without retransmitting results already sent as Preliminary
W	Post original as wrong

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
F	N		Alpha

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

PATH--SUPPLEMENTAL REPORTS AND/OR ADDENDA

Alternate Name	Item #	Length (Characters)	Source of Standard
	7470		

Description:

Additional information attached to the pathology report, generally after the original report has been issued. May address subsequent testing or stains, comparison with previous specimens, second opinions from other pathologists or laboratories, or a change in diagnosis resulting from reexamining the specimen(s) or sampling new areas within the specimen (required field—part of the minimum dataset).

Allowable Values and Format:

Alpha-numeric plus spaces, or all blank. No returns or line feeds are allowed within the text.

PATH--TEXT DIAGNOSIS

Alternate Name	Item #	Length (Characters)	Source of Standard
	7400	45k	

Description:

If text cannot be separated into the categories below, use this field for free text including, at a minimum, text to support site, laterality, histology (pathology diagnosis, notes, comments, and differential diagnosis), and stage (required field—part of the minimum dataset).

Allowable Values and Format:

Alpha-numeric plus spaces, or all blank. No returns or line feeds are allowed within the text.

PATH--VERSION NUMBER

Alternate Name	Item #	Length (Characters)	Source of Standard
	7000	6	

Description:

Designation of the layout of the message structure (required field—part of the minimum dataset).

Codes:

2.3 HL-7 2.3 file layout

1 1999 flat file layout

Allowable Values and Format:

Transmit Values	Convert*	Registry Values	Description/Comments
2.3 [†]	N	2.3, left justify	Alpha-numeric
1 [‡]	N	1, left justify	

* Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

[†] Used in HL-7 protocol.

[‡] Used in flat file.

RECORD TYPE

Alternate Name	Item #	Length (Characters)	Source of Standard
	10	1	NAACCR

Description:

Generated field length that identifies which of the NAACCR data exchange record types is being used in a file of data exchanges records. A batch should have records of only one type. This item is addressed by the Central Registry (required field—part of the minimum dataset).

Codes:

L Pathology laboratory record type. Includes narrative diagnosis.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
L	N	L	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

REPORTING FACILITY

Alternate Name	Item #	Length (Characters)	Source of Standard
Institution ID Number	7010	25	

Description:

Code for the pathology facility reporting the case (required field—part of the minimum dataset).

Codes:

Clinical Laboratory Improvement Act Identification Numbers (CLIA) are used for laboratory reporting.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>39D0903558</i>	N	Left justify	Alpha-numeric

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

REPORTING FACILITY ADDR--CITY

Alternate Name	Item #	Length (Characters)	Source of Standard
	7040	20	

Description:

Name of the city of reporting pathology facility (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>Anytown</i>	N	Left justify	Alpha-numeric, mixed case, left justified

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

REPORTING FACILITY ADDR--NO & STREET

Alternate Name	Item #	Length (Characters)	Source of Standard
	7030	25	HL-7

Description:

The number and street address or rural address of the reporting pathology facility (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>2 Pine Street</i>	N	Left justify	Alpha-numeric, mixed case, left justified

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

REPORTING FACILITY ADDR--POSTAL CODE

Alternate Name	Item #	Length (Characters)	Source of Standard
	7060	9	

Description:

USPS ZIP code for the state and city in which the pathology facility resides. May use either the 5-digit or 9-digit extended ZIP code. Blanks follow the 5-digit code. Canadian postal code is a 6-digit alpha-numeric format (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>123452222</i>	N	Left justify, blank filled	Alpha-numeric

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

REPORTING FACILITY ADDR--STATE

Alternate Name	Item #	Length (Characters)	Source of Standard
	7050	2	

Description:

USPS abbreviation for the state, commonwealth, or country of the reporting pathology facility (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>PA</i>	N		Alpha only, upper case, no blanks allowed

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

REPORTING FACILITY NAME

Alternate Name	Item #	Length (Characters)	Source of Standard
	7020	50	Reporting Facility

Description:

Name of the reporting pathology facility (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>Test Laboratory</i>	N	Left justify	Alpha-numeric, mixed case

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

REPORTING FACILITY--PHONE NUMBER

Alternate Name	Item #	Length (Characters)	Source of Standard
	7070	10	

Description:

Telephone number of the reporting pathology facility (required field—part of the minimum dataset).

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>2125551234</i>	N	Left justify	Numeric, no imbedded blanks, blank filled

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No
Italics indicate an example.

SEX

Alternate Name	Item #	Length (Characters)	Source of Standard
	220	1	

Description:

Code for sex of the patient.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
M	Y	1	Male
F	Y	2	Female
O	Y	3	Other
U	Y	9	Unknown

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

SOCIAL SECURITY NUMBER

Alternate Name	Item #	Length (Characters)	Source of Standard
	2320	9	

Description:

Records patient's social security number. The number is entered without dashes and without any letter suffix. This is not always identical to the Medicare claim number.

Special codes:

999999999 Unknown.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
<i>123456789</i>	N		Alpha-numeric
No data	Y	999999999	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

STAGING PARAMETERS

Alternate Name	Item #	Length (Characters)	Source of Standard
	2600		

Description:

Information to aid in assigning a stage to each cancer. Commonly includes a discussion of tumor size and spread, lymph node involvement, metastasis, and pathologic AJCC stage (required field—part of the minimum dataset).

Allowable Values and Format:

Alpha-numeric plus spaces, or all blank. No returns or line feeds are allowed within the text.

TELEPHONE

Alternate Name	Item #	Length (Characters)	Source of Standard
	2360	10	HL-7

Description:

Current telephone number with area code for the patient.

Allowable Values and Format:

Transmit Values*	Convert [†]	Registry Values	Description/Comments
2223245555	N		Numeric
No data	Y	999999999	

* Used in flat file or HL-7 protocol.

[†] Is it necessary to convert this item to match the NAACCR standards for this data item? Y = Yes, N = No

Italics indicate an example.

SECTION 8: PATHOLOGY LABORATORY DATA TABLE**Format Table: HL-7 Location and Pipe-Delimited Flat File Location.**

Data Item Name/ Corresponding NAACCR Name	Field Require- ment	Data Item #	HL-7 Location Name Field ID See HL-7 Note	Field Length	Flat File Field[@]
Record Type	S	10	Specified by Receiving Software	1	1
Path Version Number	S	7000	Specified by Translation Software	6	2
Path Facility ID Number (CLIA Number)	R	7010	BHS 4/Batch Sending Facility	25	3
Laboratory Name	R	7020	BHS 10/Batch Comment	50	4
Street	R	7030	BHS 10/Batch Comment	25	5
City	R	7040	BHS 10/Batch Comment	20	6
State/Province	R	7050	BHS 10/Batch Comment	2	7
ZIP Code/Postal Code	R	7060	BHS 10/Batch Comment	9	8
Telephone Number	R	7070	BHS 10/Batch Comment	10	9
Patient Name					
Last Name	R	2230	PID 5/Patient Name Component	25	10
First Name	R	2240	PID 5/Patient Name Component	14	11
Middle Name	S	2250	PID 5/Patient Name Component	14	12
Patient Address					
Street	S	2330	PID 11/Patient Address Component	40	13
City/Town	S	70	PID 11/Patient Address Component	20	14
State/Province	S	80	PID 11/Patient Address Component	2	15
ZIP Code/Postal Code	S	100	PID 11/Patient Address Component	9	16
Patient Telephone Number	S	2360	PID 13/Home Phone	10	17
Date Of Birth	S	240	PID 7/Date of Birth	8	18
Path--Age At Specimen	S	7080		10	19
Social Security Number	S	2320	PID 19/Patient SSN	9	20
Sex	S	220	PID 8/Sex	1	21
Medical Record Number	S	2300	PID 3/Internal Patient ID	11	22
Path--Slide/ Pathology Report Number	R	7090	OBR 3/Filler Order Number	20	23
Path Ordering Client/Physician (Attending)					
License Number/Physician (Attending)	S	7100	OBR 16/Contact Identifier ^A	8	24
Last Name	R	7110	OBR 16/Contact Name ^A	25	25
First Name	R	7120	OBR/Name Component ^A	14	26
Middle Name	R	7130	OBR/Name Component ^A	14	27
Street	R	7140	OBR 47/Contact Address ^A	25	28

Data Item Name/ Corresponding NAACCR Name	Field Require- ment	Data Item #	HL-7 Location Name Field ID See HL-7 Note	Field Length	Flat File Field [@]
City	R	7150	OBR 47/Contact Address ^A	20	29
State/Province	R	7160	OBR 47/Contact Address ^A	2	30
ZIP/Postal Code	R	7170	OBR 47/Contact Address ^A	9	31
Telephone Number	S	7180	OBR 17/Contact Phone Number ^A	10	32
Path--Work Facility ID Number (AHA Number)	S	7190	OBR 16/Provider Identifier Components	25	33
Name	S	7200	OBR 44/Provider Name ^A	50	34
Street	S	7210	OBR 45/Provider Address ^A	25	35
City	S	7220	OBR 45/Provider Address ^A	20	36
State/Province	S	7230	OBR 45/Provider Address ^A	2	37
ZIP/Postal Code	S	7240	OBR 45/Provider Address ^A	9	38
Telephone Number	S	7250	OBR 46/Provider Phone Number ^A	10	39
Path--Reporting Pathologist Last Name	S	7260	OBR 32/Principal Result Interpreter Component	25	40
Path--Reporting Pathologist First Name	S	7270	OBR 32/Principal Result Interpreter Component	14	41
Path--Reporting Pathologist Middle Name	S	7280	OBR 32/Principal Result Interpreter Component	14	42
Path--Reporting Pathologist Suffix	S	7290	OBR 32/Principal Result Interpreter Component	3	43
Path--Pathologist License Number	S	7300	OBR 32/Principal Result Interpreter Component	8	44
Path--Pathologist State Licenser	S	7310	OBR 32/Principal Result Interpreter Component	2	45
Path--Date Of Specimen Collection	R	7320	OBR 7/Observation Date/Time	8	46
Path--Status Individual Result	S	7330	OBX 11/Status Code	1	47
Path--SNOMED Code(s) ^C	S	7340	OBX 5/Observation Value**	18 (x 15 Sets)	48
Path--SNOMED Version Control ^D	S	7350	OBX 5/Observation Value 3rd Component	5	49
Path--ICD Code	S	7360	OBX 5/Observation Value**	10 (x 6 Sets)	50
Path--ICD Revision Number Code Version Control ^D	S	7370	OBX 5/Observation Value 3rd Component	5	51
Path--CPT Code	S	7380	OBX 5/Observation Value**	5 (x 3 Sets)	52
Path--CPT Code Version Control ^D	S	7390	OBX 5/Observation Value 3rd Component	5	53

Data Item Name/ Corresponding NAACCR Name	Field Require- ment	Data Item #	HL-7 Location Name Field ID See HL-7 Note	Field Length	Flat File Field [@]
Narrative Diagnosis					
Path--Text-Diagnosis If text cannot be separated into categories below, use this field for free text.	R	7400	OBX 5/Observation Value**	44.8k	54
Path--Clinical History	R	7410	OBX 5/Observation Value**		55
Path--Nature Of Specimen	R	7420	OBX 5/Observation Value**		56
Path--Gross Pathology	R	7430	OBX 5/Observation Value**		57
Path--Microscopic Pathology	R	7440	OBX 5/Observation Value**		58
Path--Final Diagnosis	R	7450	OBX 5/Observation Value**		59
Path--Comment Section	R	7460	OBX 5/Observation Value**		60
Path--Supplemental Reports And/Or Addenda	R	7470	OBX 5/Observation Value**		61
Path--Staging Parameters	R	2600	OBX 5/Observation Value**		62
Date Transmitted/Date Case Transmitted	R	2110	Generated by the Laboratory at the Time the File is Written	8	63
Path--Report Type	R	7480	Calculated Upon Receipt of File	2	N/A

[@] Refers to a pipe delimited flat file exchange.

“|” The pipe-delimited standard can be used to separate variables without truncating large text fields. The first variable, Record Type, will begin as the first position of a flat file exchange. For example, L|Next field 2-Path Version number|Next field 3- Facility ID|, etc. If no data are available for a specific variable, laboratories and registries are encouraged to truncate the value to null/nothing, so that there are just two pipe symbols in a row.

Missing information for dates can be truncated as necessary, for example, |199901| would be a date referring to January 1999. The full date |19990124| would refer to January 24, 1999.

Field Requirement Definitions: R = Required data items S = Supplementary recommended data items

** OBX 5, observation value, is used for all of these fields. It is part of a repeating segment that would occur once for each of these fields to be transmitted for a single case. Another field, OBX 3, indicates which field is being transmitted in each OBX segment. Standard identifier codes (such as LOINC codes) should be used in the associated OBX 3 field to identify the categories of descriptive text. Please see <http://www.mcis.duke.edu/standards/termcode/loinc.htm> for a description of LOINC codes. These also can be downloaded from the site.

CH Clinical History LOINC Code: 22636-5

NS Nature of Specimen LOINC Code: 22633-2

GP Gross Pathology LOINC Code: 22634-0

MP Microscopic Pathology LOINC Code: 22635-7

FD Final Diagnosis LOINC Code: 22637-3

CM Comment Section LOINC Code: 22638-1

SR Supplemental Reports/Addendum LOINC Code: 22639-9

PR Staging Parameters LOINC Code: 22640-7

Example:

GN General laboratory report, used if report text is stored in such a way that it may not be broken down into above categories.

^A Question HL-7 Structure. These items may be changing due to evolution of the HL-7 standard, specifically inclusion of these items into different HL-7 segments. See HL-7 2.3.1 for new additions.

^B Age at specimen can be handled several different ways in HL-7.
OBX level Option 1 OBX||21612-7^Age^LN||32|yr

^C Registries and laboratories are encouraged to negotiate the ordering and grouping of SNOMED codes. SNOMED codes are assumed to be submitted in sets of 3 (a morphology, topography, and procedure code), but this assumption may not apply to all laboratories. The central registry and laboratory must coordinate and negotiate how the SNOMED codes will be grouped and submitted. It is suggested that, if the SNOMED codes are grouped (M, T, and P together), a ^ or other character be used to delimit different groupings of codes within the allocated area. This space anticipates up to 15 sets of (or 45 individual) SNOMED codes. Morphology codes are written MXXXXXX for a total of 7 characters with position 6 as Behavior and position 7 as Grade, Procedures are written PXXXXX for a total of 5 characters, and Topography codes are written TXXXXX for a total of 6 characters.

^D Please refer to the Version Control Table.

HL-7 note: The application of HL-7 in laboratory reporting in cancer registration involves several technical challenges and will require additional documentation and expertise beyond what this section can provide. Registries and laboratories should use this chapter as a general guide. Actual HL-7 implementation may require specific vendor input and reference to materials published by HL-7 (specifically Section 7) or other documents.

SECTION 9: HL-7 ADDENDUM

Reporting to Cancer Registries Using the HL-7 Conventions for the Unsolicited Transmission of Messages

A file header segment (FHS) should be the first segment of any transmission. Data within the FHS identify the laboratory transmitting the data. After the FHS are any number of batch header segments (BHS). A batch (a group of messages) follows each batch header, and contains the data to be reported for a single laboratory. These data take the form of a series of Observational Result—Unsolicited (ORU) messages. There is one ORU message per patient being reported. This section describes the general location of the information within the structure of the ORU HL-7 style message. Future reporting standardized formats comprehensively applying the use of the HL-7 ORU message are being examined by NAACCR to include reporting from laboratories as well as use of the HL-7 standard in a hospital setting.

SECTION 10: FREQUENTLY ASKED QUESTIONS ABOUT PATHOLOGY REPORTING

This section is provided as a resource for registries to use when initiating and dealing with laboratory reporting activities. The responses to these questions are compiled from central registries active in the laboratory-reporting arena.

1. What are the resources to assist in developing a list of pathology laboratories in your state?
 - State health departments
 - CLIA lists
 - Hospital registrars
 - Registry field staff
 - State pathology associations (<http://www.cap.org/html/member/statepath.html>).
2. Do you have any sample contact letters or surveys that you used to solicit laboratory reporting of cancer data to the cancer registry?
 - See Figures 1–6 at the end of this chapter for sample letters and surveys.
3. What types of challenges have you encountered in identifying laboratories or in working with them?
 - Challenges identifying laboratories:
 - Unable to distinguish between anatomic and clinical diagnoses
 - Survey will provide information as far as caseload, electronic transmission capabilities, etc.
 - Challenges working with:
 - The two major laboratories reporting to Pennsylvania insisted on having the system call them on a scheduled basis instead of their system calling Pennsylvania, and would not agree to use a BBS.
 - SmithKline had text formatting issues requiring additional programming. Their text is saved in 100-character chunks.
 - Differences in data formats.
 - Lack of programmer time at the laboratories.
 - The need to develop mechanisms to verify that all reports are being sent.
 - Confidentiality issues.
4. Describe the reportable cancer conditions in your state. Are these listed in your legislation and regulations?
 - Many states use the SEER Program Code Manual, Third Edition, January 1998.
 - Some are investigating SNOMED codes.

5. Describe the process (or diagrams) for moving different types of pathology laboratory records into a database. How do you link to the master database tables/files? How have you tested this process?

Here is one example:

- Private pathology specimens are received through the Pathology Laboratory Reporting System developed with assistance from the Pathology Laboratory Subcommittee of NAACCR.
 - Hospital pathology specimens (both hospital patient specimens and private outpatient specimens) are reported through the hospital tumor registrar or the department responsible for reporting to the Pennsylvania Cancer Registry.
 - Registrars submit a full abstract on all pathology specimens based on services received at their hospital.
 - If they only have a private outpatient (POP) specimen for a patient and no other information, they report the case with whatever information they have available. Hospitals are instructed to hold POPs for at least 3 months to wait and see if the patient is admitted to the hospital.
 - Private pathology cases are currently maintained in a separate database. Procedures are being developed to add them to the master database.
 - Procedures are being developed to follow-up on POP specimens not matched with a hospital abstract.
6. When your state initiated laboratory reporting, what type of pilot testing did you perform?
- Initiated work groups with independent pathology laboratories.
7. What are your procedures for handling nonreportable conditions? Do you retain the nonreportable records or destroy them?
- Nonreportable conditions received through the Pathology Laboratory Reporting System can be archived and deleted after a specified number of days. POP specimens are returned to the hospital.
8. List the key partners in your organization for electronic laboratory reporting beyond cancer (examples: tuberculosis program or other communicable diseases program).
- Possibilities include the Division of Communicable Disease Epidemiology at your state health department.
 - Pathology associations.

9. What are the benefits and challenges of collaborating with these partners?
 - Benefit: can work with the same laboratories and develop a common mechanism for laboratories to electronically report all state-required diseases.
 - Challenges: different types of information needed by the different groups, different time requirements.
10. How do you solicit involvement from laboratory organizations to facilitate the electronic reporting of pathology reporting in your state?
 - In Minnesota, a request for proposals was established in 1990 to provide funds for facilities to report electronically. Most facilities that applied chose to start a hospital cancer registry. One pathology laboratory chose to submit its pathology reports electronically.
 - Iowa utilized telephone calls followed by a letter. They also had a respected Iowa pathologist contact the laboratory pathologist to solicit support.
11. Describe the percentage of reports processed through a laboratory reporting mechanism that result in a reportable condition.
 - Estimates for individual laboratories range from 12 percent to 30 percent.
- 12a. What are the national private laboratories that currently report electronically to central registries?
 - SmithKline/Quest Diagnostics
 - Laboratory Corp
 - Tamtron.
- 12b. What are the laboratory information systems that registries have used?
 - Co-Path
 - Cerner
 - SunQuest.
13. Describe the experience of your registry in using the pathology information as a source of follow-up or tracking.
 - Washington gets follow-up information from path linkages (including PAP smears).
14. What issues concerning confidentiality have arisen as a result of pathology laboratory reporting?
 - Concerns about reporting of nonreportable conditions.
 - Concerns from out-of-state laboratories that are not covered by state statutes.

15. How do you follow-up on reports with missing demographics? If you have sample letters or forms, please supply them.
 - See Figure 3 at the end of this chapter for a sample.
16. How do you confirm medical information (primary site, histology, date of diagnosis, etc.) when a laboratory report does not link to a more complete source record? If you have sample letters or forms, please supply them.
 - See Figure 3 at the end of this chapter for a sample.

FIGURE 1: SAMPLE LETTER TO ESTABLISH PATHOLOGY LABORATORY REPORTING

Dear Dr. XXXXX:

This letter is in regard to our recent telephone conversation regarding the identification and data collection of cancer cases at the Physicians Laboratory of Northwest Iowa in XXXXXX, IA. As we discussed, it is the desire of the State Health Registry of Iowa (SHRI) to obtain cancer patient pathology information from this laboratory that has been previously unavailable.

The Iowa Department of Public Health has designated the Registry as the repository for reportable cancer data in Iowa. Registry field staff collect the data during regular visits to hospitals, clinics, and numerous pathology laboratories throughout Iowa and neighboring states where Iowans receive care. It is known from previous studies done by the Registry that pathology laboratories, not located in hospital settings, are a resource of pathology reports for melanomas, cervix *in situ*, prostate, and CLL diagnoses. As health care delivery for the cancer patient has evolved into more outpatient care, the case ascertainment of some cancer data in the Registry has been slowly migrating from the traditional hospital setting.

In an attempt to improve data collection and ascertainment of not only melanoma cases but also all invasive and noninvasive cancer cases, we are requesting that Sue XXXX, field representative for the XXXXXX area, be allowed monthly access to the laboratory reports. Registry field personnel are highly trained professionals with extensive experience in reviewing pathology reports. Sue will contact the laboratory staff to make the necessary arrangements and will review all laboratory reports, looking for only those cases that have not been identified from another source, such as a hospital or outpatient clinic.

Enclosed for your review is the most recent report from the Registry, *Cancer In Iowa, 1998*, and a copy of the Registry's confidentiality policy and pledge. The Iowa Department of Public Health has approved this mechanism for the compliance with State of Iowa-mandated reporting of all cancers.

If you have any questions, please contact me at (319) 356-2986, or the Registry Administrative Director, Kathleen M. McKeen, at (319) 335-8609.

Sincerely,

Charles E. Platz, M.D.
Professor, Pathology
Investigator, Iowa Cancer Registry

Enclosures

cc: Roxy XXXXXX, M.D.
Kathleen M. McKeen
Chuck Lynch, M.D.
Sue XXXXX

FIGURE 2: SAMPLE LETTER TO ESTABLISH PATHOLOGY LABORATORY REPORTING

Dear Ms. XXXXX:

As we discussed on the telephone on Thursday, February 11, I am requesting your assistance with the ascertainment of newly diagnosed urological cancer cases among Iowans.

Cancer is reportable in the State of Iowa and the State Health Registry of Iowa (SHRI) has been designated by the Iowa Department of Public Health as the repository for cancer data in Iowa. In addition, the Iowa Cancer Registry is a member of the prestigious National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Cancer data are gathered through arrangements with hospitals, pathology laboratories, and numerous physicians' offices throughout the State of Iowa or in neighboring states where Iowans receive their care, and from vital records mortality files.

We are requesting copies of pathology reports for all Iowans with invasive and *in situ* cancers. Enclosed is a list of terms that represent a reportable cancer. In addition to the pathology report, we would also like personal identifiers for the cancer patient that would help us link with another report we may have in the Registry from another source. Please complete the patient form and attach it to the appropriate pathology report. We realize this information may or may not always be available.

I suspect going back in time will be more difficult to identify pathology reports for Iowans, but it would be extremely helpful to receive reports for earlier years. If you are unable to supply information for those earlier years, it would be desirable to begin with January 1998 and forward into 1999.

As we discussed, you would prefer to fax the reports to the Iowa Registry. Please send them to my attention: Kathleen M. McKeen, at fax number (319) 335-8610.

In addition, I would also like you to discuss the possibility of an electronic transfer of the pathology report with your computer data systems staff. We have several options available to us here for receiving your data electronically. Gary XXXXX from our data processing staff would be more than willing to discuss these options with UroCor data systems staff. Gary's phone number is (319) XXX-XXXX.

Enclosed is a copy of the Iowa Administrative Code along with a recent publication from the Registry. If you have any questions, please give me a call at (319) 335-8508, or you may call the Registry Medical Director, Chuck Lynch, M.D., Ph.D. at (319) 335-9633.

Sincerely,

Kathleen M. McKeen
Registry Director

Enclosures
cc: Chuck Lynch, M.D., Ph.D.

FIGURE 3: SAMPLE LETTER TO OBTAIN ADDITIONAL PATIENT INFORMATION

Dear XXXXX:

I am requesting your assistance in obtaining additional pertinent information regarding your patient(s) contained on the enclosed form(s). The information we recently received from a pathology laboratory report is extremely vague and will not allow us to identify, reconcile, or consolidate other reports we might have received from another source. We would appreciate it if your staff would complete the **missing information** and correct any **misinformation** contained on the form(s).

As you probably already know, the Iowa Department of Public Health has designated this Registry as the repository for reportable cancer data in Iowa. The data are collected from hospitals, surgery centers, and numerous pathology laboratories throughout Iowa and neighboring states where Iowans receive care.


It is known from previous studies performed by the Registry that pathology laboratories not located in hospital settings are a vital resource of pathology reports for melanomas, cervix *in situ*, prostate, and CLL diagnoses. As health care delivery for the cancer patient has evolved into more outpatient care, the case ascertainment of some cancer data in the Registry has been slowly migrating from the traditional hospital setting.

Unfortunately, many of the pathology laboratory-reported cases do not contain patient-specific, personal identifying information, and as a result, vital pieces of information are incomplete. Frequently, the only information received is the patients' name and the physician who referred the specimen to the laboratory. With only these variables, computerized linkage within the Registry's large database is nearly impossible.

Your help is extremely important and will provide us with the information we require for maintaining a high quality Cancer Registry program of all Iowans.

Thus, we are requesting you complete the enclosed forms and return them in the enclosed, postage-paid envelope(s) at your earliest convenience. If you have any questions, please contact me at (319) 335-8609. We appreciate your assistance and thank you in advance for your help in this important program.

Sincerely,



Kathleen M. McKeen
Registry Director

Enclosures

FIGURE 4: SAMPLE FOLLOW-UP LETTER TO PHYSICIAN

Doctor:
Case #:
Patient:
Date of Birth:
Cancer Type:
Diagnosis Date:

Minnesota Cancer Surveillance System
717 Delaware Street, S.E.
Minneapolis, MN 55414

Based on Minnesota Statutes 144.671-69, the Minnesota Cancer Surveillance System (MCSS) collects cancer data on all Minnesota residents. The majority of cases reported to MCSS are complete. A physician's office is contacted only if missing or discrepant data are not available from a hospital medical record or a Cancer Registry. The above patient still requires some data items. Please complete the information checked below and return this form in the enclosed business reply envelope (even if the patient is deceased). Thank you!

DEMOGRAPHICS:

Social Security Number: _____

Address at Diagnosis: _____
(Street) (City/State/ZIP)

Birthdate: _____

Race: _____

*** * IF THE PATIENT DID NOT LIVE IN MINNESOTA AT THE TIME OF DX, STOP HERE * ***

TUMOR INFORMATION:

Date of Diagnosis: _____

Primary Site: _____

Histology: _____

STAGE OF DISEASE AT DIAGNOSIS (Doctor should complete):

T _____ N _____ M _____ Stage _____ Clinical or Pathologic? (circle one)

INITIAL CANCER-DIRECTED THERAPY (Doctor should complete):

SURGICAL PROCEDURE: _____

Date: _____

RADIATION THERAPY: Type: _____

Date Started: _____

CHEMO/HORMONE/IMMUNOTHERAPY:

Date(s) started: _____

Drug name(s): _____

ADDITIONAL INFORMATION NEEDED: _____

If you have any questions, please call (612) 676-5216. Thank you very much for your continued cooperation with MCSS.

Sincerely,

Minnesota Cancer Surveillance System

FIGURE 5: SAMPLE SURVEY TO LABORATORIES SOLICITING INFORMATION ABOUT ABILITY TO CARRY OUT LABORATORY REPORTING

Pennsylvania Cancer Registry
Division of Health Statistics

Pathology Laboratory Questionnaire

*Please complete and return this questionnaire to the Division of Health Statistics, Pennsylvania Department of Health, 555 Walnut Street - 6th Floor, Harrisburg, PA, 19101, in the enclosed postage-paid envelope no later than **Date**. The response also may be faxed to Wendy Aldinger at (717) 772-3258. Please answer the questions by checking the correct response or entering the information in the space provided.*

I. Laboratory Information:

Is the following information correct?

☐ Yes ☐ No

If No, indicate any changes in the space provided.

Director: _____

Address: _____

Telephone Number: _____

II. Electronic Data System Functions:

A. Are your pathology reports maintained electronically?

☐ Yes ☐ No

If No, are there future plans for implementing an electronic system?

☐ Yes ☐ No

If Yes, when? _____

If no electronic pathology report system currently is in place, please skip to Section III.

B. Does your laboratory use vendor-provided software or in-house-developed software for your clinical information?

☐ Vendor ☐ In-house

If Vendor, please supply following information:

Company Name: _____

Address: _____

Telephone Number: _____

Contact Person: _____

- C. Are all specimen types included in your laboratory's electronic pathology report system? ☐ Yes ☐ No

If No, what types are not included? _____

- D. Is your laboratory's billing information maintained electronically? ☐ Yes ☐ No

- E. Does your laboratory use vendor-provided software or in-house-developed software for your billing information? ☐ Vendor ☐ In-house

If Vendor, please supply following information (if different than vendor listed in II.B.):

Company Name: _____

Address: _____

Telephone Number: _____

Contact Person: _____

- F. Is your laboratory able to transmit pathology reports in the HL-7 format? ☐ Yes ☐ No

If No, is your laboratory able to submit in a fixed-column ASCII file? ☐ Yes ☐ No

- G. Is your laboratory able to transmit files through a direct-dial into a firewall-protected FTP server at the Pennsylvania Department of Health? ☐ Yes ☐ No

- H. Does your laboratory have an FTP server the Pennsylvania Department of Health can dial into to pick up files? ☐ Yes ☐ No

- I. Is your laboratory able to submit files on diskette? ☐ Yes ☐ No

III. Specimen Information:

- A. What type of pathology specimens does your laboratory process?

Type	√ if Yes	Average # per year	Average # with cancer diagnosis per year
Anatomic			
Cytology			
Gyn Cytology			
Bone Marrow			
Autopsies			
Other			

- B. Is each specimen assigned a unique number? ☐ Yes ☐ No
 If Yes, are the different specimen types differentiated within the specimen number (i.e., specimen numbers beginning with S are surgical pathology reports, C are cytology reports, etc.)? ☐ Yes ☐ No
- C. Does your laboratory review slides more for initial diagnosis or second opinion? ☐ Initial ☐ Second
- D. What information is maintained at your laboratory ?

Item	Documented √ if Yes	Maintained on Paper √ if Yes	Maintained Electronically √ if Yes
Clinical History			
CPT Codes			
Final Dx Text			
Gross Pathology Text			
History Text			
ICD-CM Codes			
Laboratory CLIA Number			
Microscopic Pathology Text			
Nature of Specimen			
Ordering Client Address			
Ordering Client License Number			
Ordering Client Telephone Number			
Ordering Client Name			
Patient Address			
Patient Age			
Patient DOB			
Patient Name			
Patient Race			
Patient Sex			
Patient SSN			
Reporting Pathologist Name			
Reporting Pathologist License Number			
SNOMED Codes			
Specimen Number			
Specimen Date			

IV. Client Information:

A. What types of facilities/practitioners does your laboratory serve?

Hospitals

☐ Yes ☐ No

Private Physician Practices

☐ Yes ☐ No

Clinics

☐ Yes ☐ No

Other _____

B. If possible, please enclose a list of your laboratory's clients with this form.

V. Whom should we contact to discuss the details of reporting?

Name: _____

Telephone Number: _____

E-mail: _____

VI. Survey Completed By:

Name: _____

Title: _____

Signature: _____

Date: _____

**** Survey Complete. Thank you for your participation ****

FIGURE 6: COMPUTERIZATION CAPABILITY SURVEY OF PATHOLOGY LABORATORIES FOR THE SOUTH CAROLINA CENTRAL CANCER REGISTRY

Please complete this questionnaire and return it to the South Carolina Central Cancer Registry (SCCCR) using the enclosed envelope. Or, you may simply familiarize yourself with the questionnaire and provide the requested information over the telephone (telephone surveys will be conducted after April 8, 1999). Please note that questionnaires not returned by April 8 will be administered over the telephone. If you have any questions, please contact Susan Bolick or Gregory Kirkner at (803) 898-4460.

Section I.

- 1) Facility Name: _____
Address: _____
Telephone Number: _____ Fax Number: _____
- 2) Office Administrator's Name: _____
- 3) Does this facility do pathology laboratory work? _____
(If you have answered "yes" to this question, then continue to Section II. If you have answered "no," then you need only complete Question 7 and return the questionnaire.)

Section II.

- 4) List all the physicians within your facility (attach additional sheet if needed):

- 5) Designated individual(s) with whom SCCCR activities should be coordinated:

- 6) Approximate number of pathology reports read by your laboratory per year (include all surgical, bone marrow, cytology, and autopsy specimens):

- 7) Please list the name and telephone number for all reference laboratories used by your facility (in and out of state). You may attach an additional sheet if needed:

Name of Reference Laboratory

Telephone Number

Name of Reference Laboratory

Telephone Number

Name of Reference Laboratory

Telephone Number

Name of Reference Laboratory

Telephone Number

Section III (Facility Computerization Capabilities).

If there is an individual in charge of maintaining your laboratory's computer system, please have that individual complete the questions in this section.

- 8) Is there an individual responsible for maintaining your laboratory's computer system? _____

What is that person's name? _____

Telephone Number? _____

- 9) Are your laboratory reports computerized? _____

If you answered "yes" to Question 9, please list the name of the software vendor, vendor contact, and vendor's telephone number:

Name of Software Vendor

Name of Contact Person at the Software Vendor

Vendor's Telephone Number

In what formats (if any) can your laboratory report data be saved, exported, and/or submitted?

(Examples include: ASCII, HL7, and DBF)

If you answered "no" to Question 9, does your facility plan to implement a computerized system?

When? _____

10) Are demographic data/information linked to or collected as part of your laboratory software? _____

If you answered “no” to Question 10, are demographic data/information available (in an electronic format) through your laboratory’s billing system? _____

11) Is your laboratory’s billing system computerized? _____

If you answered “yes” to Question 11, list the diagnostic coding system in use:

(Examples include: SNOMED, CPT, and ICD-9)

Can billing data be sorted by diagnosis code? _____

In what formats (if any) can your billing data be saved, exported, and/or submitted? _____

(Examples include: ASCII, HL7, and DBF)

12) Do any of the computers in your facility have an Internet connection or capability? _____

If you answered “yes” to Question 12, is this connection established through a modem or through a local area network? _____

If you answered “yes” to Question 12, can this Internet connection be used to submit laboratory or billing data electronically (see Questions 9 and 11)? _____

13) If only paper reports are used, are all reports kept onsite? _____

14) Convenient time for SCCCR visit to your facility (only if needed): _____

15) Please add any additional comments or suggestions you might have: _____

Thank you for completing this questionnaire. Your cooperation is appreciated! Please return completed questionnaire using the enclosed envelope.

CHAPTER VII

REFERENCES

Code Manuals and Record Layouts

1. Abe T and Seiffert J, editors. North American Association of Center Cancer Registries, Standards for Cancer Registries, Volume I, Data Exchange Standards and Record Description. Version 9. Springfield, IL: North American Association of Center Cancer Registries; September 7, 2000. (Electronic version only; available at www.naaccr.org.)
2. American College of Surgeons Commission on Cancer. Facility Oncology Registry Data Standards (FORDS). Standards of the Commission on Cancer. Volume II. Chicago: American College of Surgeons Commission on Cancer; 2002. (See also: ROADS, published 1996 and supplement issued 1998.)
3. Surveillance, Epidemiology, and End Results Program. The SEER Program Code Manual. Third Edition. Bethesda, MD: National Institutes of Health, National Cancer Institute; January 1998. NIH Pub. No. 98-1999.

Stage and Extent of Disease Manuals

4. Surveillance, Epidemiology, and End Results Program. Comparative Staging Guide for Cancer, Major Cancer Sites. Version 1.1. Bethesda, MD: National Institutes of Health, National Cancer Institute; June 1993. NIH Pub. No. 93-3640.
5. American Joint Committee on Cancer. AJCC Cancer Staging Manual. Green F, et al., editors. Sixth Edition. New York: Springer-Verlag; 2002. (See also: Editions 1, 2, 3, and 4, which were published by Lippincott-Raven under the title Manual for Staging of Cancer; and Edition 5, published by Lippincott-Raven under the title of AJCC Cancer Staging Manual.)
6. Surveillance, Epidemiology, and End Results Program. Extent of Disease--1998: Codes and Coding Instructions. Third Edition. Bethesda, MD: National Institutes of Health, National Cancer Institute; January 1998. NIH Pub. No. 98-2313.
7. Shambaugh EM, Ries LG, and Young JL. Extent of Disease: New 4-Digit Schemes: Codes and Coding Instructions. National Institutes of Health, National Cancer Institute; March 31, 1984.
8. Surveillance, Epidemiology, and End Results Program. Extent of Disease: Codes and Coding Instructions. Bethesda, MD: National Institutes of Health, National Cancer Institute; April 1977.
9. Surveillance, Epidemiology, and End Results Program. Summary Staging Guide for the Cancer Surveillance, Epidemiology, and End Results Reporting (SEER) Program. Bethesda, MD: National Institutes of Health, National Cancer Institute; April 1977. NIH Pub. No. 86-2313. (Reprinted July 1986.)
10. Surveillance, Epidemiology, and End Results Program. Summary Staging Manual 2000. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2001.

11. American Joint Committee on Cancer. Collaborative Staging Manual and Coding Instructions, Version 1.0. Collaborative Stage Task Force. Chicago: American Joint Committee on Cancer; 2002.

Disease Classifications

12. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-10). 10th Revision. Volume 1 (of 3). Geneva: World Health Organization; 1992.
13. Health Care Financing Administration. The International Classification of Diseases, Clinical Modification (ICD-9-CM). Ninth Revision. Fourth Edition. Washington, DC: U.S. Public Health Service; 1991.
14. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin D, et al., editors. International Classification of Diseases for Oncology. Third Edition. Geneva: World Health Organization; 2000.
15. Percy C, VanHolten V, and Muir C, editors. International Classification of Diseases for Oncology. Second Edition. Geneva: World Health Organization; 1990.
16. Percy C and VanHolten V, editors. International Classification of Diseases for Oncology. Field Trial Edition. World Health Organization; March 1988.
17. Percy C and VanHolten V, editors. International Classification of Diseases for Oncology, Morphology. Field Trial Edition. World Health Organization; 1988.
18. Percy C and VanHolten V, editors. International Classification of Diseases for Oncology, Morphology. Field Trial Edition. World Health Organization; 1987.
19. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Ninth Revision. Geneva: World Health Organization; 1977.
20. World Health Organization. International Classification of Diseases for Oncology. First Edition. Geneva: World Health Organization; 1976.
21. National Center for Health Statistics. International Classification of Diseases, Adapted for Use in the United States. Eighth Revision. Volume 2. Washington, DC: U.S. Department of Health, Education, and Welfare, Public Health Service; December 1968. PHS Pub. No. 1693.

Occupation and Industry Classification and Coding

22. Centers for Disease Control and Prevention. Recommendations for Occupation and Industry Data Items. (NPCR program document). Atlanta: Centers for Disease Control and Prevention; July 20, 1995. (Note: This material is a memo to the Chair, NAACCR Uniform Data Standards Committee, dated July 20, 1995, including a report of a June 18, 1995 meeting.)
23. National Center for Health Statistics. Instructional Manual Part 19: Industry and Occupation Coding for Death Certificates, 1999. Hyattsville, MD: National Center for Health Statistics; October, 1999. (Updated.)

24. U.S. Department of Commerce Bureau of the Census. 1990 Census of Population and Housing, Alphabetical Index of Industries and Occupations. Washington, DC: U.S. Government Printing Office; 1990.
25. National Center for Health Statistics. Guidelines for Reporting Occupation and Industry on Death Certificates. Hyattsville, MD: National Center for Health Statistics; March 1988. PHS Pub. No. 88-1149.
26. U.S. Census Bureau, Housing and Household Economic Statistics Division. Census 2000 “Alphabetical Indexes of Industries and Occupations.” Available at: <http://www.census.gov/hhes/www/ioindex/view.html>. (Accessed November 27, 2001).
27. *Standard Occupational Classification (SOC) System Manual: 2000*. (Book and CD-ROM) U.S. Office of Management and Budget. Lanham, MD: Bernan Press; and Springfield, VA: National Technical Information Service; 2000. Also see: <http://www.ntis.gov/product/standard-occupational-classification.htm>.

Other References

28. American College of Surgeons Commission on Cancer. Cancer Program Standards. Standards of the Commission on Cancer. Volume I. Chicago: American College of Surgeons Commission on Cancer; 1996.
29. North American Association of Central Cancer Registries. Standard Data Edits. In: Seiffert JE, Capron S, and Tebbell J, editors. Standards for Cancer Registries. Volume IV. Sacramento, CA: North American Association of Central Cancer Registries; April 4, 1996. (Note: Updated metafiles corresponding to changes in data standards are issued periodically. These are available from the NAACCR Web Site at: www.naacr.org.)
30. Centers for Disease Control and Prevention. Program Announcement No. 426: 1994 National Program of Cancer Registries (NPCR). Atlanta: Centers for Disease Control and Prevention; March 1994. (NPCR program document.)
31. Menck HR and Smart CR, editors. Central Cancer Registries: Design, Management, and Use. Langhorne, PA: Harwood Academic Publishers; 1994.
32. North American Association of Central Cancer Registries. Standards for Completeness, Quality, Analysis, and Management of Data. In: Standards for Cancer Registries. Volume III. North American Association of Central Cancer Registries; September 2000.
33. (North) American Association of Central Cancer Registries. Working Group on Pre-Invasive Cervical Neoplasia and Population-Based Cancer Registries: Final Subcommittee Report. ([N]AACCR Conference held April 5-6, 1993, Rockville, MD. Adopted by the [N]AACCR Executive Board May 1993 and amended November 1993.)
34. Surveillance, Epidemiology, and End Results Program. SEER Edit Documentation. Bethesda, MD: National Institutes of Health, National Cancer Institute; May 1993.

35. U.S. Department of Commerce Bureau of the Census. Appendix A: Area Classifications. In: 1990 Census of Population: General Population Characteristics. Washington, DC: U.S. Government Printing Office; 1990.
36. Cancer Registries Amendment Act, Pub. No. 102-515, 106 Stat 3372 (October 24, 1992).
37. Jensen OM, Parkin DM, MacLennan R, Muir CS, and Skeet RG, editors. Cancer Registration: Principles and Methods. Lyon: International Agency for Research on Cancer; 1991. IARC Scientific Pub. No. 95.
38. National Cancer Registrars Association. Registry Staffing Manual. Lenexa, KS: National Cancer Registrars Association; 1989. (A joint study and report from the National Cancer Registrars Association, Inc., and the American College of Surgeons Commission on Cancer, with financial support of the American Cancer Society.)
39. Shambaugh E, editor-in-chief. SEER Program Self-Instructional Manual for Cancer Registrars. Bethesda, MD: National Institutes of Health, National Cancer Institute. (Various years)

Book One: Objectives and Functions of a Tumor Registry. Third Edition; 1999.

Book Two: Cancer Characteristics and Selection of Cases. Third Edition; 1992.

Book Three: Tumor Registrar Vocabulary: The Composition of Medical Terms. Second Edition; 1993.

Book Four: Human Anatomy as Related to Tumor Formation. Second Edition; 1993.

Book Five: Abstracting a Medical Record: Patient Identification, History, and Examinations. Second Edition; 1993.

Book Six: Classification for Extent of Disease; 1977.

Book Seven: Statistics and Epidemiology for Tumor Registrars; 1994.

Book Eight: Antineoplastic Drugs. Third Edition; 1993.
40. Centers for Disease Control and Prevention. Program Announcement No. 00027: National Program of Cancer Registries. Atlanta: Centers for Disease Control and Prevention; January 2000. (NPCR program document.)
41. Hutchison C, Roffers S, and Fritz A, editors. Cancer Registry Management: Principles and Practice. Dubuque, Iowa: Kendall Hunt; 1997.

CHAPTER VIII

RECORD LAYOUT TABLE (COLUMN # ORDER)

The following table presents Version 10 of the NAACCR record layout. The table has column number, length, item number, item name, section, and note fields. The table is sorted by column numbers. Differences from Version 9.1 are marked “Revised” or “New” in the “Note” column of the table. Some changes also are summarized in Appendix F. Please note that “Retired” items are not reflected in this table.

Column #	Length	Item#	Item Name	Section	Note
1-1	1	10	Record Type	Record ID	
2-9	8	20	Patient ID Number	Record ID	
10-10	1	30	Registry Type	Record ID	
11-11	1	35	FIN Coding System	Record ID	
12-18	7	37	Reserved 00	Record ID	Revised
19-19	1	50	NAACCR Record Version	Record ID	
20-29	10	40	Registry ID	Record ID	Revised
30-31	2	60	Tumor Record Number	Record ID	
32-51	20	370	Reserved 01	Record ID	Revised
52-71	20	70	Addr at DX--City	Demographic	
72-73	2	80	Addr at DX--State	Demographic	
74-82	9	100	Addr at DX--Postal Code	Demographic	
83-85	3	90	County at DX	Demographic	
86-91	6	110	Census Tract 1970/80/90	Demographic	Revised
92-92	1	120	Census Cod Sys 1970/80/90	Demographic	Revised
93-98	6	130	Census Tract 2000	Demographic	Revised
99-99	1	362	Census Tract Block Group	Demographic	
100-100	1	364	Census Tr Cert 1970/80/90	Demographic	Revised
101-101	1	365	Census Tr Certainty 2000	Demographic	New
102-102	1	150	Marital Status at DX	Demographic	
103-104	2	160	Race 1	Demographic	
105-106	2	161	Race 2	Demographic	
107-108	2	162	Race 3	Demographic	
109-110	2	163	Race 4	Demographic	
111-112	2	164	Race 5	Demographic	
113-113	1	170	Race Coding Sys--Current	Demographic	
114-114	1	180	Race Coding Sys--Original	Demographic	
115-115	1	190	Spanish/Hispanic Origin	Demographic	
116-116	1	200	Computed Ethnicity	Demographic	
117-117	1	210	Computed Ethnicity Source	Demographic	
118-118	1	220	Sex	Demographic	
119-121	3	230	Age at Diagnosis	Demographic	
122-129	8	240	Birth Date	Demographic	
130-132	3	250	Birthplace	Demographic	
133-134	2	260	Religion	Demographic	
135-137	3	270	Occupation Code--Census	Demographic	
138-140	3	280	Industry Code--Census	Demographic	

Column #	Length	Item#	Item Name	Section	Note
141-141	1	290	Occupation Source	Demographic	
142-142	1	300	Industry Source	Demographic	
143-182	40	310	Text--Usual Occupation	Demographic	
183-222	40	320	Text--Usual Industry	Demographic	
223-223	1	330	Occup/Ind Coding System	Demographic	
224-224	1	340	Tobacco History	Demographic	
225-225	1	350	Alcohol History	Demographic	
226-226	1	360	Family History of Cancer	Demographic	
227-228	2	3300	RuralUrban Continuum 1993	Demographic	New
229-230	2	3310	RuralUrban Continuum 2000	Demographic	New
231-280	50	530	Reserved 02	Demographic	Revised
281-282	2	380	Sequence Number--Central	Cancer Identification	
283-290	8	390	Date of Diagnosis	Cancer Identification	
291-294	4	400	Primary Site	Cancer Identification	
295-295	1	410	Laterality	Cancer Identification	
296-300	5	419	Morph--Type&Behav ICD-O-2	Cancer Identification	Group
296-299	4	420	Histology (92-00) ICD-O-2	Cancer Identification	
300-300	1	430	Behavior (92-00) ICD-O-2	Cancer Identification	
301-305	5	521	Morph--Type&Behav ICD-O-3	Cancer Identification	Group
301-304	4	522	Histologic Type ICD-O-3	Cancer Identification	
305-305	1	523	Behavior Code ICD-O-3	Cancer Identification	
306-306	1	440	Grade	Cancer Identification	
307-307	1	450	Site Coding Sys--Current	Cancer Identification	
308-308	1	460	Site Coding Sys--Original	Cancer Identification	
309-309	1	470	Morph Coding Sys--Current	Cancer Identification	
310-310	1	480	Morph Coding Sys--Originl	Cancer Identification	
311-311	1	490	Diagnostic Confirmation	Cancer Identification	
312-312	1	500	Type of Reporting Source	Cancer Identification	
313-320	8	510	Screening Date	Cancer Identification	
321-321	1	520	Screening Result	Cancer Identification	
322-371	50	680	Reserved 03	Cancer Identification	Revised
372-381	10	538	Reporting Hospital FAN	Hospital-Specific	
382-391	10	540	Reporting Hospital	Hospital-Specific	Revised
392-401	10	3100	Archive FIN	Hospital-Specific	New
402-410	9	550	Accession Number--Hosp	Hospital-Specific	
411-412	2	560	Sequence Number--Hospital	Hospital-Specific	
413-415	3	570	Abstracted By	Hospital-Specific	
416-423	8	580	Date of 1st Contact	Hospital-Specific	
424-431	8	590	Date of Inpatient Adm	Hospital-Specific	
432-439	8	600	Date of Inpatient Disch	Hospital-Specific	
440-440	1	610	Class of Case	Hospital-Specific	
441-444	4	620	Year First Seen This CA	Hospital-Specific	
445-446	2	630	Primary Payer at DX	Hospital-Specific	
447-447	1	640	Inpatient/Outpt Status	Hospital-Specific	

Column #	Length	Item#	Item Name	Section	Note
448-448	1	650	Presentation at CA Conf	Hospital-Specific	
449-456	8	660	Date of CA Conference	Hospital-Specific	
457-458	2	670	RX Hosp--Surg Prim Site	Hospital-Specific	
459-459	1	672	RX Hosp--Scope Reg LN Sur	Hospital-Specific	
460-460	1	674	RX Hosp--Surg Oth Reg/Dis	Hospital-Specific	
461-462	2	676	RX Hosp--Reg LN Removed	Hospital-Specific	
463-463	1	690	RX Hosp--Radiation	Hospital-specific	
464-465	2	700	RX Hosp--Chemo	Hospital-Specific	Revised
466-467	2	710	RX Hosp--Hormone	Hospital-Specific	Revised
468-469	2	720	RX Hosp--BRM	Hospital-Specific	Revised
470-470	1	730	RX Hosp--Other	Hospital-specific	
471-472	2	740	RX Hosp--DX/Stg Proc	Hospital-specific	Revised
473-473	1	3280	RX Hosp--Palliative Proc	Hospital-Specific	New
474-474	1	742	RX Hosp--Screen/BX Proc1	Hospital-Specific	
475-475	1	743	RX Hosp--Screen/BX Proc2	Hospital-Specific	
476-476	1	744	RX Hosp--Screen/BX Proc3	Hospital-Specific	
477-477	1	745	RX Hosp--Screen/BX Proc4	Hospital-Specific	
478-527	50	750	Reserved 04	Hospital-Specific	Revised
528-528	1	759	SEER Summary Stage 2000	Stage/Prognostic Factors	
529-529	1	760	SEER Summary Stage 1977	Stage/Prognostic Factors	
530-530	1	770	Loc/Reg/Distant Stage	Stage/Prognostic Factors	
531-542	12	779	Extent of Disease 10-Dig	Stage/Prognostic Factors	Group
531-533	3	780	EOD--Tumor Size	Stage/Prognostic Factors	
534-535	2	790	EOD--Extension	Stage/Prognostic Factors	
536-537	2	800	EOD--Extension Prost Path	Stage/Prognostic Factors	
538-538	1	810	EOD--Lymph Node Involv	Stage/Prognostic Factors	
539-540	2	820	Regional Nodes Positive	Stage/Prognostic Factors	
541-542	2	830	Regional Nodes Examined	Stage/Prognostic Factors	
543-555	13	840	EOD--Old 13 Digit	Stage/Prognostic Factors	
556-557	2	850	EOD--Old 2 Digit	Stage/Prognostic Factors	
558-561	4	860	EOD--Old 4 Digit	Stage/Prognostic Factors	
562-562	1	870	Coding System for EOD	Stage/Prognostic Factors	
563-564	2	880	TNM Path T	Stage/Prognostic Factors	
565-566	2	890	TNM Path N	Stage/Prognostic Factors	
567-568	2	900	TNM Path M	Stage/Prognostic Factors	
569-570	2	910	TNM Path Stage Group	Stage/Prognostic Factors	
571-571	1	920	TNM Path Descriptor	Stage/Prognostic Factors	
572-572	1	930	TNM Path Staged By	Stage/Prognostic Factors	
573-574	2	940	TNM Clin T	Stage/Prognostic Factors	
575-576	2	950	TNM Clin N	Stage/Prognostic Factors	
577-578	2	960	TNM Clin M	Stage/Prognostic Factors	
579-580	2	970	TNM Clin Stage Group	Stage/Prognostic Factors	
581-581	1	980	TNM Clin Descriptor	Stage/Prognostic Factors	
582-582	1	990	TNM Clin Staged By	Stage/Prognostic Factors	
583-584	2	1000	TNM Other T	Stage/Prognostic Factors	

Column #	Length	Item#	Item Name	Section	Note
585-586	2	1010	TNM Other N	Stage/Prognostic Factors	
587-588	2	1020	TNM Other M	Stage/Prognostic Factors	
589-590	2	1030	TNM Other Stage Group	Stage/Prognostic Factors	
591-591	1	1040	TNM Other Staged By	Stage/Prognostic Factors	
592-592	1	1050	TNM Other Descriptor	Stage/Prognostic Factors	
593-594	2	1060	TNM Edition Number	Stage/Prognostic Factors	Revised
595-609	15	1070	Other Staging System	Stage/Prognostic Factors	
610-617	8	1080	Date of 1st Positive BX	Stage/Prognostic Factors	
618-618	1	1090	Site of Distant Met 1	Stage/Prognostic Factors	
619-619	1	1100	Site of Distant Met 2	Stage/Prognostic Factors	
620-620	1	1110	Site of Distant Met 3	Stage/Prognostic Factors	
621-622	2	1120	Pediatric Stage	Stage/Prognostic Factors	
623-624	2	1130	Pediatric Staging System	Stage/Prognostic Factors	
625-625	1	1140	Pediatric Staged By	Stage/Prognostic Factors	
626-626	1	1150	Tumor Marker 1	Stage/Prognostic Factors	
627-627	1	1160	Tumor Marker 2	Stage/Prognostic Factors	
628-628	1	1170	Tumor Marker 3	Stage/Prognostic Factors	
629-631	3	2800	CS Tumor Size	Stage/Prognostic Factors	New
632-633	2	2810	CS Extension	Stage/Prognostic Factors	New
634-634	1	2820	CS Tumor Size/Ext Eval	Stage/Prognostic Factors	New
635-636	2	2830	CS Lymph Nodes	Stage/Prognostic Factors	New
637-637	1	2840	CS Reg Nodes Eval	Stage/Prognostic Factors	New
638-639	2	2850	CS Mets at DX	Stage/Prognostic Factors	New
640-640	1	2860	CS Mets Eval	Stage/Prognostic Factors	New
641-643	3	2880	CS Site-Specific Factor 1	Stage/Prognostic Factors	New
644-646	3	2890	CS Site-Specific Factor 2	Stage/Prognostic Factors	New
647-649	3	2900	CS Site-Specific Factor 3	Stage/Prognostic Factors	New
650-652	3	2910	CS Site-Specific Factor 4	Stage/Prognostic Factors	New
653-655	3	2920	CS Site-Specific Factor 5	Stage/Prognostic Factors	New
656-658	3	2930	CS Site-Specific Factor 6	Stage/Prognostic Factors	New
659-660	2	2940	Derived AJCC T	Stage/Prognostic Factors	New
661-661	1	2950	Derived AJCC T Descriptor	Stage/Prognostic Factors	New
662-663	2	2960	Derived AJCC N	Stage/Prognostic Factors	New
664-664	1	2970	Derived AJCC N Descriptor	Stage/Prognostic Factors	New
665-666	2	2980	Derived AJCC M	Stage/Prognostic Factors	New
667-667	1	2990	Derived AJCC M Descriptor	Stage/Prognostic Factors	New
668-669	2	3000	Derived AJCC Stage Group	Stage/Prognostic Factors	New
670-670	1	3010	Derived SS1977	Stage/Prognostic Factors	New
671-671	1	3020	Derived SS2000	Stage/Prognostic Factors	New
672-672	1	3030	Derived AJCC--Flag	Stage/Prognostic Factors	New
673-673	1	3040	Derived SS1977--Flag	Stage/Prognostic Factors	New
674-674	1	3050	Derived SS2000--Flag	Stage/Prognostic Factors	New
675-679	5	3110	Comorbid/Complication 1	Stage/Prognostic Factors	New
680-684	5	3120	Comorbid/Complication 2	Stage/Prognostic Factors	New
685-689	5	3130	Comorbid/Complication 3	Stage/Prognostic Factors	New

Column #	Length	Item#	Item Name	Section	Note
690-694	5	3140	Comorbid/Complication 4	Stage/Prognostic Factors	New
695-699	5	3150	Comorbid/Complication 5	Stage/Prognostic Factors	New
700-704	5	3160	Comorbid/Complication 6	Stage/Prognostic Factors	New
705-754	50	1180	Reserved 05	Stage/Prognostic Factors	Revised
755-762	8	1200	RX Date--Surgery	Treatment-1st Course	
763-770	8	3170	RX Date--Most Defin Surg	Treatment-1st Course	New
771-778	8	3180	RX Date--Surgical Disch	Treatment-1st Course	New
779-786	8	1210	RX Date--Radiation	Treatment-1st Course	
787-794	8	3220	RX Date--Radiation Ended	Treatment-1st Course	New
795-802	8	3230	RX Date--Systemic	Treatment-1st Course	New
803-810	8	1220	RX Date--Chemo	Treatment-1st Course	
811-818	8	1230	RX Date--Hormone	Treatment-1st Course	
819-826	8	1240	RX Date--BRM	Treatment-1st Course	
827-834	8	1250	RX Date--Other	Treatment-1st Course	
835-842	8	1260	Date of Initial RX--SEER	Treatment-1st Course	
843-850	8	1270	Date of 1st Crs RX--COC	Treatment-1st Course	
851-858	8	1280	RX Date--DX/Stg Proc	Treatment-1st Course	Revised
859-860	2	1290	RX Summ--Surg Prim Site	Treatment-1st Course	
861-861	1	1292	RX Summ--Scope Reg LN Sur	Treatment-1st Course	
862-862	1	1294	RX Summ--Surg Oth Reg/Dis	Treatment-1st Course	
863-864	2	1296	RX Summ--Reg LN Examined	Treatment-1st Course	
865-865	1	1310	RX Summ--Surgical Approch	Treatment-1st Course	
866-866	1	1320	RX Summ--Surgical Margins	Treatment-1st Course	
867-867	1	1330	RX Summ--Reconstruct 1st	Treatment-1st Course	
868-868	1	1340	Reason for No Surgery	Treatment-1st Course	
869-870	2	1350	RX Summ--DX/Stg Proc	Treatment-1st Course	Revised
871-871	1	3270	RX Summ--Palliative Proc	Treatment-1st Course	New
872-872	1	3260	Pain Assessment	Treatment-1st Course	New
873-873	1	1360	RX Summ--Radiation	Treatment-1st Course	
874-874	1	1370	RX Summ--Rad to CNS	Treatment-1st Course	
875-875	1	1380	RX Summ--Surg/Rad Seq	Treatment-1st Course	
876-877	2	3250	RX Summ--Transplnt/Endocr	Treatment-1st Course	New
878-879	2	1390	RX Summ--Chemo	Treatment-1st Course	Revised
880-881	2	1400	RX Summ--Hormone	Treatment-1st Course	Revised
882-883	2	1410	RX Summ--BRM	Treatment-1st Course	Revised
884-884	1	1420	RX Summ--Other	Treatment-1st Course	
885-885	1	1430	Reason for No Radiation	Treatment-1st Course	
886-886	1	1440	Reason for No Chemo	Treatment-1st Course	
887-887	1	1450	Reason for No Hormone	Treatment-1st Course	
888-889	2	1460	RX Coding System--Current	Treatment-1st Course	Revised
890-890	1	1470	Protocol Eligibility Stat	Treatment-1st Course	
891-892	2	1480	Protocol Participation	Treatment-1st Course	
893-893	1	1490	Referral to Support Serv	Treatment-1st Course	
894-894	1	1500	First Course Calc Method	Treatment-1st Course	
895-899	5	1510	Rad--Regional Dose: cGy	Treatment-1st Course	

Column #	Length	Item#	Item Name	Section	Note
900-901	2	1520	Rad--No of Treatment Vol	Treatment-1st Course	
902-904	3	1530	Rad--Elapsed RX Days	Treatment-1st Course	
905-906	2	1540	Rad--Treatment Volume	Treatment-1st Course	
907-907	1	1550	Rad--Location of RX	Treatment-1st Course	
908-908	1	1560	Rad--Intent of Treatment	Treatment-1st Course	
909-910	2	1570	Rad--Regional RX Modality	Treatment-1st Course	
911-912	2	3200	Rad--Boost RX Modality	Treatment-1st Course	New
913-917	5	3210	Rad--Boost Dose cGy	Treatment-1st Course	New
918-918	1	1580	Rad--RX Completion Status	Treatment-1st Course	
919-919	1	1590	Rad--Local Control Status	Treatment-1st Course	
920-922	3	1600	Chemotherapy Field 1	Treatment-1st Course	
923-925	3	1610	Chemotherapy Field 2	Treatment-1st Course	
926-928	3	1620	Chemotherapy Field 3	Treatment-1st Course	
929-931	3	1630	Chemotherapy Field 4	Treatment-1st Course	
932-933	2	1640	RX Summ--Surgery Type	Treatment-1st Course	
934-934	1	1642	RX Summ--Screen/BX Proc1	Treatment-1st Course	
935-935	1	1643	RX Summ--Screen/BX Proc2	Treatment-1st Course	
936-936	1	1644	RX Summ--Screen/BX Proc3	Treatment-1st Course	
937-937	1	1645	RX Summ--Screen/BX Proc4	Treatment-1st Course	
938-938	1	3190	Readm Same Hosp 30 Days	Treatment-1st Course	New
939-987	49	1190	Reserved 06	Treatment-1st Course	Revised
988-995	8	1660	Subsq RX 2nd Course Date	Treatment-Subsequent & Other	
996-1002	7	1670	Subsq RX 2nd Course Codes	Treatment-Subsequent & Other	Group
996-997	2	1671	Subsq RX 2nd Course Surg	Treatment-Subsequent & Other	
998-998	1	1672	Subsq RX 2nd Course Rad	Treatment-Subsequent & Other	
999-999	1	1673	Subsq RX 2nd Course Chemo	Treatment-Subsequent & Other	
1000-1000	1	1674	Subsq RX 2nd Course Horm	Treatment-Subsequent & Other	
1001-1001	1	1675	Subsq RX 2nd Course BRM	Treatment-Subsequent & Other	
1002-1002	1	1676	Subsq RX 2nd Course Oth	Treatment-Subsequent & Other	
1003-1010	8	1680	Subsq RX 3rd Course Date	Treatment-Subsequent & Other	
1011-1017	7	1690	Subsq RX 3rd Course Codes	Treatment-Subsequent & Other	Group
1011-1012	2	1691	Subsq RX 3rd Course Surg	Treatment-Subsequent & Other	
1013-1013	1	1692	Subsq RX 3rd Course Rad	Treatment-Subsequent & Other	
1014-1014	1	1693	Subsq RX 3rd Course Chemo	Treatment-Subsequent & Other	
1015-1015	1	1694	Subsq RX 3rd Course Horm	Treatment-Subsequent & Other	
1016-1016	1	1695	Subsq RX 3rd Course BRM	Treatment-Subsequent & Other	
1017-1017	1	1696	Subsq RX 3rd Course Oth	Treatment-Subsequent & Other	
1018-1025	8	1700	Subsq RX 4th Course Date	Treatment-Subsequent & Other	
1026-1032	7	1710	Subsq RX 4th Course Codes	Treatment-Subsequent & Other	Group
1026-1027	2	1711	Subsq RX 4th Course Surg	Treatment-Subsequent & Other	
1028-1028	1	1712	Subsq RX 4th Course Rad	Treatment-Subsequent & Other	
1029-1029	1	1713	Subsq RX 4th Course Chemo	Treatment-Subsequent & Other	
1030-1030	1	1714	Subsq RX 4th Course Horm	Treatment-Subsequent & Other	
1031-1031	1	1715	Subsq RX 4th Course BRM	Treatment-Subsequent & Other	
1032-1032	1	1716	Subsq RX 4th Course Oth	Treatment-Subsequent & Other	

Column #	Length	Item#	Item Name	Section	Note
1033-1040	8	1720	Subsq RX 5th Course Date	Treatment-Subsequent & Other	
1041-1047	7	1730	Subsq RX 5th Course Codes	Treatment-Subsequent & Other	Group
1041-1042	2	1731	Subsq RX 5th Course Surg	Treatment-Subsequent & Other	
1043-1043	1	1732	Subsq RX 5th Course Rad	Treatment-Subsequent & Other	
1044-1044	1	1733	Subsq RX 5th Course Chemo	Treatment-Subsequent & Other	
1045-1045	1	1734	Subsq RX 5th Course Horm	Treatment-Subsequent & Other	
1046-1046	1	1735	Subsq RX 5th Course BRM	Treatment-Subsequent & Other	
1047-1047	1	1736	Subsq RX 5th Course Oth	Treatment-Subsequent & Other	
1048-1048	1	1677	Subsq RX 2nd--Scope LN SU	Treatment-Subsequent & Other	
1049-1049	1	1678	Subsq RX 2nd--Surg Oth	Treatment-Subsequent & Other	
1050-1051	2	1679	Subsq RX 2nd--Reg LN Rem	Treatment-Subsequent & Other	
1052-1052	1	1697	Subsq RX 3rd--Scope LN Su	Treatment-Subsequent & Other	
1053-1053	1	1698	Subsq RX 3rd--Surg Oth	Treatment-Subsequent & Other	
1054-1055	2	1699	Subsq RX 3rd--Reg LN Rem	Treatment-Subsequent & Other	
1056-1056	1	1717	Subsq RX 4th--Scope LN Su	Treatment-Subsequent & Other	
1057-1057	1	1718	Subsq RX 4th--Surg Oth	Treatment-Subsequent & Other	
1058-1059	2	1719	Subsq RX 4th--Reg LN Rem	Treatment-Subsequent & Other	
1060-1060	1	1737	Subsq RX 5th--Scope LN Su	Treatment-Subsequent & Other	
1061-1061	1	1738	Subsq RX 5th--Surg Oth	Treatment-Subsequent & Other	
1062-1063	2	1739	Subsq RX 5th--Reg LN Rem	Treatment-Subsequent & Other	
1064-1064	1	1741	Subsq RX--Reconstruct Del	Treatment-Subsequent & Other	
1065-1114	50	1300	Reserved 07	Treatment-Subsequent & Other	Revised
1115-1115	1	1981	Over-ride SS/NodesPos	Edit Overrides/Conversion History/System Admin	
1116-1116	1	1982	Over-ride SS/TNM-N	Edit Overrides/Conversion History/System Admin	
1117-1117	1	1983	Over-ride SS/TNM-M	Edit Overrides/Conversion History/System Admin	
1118-1118	1	1984	Over-ride SS/DisMet1	Edit Overrides/Conversion History/System Admin	
1119-1119	1	1985	Over-ride Acsn/Class/Seq	Edit Overrides/Conversion History/System Admin	
1120-1120	1	1986	Over-ride HospSeq/DxConf	Edit Overrides/Conversion History/System Admin	
1121-1121	1	1987	Over-ride COC-Site/Type	Edit Overrides/Conversion History/System Admin	
1122-1122	1	1988	Over-ride HospSeq/Site	Edit Overrides/Conversion History/System Admin	
1123-1123	1	1989	Over-ride Site/TNM-StgGrp	Edit Overrides/Conversion History/System Admin	
1124-1124	1	1990	Over-ride Age/Site/Morph	Edit Overrides/Conversion History/System Admin	
1125-1125	1	2000	Over-ride SeqNo/DxConf	Edit Overrides/Conversion History/System Admin	
1126-1126	1	2010	Over-ride Site/Lat/SeqNo	Edit Overrides/Conversion History/System Admin	
1127-1127	1	2020	Over-ride Surg/DxConf	Edit Overrides/Conversion History/System Admin	

Column #	Length	Item#	Item Name	Section	Note
1128-1128	1	2030	Over-ride Site/Type	Edit Overrides/Conversion History/System Admin	
1129-1129	1	2040	Over-ride Histology	Edit Overrides/Conversion History/System Admin	
1130-1130	1	2050	Over-ride Report Source	Edit Overrides/Conversion History/System Admin	
1131-1131	1	2060	Over-ride Ill-define Site	Edit Overrides/Conversion History/System Admin	
1132-1132	1	2070	Over-ride Leuk, Lymphoma	Edit Overrides/Conversion History/System Admin	
1133-1133	1	2071	Over-ride Site/Behavior	Edit Overrides/Conversion History/System Admin	
1134-1134	1	2072	Over-ride Site/EOD/DX Dt	Edit Overrides/Conversion History/System Admin	
1135-1135	1	2073	Over-ride Site/Lat/EOD	Edit Overrides/Conversion History/System Admin	
1136-1136	1	2074	Over-ride Site/Lat/Morph	Edit Overrides/Conversion History/System Admin	
1137-1140	4	1960	Site (73-91) ICD-O-1	Edit Overrides/Conversion History/System Admin	
1141-1146	6	1970	Morph (73-91) ICD-O-1	Edit Overrides/Conversion History/System Admin	Group
1141-1144	4	1971	Histology (73-91) ICD-O-1	Edit Overrides/Conversion History/System Admin	
1145-1145	1	1972	Behavior (73-91) ICD-O-1	Edit Overrides/Conversion History/System Admin	
1146-1146	1	1973	Grade (73-91) ICD-O-1	Edit Overrides/Conversion History/System Admin	
1147-1147	1	1980	ICD-O-2 Conversion Flag	Edit Overrides/Conversion History/System Admin	
1148-1155	8	2114	Future Use Timeliness 1	Edit Overrides/Conversion History/System Admin	
1156-1163	8	2115	Future Use Timeliness 2	Edit Overrides/Conversion History/System Admin	
1164-1173	10	2081	CRC CHECKSUM	Edit Overrides/Conversion History/System Admin	
1174-1181	8	2090	Date Case Completed	Edit Overrides/Conversion History/System Admin	
1182-1189	8	2100	Date Case Last Changed	Edit Overrides/Conversion History/System Admin	
1190-1197	8	2110	Date Case Report Exported	Edit Overrides/Conversion History/System Admin	
1198-1198	1	2120	SEER Coding Sys--Current	Edit Overrides/Conversion History/System Admin	
1199-1199	1	2130	SEER Coding Sys--Original	Edit Overrides/Conversion History/System Admin	
1200-1201	2	2140	COC Coding Sys--Current	Edit Overrides/Conversion History/System Admin	Revised
1202-1203	2	2150	COC Coding Sys--Original	Edit Overrides/Conversion History/System Admin	Revised

Column #	Length	Item#	Item Name	Section	Note
1204-1213	10	2170	Vendor Name	Edit Overrides/Conversion History/System Admin	
1214-1214	1	2180	SEER Type of Follow-Up	Edit Overrides/Conversion History/System Admin	
1215-1216	2	2190	SEER Record Number	Edit Overrides/Conversion History/System Admin	
1217-1218	2	2200	Diagnostic Proc 73-87	Edit Overrides/Conversion History/System Admin	
1219-1226	8	2111	Date Case Report Received	Edit Overrides/Conversion History/System Admin	
1227-1234	8	2112	Date Case Report Loaded	Edit Overrides/Conversion History/System Admin	
1235-1242	8	2113	Date Tumor Record Availbl	Edit Overrides/Conversion History/System Admin	
1243-1243	1	2116	ICD-O-3 Conversion Flag	Edit Overrides/Conversion History/System Admin	
1244-1293	50	1650	Reserved 08	Edit Overrides/Conversion History/System Admin	Revised
1294-1301	8	1750	Date of Last Contact	Follow-up/Recurrence/Death	
1302-1302	1	1760	Vital Status	Follow-Up/Recurrence/Death	
1303-1303	1	1770	Cancer Status	Follow-up/Recurrence/Death	
1304-1304	1	1780	Quality of Survival	Follow-Up/Recurrence/Death	
1305-1305	1	1790	Follow-Up Source	Follow-Up/Recurrence/Death	
1306-1306	1	1800	Next Follow-Up Source	Follow-Up/Recurrence/Death	
1307-1326	20	1810	Addr Current--City	Follow-Up/Recurrence/Death	
1327-1328	2	1820	Addr Current--State	Follow-Up/Recurrence/Death	
1329-1337	9	1830	Addr Current--Postal Code	Follow-Up/Recurrence/Death	
1338-1340	3	1840	County--Current	Follow-Up/Recurrence/Death	
1341-1341	1	1850	Unusual Follow-Up Method	Follow-Up/Recurrence/Death	
1342-1349	8	1860	Recurrence Date--1st	Follow-Up/Recurrence/Death	
1350-1350	1	1871	Recurrence Distant Site 1	Follow-Up/Recurrence/Death	
1351-1351	1	1872	Recurrence Distant Site 2	Follow-Up/Recurrence/Death	
1352-1352	1	1873	Recurrence Distant Site 3	Follow-Up/Recurrence/Death	
1353-1354	2	1880	Recurrence Type--1st	Follow-Up/Recurrence/Death	
1355-1356	2	1890	Recurrence Type--1st--Oth	Follow-Up/Recurrence/Death	
1357-1376	20	1842	Follow-Up Contact--City	Follow-Up/Recurrence/Death	
1377-1378	2	1844	Follow-Up Contact--State	Follow-Up/Recurrence/Death	
1379-1387	9	1846	Follow-Up Contact--Postal	Follow-Up/Recurrence/Death	
1388-1391	4	1910	Cause of Death	Follow-Up/Recurrence/Death	
1392-1392	1	1920	ICD Revision Number	Follow-Up/Recurrence/Death	
1393-1393	1	1930	Autopsy	Follow-Up/Recurrence/Death	
1394-1396	3	1940	Place of Death	Follow-Up/Recurrence/Death	
1397-1446	50	1740	Reserved 09	Follow-Up/Recurrence/Death	Revised
1447-1946	500	2220	State/Requestor Items	Special Use	
1947-1971	25	2230	Name--Last	Patient-Confidential	
1972-1985	14	2240	Name--First	Patient-Confidential	
1986-1999	14	2250	Name--Middle	Patient-Confidential	

Column #	Length	Item#	Item Name	Section	Note
2000-2002	3	2260	Name--Prefix	Patient-Confidential	
2003-2005	3	2270	Name--Suffix	Patient-Confidential	
2006-2020	15	2280	Name--Alias	Patient-Confidential	
2021-2035	15	2390	Name--Maiden	Patient-Confidential	
2036-2085	50	2290	Name--Spouse/Parent	Patient-Confidential	
2086-2096	11	2300	Medical Record Number	Patient-Confidential	
2097-2098	2	2310	Military Record No Suffix	Patient-Confidential	
2099-2107	9	2320	Social Security Number	Patient-Confidential	
2108-2147	40	2330	Addr at DX--No & Street	Patient-Confidential	Revised
2148-2187	40	2335	Addr at DX--Supplementl	Patient-Confidential	New
2188-2227	40	2350	Addr Current--No & Street	Patient-Confidential	Revised
2228-2267	40	2355	Addr Current--Supplementl	Patient-Confidential	New
2268-2277	10	2360	Telephone	Patient-Confidential	
2278-2283	6	2380	DC State File Number	Patient-Confidential	
2284-2313	30	2394	Follow-Up Contact--Name	Patient-Confidential	
2314-2353	40	2392	Follow-Up Contact--No&St	Patient-Confidential	Revised
2354-2393	40	2393	Follow-Up Contact--Suppl	Patient-Confidential	New
2394-2403	10	2352	Latitude	Patient-Confidential	New
2404-2414	11	2354	Longitude	Patient-Confidential	New
2415-2464	50	1835	Reserved 10	Patient-Confidential	Revised
2465-2474	10	2430	Last Follow-Up Hospital	Hospital-Confidential	Revised
2475-2484	10	2440	Following Registry	Hospital-Confidential	Revised
2485-2494	10	2410	Institution Referred From	Hospital-Confidential	Revised
2495-2504	10	2420	Institution Referred To	Hospital-Confidential	Revised
2505-2554	50	1900	Reserved 11	Hospital-Confidential	Revised
2555-2562	8	2460	Physician--Managing	Other-Confidential	
2563-2570	8	2470	Physician--Follow-Up	Other-Confidential	
2571-2578	8	2480	Physician--Primary Surg	Other-Confidential	
2579-2586	8	2490	Physician 3	Other-Confidential	
2587-2594	8	2500	Physician 4	Other-Confidential	
2595-2644	50	1950	Reserved 12	Other-Confidential	Revised
2645-2844	200	2520	Text--DX Proc--PE	Text - Diagnosis	
2845-3094	250	2530	Text--DX Proc--X-ray/scan	Text - Diagnosis	
3095-3344	250	2540	Text--DX Proc--Scopes	Text - Diagnosis	
3345-3594	250	2550	Text--DX Proc--Lab Tests	Text - Diagnosis	
3595-3844	250	2560	Text--DX Proc--Op	Text - Diagnosis	
3845-4094	250	2570	Text--DX Proc--Path	Text - Diagnosis	
4095-4134	40	2580	Text--Primary Site Title	Text - Diagnosis	
4135-4174	40	2590	Text--Histology Title	Text - Diagnosis	
4175-4474	300	2600	Text--Staging	Text - Diagnosis	
4475-4624	150	2610	RX Text--Surgery	Text-Treatment	
4625-4774	150	2620	RX Text--Radiation (Beam)	Text-Treatment	
4775-4924	150	2630	RX Text--Radiation Other	Text-Treatment	
4925-5124	200	2640	RX Text--Chemo	Text-Treatment	
5125-5324	200	2650	RX Text--Hormone	Text-Treatment	

Column #	Length	Item#	Item Name	Section	Note
5325-5424	100	2660	RX Text--BRM	Text-Treatment	
5425-5524	100	2670	RX Text--Other	Text-Treatment	
5525-5874	350	2680	Text--Remarks	Text-Miscellaneous	
5875-5924	50	2690	Place of Diagnosis	Text-Miscellaneous	
5925-6694	770	2700	Reserved 19	Text-Miscellaneous	Revised

CHAPTER IX

REQUIRED STATUS TABLE (ITEM # ORDER)

Effective with tumors diagnosed on or after January 1, 2003, Version 10.

The following table presents Version 10 of the NAACCR required status summarizing the requirements and recommendations for collection of each item by standard-setting groups. Differences from Version 9.1 are marked “Revised,” “New,” or “Retired” in the “Note” column of the table. Some changes are summarized in Appendix F.

The following abbreviations and symbols are used in the table:

NAACCR Exc	NAACCR committees are reviewing and will make recommendations in Version 10.1.
NAACCR Inc	NAACCR committees are reviewing and will make recommendations in Version 10.1.
NAACCR Full	NAACCR committees are reviewing and will make recommendations in Version 10.1.
NPCR	Refers to requirements and recommendations of the NPCR regarding data items that should be collected or computed by NPCR state registries. Note: Personal identifying data items that are collected are not transmitted to CDC.
COC	Refers to requirements of COC. Facilities should refer to the <i>COC FORDS Manual</i> for further clarification of required fields.
SEER	Refers to requirements of NCI’s SEER Program. Facilities and central registries should refer to the <i>SEER Program Code Manual</i> for further clarification of required fields.

Note: A code of “T” indicates that the required status of some staging data items depends upon the implementation date for the Collaborative Staging (CS) system. The CS data items will be required with 2003 or 2004 diagnoses, but the implementation date had not been finalized when this document went to press. The date of implementation for these data items will be noted on the NAACCR Web site (www.naacr.org) by no later than July 1, 2002. An updated “Required Status” table also will also be available at this site. The updated table will substitute “R,” “S,” “RH,” or “•” for the “T.”

Codes for Recommendations: R = Required. RH = Historically collected and currently transmitted. RC = Collected by SEER from COC-approved hospitals. RS = Required, site specific. S = Supplementary/recommended. D = Derived. T = Required status to be determined based upon implementation date of CS (see note on the first page of Chapter IX). • = Not in dataset but available. * = When available. # = Central registries may code available data using either the SEER or COC data item and associated rules. ^ = These text requirements may be met with one or several text block fields.

Item #	Item Name	NPCR	COC		SEER		Source of Standard	Note
			Collect	Transmit	Collect	Transmit		
10	Record Type	•	•	R	•	R	NAACCR	Revised
20	Patient ID Number	R	•	•	R	R	Reporting Registry	
30	Registry Type	•	•	•	•	•	NAACCR	
35	FIN Coding System	S	•	•	•	•	NAACCR	
37	Reserved 00	•	•	•	•	•		
40	Registry ID	S	•	•	R	R	NAACCR	
50	NAACCR Record Version	R	•	R	•	•	NAACCR	Revised
60	Tumor Record Number	S	•	•	R	R	NAACCR	
70	Addr at DX--City	R	R	R	R	•	COC	Revised
80	Addr at DX--State	R	R	R	R	•	NAACCR	Revised
90	County at DX	R	R	R	R	R	FIPS/SEER	
100	Addr at DX--Postal Code	R	R	R	R	•	NAACCR	Revised
110	Census Tract 1970/80/90	RH	•	•	RH	RH	SEER	Revised
120	Census Cod Sys 1970/80/90	RH	•	•	RH	RH	SEER	Revised
130	Census Tract 2000	R	•	•	R	R	SEER	Revised
140	Census Tract Cod Sys--Alt	•	•	•	•	•	NAACCR	Retired
150	Marital Status at DX	S	•	•	R	R	SEER	Revised
160	Race 1	R	R	R	R	R	SEER/COC	
161	Race 2	R	R	R	R	R	SEER/COC	
162	Race 3	R	R	R	R	R	SEER/COC	
163	Race 4	R	R	R	R	R	SEER/COC	
164	Race 5	R	R	R	R	R	SEER/COC	
170	Race Coding Sys--Current	•	R	R	•	•	NAACCR	Revised
180	Race Coding Sys--Original	•	R	R	•	•	NAACCR	Revised
190	Spanish/Hispanic Origin	R	R	R	R	R	SEER/COC	
200	Computed Ethnicity	S	•	•	R	R	NAACCR	
210	Computed Ethnicity Source	S	•	•	R	R	NAACCR	
220	Sex	R	R	R	R	R	SEER/COC	
230	Age at Diagnosis	R	R	R	R	R	SEER/COC	Revised
240	Birth Date	R	R	R	R	R	SEER/COC	
250	Birthplace	R*	R	R	R	R	SEER/COC	Revised
260	Religion	•	•	•	•	•	Varies	
270	Occupation Code--Census	S	•	•	•	•	Census/ NPCR	
280	Industry Code--Census	S	•	•	•	•	Census/ NPCR	
290	Occupation Source	S	•	•	•	•	NPCR	
300	Industry Source	S	•	•	•	•	NPCR	

Codes for Recommendations: R = Required. RH = Historically collected and currently transmitted. RC = Collected by SEER from COC-approved hospitals. RS = Required, site specific. S = Supplementary/recommended. D = Derived. T = Required status to be determined based upon implementation date of CS (see note on the first page of Chapter IX). • = Not in dataset but available. * = When available. # = Central registries may code available data using either the SEER or COC data item and associated rules. ^ = These text requirements may be met with one or several text block fields.

Item #	Item Name	NPCR	COC		SEER		Source of Standard	Note
			Collect	Transmit	Collect	Transmit		
310	Text--Usual Occupation	R*	•	•	•	•	NPCR	Revised
320	Text--Usual Industry	R*	•	•	•	•	NPCR	Revised
330	Occup/Ind Coding System	S	•	•	•	•	NPCR	
340	Tobacco History	•	•	•	•	•	Varies	Revised
350	Alcohol History	•	•	•	•	•	Varies	Revised
360	Family History of Cancer	•	•	•	•	•	Varies	Revised
362	Census Tract Block Group	•	•	•	•	•	Census	
364	Census Tr Cert 1970/80/90	RH	•	•	RH	RH	SEER	Revised
365	Census Tr Certainty 2000	R	•	•	R	R	SEER	New
370	Reserved 01	•	•	•	•	•		
380	Sequence Number--Central	R	•	•	R	R	NAACCR	
390	Date of Diagnosis	R	R	R	R	R	SEER/COC	
400	Primary Site	R	R	R	R	R	SEER/COC	
410	Laterality	R	R	R	R	R	SEER/COC	
419	Morph--Type&Behav ICD-O-2							
420	Histology (92-00) ICD-O-2	RH	•	RH	RH	RH	SEER/COC	Revised
430	Behavior (92-00) ICD-O-2	RH	•	RH	RH	RH	SEER/COC	Revised
440	Grade	R	R	R	R	R	SEER/COC	
450	Site Coding Sys--Current	S	R	R	•	•	NAACCR	Revised
460	Site Coding Sys--Original	•	R	R	•	•	NAACCR	Revised
470	Morph Coding Sys--Current	S	R	R	•	•	NAACCR	Revised
480	Morph Coding Sys--Originl	•	R	R	•	•	NAACCR	Revised
490	Diagnostic Confirmation	R	R	R	R	R	SEER/COC	
500	Type of Reporting Source	R	•	•	R	R	SEER	Revised
510	Screening Date	•	•	•	•	•	COC	Revised
520	Screening Result	•	•	•	•	•	COC	Revised
521	Morph--Type&Behav ICD-O-3							
522	Histologic Type ICD-O-3	R	R	R	R	R	SEER/COC	
523	Behavior Code ICD-O-3	R	R	R	R	R	SEER/COC	
530	Reserved 02	•	•	•	•	•		
538	Reporting Hospital FAN	•	•	•	•	•	COC	Revised
540	Reporting Hospital	S	R	R	R	•	COC	Revised
550	Accession Number--Hosp	S	R	R	R	•	COC	Revised
560	Sequence Number--Hospital	S	R	R	R	•	COC	Revised
570	Abstracted By	•	R	R	R	•	COC	Revised
580	Date of 1st Contact	R	R	R	•	•	NAACCR	Revised
590	Date of Inpatient Adm	•	•	•	•	•	COC	Revised
600	Date of Inpatient Disch	•	•	•	•	•	COC	Revised
610	Class of Case	S	R	R	RC	•	COC	Revised

Codes for Recommendations: R = Required. RH = Historically collected and currently transmitted. RC = Collected by SEER from COC-approved hospitals. RS = Required, site specific. S = Supplementary/recommended. D = Derived. T = Required status to be determined based upon implementation date of CS (see note on the first page of Chapter IX). • = Not in dataset but available. * = When available. # = Central registries may code available data using either the SEER or COC data item and associated rules. ^ = These text requirements may be met with one or several text block fields.

Item #	Item Name	NPCR	COC		SEER		Source of Standard	Note
			Collect	Transmit	Collect	Transmit		
620	Year First Seen This CA	•	•	•	•	•	COC	Revised
630	Primary Payer at DX	•	R	R	•	•	COC	
640	Inpatient/Outpt Status	•	•	•	•	•	COC	Revised
650	Presentation at CA Conf	•	•	•	•	•	COC	Revised
660	Date of CA Conference	•	•	•	•	•	COC	Revised
670	RX Hosp--Surg Prim Site	•	R	R	R	•	COC	Revised
672	RX Hosp--Scope Reg LN Sur	•	R	R	R	•	COC	Revised
674	RX Hosp--Surg Oth Reg/Dis	•	R	R	R	•	COC	Revised
676	RX Hosp--Reg LN Removed	•	•	•	•	•	COC	Revised
680	Reserved 03	•	•	•	•	•		
690	RX Hosp--Radiation	•	•	•	R	•	SEER	Revised
700	RX Hosp--Chemo	•	R	R	R	•	COC	Revised
710	RX Hosp--Hormone	•	R	R	R	•	COC	Revised
720	RX Hosp--BRM	•	R	R	R	•	COC	Revised
730	RX Hosp--Other	•	R	R	R	•	COC	Revised
740	RX Hosp--DX/Stg Proc	•	R	R	•	•	COC	Revised
742	RX Hosp--Screen/BX Proc1	•	•	•	•	•	COC	
743	RX Hosp--Screen/BX Proc2	•	•	•	•	•	COC	
744	RX Hosp--Screen/BX Proc3	•	•	•	•	•	COC	
745	RX Hosp--Screen/BX Proc4	•	•	•	•	•	COC	
750	Reserved 04	•	•	•	•	•		
759	SEER Summary Stage 2000	T	T	T	•	•	SEER	Revised
760	SEER Summary Stage 1977	RH	•	RH	•	•	SEER	Revised
770	Loc/Reg/Distant Stage	•	•	•	•	•	Varies	
779	Extent of Disease 10-Dig							
780	EOD--Tumor Size	T	T	T	T	T	SEER/COC	Revised
790	EOD--Extension	T	•	•	T	T	SEER	Revised
800	EOD--Extension Prost Path	T	•	•	T	T	SEER	Revised
810	EOD--Lymph Node Involv	T	•	•	T	T	SEER	Revised
820	Regional Nodes Positive	S	R	R	R	R	SEER/COC	
830	Regional Nodes Examined	S	R	R	R	R	SEER/COC	
840	EOD--Old 13 Digit	•	•	•	RH	RH	SEER	Revised
850	EOD--Old 2 Digit	•	•	•	RH	RH	SEER	Revised
860	EOD--Old 4 Digit	•	•	•	RH	RH	SEER	Revised
870	Coding System for EOD	•	•	•	R	R	SEER	
880	TNM Path T	•	R	R	•	•	AJCC	
890	TNM Path N	•	R	R	•	•	AJCC	
900	TNM Path M	•	R	R	•	•	AJCC	
910	TNM Path Stage Group	•	R	R	•	•	AJCC	

Codes for Recommendations: R = Required. RH = Historically collected and currently transmitted. RC = Collected by SEER from COC-approved hospitals. RS = Required, site specific. S = Supplementary/recommended. D = Derived. T = Required status to be determined based upon implementation date of CS (see note on the first page of Chapter IX). • = Not in dataset but available. * = When available. # = Central registries may code available data using either the SEER or COC data item and associated rules. ^ = These text requirements may be met with one or several text block fields.

Item #	Item Name	NPCR	COC		SEER		Source of Standard	Note
			Collect	Transmit	Collect	Transmit		
920	TNM Path Descriptor	•	R	R	•	•	COC	Revised
930	TNM Path Staged By	•	R	R	•	•	COC	
940	TNM Clin T	•	R	R	•	•	AJCC	
950	TNM Clin N	•	R	R	•	•	AJCC	
960	TNM Clin M	•	R	R	•	•	AJCC	
970	TNM Clin Stage Group	•	R	R	•	•	AJCC	
980	TNM Clin Descriptor	•	R	R	•	•	COC	Revised
990	TNM Clin Staged By	•	R	R	•	•	COC	
1000	TNM Other T	•	•	•	•	•	AJCC	Revised
1010	TNM Other N	•	•	•	•	•	AJCC	Revised
1020	TNM Other M	•	•	•	•	•	AJCC	Revised
1030	TNM Other Stage Group	•	•	•	•	•	AJCC	Revised
1040	TNM Other Staged By	•	•	•	•	•	COC	Revised
1050	TNM Other Descriptor	•	•	•	•	•	COC	Revised
1060	TNM Edition Number	•	R	R	•	•	COC	
1070	Other Staging System	•	•	•	•	•	COC	Revised
1080	Date of 1st Positive BX	•	•	•	•	•	COC	Revised
1090	Site of Distant Met 1	•	•	RH	•	•	COC	Revised
1100	Site of Distant Met 2	•	•	RH	•	•	COC	Revised
1110	Site of Distant Met 3	•	•	RH	•	•	COC	Revised
1120	Pediatric Stage	•	•	•	•	•	COC	Revised
1130	Pediatric Staging System	•	•	•	•	•	COC	Revised
1140	Pediatric Staged By	•	•	•	•	•	COC	Revised
1150	Tumor Marker 1	•	•	•	RH	T	SEER	Revised
1160	Tumor Marker 2	•	•	•	RH	T	SEER	Revised
1170	Tumor Marker 3	•	•	•	RH	T	SEER	Revised
1180	Reserved 05	•	•	•	•	•		
1190	Reserved 06	•	•	•	•	•		
1200	RX Date--Surgery	S	R	R	•	•	COC	
1210	RX Date--Radiation	S	R	R	•	•	COC	
1220	RX Date--Chemo	•	•	•	•	•	COC	Revised
1230	RX Date--Hormone	•	•	•	•	•	COC	Revised
1240	RX Date--BRM	•	•	•	•	•	COC	Revised
1250	RX Date--Other	S	R	R	•	•	COC	
1260	Date of Initial RX--SEER	#	•	•	R	R	SEER	
1270	Date of 1st Crs RX--COC	#	R	R	•	•	COC	
1280	RX Date--DX/Stg Proc	•	R	R	•	•	COC	
1290	RX Summ--Surg Prim Site	R	R	R	R	R	SEER/COC	

Codes for Recommendations: R = Required. RH = Historically collected and currently transmitted. RC = Collected by SEER from COC-approved hospitals. RS = Required, site specific. S = Supplementary/recommended. D = Derived. T = Required status to be determined based upon implementation date of CS (see note on the first page of Chapter IX). • = Not in dataset but available. * = When available. # = Central registries may code available data using either the SEER or COC data item and associated rules. ^ = These text requirements may be met with one or several text block fields.

Item #	Item Name	NPCR	COC		SEER		Source of Standard	Note
			Collect	Transmit	Collect	Transmit		
1292	RX Summ--Scope Reg LN Sur	R	R	R	R	R	SEER/COC	
1294	RX Summ--Surg Oth Reg/Dis	R	R	R	R	R	SEER/COC	
1296	RX Summ--Reg LN Examined	•	•	•	R	R	SEER/COC	Revised
1300	Reserved 07	•	•	•	•	•		
1310	RX Summ--Surgical Approch	•	•	•	•	•	COC	Revised
1320	RX Summ--Surgical Margins	•	R	R	•	•	COC	
1330	RX Summ--Reconstruct 1st	•	•	•	RH	RH	COC	Revised
1340	Reason for No Surgery	S	R	R	R	R	SEER/COC	Revised
1350	RX Summ--DX/Stg Proc	•	R	R	•	•	COC	
1360	RX Summ--Radiation	•	•	•	R	R	SEER	Revised
1370	RX Summ--Rad to CNS	•	•	•	RH	RH	SEER/COC	Revised
1380	RX Summ--Surg/Rad Seq	S	R	R	R	R	SEER/COC	Revised
1390	RX Summ--Chemo	S	R	R	R	R	SEER/COC	
1400	RX Summ--Hormone	S	R	R	R	R	SEER/COC	
1410	RX Summ--BRM	S	R	R	R	R	SEER/COC	
1420	RX Summ--Other	S	R	R	R	R	SEER/COC	
1430	Reason for No Radiation	S	R	R	•	•	COC	Revised
1440	Reason for No Chemo	•	•	•	•	•	COC	Revised
1450	Reason for No Hormone	•	•	•	•	•	COC	Revised
1460	RX Coding System--Current	R	R	R	•	•	NAACCR	Revised
1470	Protocol Eligibility Stat	•	•	•	•	•	COC	Revised
1480	Protocol Participation	•	•	•	•	•	COC	Revised
1490	Referral to Support Serv	•	•	•	•	•	COC	Revised
1500	First Course Calc Method	•	•	•	•	•	NAACCR	
1510	Rad--Regional Dose: cGy	•	R	R	•	•	COC	Revised
1520	Rad--No of Treatment Vol	•	R	R	•	•	COC	Revised
1530	Rad--Elapsed RX Days	•	•	•	•	•	COC	Revised
1540	Rad--Treatment Volume	•	R	R	•	•	COC	Revised
1550	Rad--Location of RX	•	R	R	•	•	COC	Revised
1560	Rad--Intent of Treatment	•	•	•	•	•	COC	Revised
1570	Rad--Regional RX Modality	S	R	R	RC		COC	Revised
1580	Rad--RX Completion Status	•	•	•	•	•	COC	Revised
1590	Rad--Local Control Status	•	•	•	•	•	COC	Revised
1600	Chemotherapy Field 1	•	•	•	•	•	COC	Revised
1610	Chemotherapy Field 2	•	•	•	•	•	COC	Revised
1620	Chemotherapy Field 3	•	•	•	•	•	COC	Revised
1630	Chemotherapy Field 4	•	•	•	•	•	COC	Revised
1640	RX Summ--Surgery Type	•	•	•	RH	RH	SEER	Revised
1642	RX Summ--Screen/BX Proc1	•	•	•	•	•	COC	Revised

Codes for Recommendations: R = Required. RH = Historically collected and currently transmitted. RC = Collected by SEER from COC-approved hospitals. RS = Required, site specific. S = Supplementary/recommended. D = Derived. T = Required status to be determined based upon implementation date of CS (see note on the first page of Chapter IX). • = Not in dataset but available. * = When available. # = Central registries may code available data using either the SEER or COC data item and associated rules. ^ = These text requirements may be met with one or several text block fields.

Item #	Item Name	NPCR	COC		SEER		Source of Standard	Note
			Collect	Transmit	Collect	Transmit		
1643	RX Summ--Screen/BX Proc2	•	•	•	•	•	COC	Revised
1644	RX Summ--Screen/BX Proc3	•	•	•	•	•	COC	Revised
1645	RX Summ--Screen/BX Proc4	•	•	•	•	•	COC	Revised
1650	Reserved 08	•	•	•	•	•		
1660	Subsq RX 2nd Course Date	•	•	•	•	•	COC	Revised
1670	Subsq RX 2nd Course Codes							
1671	Subsq RX 2nd Course Surg	•	•	•	•	•	COC	Revised
1672	Subsq RX 2nd Course Rad	•	•	•	•	•	COC	Revised
1673	Subsq RX 2nd Course Chemo	•	•	•	•	•	COC	Revised
1674	Subsq RX 2nd Course Horm	•	•	•	•	•	COC	Revised
1675	Subsq RX 2nd Course BRM	•	•	•	•	•	COC	Revised
1676	Subsq RX 2nd Course Oth	•	•	•	•	•	COC	Revised
1677	Subsq RX 2nd--Scope LN SU	•	•	•	•	•	COC	Revised
1678	Subsq RX 2nd--Surg Oth	•	•	•	•	•	COC	Revised
1679	Subsq RX 2nd--Reg LN Rem	•	•	•	•	•	COC	Revised
1680	Subsq RX 3rd Course Date	•	•	•	•	•	COC	Revised
1690	Subsq RX 3rd Course Codes							
1691	Subsq RX 3rd Course Surg	•	•	•	•	•	COC	Revised
1692	Subsq RX 3rd Course Rad	•	•	•	•	•	COC	Revised
1693	Subsq RX 3rd Course Chemo	•	•	•	•	•	COC	Revised
1694	Subsq RX 3rd Course Horm	•	•	•	•	•	COC	Revised
1695	Subsq RX 3rd Course BRM	•	•	•	•	•	COC	Revised
1696	Subsq RX 3rd Course Oth	•	•	•	•	•	COC	Revised
1697	Subsq RX 3rd--Scope LN Su	•	•	•	•	•	COC	Revised
1698	Subsq RX 3rd--Surg Oth	•	•	•	•	•	COC	Revised
1699	Subsq RX 3rd--Reg LN Rem	•	•	•	•	•	COC	Revised
1700	Subsq RX 4th Course Date	•	•	•	•	•	COC	Revised
1710	Subsq RX 4th Course Codes							
1711	Subsq RX 4th Course Surg	•	•	•	•	•	COC	Revised
1712	Subsq RX 4th Course Rad	•	•	•	•	•	COC	Revised
1713	Subsq RX 4th Course Chemo	•	•	•	•	•	COC	Revised
1714	Subsq RX 4th Course Horm	•	•	•	•	•	COC	Revised
1715	Subsq RX 4th Course BRM	•	•	•	•	•	COC	Revised
1716	Subsq RX 4th Course Oth	•	•	•	•	•	COC	Revised
1717	Subsq RX 4th--Scope LN Su	•	•	•	•	•	COC	Revised
1718	Subsq RX 4th--Surg Oth	•	•	•	•	•	COC	Revised
1719	Subsq RX 4th--Reg LN Rem	•	•	•	•	•	COC	Revised
1720	Subsq RX 5th Course Date	•	•	•	•	•	NAACCR	Revised
1730	Subsq RX 5th Course Codes							

Codes for Recommendations: R = Required. RH = Historically collected and currently transmitted. RC = Collected by SEER from COC-approved hospitals. RS = Required, site specific. S = Supplementary/recommended. D = Derived. T = Required status to be determined based upon implementation date of CS (see note on the first page of Chapter IX). • = Not in dataset but available. * = When available. # = Central registries may code available data using either the SEER or COC data item and associated rules. ^ = These text requirements may be met with one or several text block fields.

Item #	Item Name	NPCR	COC		SEER		Source of Standard	Note
			Collect	Transmit	Collect	Transmit		
1731	Subsq RX 5th Course Surg	•	•	•	•	•	NAACCR	Revised
1732	Subsq RX 5th Course Rad	•	•	•	•	•	NAACCR	Revised
1733	Subsq RX 5th Course Chemo	•	•	•	•	•	NAACCR	Revised
1734	Subsq RX 5th Course Horm	•	•	•	•	•	NAACCR	Revised
1735	Subsq RX 5th Course BRM	•	•	•	•	•	NAACCR	Revised
1736	Subsq RX 5th Course Oth	•	•	•	•	•	NAACCR	Revised
1737	Subsq RX 5th--Scope LN Su	•	•	•	•	•	NAACCR	Revised
1738	Subsq RX 5th--Surg Oth	•	•	•	•	•	NAACCR	Revised
1739	Subsq RX 5th--Reg LN Rem	•	•	•	•	•	NAACCR	Revised
1740	Reserved 09	•	•	•	•	•		
1741	Subsq RX--Reconstruct Del	•	•	•	•	•	COC	Revised
1750	Date of Last Contact	R	R	R	R	R	SEER/COC	
1760	Vital Status	R	R	R	R	R	SEER/COC	
1770	Cancer Status	•	R	R	•	•	COC	
1780	Quality of Survival	•	•	•	•	•	COC	Revised
1790	Follow-Up Source	•	R		•	•	COC	Revised
1800	Next Follow-Up Source	•	R		•	•	COC	Revised
1810	Addr Current--City	•	R		R	•	COC	Revised
1820	Addr Current--State	•	R		R	•	NAACCR	Revised
1830	Addr Current--Postal Code	•	R		R	•	NAACCR	Revised
1835	Reserved 10	•	•	•	•	•		
1840	County--Current	•	•	•	•	•	COC	Revised
1842	Follow-Up Contact--City	•	•	•	R	•	NAACCR	Revised
1844	Follow-Up Contact--State	•	•	•	R	•	NAACCR	Revised
1846	Follow-Up Contact--Postal	•	•	•	R	•	NAACCR	Revised
1850	Unusual Follow-Up Method	•	•	•	•	•	COC	Revised
1860	Recurrence Date--1st	S	R	R	RC	•	COC	Revised
1871	Recurrence Distant Site 1	•	•	•	•	•	COC	Revised
1872	Recurrence Distant Site 2	•	•	•	•	•	COC	Revised
1873	Recurrence Distant Site 3	•	•	•	•	•	COC	Revised
1880	Recurrence Type--1st	S	R	R	RC	•	COC	Revised
1890	Recurrence Type--1st--Oth	•	•	•	•	•	COC	Revised
1900	Reserved 11	•	•	•	•	•		
1910	Cause of Death	R	•	•	R	R	SEER/COC	Revised
1920	ICD Revision Number	R	•	•	R	R	SEER/COC	Revised
1930	Autopsy	•	•	•	•	•	COC	Revised
1940	Place of Death	S	•	•	•	•	NAACCR	
1950	Reserved 12	•	•	•	•	•		
1960	Site (73-91) ICD-O-1	•	•	RH	RH	RH	SEER	Revised

Codes for Recommendations: R = Required. RH = Historically collected and currently transmitted. RC = Collected by SEER from COC-approved hospitals. RS = Required, site specific. S = Supplementary/recommended. D = Derived. T = Required status to be determined based upon implementation date of CS (see note on the first page of Chapter IX). • = Not in dataset but available. * = When available. # = Central registries may code available data using either the SEER or COC data item and associated rules. ^ = These text requirements may be met with one or several text block fields.

Item #	Item Name	NPCR	COC		SEER		Source of Standard	Note
			Collect	Transmit	Collect	Transmit		
1971	Histology (73-91) ICD-O-1	•	•	RH	RH	RH	SEER	Revised
1972	Behavior (73-91) ICD-O-1	•	•	RH	RH	RH	SEER	Revised
1973	Grade (73-91) ICD-O-1	•	•	RH	RH	RH	SEER	Revised
1980	ICD-O-2 Conversion Flag	•	R	R	RH	RH	SEER	Revised
1981	Over-ride SS/NodesPos	•	•	•	•	•	NAACCR	
1982	Over-ride SS/TNM-N	•	•	•	•	•	NAACCR	
1983	Over-ride SS/TNM-M	•	•	•	•	•	NAACCR	
1984	Over-ride SS/DisMet1	•	•	•	•	•	NAACCR	
1985	Over-ride Acsn/Class/Seq	•	R	R	•	•	NAACCR	Revised
1986	Over-ride HospSeq/DxConf	•	R	R	•	•	NAACCR	Revised
1987	Over-ride COC-Site/Type	•	R	R	•	•	NAACCR	Revised
1988	Over-ride HospSeq/Site	•	R	R	•	•	NAACCR	Revised
1989	Over-ride Site/TNM-StgGrp	•	R	R	•	•	NAACCR	Revised
1990	Over-ride Age/Site/Morph	R	R	R	R	R	SEER	Revised
2000	Over-ride SeqNo/DxConf	R	•	•	R	R	SEER	
2010	Over-ride Site/Lat/SeqNo	S	•	•	R	R	SEER	
2020	Over-ride Surg/DxConf	R	R	R	R	R	SEER	Revised
2030	Over-ride Site/Type	R	R	R	R	R	SEER	Revised
2040	Over-ride Histology	R	R	R	R	R	SEER	Revised
2050	Over-ride Report Source	R	•	•	R	R	SEER	
2060	Over-ride Ill-define Site	R	•	•	R	R	SEER	
2070	Over-ride Leuk, Lymphoma	R	R	R	R	R	SEER	Revised
2071	Over-ride Site/Behavior	R	R	R	R	R	SEER	Revised
2072	Over-ride Site/EOD/DX Dt	S	•	•	R	R	SEER	
2073	Over-ride Site/Lat/EOD	S	•	•	R	R	SEER	
2074	Over-ride Site/Lat/Morph	R	R	R	R	R	SEER	Revised
2081	CRC CHECKSUM	•	•	•	•	•	NAACCR	
2090	Date Case Completed	•	•	•	•	•	Varies	
2100	Date Case Last Changed	•	•	•	•	•	Varies	
2110	Date Case Report Exported	S	•	R	•	•	NAACCR	Revised
2111	Date Case Report Received	R	•	•	•	•	NAACCR	
2112	Date Case Report Loaded	S	•	•	•	•	NAACCR	
2113	Date Tumor Record Availbl	S	•	•	•	•	NAACCR	
2114	Future Use Timeliness 1	•	•	•	•	•		
2115	Future Use Timeliness 2	•	•	•	•	•		
2116	ICD-O-3 Conversion Flag	R	R	R	R	R	SEER/COC	
2120	SEER Coding Sys--Current	S	•	•	•	•	NAACCR	
2130	SEER Coding Sys--Original	S	•	•	•	•	NAACCR	
2140	COC Coding Sys--Current	S	R	R	•	•	COC	Revised

Codes for Recommendations: R = Required. RH = Historically collected and currently transmitted. RC = Collected by SEER from COC-approved hospitals. RS = Required, site specific. S = Supplementary/recommended. D = Derived. T = Required status to be determined based upon implementation date of CS (see note on the first page of Chapter IX). • = Not in dataset but available. * = When available. # = Central registries may code available data using either the SEER or COC data item and associated rules. ^ = These text requirements may be met with one or several text block fields.

Item #	Item Name	NPCR	COC		SEER		Source of Standard	Note
			Collect	Transmit	Collect	Transmit		
2150	COC Coding Sys--Original	S	R	R	•	•	NAACCR	Revised
2160	Subsq Report for Primary	•	•	•	•	•	NAACCR	Retired
2161	Reserved for Expansion	•	•	•	•	•		Retired
2170	Vendor Name	•	•	R	•	•	NAACCR	Revised
2180	SEER Type of Follow-Up	•	•	•	R	R	SEER	
2190	SEER Record Number	•	•	•	R	R	SEER	
2200	Diagnostic Proc 73-87	•	•	•	RH	RH	SEER	Revised
2210	Reserved for Expansion	•	•	•	•	•		
2220	State/Requestor Items	•	•	•	•	•	Varies	
2230	Name--Last	R	R	•	R	•	NAACCR	Revised
2240	Name--First	R	R	•	R	•	NAACCR	Revised
2250	Name--Middle	R	R	•	R	•	COC	Revised
2260	Name--Prefix	•	•	•	•	•	COC	Revised
2270	Name--Suffix	•	•	•	R	•	COC	Revised
2280	Name--Alias	S	•	•	R	•	COC	Revised
2290	Name--Spouse/Parent	•	•	•	•	•	Varies	
2300	Medical Record Number	S	R	•	R	•	NAACCR	Revised
2310	Military Record No Suffix	•	R	•	•	•	COC	
2320	Social Security Number	R	R	•	R	•	COC	Revised
2330	Addr at DX--No & Street	S	R	•	R	•	COC	Revised
2335	Addr at DX--Supplementl	S	R	•	•	•	NAACCR	New
2350	Addr Current--No & Street	•	R	•	R	•	COC	Revised
2352	Latitude	•	•	•	•	•	NAACCR	New
2354	Longitude	•	•	•	•	•	NAACCR	New
2355	Addr Current--Supplementl	•	R	•	•	•	NAACCR	New
2360	Telephone	•	R	•	R	•	COC	Revised
2370	DC State	•	•	•	•	•		Retired
2371	Reserved for Expansion	•	•	•	•	•		Retired
2380	DC State File Number	S	•	•	•	•	State	
2390	Name--Maiden	S	•	•	R	•	NAACCR	Revised
2392	Follow-Up Contact--No&St	•	•	•	R	•	NAACCR	Revised
2393	Follow-Up Contact--Suppl	•	•	•	•	•	NAACCR	New
2394	Follow-Up Contact--Name	•	•	•	R	•	NAACCR	Revised
2400	Reserved for Expansion	•	•	•	•	•		Retired
2410	Institution Referred From	•	R	•	•	•	NAACCR	Revised
2420	Institution Referred To	•	R	•	•	•	NAACCR	Revised
2430	Last Follow-Up Hospital	•	•	•	•	•	NAACCR	
2440	Following Registry	•	R	•	R	•	NAACCR	Revised
2450	Reserved for Expansion	•	•	•	•	•		Retired

Codes for Recommendations: R = Required. RH = Historically collected and currently transmitted. RC = Collected by SEER from COC-approved hospitals. RS = Required, site specific. S = Supplementary/recommended. D = Derived. T = Required status to be determined based upon implementation date of CS (see note on the first page of Chapter IX). • = Not in dataset but available. * = When available. # = Central registries may code available data using either the SEER or COC data item and associated rules. ^ = These text requirements may be met with one or several text block fields.

Item #	Item Name	NPCR	COC		SEER		Source of Standard	Note
			Collect	Transmit	Collect	Transmit		
2460	Physician--Managing	•	•	•	•	•	COC	Revised
2470	Physician--Follow-Up	•	R	•	R	•	COC	
2480	Physician--Primary Surg	•	R	•	•	•	COC	
2490	Physician 3	•	R	•	•	•	COC	Revised
2500	Physician 4	•	R	•	•	•	COC	Revised
2520	Text--DX Proc--PE	R^	•	•	R	•	NAACCR	Revised
2530	Text--DX Proc--X-ray/scan	R^	•	•	R	•	NAACCR	Revised
2540	Text--DX Proc--Scopes	R^	•	•	R	•	NAACCR	Revised
2550	Text--DX Proc--Lab Tests	R^	•	•	R	•	NAACCR	Revised
2560	Text--DX Proc--Op	R^	•	•	R	•	NAACCR	Revised
2570	Text--DX Proc--Path	R^	•	•	R	•	NAACCR	Revised
2580	Text--Primary Site Title	S	•	•	R	•	NAACCR	Revised
2590	Text--Histology Title	S	•	•	R	•	NAACCR	Revised
2600	Text--Staging	R^	•	•	R	•	NAACCR	Revised
2610	RX Text--Surgery	R^	•	•	R	•	NAACCR	Revised
2620	RX Text--Radiation (Beam)	S	•	•	R	•	NAACCR	Revised
2630	RX Text--Radiation Other	S	•	•	R	•	NAACCR	Revised
2640	RX Text--Chemo	S	•	•	R	•	NAACCR	Revised
2650	RX Text--Hormone	S	•	•	R	•	NAACCR	Revised
2660	RX Text--BRM	S	•	•	R	•	NAACCR	Revised
2670	RX Text--Other	S	•	•	R	•	NAACCR	Revised
2680	Text--Remarks	S	•	•	R	•	NAACCR	Revised
2690	Place of Diagnosis	S	•	•	•	•	NAACCR	
2700	Reserved 19	•	•	•	•	•		
2800	CS Tumor Size	T	T	T	T	T	AJCC	New
2810	CS Extension	T	T	T	T	T	AJCC	New
2820	CS Tumor Size/Ext Eval	T	T	T	•	•	AJCC	New
2830	CS Lymph Nodes	T	T	T	T	T	AJCC	New
2840	CS Reg Nodes Eval	T	T	T	•	•	AJCC	New
2850	CS Mets at DX	T	T	T	T	T	AJCC	New
2860	CS Mets Eval	T	T	T	•	•	AJCC	New
2880	CS Site-Specific Factor 1	T	T	T	T	T	AJCC	New
2890	CS Site-Specific Factor 2	T	T	T	T	T	AJCC	New
2900	CS Site-Specific Factor 3	T	T	T	T	T	AJCC	New
2910	CS Site-Specific Factor 4	T	T	T	T	T	AJCC	New
2920	CS Site-Specific Factor 5	T	T	T	T	T	AJCC	New
2930	CS Site-Specific Factor 6	T	T	T	T	T	AJCC	New
2940	Derived AJCC T	T	T	T	T	T	AJCC	New
2950	Derived AJCC T Descriptor	T	T	T	•	•	AJCC	New

Codes for Recommendations: R = Required. RH = Historically collected and currently transmitted. RC = Collected by SEER from COC-approved hospitals. RS = Required, site specific. S = Supplementary/recommended. D = Derived. T = Required status to be determined based upon implementation date of CS (see note on the first page of Chapter IX). • = Not in dataset but available. * = When available. # = Central registries may code available data using either the SEER or COC data item and associated rules. ^ = These text requirements may be met with one or several text block fields.

Item #	Item Name	NPCR	COC		SEER		Source of Standard	Note
			Collect	Transmit	Collect	Transmit		
2960	Derived AJCC N	T	T	T	T	T	AJCC	New
2970	Derived AJCC N Descriptor	T	T	T	•	•	AJCC	New
2980	Derived AJCC M	T	T	T	T	T	AJCC	New
2990	Derived AJCC M Descriptor	T	T	T	•	•	AJCC	New
3000	Derived AJCC Stage Group	T	T	T	T	T	AJCC	New
3010	Derived SS1977	T	T	T	T	T	AJCC	New
3020	Derived SS2000	T	T	T	T	T	AJCC	New
3030	Derived AJCC--Flag	T	T	T	T	T	AJCC	New
3040	Derived SS1977--Flag	T	T	T	T	T	AJCC	New
3050	Derived SS2000--Flag	T	T	T	T	T	AJCC	New
3100	Archive FIN	•	R	R	•	•	COC	New
3110	Comorbid/Complication 1	•	R	R	•	•	COC	New
3120	Comorbid/Complication 2	•	R	R	•	•	COC	New
3130	Comorbid/Complication 3	•	R	R	•	•	COC	New
3140	Comorbid/Complication 4	•	R	R	•	•	COC	New
3150	Comorbid/Complication 5	•	R	R	•	•	COC	New
3160	Comorbid/Complication 6	•	R	R	•	•	COC	New
3170	RX Date--Most Defin Surg	S	R	R	•	•	COC	New
3180	RX Date--Surgical Disch	•	R	R	•	•	COC	New
3190	Readm Same Hosp 30 Days	•	R	R	•	•	COC	New
3200	Rad--Boost RX Modality	•	R	R			COC	New
3210	Rad--Boost Dose cGy	•	R	R	•	•	COC	New
3220	RX Date--Radiation Ended	•	R	R	•	•	COC	New
3230	RX Date--Systemic	S	R	R	•	•	COC	New
3250	RX Summ--Transplnt/Endocr	S	R	R	R	R	COC	New
3260	Pain Assessment	•	R	R	•	•	COC	New
3270	RX Summ--Palliative Proc	•	R	R	•	•	COC	New
3280	RX Hosp--Palliative Proc	•	R	R	•	•	COC	New
3300	RuralUrban Continuum 1993	D	•	•	D	D	NAACCR	New
3310	RuralUrban Continuum 2000	D	•	•	D	D	NAACCR	New

Codes for Recommendations: R = Required. RH = Historically collected and currently transmitted. RC = Collected by SEER from COC-approved hospitals. RS = Required, site specific. S = Supplementary/recommended. D = Derived. T = Required status to be determined based upon implementation date of CS (see note on the first page of Chapter IX). • = Not in dataset but available. * = When available. # = Central registries may code available data using either the SEER or COC data item and associated rules. ^ = These text requirements may be met with one or several text block fields.

CHAPTER X

DATA DESCRIPTOR TABLE (ITEM # ORDER)

The following table presents Version 10 of the NAACCR data descriptor table summarizing the item number, item name, data type, format, allowable values, and length of each item. The sort is in the Item Number order. Differences from Version 9.1 are marked “Revised,” “New,” or “Retired” in the “Note” column of the table. Some changes also are summarized in Appendix F.

A program that generates a file of records in the NAACCR data exchange format should handle instances where information is unavailable for any given field. A general rule is as follows:

When ALL of the records in the file to be generated contain no information on a specific data item, then the corresponding columns in the exchange record should be left as blanks.

When some of the records contain information for a given field, and other records will not contain information for that field, then the code that indicates “unknown,” “not available,” or “not applicable” (as appropriate) must be written in the corresponding columns in the exchange record.

Examples:

- ❖ You are submitting data in NAACCR 10 format, but your registry does not collect data on AJCC stage. The columns in the file you generate that are supposed to contain the information on AJCC stage should all contain blanks.
- ❖ You are submitting data in NAACCR 10 format, and you collect information on surgery date. However, in some cases the date is not there because your program stores it as a date-time variable and either no surgery was given, it is unknown whether surgery was given, or it was an autopsy or death certificate-only (DCO) case. Those columns in the file you generate must contain no blanks; instead, the columns should contain “99999999” when it is unknown whether or not surgery was given or when the case was DCO or autopsy-only, and “00000000” when no surgery was given.

Exception:

- ❖ You are submitting in the NAACCR 10 format, and cases diagnosed in the years 1997-2001 are included. The Morph--Type&Behavior ICD-O-2 fields should contain the original ICD-O-2 codes for cases diagnosed in or before 2000, but the fields should be blank for cases diagnosed in 2001 (unless you have back-translated the ICD-O-3 morphology codes).

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
10	Record Type	Character		I, C, A, U, R, M	1	Revised
20	Patient ID Number	Character	Right justified, zero filled		8	
30	Registry Type	Character		1-3	1	
35	FIN Coding System	Character		1-3, 9	1	Revised
37	Reserved 00	Character			7	
40	Registry ID	Character	Right justified, zero filled	10-digit number. Reference to EDITS table REGID.DBF in Appendix B	10	Revised
50	NAACCR Record Version	Character		Blank, 1, 4-9, A	1	Revised
60	Tumor Record Number	Character	Right justified, zero filled	01-99	2	
70	Addr at DX--City	Character	Mixed case letters, no special characters, embedded spaces allowed, left justified, blank filled	City Name or UNKNOWN	20	
80	Addr at DX--State	Character	Upper case	Refer to EDITS table STATE.DBF in Appendix B	2	
90	County at DX	Character	Right justified, zero filled	See Appendix A for standard FIPS county codes. See Edits table BPLACE.DBF in Appendix B for geocodes used by CoC for non-U.S. residents. Also 998, 999.	3	
100	Addr at DX--Postal Code	Character	Numbers or upper case letters. No special characters or embedded spaces allowed. Left justified, blank filled.	5-digit or 9-digit U.S. ZIP codes; 6 character Canadian postal codes; valid postal codes from other countries, 888888888, 999999999	9	
110	Census Tract 1970/80/90	Character	Right justified, zero filled	Census Tract Codes 000100-949999, BNA Codes 950100-998999, 000000, 999999, blank	6	Revised
120	Census Cod Sys 1970/80/90	Character		0-3, blank	1	Revised
130	Census Tract 2000	Character	Right justified, zero filled	Census Tract Codes 000101-999998, 000000, 999999, blank	6	Revised
140	Census Tract Cod Sys--Alt	Character			0	Retired
150	Marital Status at DX	Character		1-5, 9	1	
160	Race 1	Character	Right justified, zero filled	01-14, 20-22, 25-28, 30-32, 96-99	2	
161	Race 2	Character	Right justified, zero filled	01-14, 20-22, 25-28, 30-32, 88, 96-99, blank	2	

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
162	Race 3	Character	Right justified, zero filled	01-14, 20-22, 25-28, 30-32, 88, 96-99, blank	2	
163	Race 4	Character	Right justified, zero filled	01-14, 20-22, 25-28, 30-32, 88, 96-99, blank	2	
164	Race 5	Character	Right justified, zero filled	01-14, 20-22, 25-28, 30-32, 88, 96-99, blank	2	
170	Race Coding Sys--Current	Character		1-6, 9	1	
180	Race Coding Sys--Original	Character		1-6, 9	1	
190	Spanish/Hispanic Origin	Character		0-7, 9	1	
200	Computed Ethnicity	Character		0-7, blank	1	
210	Computed Ethnicity Source	Character		0-9, blank	1	
220	Sex	Character		1-4, 9	1	
230	Age at Diagnosis	Character	Right justified, zero filled	000-120, 999	3	
240	Birth Date	Character	MMDDCCYY	Valid date or 99999999	8	
250	Birthplace	Character	Right justified, zero filled	Reference to EDITS table BPLACE.DBF in Appendix B	3	
260	Religion	Character	No standard	Any	2	
270	Occupation Code--Census	Character		Reference Industry and Occupation Coding for Death Certificates	3	
280	Industry Code--Census	Character		Reference Industry and Occupation Coding for Death Certificates	3	
290	Occupation Source	Character		0-3, 7-9, blank	1	
300	Industry Source	Character		0-3, 7-9, blank	1	
310	Text--Usual Occupation	Character	Free text	Neither carriage return nor line feed characters allowed	40	
320	Text--Usual Industry	Character	Free text	Neither carriage return nor line feed characters allowed	40	
330	Occup/Ind Coding System	Character		1-4, 7, 9, blank	1	
340	Tobacco History	Character	No standard	Any	1	
350	Alcohol History	Character	No standard	Any	1	
360	Family History of Cancer	Character	No standard	Any	1	
362	Census Tract Block Group	Character	No standard	Any	1	
364	Census Tr Cert 1970/80/90	Character		1-5, 9, blank	1	Revised
365	Census Tr Certainty 2000	Character		1-5, 9, blank	1	New
370	Reserved 01	Character			20	
380	Sequence Number--Central	Character	Right justified, zero filled	00-35, 60-87, 88, 99	2	Revised
390	Date of Diagnosis	Character	MMDDCCYY	Valid date or 99999999	8	
400	Primary Site	Character	C followed by 3 digits, no special characters, no embedded blanks	Reference ICD-O-3 for valid entries	4	

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
410	Laterality	Character		0-4, 9	1	
419	Morph--Type&Behav ICD-O-2	Character		Reference to ICD-0-2	5	
420	Histology (92-00) ICD-O-2	Character		Reference to ICD-0-2	4	
430	Behavior (92-00) ICD-O-2	Character		Reference to ICD-0-2	1	
440	Grade	Character		1-9	1	
450	Site Coding Sys--Current	Character		1-6, 9	1	
460	Site Coding Sys--Original	Character		1-6, 9	1	
470	Morph Coding Sys--Current	Character		1-7, 9	1	
480	Morph Coding Sys--Originl	Character		1-7, 9	1	
490	Diagnostic Confirmation	Character		1, 2, 4-9	1	
500	Type of Reporting Source	Character		1, 3-7	1	
510	Screening Date	Character	MMDDCCYY	Valid date, 00000000, 99999999	8	
520	Screening Result	Character		0-4, 8, 9	1	
521	Morph--Type&Behav ICD-O-3	Character		Reference to ICD-O-3	5	
522	Histologic Type ICD-O-3	Character		Reference to ICD-O-3	4	
523	Behavior Code ICD-O-3	Character		Reference to ICD-O-3	1	
530	Reserved 02	Character			50	
538	Reporting Hospital FAN	Character			10	
540	Reporting Hospital	Character	Right justified, zero filled	10-digit number	10	Revised
550	Accession Number--Hosp	Character		9-digit number	9	
560	Sequence Number--Hospital	Character	Right justified, zero filled	00-35, 60-87, 88, 99	2	Revised
570	Abstracted By	Character	No special characters	Letters and numbers	3	
580	Date of 1st Contact	Character	MMDDCCYY	Valid dates or 99999999	8	
590	Date of Inpatient Adm	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
600	Date of Inpatient Disch	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
610	Class of Case	Character		0-9	1	Revised
620	Year First Seen This CA	Character	CCYY	1944 to current year	4	
630	Primary Payer at DX	Character	Right justified, zero filled	01, 02, 10, 20, 31, 35, 36, 50-56, 99	2	Revised
640	Inpatient/Outpt Status	Character		1-3, 8, 9	1	
650	Presentation at CA Conf	Character		0-9	1	
660	Date of CA Conference	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
670	RX Hosp--Surg Prim Site	Character	Right justified, zero filled	00, 10-80, 90, 98, 99 (site specific)	2	Revised

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
672	RX Hosp--Scope Reg LN Sur	Character		0-7, 9	1	Revised
674	RX Hosp--Surg Oth Reg/Dis	Character		0-5, 9	1	Revised
676	RX Hosp--Reg LN Removed	Character		00-90, 95-99	2	
680	Reserved 03	Character			50	
690	RX Hosp--Radiation	Character		0-5, 9	1	
700	RX Hosp--Chemo	Character	Right justified, zero filled	00-03, 82, 85-88, 99	2	Revised
710	RX Hosp--Hormone	Character	Right justified, zero filled	00, 01, 82, 85-88, 99	2	Revised
720	RX Hosp--BRM	Character	Right justified, zero filled	00, 01, 82, 85-88, 99	2	Revised
730	RX Hosp--Other	Character		0-3, 6-9	1	Revised
740	RX Hosp--DX/Stg Proc	Character	Right justified, zero filled	00-07, 09	2	Revised
742	RX Hosp--Screen/BX Proc1	Character		Site-specific: 0 (all cases); 1-3, 5, 9 (breast); 1-4, 9 (prostate)	1	
743	RX Hosp--Screen/BX Proc2	Character		Site-specific: 0 (all cases); 1-7, 9 (breast); 1-3, 9 (prostate)	1	
744	RX Hosp--Screen/BX Proc3	Character		Site-specific: 0 (all cases); 1, 9 (breast); 1-5, 9 (prostate)	1	
745	RX Hosp--Screen/BX Proc4	Character		Site-specific: 0 (all cases); 1-4, 9 (breast); 1-7, 9 (prostate)	1	
750	Reserved 04	Character			50	
759	SEER Summary Stage 2000	Character		0-5, 7, 9	1	
760	SEER Summary Stage 1977	Character		0-5, 7, 9	1	
770	Loc/Reg/Distant Stage	Character		0-3, 9, blank	1	
779	Extent of Disease 10-Dig	Character			12	
780	EOD--Tumor Size	Character	Right justified, zero filled	See respective source references	3	
790	EOD--Extension	Character	Right justified, zero filled	Reference SEER Extent of Disease manual	2	
800	EOD--Extension Prost Path	Character	Right justified, zero filled	Reference SEER Extent of Disease manual	2	
810	EOD--Lymph Node Involv	Character		Reference SEER Extent of Disease manual	1	
820	Regional Nodes Positive	Character	Right justified, zero filled	See respective source references	2	
830	Regional Nodes Examined	Character	Right justified, zero filled	See respective source references	2	
840	EOD--Old 13 Digit	Character	Numeric and special characters		13	

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
850	EOD--Old 2 Digit	Character	Numeric plus special characters "&" and "dash" ("-")		2	
860	EOD--Old 4 Digit	Character			4	
870	Coding System for EOD	Character		0-4	1	
880	TNM Path T	Character	Upper case, alphanumeric, left justified, blank filled	See AJCC Cancer Staging Manual and FORDS Manual; also 88, blank	2	Revised
890	TNM Path N	Character	Upper case, alphanumeric, left justified, blank filled	See AJCC Cancer Staging Manual and FORDS Manual; also 88, blank	2	Revised
900	TNM Path M	Character	Upper case, alphanumeric, left justified, blank filled	See AJCC Cancer Staging Manual and FORDS Manual; also 88, blank	2	Revised
910	TNM Path Stage Group	Character	Upper case, alphanumeric. Convert AJCC Roman numerals to Arabic numerals. Left justified, blank filled.	See AJCC Cancer Staging Manual and FORDS Manual; also 88, blank	2	Revised
920	TNM Path Descriptor	Character		0-6, 9	1	
930	TNM Path Staged By	Character		0-9	1	Revised
940	TNM Clin T	Character	Upper case, alphanumeric, left justified, blank filled	See AJCC Cancer Staging Manual and FORDS Manual; also 88, blank	2	Revised
950	TNM Clin N	Character	Upper case, alphanumeric, left justified, blank filled	See AJCC Cancer Staging Manual and FORDS Manual; also 88, blank	2	Revised
960	TNM Clin M	Character	Upper case, alphanumeric, left justified, blank filled	See AJCC Cancer Staging Manual and FORDS Manual; also 88, blank	2	Revised
970	TNM Clin Stage Group	Character	Upper case, alphanumeric. Convert AJCC Roman numerals to Arabic numerals. Left justified, blank filled.	See AJCC Cancer Staging Manual and FORDS Manual; also 88, blank	2	Revised
980	TNM Clin Descriptor	Character		0-6, 9	1	
990	TNM Clin Staged By	Character		0-9	1	Revised
1000	TNM Other T	Character	Upper case, alphanumeric, left justified, blank filled	See AJCC Cancer Staging Manual; also 88, blank	2	
1010	TNM Other N	Character	Upper case, alphanumeric, left justified, blank filled	See AJCC Cancer Staging Manual; also 88, blank	2	
1020	TNM Other M	Character	Upper case, alphanumeric, left justified, blank filled	See AJCC Cancer Staging Manual; also 88, blank	2	
1030	TNM Other Stage Group	Character	Upper case, alphanumeric. Convert AJCC Roman numerals to Arabic numerals. Left justified, blank filled	See AJCC Cancer Staging Manual; also 88, 99	2	
1040	TNM Other Staged By	Character		0-9	1	

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
1050	TNM Other Descriptor	Character		0-6, 9	1	
1060	TNM Edition Number	Character	Right justified, zero filled	00-06, 88, 99	2	Revised
1070	Other Staging System	Character	Free text	Neither carriage return nor line feed characters allowed	15	
1080	Date of 1st Positive BX	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
1090	Site of Distant Met 1	Character		0-9	1	
1100	Site of Distant Met 2	Character		0-9	1	
1110	Site of Distant Met 3	Character		0-9	1	
1120	Pediatric Stage	Character		Reference to EDITS table PEDSTAGE.DBF. CODE in Appendix B	2	
1130	Pediatric Staging System	Character		00-15, 88, 97, 99	2	
1140	Pediatric Staged By	Character		0-9	1	
1150	Tumor Marker 1	Character		0-6, 8, 9	1	
1160	Tumor Marker 2	Character		0-6, 8, 9	1	
1170	Tumor Marker 3	Character		0-6, 8, 9	1	
1180	Reserved 05	Character			50	
1190	Reserved 06	Character			49	
1200	RX Date--Surgery	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
1210	RX Date--Radiation	Character	MMDDCCYY	Valid dates, 00000000, 88888888, 99999999	8	
1220	RX Date--Chemo	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
1230	RX Date--Hormone	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
1240	RX Date--BRM	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
1250	RX Date--Other	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
1260	Date of Initial RX--SEER	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
1270	Date of 1st Crs RX--COC	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
1280	RX Date--DX/Stg Proc	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	Revised
1290	RX Summ--Surg Prim Site	Character	Right justified, zero filled	00, 10-80, 90, 98, 99 (site specific)	2	Revised

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
1292	RX Summ--Scope Reg LN Sur	Character		0-7, 9	1	Revised
1294	RX Summ--Surg Oth Reg/Dis	Character		0-5, 9	1	Revised
1296	RX Summ--Reg LN Examined	Character	Right justified, zero filled	00-90, 95-99	2	
1300	Reserved 07	Character			50	
1310	RX Summ--Surgical Approch	Character		0-9 (site-specific)	1	
1320	RX Summ--Surgical Margins	Character		0-3, 7-9	1	Revised
1330	RX Summ--Reconstruct 1st	Character		0-9 (site-specific)	1	
1340	Reason for No Surgery	Character		0-2, 5-9	1	Revised
1350	RX Summ--DX/Stg Proc	Character	Right justified, zero filled	00-07, 09	2	Revised
1360	RX Summ--Radiation	Character		0-5, 7-9	1	
1370	RX Summ--Rad to CNS	Character		0, 1, 7-9	1	
1380	RX Summ--Surg/Rad Seq	Character		0, 2-6, 9	1	
1390	RX Summ--Chemo	Character	Right justified, zero filled	00-03, 82, 85-88, 99	2	Revised
1400	RX Summ--Hormone	Character	Right justified, zero filled	00, 01, 82, 85-88, 99	2	Revised
1410	RX Summ--BRM	Character	Right justified, zero filled	00, 01, 82, 85-88, 99	2	Revised
1420	RX Summ--Other	Character		0-3, 6-9	1	Revised
1430	Reason for No Radiation	Character		0-2, 5-9	1	Revised
1440	Reason for No Chemo	Character		0-2, 6-9	1	
1450	Reason for No Hormone	Character		0-2, 6-9	1	
1460	RX Coding System--Current	Character	Right justified, zero filled	00-06, 99	2	Revised
1470	Protocol Eligibility Stat	Character		0-4, 6-9	1	
1480	Protocol Participation	Character	Right justified, zero filled	00-99	2	
1490	Referral to Support Serv	Character		0, 1, 9	1	
1500	First Course Calc Method	Character		1, 2, 9	1	
1510	Rad--Regional Dose: cGy	Character	Right justified, zero filled	00000-99999	5	
1520	Rad--No of Treatment Vol	Character	Right justified, zero filled	00-99	2	
1530	Rad--Elapsed RX Days	Character	Right justified, zero filled	000-999	3	
1540	Rad--Treatment Volume	Character	Right justified, zero filled	00-41, 50, 60, 98, 99	2	Revised
1550	Rad--Location of RX	Character		0-4, 8, 9	1	
1560	Rad--Intent of Treatment	Character		0-2, 4-6, 8, 9	1	
1570	Rad--Regional RX Modality	Character	Right justified, zero filled	00, 20-32, 40-43, 50-55, 60-62, 80, 85, 98, 99	2	Revised
1580	Rad--RX Completion Status	Character		0-9	1	
1590	Rad--Local Control Status	Character		0-4, 8, 9	1	
1600	Chemotherapy Field 1	Character	No standard		3	
1610	Chemotherapy Field 2	Character	No standard		3	
1620	Chemotherapy Field 3	Character	No standard		3	
1630	Chemotherapy Field 4	Character	No standard		3	
1640	RX Summ--Surgery Type	Character	Right justified, zero filled	00-99 (site-specific)	2	

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
1642	RX Summ--Screen/BX Proc1	Character		Site-specific: 0 (all cases); 1-3, 5, 9 (breast); 1-4, 9 (prostate)	1	
1643	RX Summ--Screen/BX Proc2	Character		Site-specific: 0 (all cases); 1-7, 9 (breast); 1-3, 9 (prostate)	1	
1644	RX Summ--Screen/BX Proc3	Character		Site-specific: 0 (all cases); 1, 9 (breast); 1-5, 9 (prostate)	1	
1645	RX Summ--Screen/BX Proc4	Character		Site-specific: 0 (all cases); 1-4, 9 (breast); 1-7, 9 (prostate)	1	
1650	Reserved 08	Character			50	
1660	Subsq RX 2nd Course Date	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
1670	Subsq RX 2nd Course Codes	Character			7	
1671	Subsq RX 2nd Course Surg	Character	Right justified, zero filled	00, 10-90, 99	2	
1672	Subsq RX 2nd Course Rad	Character		0-5, 9	1	
1673	Subsq RX 2nd Course Chemo	Character		0-3, 9	1	
1674	Subsq RX 2nd Course Horm	Character		0-3, 9	1	
1675	Subsq RX 2nd Course BRM	Character		0-9	1	
1676	Subsq RX 2nd Course Oth	Character		0-3, 6-9	1	
1677	Subsq RX 2nd--Scope LN Su	Character		0-9	1	
1678	Subsq RX 2nd--Surg Oth	Character		0-9	1	
1679	Subsq RX 2nd--Reg LN Rem	Character	Right justified, zero filled	00-90, 95-99	2	
1680	Subsq RX 3rd Course Date	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
1690	Subsq RX 3rd Course Codes	Character			7	
1691	Subsq RX 3rd Course Surg	Character	Right justified, zero filled	00, 10-90, 99	2	
1692	Subsq RX 3rd Course Rad	Character		0-5, 9	1	
1693	Subsq RX 3rd Course Chemo	Character		0-3, 9	1	
1694	Subsq RX 3rd Course Horm	Character		0-3, 9	1	
1695	Subsq RX 3rd Course BRM	Character		0-9	1	
1696	Subsq RX 3rd Course Oth	Character		0-3, 6-9	1	
1697	Subsq RX 3rd--Scope LN Su	Character		0-9	1	
1698	Subsq RX 3rd--Surg Oth	Character		0-9	1	
1699	Subsq RX 3rd--Reg LN Rem	Character	Right justified, zero filled	00-90, 95-99	2	

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
1700	Subsq RX 4th Course Date	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
1710	Subsq RX 4th Course Codes	Character			7	
1711	Subsq RX 4th Course Surg	Character	Right justified, zero filled	00, 10-90, 99	2	
1712	Subsq RX 4th Course Rad	Character		0-5, 9	1	
1713	Subsq RX 4th Course Chemo	Character		0-3, 9	1	
1714	Subsq RX 4th Course Horm	Character		0-3, 9	1	
1715	Subsq RX 4th Course BRM	Character		0-9	1	
1716	Subsq RX 4th Course Oth	Character		0-3, 6-9	1	
1717	Subsq RX 4th--Scope LN Su	Character		0-9	1	
1718	Subsq RX 4th--Surg Oth	Character		0-9	1	
1719	Subsq RX 4th--Reg LN Rem	Character	Right justified, zero filled	00-90, 95-99	2	
1720	Subsq RX 5th Course Date	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
1730	Subsq RX 5th Course Codes	Character			7	
1731	Subsq RX 5th Course Surg	Character	Right justified, zero filled	00, 10-90, 99	2	
1732	Subsq RX 5th Course Rad	Character		0-5, 9	1	
1733	Subsq RX 5th Course Chemo	Character		0-3, 9	1	
1734	Subsq RX 5th Course Horm	Character		0-3, 9	1	
1735	Subsq RX 5th Course BRM	Character		0-9	1	
1736	Subsq RX 5th Course Oth	Character		0-3, 6-9	1	
1737	Subsq RX 5th--Scope LN Su	Character		0-9	1	
1738	Subsq RX 5th--Surg Oth	Character		0-9	1	
1739	Subsq RX 5th--Reg LN Rem	Character	Right justified, zero filled	00-90, 95-99	2	
1740	Reserved 09	Character			50	
1741	Subsq RX--Reconstruct Del	Character		Site-specific	1	
1750	Date of Last Contact	Character	MMDDCCYY	Valid dates or 99999999	8	
1760	Vital Status	Character		0, 1, 4	1	
1770	Cancer Status	Character		1, 2, 9	1	
1780	Quality of Survival	Character		0-4, 8, 9	1	
1790	Follow-Up Source	Character		0-5, 7-9	1	
1800	Next Follow-Up Source	Character		0-5, 8, 9	1	
1810	Addr Current--City	Character	Mixed case letters, no special characters, embedded spaces allowed, left justified, blank filled		20	
1820	Addr Current--State	Character	Upper case	See EDITS table STATE.DBF in Appendix B	2	

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
1830	Addr Current--Postal Code	Character	Numbers or upper case letters. No special characters or embedded spaces allowed. Left justified, blank filled.	5-digit or 9-digit U.S. ZIP codes; 6-character Canadian postal codes; valid postal codes from other countries, 888888888, 999999999	9	
1835	Reserved 10	Character			50	
1840	County--Current	Character	Right justified, zero filled	See Appendix A for standard FIPS county codes. See Edits table BPLACE.DBF in Appendix B for geocodes used by CoC for non-U.S. residents. Also 998, 999.	3	
1842	Follow-Up Contact--City	Character	Mixed case letters, no special characters, embedded spaces allowed, left justified, blank filled		20	
1844	Follow-Up Contact--State	Character	Upper case	See EDITS table STATE.DBF in Appendix B	2	
1846	Follow-Up Contact--Postal	Character	Numbers or upper case letters. No special characters or embedded spaces allowed. Left justified, blank filled	5-digit or 9-digit U.S. ZIP codes; 6-character Canadian postal codes; valid postal codes from other countries, 888888888, 999999999	9	
1850	Unusual Follow-Up Method	Character		0-9	1	
1860	Recurrence Date--1st	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	
1871	Recurrence Distant Site 1	Character		0-9	1	
1872	Recurrence Distant Site 2	Character		0-9	1	
1873	Recurrence Distant Site 3	Character		0-9	1	
1880	Recurrence Type--1st	Character	Right justified, zero filled	00, 01, 04, 06, 10, 13-17, 20-22, 25-27, 30, 36, 40, 46, 51-60, 62, 70, 88, 99	2	Revised
1890	Recurrence Type--1st--Oth	Character		00, 01, 06, 10, 11, 15-17, 20-22, 25-27, 30, 36, 40, 46, 70, 88, 99	2	
1900	Reserved 11	Character			50	
1910	Cause of Death	Character	4 digits (for ICD-7, 8, 9) or upper case letter followed by 3 digits (for ICD-10)	Valid ICD-7, ICD-8, ICD-9, and ICD-10 codes; also 0000, 7777, 7797	4	

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
1920	ICD Revision Number	Character		0, 1, 7, 8, 9	1	
1930	Autopsy	Character		0-2, 9	1	
1940	Place of Death	Character	Right justified, zero filled	Reference SEER Manual	3	
1950	Reserved 12	Character			50	
1960	Site (73-91) ICD-O-1	Character	Four digits, first digit equals 1	Reference ICD-O-1 for valid entries	4	
1971	Histology (73-91) ICD-O-1	Character		Reference ICD-O-1 for valid entries	4	
1972	Behavior (73-91) ICD-O-1	Character		Reference ICD-O-1 for valid entries	1	
1973	Grade (73-91) ICD-O-1	Character		Reference ICD-O-1 for valid entries	1	
1980	ICD-O-2 Conversion Flag	Character		0-6	1	
1981	Over-ride SS/NodesPos	Character		1 or blank	1	
1982	Over-ride SS/TNM-N	Character		1 or blank	1	
1983	Over-ride SS/TNM-M	Character		1 or blank	1	
1984	Over-ride SS/DisMet1	Character		1 or blank	1	
1985	Over-ride Acsn/Class/Seq	Character		1 or blank	1	
1986	Over-ride HospSeq/DxConf	Character		1 or blank	1	
1987	Over-ride COC-Site/Type	Character		1 or blank	1	
1988	Over-ride HospSeq/Site	Character		1 or blank	1	
1989	Over-ride Site/TNM-StgGrp	Character		1 or blank	1	
1990	Over-ride Age/Site/Morph	Character		1 or blank	1	
2000	Over-ride SeqNo/DxConf	Character		1 or blank	1	
2010	Over-ride Site/Lat/SeqNo	Character		1 or blank	1	
2020	Over-ride Surg/DxConf	Character		1 or blank	1	
2030	Over-ride Site/Type	Character		1 or blank	1	
2040	Over-ride Histology	Character		1-3 or blank	1	
2050	Over-ride Report Source	Character		1 or blank	1	
2060	Over-ride Ill-define Site	Character		1 or blank	1	
2070	Over-ride Leuk, Lymphoma	Character		1 or blank	1	
2071	Over-ride Site/Behavior	Character		1 or blank	1	
2072	Over-ride Site/EOD/DX Dt	Character		1 or blank	1	
2073	Over-ride Site/Lat/EOD	Character		1 or blank	1	
2074	Over-ride Site/Lat/Morph	Character		1 or blank	1	
2081	CRC CHECKSUM	Character		Calculated or blank	10	
2090	Date Case Completed	Character	MMDDCCYY		8	
2100	Date Case Last Changed	Character	MMDDCCYY		8	
2110	Date Case Report Exported	Character	MMDDCCYY		8	
2111	Date Case Report Received	Character	MMDDCCYY		8	
2112	Date Case Report Loaded	Character	MMDDCCYY		8	
2113	Date Tumor Record Availbl	Character	MMDDCCYY		8	
2114	Future Use Timeliness 1	Character	No standard		8	
2115	Future Use Timeliness 2	Character	No standard		8	

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
2116	ICD-O-3 Conversion Flag	Character		Blank, 0, 1, 3	1	
2120	SEER Coding Sys--Current	Character		0-6	1	Revised
2130	SEER Coding Sys--Original	Character		0-6	1	Revised
2140	COC Coding Sys--Current	Character	Right justified, zero filled	00-08, 99	2	Revised
2150	COC Coding Sys--Original	Character	Right justified, zero filled	00-08, 99	2	Revised
2160	Subsq Report for Primary	Character			0	Retired
2161	Reserved 20	Character			0	Retired
2170	Vendor Name	Character	Embedded spaces allowed		10	
2180	SEER Type of Follow-Up	Character		1-4	1	
2190	SEER Record Number	Character	Right justified, zero filled	01-99	2	
2200	Diagnostic Proc 73-87	Character			2	
2210	Reserved 14	Character			0	Retired
2220	State/Requestor Items	Character			500	
2230	Name--Last	Character	Mixed case, no embedded spaces, left justified, blank filled. Embedded hyphen allowed, but no other special characters.		25	
2240	Name--First	Character	Mixed case, no embedded spaces, no special characters, left justified, blank filled		14	
2250	Name--Middle	Character	Mixed case, no embedded spaces, no special characters, left justified, blank filled		14	
2260	Name--Prefix	Character	Mixed case, no special characters		3	
2270	Name--Suffix	Character	Mixed case, no special characters		3	
2280	Name--Alias	Character	Left justified, blank filled		15	
2290	Name--Spouse/Parent	Character	No standard		50	
2300	Medical Record Number	Character	Embedded spaces, right justified		11	
2310	Military Record No Suffix	Character	Right justified, zero filled	01-20, 30-69, 98, 99	2	
2320	Social Security Number	Character	9 digits, no dashes	Any 9-digit number except 000000000	9	
2330	Addr at DX--No & Street	Character	Mixed case, embedded spaces, punctuation limited to periods, slashes, hyphens, and pound signs. Left justified, space filled.		40	Revised
2335	Addr at DX--Supplementl	Character	Mixed case, embedded spaces, punctuation limited to periods, slashes, hyphens, and pound signs. Left justified, space filled.		40	New
2350	Addr Current--No & Street	Character	Mixed case, embedded spaces, punctuation limited to periods, slashes, hyphens, and pound signs. Left justified, space filled.		40	Revised
2352	Latitude	Character	Right justify	See Data Dictionary	10	New
2354	Longitude	Character	Right justify	See Data Dictionary	11	New
2355	Addr Current--Supplementl	Character	Mixed case, embedded spaces, punctuation limited to periods, slashes, hyphens, and pound signs. Left justified, space filled.		40	New
2360	Telephone	Character	10-digit number	Any 10-digit number	10	

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
2370	DC State	Character			0	Retired
2371	Reserved 21	Character			0	Retired
2380	DC State File Number	Character		Any characters or blank	6	
2390	Name--Maiden	Character	Mixed case, no embedded spaces, left justified, blank filled, embedded hyphen allowed, no other special characters		15	
2392	Follow-Up Contact--No&St	Character	Mixed case, embedded spaces, punctuation limited to periods, slashes, hyphens, and pound signs. Left justified, space filled.		40	
2393	Follow-Up Contact--Suppl	Character	Mixed case, embedded spaces, punctuation limited to periods, slashes, hyphens, and pound signs. Left justified, space filled.		40	
2394	Follow-Up Contact--Name	Character	Mixed case, embedded spaces, no special characters, left justified, blank fill		30	
2400	Reserved 16	Character			0	Retired
2410	Institution Referred From	Character	Right justified and zero filled	10-digit number	10	Revised
2420	Institution Referred To	Character	Right justified and zero filled	10-digit number	10	Revised
2430	Last Follow-Up Hospital	Character	Right justified and zero filled	10-digit number	10	Revised
2440	Following Registry	Character	Right justified and zero filled	10-digit number	10	Revised
2450	Reserved for Expansion	Character			0	
2460	Physician--Managing	Character	Left justified		8	
2470	Physician--Follow-Up	Character	Left justified		8	
2480	Physician--Primary Surg	Character	Left justified		8	
2490	Physician 3	Character	Left justified		8	
2500	Physician 4	Character	Left justified		8	
2520	Text--DX Proc--PE	Character	Free text	Neither carriage return nor line feed characters allowed	200	
2530	Text--DX Proc--X-ray/Scan	Character	Free text	Neither carriage return nor line feed characters allowed	250	
2540	Text--DX Proc--Scopes	Character	Free text	Neither carriage return nor line feed characters allowed	250	
2550	Text--DX Proc--Lab Tests	Character	Free text	Neither carriage return nor line feed characters allowed	250	
2560	Text--DX Proc--Op	Character	Free text	Neither carriage return nor line feed characters allowed	250	
2570	Text--DX Proc--Path	Character	Free text	Neither carriage return nor line feed characters allowed	250	
2580	Text--Primary Site Title	Character	Free text	Neither carriage return nor line feed characters allowed	40	

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
2590	Text--Histology Title	Character	Free text	Neither carriage return nor line feed characters allowed	40	
2600	Text--Staging	Character	Free text	Neither carriage return nor line feed characters allowed	300	
2610	RX Text--Surgery	Character	Free text	Neither carriage return nor line feed characters allowed	150	
2620	RX Text--Radiation (Beam)	Character	Free text	Neither carriage return nor line feed characters allowed	150	
2630	RX Text--Radiation Other	Character	Free text	Neither carriage return nor line feed characters allowed	150	
2640	RX Text--Chemo	Character	Free text	Neither carriage return nor line feed characters allowed	200	
2650	RX Text--Hormone	Character	Free text	Neither carriage return nor line feed characters allowed	200	
2660	RX Text--BRM	Character	Free text	Neither carriage return nor line feed characters allowed	100	
2670	RX Text--Other	Character	Free text	Neither carriage return nor line feed characters allowed	100	
2680	Text--Remarks	Character	Free text	Neither carriage return nor line feed characters allowed	350	
2690	Place of Diagnosis	Character	Free text	Neither carriage return nor line feed characters allowed	50	
2700	Reserved 19	Character			770	
2800	CS Tumor Size	Character	Right justified, zero filled	000-990, 999	3	New
2810	CS Extension	Character	Right justified, zero filled	00-99 (site specific)	2	New
2820	CS Tumor Size/Ext Eval	Character		0-3, 5, 6, 8, 9	1	New
2830	CS Lymph Nodes	Character	Right justified, zero filled	00-99 (site specific)	2	New
2840	CS Reg Nodes Eval	Character		0-3, 5, 6, 8, 9	1	New
2850	CS Mets at DX	Character	Right justified, zero filled	00-99 (site specific)	2	New
2860	CS Mets Eval	Character		0-3, 5, 6, 8, 9	1	New
2880	CS Site-Specific Factor 1	Character	Right justified, zero filled	000-999 (site specific)	3	New
2890	CS Site-Specific Factor 2	Character	Right justified, zero filled	000-999 (site specific)	3	New
2900	CS Site-Specific Factor 3	Character	Right justified, zero filled	000-999 (site specific)	3	New
2910	CS Site-Specific Factor 4	Character	Right justified, zero filled	000-999 (site specific)	3	New
2920	CS Site-Specific Factor 5	Character	Right justified, zero filled	000-999 (site specific)	3	New
2930	CS Site-Specific Factor 6	Character	Right justified, zero filled	000-999 (site specific)	3	New

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
2940	Derived AJCC T	Character		Derived from Collaborative Stage fields	2	New
2950	Derived AJCC T Descriptor	Character		c, p, a, y (derived from Collaborative Stage fields)	1	New
2960	Derived AJCC N	Character		Derived from Collaborative Stage fields	2	New
2970	Derived AJCC N Descriptor	Character		c, p, a, y (derived from Collaborative Stage fields)	1	New
2980	Derived AJCC M	Character		Derived from Collaborative Stage fields	2	New
2990	Derived AJCC M Descriptor	Character		c, p, a, y (derived from Collaborative Stage fields)	1	New
3000	Derived AJCC Stage Group	Character		Derived from Collaborative Stage fields	2	New
3010	Derived SS1977	Character		0-5, 7-9 (derived from Collaborative Stage fields)	1	New
3020	Derived SS2000	Character		0-5, 7-9 (derived from Collaborative Stage fields)	1	New
3030	Derived AJCC--Flag	Character		1, 2, blank	1	New
3040	Derived SS1977--Flag	Character		1, 2, blank	1	New
3050	Derived SS2000--Flag	Character		1, 2, blank	1	New
3100	Archive FIN	Character	Right justified, zero filled	10-digit number	10	New
3110	Comorbid/Complication 1	Character	Left justified, zero filled	00000, 00100-13980, 24000-99990, E8700-E8799, E9300-E9499	5	New
3120	Comorbid/Complication 2	Character	Left justified, zero filled	00100-13980, 24000-99990, E8700-E8799, E9300-E9499, blank	5	New
3130	Comorbid/Complication 3	Character	Left justified, zero filled	00100-13980, 24000-99990, E8700-E8799, E9300-E9499, blank	5	New
3140	Comorbid/Complication 4	Character	Left justified, zero filled	00100-13980, 24000-99990, E8700-E8799, E9300-E9499, blank	5	New

Item #	Item Name	Data Type	Format	Allowable Values	Length	Note
3150	Comorbid/Complication 5	Character	Left justified, zero filled	00100-13980, 24000-99990, E8700-E8799, E9300-E9499, blank	5	New
3160	Comorbid/Complication 6	Character	Left justified, zero filled	00100-13980, 24000-99990, E8700-E8799, E9300-E9499, blank	5	New
3170	RX Date--Most Defin Surg	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	New
3180	RX Date--Surgical Disch	Character	MMDDCCYY	Valid dates, 00000000, 99999999	8	New
3190	Readm Same Hosp 30 Days	Character		0-3, 9	1	New
3200	Rad--Boost RX Modality	Character	Right justified, zero filled	00, 20-32, 40-43, 50-55, 60-62, 98, 99	2	New
3210	Rad--Boost Dose cGy	Character	Right justified, zero filled	00000-99999	5	New
3220	RX Date--Radiation Ended	Character	MMDDCCYY	Valid dates, 00000000, 88888888, 99999999	8	New
3230	RX Date--Systemic	Character	MMDDCCYY	Valid dates, 00000000, 88888888, 99999999	8	New
3250	RX Summ--Transplnt/Endocr	Character	Right justified, zero filled	00, 10-12, 20, 30, 40, 82, 85-88, 99	2	New
3260	Pain Assessment	Character		0-3, 9	1	New
3270	RX Summ--Palliative Proc	Character		0-7, 9	1	New
3280	RX Hosp--Palliative Proc	Character		0-7, 9	1	New
3300	RuralUrban Continuum 1993	Character	Right justified, zero filled	00-09, 98, 99, blank (calculated)	2	New
3310	RuralUrban Continuum 2000	Character	Right justified, zero filled	00-09, 98, 99, blank (calculated)	2	New

CHAPTER XI

DATA DICTIONARY

In this chapter, data items are presented in alphabetical order by item names. For each item, a general description, specific codes and meanings are given. For many items, the document provides a brief rationale for collecting the data item or for using the codes listed. The at-a-glance header for each data item has alternate name(s), item number, length, source of standard, and column numbers (for a discussion of NAACCR's standard naming conventions, see Chapter I).

Differences from Version 9.1 are marked "Revised" or "New item" following the item name and item number. Black vertical lines in the outside margins highlight changes. Some changes are summarized in Appendix F.

Other names by which the same item is called under NAACCR's naming convention are listed in Appendix D.

ABSTRACTED BY

Alternate Name	Item #	Length	Source of Standard	Column #
	570	3	COC	413-415

Description

An alphanumeric code assigned by the reporting facility that identifies the individual abstracting the case.

ACCESSION NUMBER--HOSP

Alternate Name	Item #	Length	Source of Standard	Column #
Accession Number (COC)	550	9	COC	402-410

Description

Unique number assigned by the hospital registry to identify the patient. The first 4 digits identify the year (in the format CCYY) the patient was first seen at that institution for the diagnosis or treatment of cancer. The first 4 digits must be greater than or equal to 1944.

The last five numbers are the numeric order in which the registry entered the case into the database. Within a registry, all primaries for an individual must have the same accession number.

Rationale

Hospitals use this number to identify cases. If the central registry preserves this number, they can refer to it when communicating with the hospital. It also provides a way to link computerized follow-up reports from hospitals into the central database.

ADDR AT DX--CITY

Alternate Name	Item #	Length	Source of Standard	Column #
City or Town (pre-96 COC) City/Town at Diagnosis (COC)	70	20	COC	52-71

Description

Name of the city in which the patient resides at the time the reportable tumor was diagnosed. If the patient resides in a rural area, record the name of the city used in their mailing address. If the patient has multiple primaries, the city of residence may be different for each primary.

Codes

UNKNOWN (in addition to valid City)

ADDR AT DX--NO & STREET**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Patient Address (Number and Street) at Diagnosis (COC) Number and Street (pre-96 COC)	2330	40	COC	2108-2147

Description

The number and street address or the rural mailing address of the patient's residence at the time the reportable tumor was diagnosed. If the patient has multiple tumors, address at diagnosis may be different for each tumor. Additional address information such as facility, nursing home, or name of apartment complex should be entered in item (2335) Addr At DX-Supplementl.

U.S. addresses should conform to the USPS Postal Addressing Standards. These standards are referenced in USPS Publication 28, November 2000, *Postal Addressing Standards*. Canadian addresses should conform to the *Canada Postal Guide*.

Rationale

Addresses that are formatted to conform to U.S. Postal Service (USPS) Postal Addressing Standards can be more properly geocoded by geographic information systems (GIS) software and vendors to the correct census tract, which is required by NPCR and SEER registries. The USPS Standards also address a number of issues that are problematic in producing precise addresses, including the use of punctuation, abbreviations, and proper placement of address elements, such as street direction, apartment and suite numbers, and unusual addressing situations. Spanish-language addresses also are covered by the USPS Standard.

Coding Instructions (summary of USPS guidelines)

The address should be fully spelled out with standardized use of abbreviations and punctuation per USPS postal addressing standards (USPS Postal Addressing Standards, Pub. 28, November 2000). Upper case recommended. Mixed case allowed.

Abbreviations should be limited to those recognized by USPS standard abbreviations. These include but are not limited to: AVE (avenue), BLVD (boulevard), CIR (circle), CT (court), DR (drive), PLZ (plaza), PARK (park), PKWY (parkway), RD (road), SQ (square), ST (street), APT (apartment), BLDG (building), FL (floor), STE (suite), UNIT (unit), RM (room), DEPT (department), N (north), NE (northeast), NW (northwest), S (south), SE (southeast), SW (southwest), E (east), and W (west). A complete list of recognized street abbreviations is provided in Appendix C of USPS Pub. 28.

Punctuation marks should be avoided, except when punctuation is necessary to convey the meaning. Punctuation normally is limited to periods when the period carries meaning (e.g., 39.2 RD), slashes for fractional addresses (e.g., 101 1/2 MAIN ST), and hyphens when the hyphen carries meaning (e.g., 289-01 MONTGOMERY AVE). Use of the pound sign (#) to designate address units should be avoided whenever possible. The preferred notation is as follows: 102 MAIN ST APT 101. If a pound sign is used, there must be a space between the pound sign and the secondary number (e.g., 425 FLOWER BLVD # 72).

Codes (in addition to valid street address)

UNKNOWN Patient's address is unknown

Note: The current USPS Pub. 28 may be found and downloaded from the following Web Site:
<http://e.usps.gov/cpim/ftp/pubs/Pub28/pub28.pdf>.

Note: The current Canadian Postal Address standards may be found at the following Web Site:
<http://www.canadapost.ca/tools/pg/manual/b03-e.asp#top>.

ADDR AT DX--POSTAL CODE

Alternate Name	Item #	Length	Source of Standard	Column #
Postal Code at Diagnosis (COC)	100	9	NAACCR	74-82
ZIP Code (pre-COC)				

Description

Postal code for the address of the patient's residence at the time the reportable tumor is diagnosed. If the patient has multiple tumors, the postal code may be different for each tumor.

For U.S. residents, use either the 5-digit or the extended 9-digit ZIP code. Blanks follow the 5-digit code.

For Canadian residents, use the 6-character alphanumeric postal code. Blanks follow the 6-character code.

When available, enter the postal code for other countries.

Codes (in addition to U.S. and Canadian postal codes)

888888888 Resident of country other than the United States, U.S. possessions or territories, or Canada
AND the postal code is unknown
 999999999 Resident of the United States or U.S. possessions, territories, or Canada **AND** the postal code
 is unknown; **OR**
 Residence is unknown

ADDR AT DX--STATE

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
State (pre-96 COC)	80	2	NAACCR	72-73
State at Diagnosis (COC)				

Description

USPS abbreviation for the state, territory, commonwealth, U.S. possession, or Canadian province/ territory in which the patient resides at the time the reportable tumor is diagnosed. If the patient has multiple primaries, the state of residence may be different for each tumor.

Codes (in addition to USPS abbreviations)

XX Resident of country other than the United States (including its territories, commonwealths, or possessions) or Canada, and country is known
 YY Resident of country other than the United States (including its territories, commonwealths, or possessions) or Canada, and country is unknown
 ZZ Resident of the United States, NOS (including its territories, commonwealths, or possessions); Canada, NOS; residence unknown

ADDR AT DX--SUPPLEMENTL**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Patient Address (Number and Street) at Diagnosis—Supplemental (COC)	2335	40	COC	2148-2187

Description

This data item provides the ability to store additional address information such as the name of a place or facility, a nursing home, or the name of an apartment complex.

U.S. addresses should conform to the USPS Postal Addressing Standards. These standards are referenced in USPS Pub. 28, November 2000, *Postal Addressing Standards*. Canadian addresses should conform to the *Canada Postal Guide*.

Rationale

Sometimes the registry receives the name of a facility instead of a proper street address containing the street number, name, direction, and other elements necessary to locate an address on a street file for the purpose of geocoding. By having a second street address field to hold address information, the registry can look up and store the street address and not lose the facility name due to a shortage of space. The presence of a second street address field to hold additional address information also aids in follow-up.

Addresses that are formatted to conform to USPS Postal Addressing Standards can be more properly geocoded by GIS software and vendors to the correct census tract, which is required by NPCR and SEER registries. The USPS Standards also address a number of issues that are problematic in producing precise addresses, including the use of punctuation, abbreviations, and proper placement of address elements, such as street direction, apartment and suite numbers, and unusual addressing situations. Spanish-language addresses also are covered by the USPS Standard. Upper case recommended. Mixed case allowed.

Coding Instructions (summary of USPS guidelines)

The address should be fully spelled out with standardized use of abbreviations and punctuation per USPS postal addressing standards (USPS Postal Addressing Standards, Pub. 28, November 2000).

Abbreviations should be limited to those recognized by the Postal Service standard abbreviations. These include but are not limited to:

APT (apartment)	N (north)
BLDG (building)	NE (northeast)
FL (floor)	NW (northwest)
STE (suite)	S (south)
UNIT (unit)	SE (southeast)
RM (room)	SW (southwest)
DEPT (department)	E (east)
	W (west)

A complete list of recognized abbreviations is provided in Appendix C of USPS Pub. 28.

Note: Prior to Version 5, Follow-Up Contact fields may have been used for patient current address in the NAACCR record layout.

Note: The nonconfidential parts of the patient's current address and telephone are in the Follow-Up/Recurrence/Death Section of the record layout. The confidential parts of the patient's current address are in the Patient-Confidential Section.

Note: The current USPS Pub. 28 may be found and downloaded from the following Web Site:
<http://pe.usps.gov/cpim/ftp/pubs/Pub28/pub28.pdf>.

Note: The current *Canada Postal Guide* may be found at the following Web Site:
<http://www.canadapost.ca/tools/pg/manual/b03-e.asp#top>

ADDR CURRENT--CITY

Alternate Name	Item #	Length	Source of Standard	Column #
City/Town--Current (COC)	1810	20	COC	1307-1326

Description

Name of city of the patient's current usual residence. If the patient has multiple tumors, the current city of residence should be the same for all tumors.

Rationale

"Current address" can be used to measure the regional "cancer burden" (cost, medical care needs), especially in major retirement regions. Sometimes central registries carry out follow-up by contacting the patients via letter or telephone calls to ascertain their vital status. The most current reported address and telephone number are needed. This information is also useful for conducting interview studies.

Note: Prior to Version 5, Follow-Up Contact fields may have been used for patient current address in the NAACCR record layout.

Note: The nonconfidential parts of the patient's current address and telephone are in the Follow-Up/Recurrence/Death Section of the record layout. The confidential parts of the patient's current address are in the Patient-Confidential Section.

ADDR CURRENT--NO & STREET**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Patient Address (Number and Street)- Current (COC)	2350	40	COC	2188-2227

Description

The number and street address or the rural mailing address of the patient's current usual residence. This can be used to generate a follow-up inquiry, and must correspond to other fields in the current address. If the patient has multiple tumors, the current address should be the same. Additional address information such as facility, nursing home, or name of apartment complex should be entered in item (2355) Addr Current--Supplemental.

U.S. addresses should conform to the USPS Postal Addressing Standards. These standards are referenced in USPS Pub. 28, November 2000, *Postal Addressing Standards*. Canadian addresses should conform to the *Canada Postal Guide*.

Rationale

"Current address" can be used to measure the regional "cancer burden" (cost, medical care needs), especially in major retirement regions. Sometimes central registries carry out follow-up by contacting the patients via letter or telephone calls to ascertain their vital status. The most current reported address and telephone number are needed. This information also is useful for conducting interview studies.

Addresses that are formatted to conform to USPS Postal Addressing Standards can be more properly geocoded by GIS software and vendors to the correct census tract. The USPS Standards also address a number of issues that are problematic in producing precise addresses, including the use of punctuation, abbreviations, and proper placement of address elements, such as street direction, apartment and suite numbers, and unusual addressing situations. Spanish-language addresses also are covered by the USPS Standard.

Coding Instructions (summary of USPS guidelines)

The address should be fully spelled out with standardized use of abbreviations and punctuation per USPS postal addressing standards (USPS Postal Addressing Standards, Pub. 28, November 2000). Upper case is recommended. Mixed case allowed.

Abbreviations should be limited to those recognized by the Postal Service standard abbreviations. These include but are not limited to: AVE (avenue), BLVD (boulevard), CIR (circle), CT (court), DR (drive), PLZ (plaza), PARK (park), PKWY (parkway), RD (road), SQ (square), ST (street), APT (apartment), BLDG (building), FL (floor), STE (suite), UNIT (unit), RM (room), DEPT (department), N (north), NE (northeast), NW (northwest), S (south), SE (southeast), SW (southwest), E (east), and W (west). A complete list of recognized street abbreviations is provided in Appendix C of USPS Pub. 28.

Punctuation marks should be avoided except when punctuation is necessary to convey the meaning. Punctuation normally is limited to periods when the period carries meaning (e.g., 39.2 RD), slashes for fractional addresses (e.g., 101 1/2 MAIN ST), and hyphens when the hyphen carries meaning (e.g., 289-01 MONTGOMERY AVE). Use of the pound sign (#) to designate address units should be avoided whenever possible. The preferred notation is as follows: 102 MAIN ST APT 101. If a pound sign is used, there must be a space between the pound sign and the secondary number (e.g., 425 FLOWER BLVD # 72).

- Note:* Prior to Version 5, Follow-Up Contact fields may have been used for patient current address in the NAACCR record layout.
- Note:* The nonconfidential parts of the patient's current address and telephone are in the Follow-Up/Recurrence/Death Section of the record layout. The confidential parts of the Patient's current address are in the Patient-Confidential Section.
- Note:* The current USPS Pub. 28 may be found and downloaded from the following Web Site:
<http://pe.usps.gov/cpim/ftp/pubs/Pub28/pub28.pdf>.
- Note:* The current Canadian Postal Address standards may be found at the following Web Site:
<http://www.canadapost.ca/tools/pg/manual/b03-e.asp#top>.

ADDR CURRENT--POSTAL CODE

Alternate Name	Item #	Length	Source of Standard	Column #
Postal Code--Current (COC)	1830	9	NAACCR	1329-1337

Description

Postal code for the address of the patient's current usual residence. If the patient has multiple tumors, the postal codes should be the same. For U.S. residents, use either the 5-digit or the extended 9-digit ZIP code. Blanks follow the 5-digit code. For Canadian residents, use the 6-character alphanumeric postal code. Blanks follow the 6-character code. When available, enter postal code for other countries.

Rationale

"Current address" can be used to measure the regional "cancer burden" (cost, medical care needs), especially in major retirement regions. Sometimes central registries carry out follow-up by contacting the patients via letter or telephone calls to ascertain their vital status. The most current reported address and telephone number are needed. This information also is useful for conducting interview studies.

Codes (in addition to U.S., Canadian, and Foreign postal codes)

- 888888888 Resident of country other than the United States (including its possessions, etc.) or Canada, **and** postal code **unknown**
- 999999999 Resident of the United States (including its possessions, etc.) or Canada, **and** postal code **unknown**

- Note:* Prior to Version 5, Follow-Up Contact fields may have been used for patient current address in the NAACCR record layout.
- Note:* The nonconfidential parts of the patient's current address and telephone are in the Follow-Up/Recurrence/Death Section of the record layout. The confidential parts of the Patient's current address are in the Patient-Confidential Section.

ADDR CURRENT--STATE**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
State--Current (COC)	1820	2	NAACCR	1327-1328

Description

USPS abbreviation for the state (including U.S. territories, commonwealths, or possessions) or Canadian province/territory of the patient's current usual residence. If the patient has multiple tumors, the current state of residence should be the same for all tumors.

Rationale

Sometimes the registry receives the name of a facility instead of a proper street address containing the street number, name, direction, and other elements necessary to locate an address on a street file for the purpose of geocoding. By having a second street address field to hold address information, the registry can look up and store the street address and not lose the facility name due to a shortage of space. The presence of a second street address field to hold additional address information also aids in follow-up.

"Current address" can be used to measure the regional "cancer burden" (cost, medical care needs), especially in major retirement regions. Sometimes central registries carry out follow-up by contacting the patients via letter or telephone calls to ascertain vital status. The most current reported address and telephone number are needed. This information also is useful for conducting interview studies.

Codes (in addition to the U.S. and Canadian postal service abbreviations)

- XX Resident of country other than the United States (including its territories, commonwealths, or possessions) or Canada, and country is known
- YY Resident of country other than the United States (including its territories, commonwealths, or possessions) or Canada, and country is unknown
- ZZ Resident of the United States, NOS (including its territories, commonwealths, or possessions); Canada, NOS; residence unknown

Note: Prior to Version 5, Follow-Up Contact fields may have been used for patient current address in the NAACCR record layout.

Note: The nonconfidential parts of the patient's current address and telephone are in the Follow-Up/Recurrence/Death Section of the record layout. The confidential parts of the Patient's current address are in the Patient-Confidential Section.

ADDR CURRENT--SUPPLEMENTL**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Patient Address (Number and Street) Current--Supplemental (COC)	2355	40	COC	2228-2267

Description

This data item provides the ability to store additional address information such as the name of a place or facility, a nursing home, or the name of an apartment complex.

This can be used to generate a follow-up inquiry, and must correspond to other fields in the current address. If the patient has multiple tumors, the current address should be the same.

U.S. addresses should conform to the USPS Postal Addressing Standards. These standards are referenced in USPS Pub. 28, November 2000, *Postal Addressing Standards*. Canadian addresses should conform to the *Canada Postal Guide*.

Rationale

Sometimes the registry receives the name of a facility instead of a proper street address containing the street number, name, direction, and other elements necessary to locate an address on a street file for the purpose of geocoding. By having a second street address field to hold address information, the registry can look up and store the street address and not lose the facility name due to a shortage of space. The presence of a second street address field to hold additional address information also aids in follow-up.

“Current address” can be used to measure the regional “cancer burden” (cost, medical care needs), especially in major retirement regions. Sometimes central registries carry out follow-up by contacting the patients via letter or telephone calls to ascertain their vital status. The most current reported address and telephone number are needed. This information is also useful for conducting interview studies.

Coding Instructions (summary of USPS guidelines)

The address should be fully spelled out with standardized use of abbreviations and punctuation per USPS postal addressing standards (USPS Postal Addressing Standards, Pub. 28, November 2000).

Abbreviations should be limited to those recognized by the Postal Service standard abbreviations. These include but are not limited to:

APT (apartment)	N (north)
BLDG (building)	NE (northeast)
FL (floor)	NW (northwest)
STE (suite)	S (south)
UNIT (unit)	SE (southeast)
RM (room)	SW (southwest)
DEPT (department)	E (east)
	W (west)

A complete list of recognized abbreviations is provided in Appendix C of USPS Pub. 28.

Note: Prior to Version 5, Follow-Up Contact fields may have been used for patient current address in the NAACCR record layout.

Note: The nonconfidential parts of the patient's current address and telephone are in the Follow-Up/Recurrence/Death Section of the record layout. The confidential parts of the Patient's current address are in the Patient-Confidential Section.

Note: The current USPS Pub. 28 may be found and downloaded from the following Web Site:
<http://pe.usps.gov/cpim/ftp/pubs/Pub28/pub28.pdf>.

Note: The current *Canada Postal Guide* may be found at the following Web Site:
<http://www.canadapost.ca/tools/pg/manual/b03-e.asp#top>.

AGE AT DIAGNOSIS

Alternate Name	Item #	Length	Source of Standard	Column #
	230	3	SEER/COC	119-121

Description

Age of the patient at diagnosis in complete years. Different tumors for the same patient may have different values.

Codes

000 Less than 1 year old
001 1 year old, but less than 2 years
002 2 years old
... (show actual age in completed years)
101 101 years old
...
120 120 years old
999 Unknown age

ALCOHOL HISTORY

Alternate Name	Item #	Length	Source of Standard	Column #
	350	1	Varies	225-225

Description

NAACCR has not adopted standards for this item.

ARCHIVE FIN**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
	3100	10	COC	392-401

Description

This field identifies the facility that originally accessioned the case.

Rationale

Each facility's facility identification number (FIN) is unique. It is essential for hospital registries to have the ability to distinguish cases originally accessioned by each registry of a merged unit. This enables the central registry to manage the receipt of historical data and to appropriately attribute these data.

Efforts are underway at the federal level to establish uniform national provider ID numbers. COC and NAACCCR committees will consider the adoption of any federal standards when they become available.

Instructions for Coding

COC maintains the codes, including those for non-hospital sources of reporting.

For facilities with 7-digit FINs in the range of 6020009-6953290 that were assigned by COC before January 1, 2001, the coded FIN will consist of three leading zeroes followed by the full 7-digit number.

For facilities with FINs greater than or equal to 10000000 that were assigned by COC after January 1, 2001, enter FIN codes of this type as two zeroes followed by the full 8-digit code. These sometimes are called COC FIN 10-digit codes.

AUTOPSY

Alternate Name	Item #	Length	Source of Standard	Column #
	1930	1	COC	1393-1393

Description

Code indicating whether or not an autopsy was performed.

Codes

- 0 Not applicable; patient alive
- 1 Autopsy performed
- 2 No autopsy performed
- 9 Patient expired, unknown if autopsy performed

Note: Codes 1–9 used only if the patient has expired.

Note: Beginning January 1, 2003, COC will no longer support this data item.

BEHAVIOR (73-91) ICD-O-1

Alternate Name	Item #	Length	Source of Standard	Column #
	1972	1	SEER	1145-1145

Description

Area for retaining behavior portion (1 digit) of the ICD-O-1 or field trial morphology codes entered before a conversion to ICD-O-2. See grouped data item Morph (73-91) ICD-O-1 [1970] in Appendix E. The item name includes years 73-91. However, some states may have used the codes for cases before 1973. It is a subfield of the morphology code.

Codes

For cases diagnosed before 1992, contains the ICD-O-1 or field trial 1-digit behavior code as originally coded, if available. Blank for cases coded directly into ICD-O-2 (i.e., 1992 and later cases).

BEHAVIOR (92-00) ICD-O-2

Alternate Name	Item #	Length	Source of Standard	Column #
	430	1	SEER/COC	300-300

Description

Code for the behavior of the tumor being reported using ICD-O-2. NAACCR adopted ICD-O-2 as the standard coding system for cases diagnosed from January 1, 1992, through December 31, 2000. In addition, NAACCR recommended that cases diagnosed prior to 1992 be converted to ICD-O-2.

Note: See Behavior (73-91) ICD-O-1, item 1972 for ICD-O-1 and field trial codes.

Codes

See ICD-O-2,¹⁵ page 22, for behavior codes.

Clarification of Required Status

This data item is required by all standard-setting organizations for cancer cases diagnosed from January 1, 1992, through December 31, 2000, and recommended for cases diagnosed before 1992.

When the histologic type is coded according to the ICD-O-2, the histology code must be reported in Data Item 420 - Histology (92-00) ICD-O-2, with behavior coded in Data Item 430 - Behavior (92-00) ICD-O-2.

For information on required status for related data items for histologic type and behavior when coded according to ICD-O-3, see Data Item 522 - Histologic Type ICD-O-3 and Data Item 523 - Behavior Code ICD-O-3.

BEHAVIOR CODE ICD-O-3

Alternate Name	Item #	Length	Source of Standard	Column #
	523	1	SEER/COC	305-305

Description

Code for the behavior of the tumor being reported using ICD-O-3. NAACCR adopted ICD-O-3 as the standard coding system for cases diagnosed beginning January 1, 2001, and later recommended that prior cases be converted from ICD-O-2.

Note: See Behavior (92-00) ICD-O-2, item 430, for ICD-O-2 codes.

Codes

See ICD-O-3,¹⁴ page 66, for behavior codes.

Clarification of Required Status

Behavior is required by all standard-setting organizations for cancer cases diagnosed on or after January 1, 2001, and recommended (by conversion from ICD-O-2 codes) for cases diagnosed before 2001.

When the histologic type is coded according to the ICD-O-3, the histology code must be reported in Data Item 522 - Histologic Type ICD-O-3, with behavior coded in Data Item 523 - Behavior Code ICD-O-3.

For information on required status for related data items for histologic type and behavior when coded according to ICD-O-2, see Data Item 420 - Histology (92-00) ICD-O-2 and Data Item 430 - Behavior (92-00) ICD-O-2.

BIRTH DATE

Alternate Name	Item #	Length	Source of Standard	Column #
Date of Birth (SEER/COC)	240	8	SEER/COC	122-129

Description

Date of birth of the patient. The birthdate is recorded in the month, day, year format (MMDDCCYY). A zero must precede single-digit months and days. Estimate date of birth when information is not available. It is better to estimate than to code as an unknown value.

BIRTHPLACE

Alternate Name	Item #	Length	Source of Standard	Column #
Place of Birth (SEER/COC)	250	3	SEER/COC	130-132

Description

Code for place of birth of the patient. If a patient has multiple tumors, all records should contain the same code.

Rationale

Place of Birth is helpful for patient matching and can be used when reviewing race and ethnicity. In addition, adding birthplace data to race and ethnicity allows for a more specific definition of the population being reported. Careful descriptions of ancestry, birthplace, and immigration history of populations studied are needed to make the basis for classification into ethnic groups clear. Birthplace has been associated with variation in genetic, socioeconomic, cultural, and nutritional characteristics that affect patterns of disease. A better understanding of the differences within racial and ethnic categories also can help states develop effective, culturally sensitive public health prevention programs to decrease the prevalence of high-risk behaviors and increase the use of preventive services.

Code

See Appendix B (also Appendix B of the *SEER Program Code Manual*) for numeric and alphabetic lists of places and codes.

CANCER STATUS

Alternate Name	Item #	Length	Source of Standard	Column #
	1770	1	COC	1303-1303

Description

Records the cancer status for this primary as of the date entered in item 1750 (Date of Last Contact). If the patient has multiple primaries, the values may be different for each primary.

Rationale

Hospitals use this field to compute survival analysis (disease-free intervals). By maintaining this data item, central registries can assist hospital registries by sharing this information with other hospital registries that serve the same patients, if the state's privacy laws so permit.

Codes

- 1 No evidence of this cancer
- 2 Evidence of this cancer
- 9 Unknown, indeterminate whether this cancer is present

CAUSE OF DEATH

Alternate Name	Item #	Length	Source of Standard	Column #
Underlying Cause of Death (SEER) Underlying Cause of Death (ICD Code) (pre-96 COC)	1910	4	SEER/COC	1388-1391

Description

Official cause of death as coded from the death certificate in valid ICD-7, ICD-8, ICD-9, and ICD-10 codes.

| *Note:* See *SEER Program Code Manual* for additional instructions.

Rationale

Cause of death is used for calculation of adjusted survival rates by the life table method. The adjustment corrects for deaths other than from the diagnosed cancer.

Special codes (in addition to ICD-7, ICD-8, ICD-9, and ICD-10)

0000 Patient alive at last contact

7777 State death certificate not available

7797 State death certificate available but underlying cause of death is not coded

| *Note:* Beginning January 1, 2003, COC will no longer support this data item.

CENSUS COD SYS 1970/80/90**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Census Coding System (COC) Coding System for Census Tract (pre-96 SEER/COC)	120	1	SEER	92-92

Description

Identified the set of Census Bureau census tract definitions (boundaries) that were used to code the census tract in item 110 (Census Tract 1970/80/90) for a specific record.

Rationale

Allows for changes in census tracts over time. The census tract definition used to code the case must be recorded so that data are correctly grouped and analyzed. If the coding system were not recorded, the census codes would have to be converted or recoded every time the census tracts were changed.

Codes

0 Not tracted
 1 1970 Census Tract Definitions
 2 1980 Census Tract Definitions
 3 1990 Census Tract Definitions
 Blank Census Tract 1970/80/90 not coded

Clarification of NPCR Required StatusCensus-1990 data items:

Census Tract 1970/80/90 [110]
 Census Tr Cert 1970/80/90 [364]
 Census Tract Cod Sys -- 1970/80/90 [120]

Census-2000 data items:

Census Tract 2000 [130]
 Census Tr Certainty 2000 [365]

Information on census tract, census tract certainty, and census tract coding system is required. For cancer cases diagnosed in or after 2003, Census Tract 2000 [130] and Census Tr Certainty 2000 [365] ("Census-2000 data items") are required. For cancer cases diagnosed in or before 2002, the requirement can be met by collecting either the Census-1990 data items [110, 364, 120] or the Census-2000 data items, although the Census-2000 data items [130 and 365] are recommended for cancer cases diagnosed in 1998 through 2002.

CENSUS TR CERT 1970/80/90**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	364	1	SEER	100-100

Description

Code indicating basis of assignment of census tract or block numbering area (BNA) for an individual record. Helpful in identifying cases tracted from incomplete information or P.O. Box. Most of the time, this information is provided by a geocoding vendor service. Alternatively, a central registry staff manually assigns the code. This item is not coded by the hospital. Codes are hierarchical, with lower numbers having priority.

Codes

- 1 Census tract/BNA based on complete and valid street address of residence
- 2 Census tract/BNA based on residence ZIP + 4
- 3 Census tract/BNA based on residence ZIP + 2
- 4 Census tract/BNA based on residence ZIP code only
- 5 Census tract/BNA based on ZIP code of P.O. Box
- 9 Unable to assign census tract or bloc numbering based on available information
- Blank Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded

Clarification of NPCR Required StatusCensus-1990 data items:

Census Tract 1970/80/90 [110]
 Census Tr Cert 1970/80/90 [364]
 Census Tract Cod Sys -- 1970/80/90 [120]

Census-2000 data items:

Census Tract 2000 [130]
 Census Tr Certainty 2000 [365]

Information on census tract, census tract certainty, and census tract coding system is required. For cancer cases diagnosed in or after 2003, Census Tract 2000 [130] and Census Tr Certainty 2000 [365] ("Census-2000 data items") are required. For cancer cases diagnosed in or before 2002, the requirement can be met by collecting either the Census-1990 data items [110, 364, 120] or the Census-2000 data items, although the Census-2000 data items [130 and 365] are recommended for cancer cases diagnosed in 1998 through 2002.

CENSUS TR CERTAINTY 2000**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
	365	1	NAACCR	101-101

Description

Code indicating basis of assignment of census tract for an individual record. Helpful in identifying cases tracted from incomplete information or P.O. Box. Most of the time, this information is provided by a geocoding vendor service. Alternatively, a central registry staff manually assigns the code. This item is not coded by the hospital. Codes are hierarchical, with lower numbers having priority.

Codes

- 1 Census tract based on complete and valid street address of residence
- 2 Census tract based on residence ZIP + 4
- 3 Census tract based on residence ZIP + 2
- 4 Census tract based on residence ZIP code only
- 5 Census tract based on ZIP code of P.O. Box
- 9 Unable to assign census tract or bloc numbering based on available information
- Blank Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded

Clarification of NPCR Required StatusCensus-1990 data items:

Census Tract 1970/80/90 [110]
Census Tr Cert 1970/80/90 [364]
Census Tract Cod Sys -- 1970/80/90 [120]

Census-2000 data items:

Census Tract 2000 [130]
Census Tr Certainty 2000 [365]

Information on census tract, census tract certainty, and census tract coding system is required. For cancer cases diagnosed in or after 2003, Census Tract 2000 [130] and Census Tr Certainty 2000 [365] ("Census-2000 data items") are required. For cancer cases diagnosed in or before 2002, the requirement can be met by collecting either the Census-1990 data items [110, 364, 120] or the Census-2000 data items, although the Census-2000 data items [130 and 365] are recommended for cancer cases diagnosed in 1998 through 2002.

CENSUS TRACT 1970/80/90**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Census Tract/Block Numbering Area (BNA) (SEER) Census Tract	110	6	SEER	86-91

Description

Code for the census tract or BNA of the patient's residence at the time of diagnosis. SEER used this field for cases reported before 1998. If the patient has more than one tumor, the codes may be different for each tumor.

Codes are those used by the U.S. Census Bureau. Census Bureau codes for BNA also are entered in this field.

Both census tracts and BNAs have a 4-digit basic number and also may have a 2-digit suffix. Census tract numbers range from 0001.00 to 9499.99. BNA numbers range from 9501.00 to 9989.99. See the Census Bureau's "Area Classifications"³⁵ for further details.

Rationale

Allows central registries to calculate incidence rates for geographical areas having population estimates. The Census Bureau provides population data for census tracts. Those rates can be used for general surveillance or special geographical and socioeconomic analysis.

Codes

Census Tract Codes 000100-949999
BNA Codes 950100-998999

000000 Area not census-tracted
999999 Area census-tracted, but census tract is not available
Blank Census Tract 1970/80/90 not coded

Clarification of NPCR Required StatusCensus-1990 data items:

Census Tract 1970/80/90 [110]
Census Tr Cert 1970/80/90 [364]
Census Tract Cod Sys -- 1970/80/90 [120]

Census-2000 data items:

Census Tract 2000 [130]
Census Tr Certainty 2000 [365]

Information on census tract, census tract certainty, and census tract coding system is required. For cancer cases diagnosed in or after 2003, Census Tract 2000 [130] and Census Tr Certainty 2000 [365] ("Census-2000 data items") are required. For cancer cases diagnosed in or before 2002, the requirement can be met by collecting either the Census-1990 data items [110, 364, 120] or the Census-2000 data items, although the Census-2000 data items [130 and 365] are recommended for cancer cases diagnosed in 1998 through 2002.

CENSUS TRACT 2000**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Census Tract --Alternate (pre-2003)	130	6	NAACCR	93-98

Description

This field is provided for coding census tract of patient's residence at time of diagnosis. See item 110 (Census Tract 1970/80/90). Codes are those used by the U.S. Census Bureau for the Year 2000 Census. Census tract codes have a 4-digit basic number and also may have a 2-digit suffix. Census tract numbers range from 0001.01 to 9999.98. See the Census Bureau's "Area Classifications" at the following Web Site: <http://www.census.gov/prod/cen2000/doc/sf1.pdf> for further details.

Rationale

Census tract codes allow central registries to calculate incidence rates for geographical areas having population estimates. This field allows a central registry to add Year 2000 Census tracts to cases diagnosed in previous years, without losing the codes in data item 110.

The Census Bureau provides population data for census tracts. Those rates can be used for general surveillance or special geographical and socioeconomic analysis.

Because census tracts for particular cases can change between censuses, the central registry may wish to assign an alternate census tract code to its cases. For example, a registry may code its 1985 cases using both the 1980 and 1990 census tract boundaries. The central registry can use this information for different comparisons.

Codes

Census Tract Codes 000101-999998

000000 Area not census tracted
 999999 Area census-tracted, but census tract is not available
 Blank Census Tract 2000 not coded

Clarification of NPCR Required StatusCensus-1990 data items:

Census Tract 1970/80/90 [110]
 Census Tr Cert 1970/80/90 [364]
 Census Tract Cod Sys -- 1970/80/90 [120]

Census-2000 data items:

Census Tract 2000 [130]
 Census Tr Certainty 2000 [365]

Information on census tract, census tract certainty, and census tract coding system is required. For cancer cases diagnosed in or after 2003, Census Tract 2000 [130] and Census Tr Certainty 2000 [365] ("Census-2000 data items") are required. For cancer cases diagnosed in or before 2002, the requirement can be met by collecting either the Census-1990 data items [110, 364, 120] or the Census-2000 data items, although the Census-2000 data items [130 and 365] are recommended for cancer cases diagnosed in 1998 through 2002.

CENSUS TRACT BLOCK GROUP

Alternate Name	Item #	Length	Source of Standard	Column #
	362	1	Census	99-99

Description

NAACCR has not adopted standards for this item.

CENSUS TRACT COD SYS--ALT**(Retired)**

Alternate Name	Item #	Length	Source of Standard	Column #
	140	0	NAACCR	

Description

Identify the set of Census Bureau census tract definitions (boundaries) that were used to code item 130 (Census Tract--Alternate [pre-2003]) for a specific record.

Rationale

This data item was retired for Version 10 because item 130 (Census Tract--2000) is expected to contain only Census 2000 codes.

Codes

- 0 Not tracted
- 1 1970 Census Tract Definitions
- 2 1980 Census Tract Definitions
- 3 1990 Census Tract Definitions

CHEMOTHERAPY FIELD 1

Alternate Name	Item #	Length	Source of Standard	Column #
	1600	3	COC	920-922

Description

These fields have been listed as in development since 1996. Beginning January 1, 2003, COC no longer supports these data items.

Codes

Blank

CHEMOTHERAPY FIELD 2

Alternate Name	Item #	Length	Source of Standard	Column #
	1610	3	COC	923-925

Description

These fields have been listed as in development since 1996. Beginning January 1, 2003, COC no longer supports these data items.

Codes

Blank

CHEMOTHERAPY FIELD 3

Alternate Name	Item #	Length	Source of Standard	Column #
	1620	3	COC	926-928

Description

These fields have been listed as in development since 1996. Beginning January 1, 2003, COC no longer supports these data items.

Codes

Blank

CHEMOTHERAPY FIELD 4

Alternate Name	Item #	Length	Source of Standard	Column #
	1630	3	COC	929-931

Description

These fields have been listed as in development since 1996. Beginning January 1, 2003, COC no longer supports these data items.

Codes

Blank

CLASS OF CASE**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	610	1	COC	440-440

Description

For a hospital registry, divides cases into two groups: analytic cases are those included in reports on patient treatment and outcomes; nonanalytic cases are those not included in such reports. Class of Case codes 0-2 identify cases that are analytic (i.e., cases that were first diagnosed and/or received all or part of their first course of treatment or had treatment planned at the reporting hospital). Class of Case codes 3-5, 7, 8, and 9 identify cases that are considered nonanalytic (i.e., were first diagnosed and received all of their first course of treatment at a facility other than the reporting institution, or were diagnosed at autopsy or by death certificate only). Class of Case 6 identifies cases that were first diagnosed and received their entire first course of treatment in the same staff physician's office. These cases were considered analytic for diagnosis dates January 1, 1998, through December 31, 1999. For diagnosis dates on or after January 1, 2000, these cases are considered nonanalytic.

Class of Case can be used in conjunction with item 500 (Type of Reporting Source). Type of Reporting Source is designed to document the source of documents used to abstract the cancer being reported.

Codes

- 0 Diagnosis at the reporting facility and all of the first course of treatment was performed elsewhere or the decision not to treat was made at another facility.
- 1 Diagnosis at the reporting facility, and all or part of the first course of treatment was performed at the reporting facility.
- 2 Diagnosis elsewhere, and all or part of the first course of treatment was performed at the reporting facility.
- 3 Diagnosis and all of the first course of treatment was performed elsewhere. Presents at your facility with recurrence or persistent disease.
- 4 Diagnosis and/or first course of treatment were performed at the reporting facility prior to the reference date of the registry.
- 5 Diagnosed at autopsy.
- 6 Diagnosis and all of the first course of treatment were completed by the same staff physician in an office setting. "Staff physician" is any medical staff with admitting privileges at the reporting facility.
- 7 Pathology report only. Patient does not enter the reporting facility at any time for diagnosis or treatment. This category excludes cases diagnosed at autopsy.
- 8 Diagnosis was established by death certificate only. *Used by central registries only.*
- 9 Unknown. Sufficient detail for determining Class of Case is not stated in patient record. *Used by central registries only.*

COC CODING SYS--CURRENT**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Commission on Cancer Coding System-Current (COC)	2140	2	COC	1200-1201

Description

Code the ACoS COC coding system currently used in the record. COC codes may be converted from an earlier version.

Codes

- 00 No COC coding system used
- 01 Pre-1988 (Cancer Program Manual Supplement)
- 02 1988 *Data Acquisition Manual*
- 03 1989 *Data Acquisition Manual* Revisions
- 04 1990 *Data Acquisition Manual* Revisions
- 05 1994 *Data Acquisition Manual* (Interim/Revised)
- 06 *ROADS* (effective with cases diagnosed 1996-1997)
- 07 *ROADS* and 1998 Supplement (effective with cases diagnosed 1998-2002)
- 08 *FORDS* (effective with cases diagnosed 2003 and forward)
- 99 Unknown. Original COC coding system used, not known. Use code 99 for cases coded prior to 2003 if the correct COC coding system is not known, or if multiple coding systems were used to code a single case.

COC CODING SYS--ORIGINAL**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2150	2	NAACCR	1202-1203

Description

Code for the ACoS COC coding system originally used to code the record.

Codes

- 00 No COC coding system used
- 01 Pre-1988 (Cancer Program Manual Supplement)
- 02 1988 *Data Acquisition Manual*
- 03 1989 *Data Acquisition Manual* Revisions
- 04 1990 *Data Acquisition Manual* Revisions
- 05 1994 *Data Acquisition Manual* (Interim/Revised)
- 06 *ROADS* (effective with cases diagnosed 1996-1997)
- 07 *ROADS* and 1998 Supplement (effective with cases diagnosed 1998-2002)
- 08 *FORDS* (effective with cases diagnosed 2003 and forward)
- 99 Unknown. Original COC coding system used, not known. Use code 99 for cases coded prior to 2003 if the correct COC coding system is not known, or if multiple coding systems were used to code a single case.

CODING SYSTEM FOR EOD

Alternate Name	Item #	Length	Source of Standard	Column #
Coding System for Extent of Disease (SEER)	870	1	SEER	562-562

Description

Indicates the type of SEER EOD code applied to the case. Should be used whenever EOD coding is applied.

Rationale

Used in data editing and analysis.

Codes

- 0 2-Digit Nonspecific Extent of Disease (1973-82)
- 1 2-Digit Site-Specific Extent of Disease (1973-82)
- 2 13-Digit (expanded) Site-Specific Extent of Disease (1973-1982)
- 3 4-Digit Extent of Disease (1983-87)
- 4 10-Digit Extent of Disease, 1988 (1988+)

COMORBID/COMPLICATION 1**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Comorbidities and Complications #1	3110	5	COC	675-679

Description

Records the patient's pre-existing medical conditions and/or complications, other than neoplasms, during the patient's hospital stay for the treatment of this cancer.

Rationale

Comorbidities may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust risk outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Codes (in addition to valid ICD-9-CM Codes 00100-13980, 24000-99990, E8700-E8799, and E9300-E9499)

00000 No secondary diagnoses documented

Note: For comorbid conditions (ICD-9-CM codes 00100-13980 and 24000-99990), there is an assumed decimal point between the third and fourth characters. For complications (ICD-9-CM codes E8700-E8799 and E9300-E9499), there is an assumed decimal point between the fourth and fifth characters.

COMORBID/COMPLICATION 2

(New)

Alternate Name	Item #	Length	Source of Standard	Column #
Comorbidities and Complications #2	3120	5	COC	680-684

Description

Records the patient's pre-existing medical conditions and/or complications, other than neoplasms, during the patient's hospital stay for the treatment of this cancer.

Rationale

Comorbidities may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust risk outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality-of-care.

Codes

ICD-9-CM Codes 00100-13980, 24000-99990, E8700-E8799, and E9300-E9499

Note: For comorbid conditions (ICD-9-CM codes 00100-13980 and 24000-99990), there is an assumed decimal point between the third and fourth characters. For complications (ICD-9-CM codes E8700-E8799 and E9300-E9499), there is an assumed decimal point between the fourth and fifth characters.

COMORBID/COMPLICATION 3

(New)

Alternate Name	Item #	Length	Source of Standard	Column #
Comorbidities and Complications #3	3130	5	COC	685-689

Description

Records the patient's pre-existing medical conditions and/or complications, other than neoplasms, during the patient's hospital stay for the treatment of this cancer.

Rationale

Comorbidities may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust risk outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality-of-care.

Codes

ICD-9-CM Codes 00100-13980, 24000-99990, E8700-E8799, and E9300-E9499

Note: For comorbid conditions (ICD-9-CM codes 00100-13980 and 24000-99990), there is an assumed decimal point between the third and fourth characters. For complications (ICD-9-CM codes E8700-E8799 and E9300-E9499), there is an assumed decimal point between the fourth and fifth characters.

COMORBID/COMPLICATION 4**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Comorbidities and Complications #4	3140	5	COC	690-694

Description

Records the patient's pre-existing medical conditions and/or complications, other than neoplasms, during the patient's hospital stay for the treatment of this cancer.

Rationale

Comorbidities may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust risk outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality-of-care.

Codes

ICD-9-CM Codes 00100-13980, 24000-99990, E8700-E8799, and E9300

Note: For comorbid conditions (ICD-9-CM codes 00100-13980 and 24000-99990), there is an assumed decimal point between the third and fourth characters. For complications (ICD-9-CM codes E8700-E8799 and E9300-E9499), there is an assumed decimal point between the fourth and fifth characters.

COMORBID/COMPLICATION 5**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Comorbidities and Complications #5	3150	5	COC	695-699

Description

Records the patient's pre-existing medical conditions and/or complications, other than neoplasms, during the patient's hospital stay for the treatment of this cancer.

Rationale

Comorbidities may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust risk outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality-of-care.

Codes

ICD-9-CM Codes 00100-13980, 24000-99990, E8700-E8799, and E9300-E9499

Note: For comorbid conditions (ICD-9-CM codes 00100-13980 and 24000-99990), there is an assumed decimal point between the third and fourth characters. For complications (ICD-9-CM codes E8700-E8799 and E9300-E9499), there is an assumed decimal point between the fourth and fifth characters.

COMORBID/COMPLICATION 6**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Comorbidities and Complications #6	3160	5	COC	700-704

Description

Records the patient's pre-existing medical conditions and/or complications, other than neoplasms, during the patient's hospital stay for the treatment of this cancer.

Rationale

Comorbidities may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust risk outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality-of-care.

Codes

ICD-9-CM Codes 00100-13980, 24000-99990, E8700-E8799, and E9300-E9499

Note: For comorbid conditions (ICD-9-CM codes 00100-13980 and 24000-99990), there is an assumed decimal point between the third and fourth characters. For complications (ICD-9-CM codes E8700-E8799 and E9300-E9499), there is an assumed decimal point between the fourth and fifth characters.

COMPUTED ETHNICITY

Alternate Name	Item #	Length	Source of Standard	Column #
	200	1	NAACCR	116-116

Description

Code identifying those cases for which ethnicity was determined by matching items 2230 (Name--Last) and 2390 (Name--Maiden) to a computer list of Spanish/Hispanic names or by a software algorithm. This field was adopted for use for cases diagnosed 1994 forward.

See also item 210 (Computed Ethnicity Source).

Rationale

One method of identifying persons of Hispanic origin is to apply a standard computer list or algorithm to items 2230 and 2390, the patient's surname and/or maiden name. This has advantages across large populations of being reproducible and facilitating comparisons between areas using identical methods. It may sometimes be possible to identify population denominators in which the same method was used to identify Hispanics. Generally, only central registries will have this capability.

This field provides coding to indicate both that such a computerized name-based method was applied and the results of the method. Coding is independent of that in item 190 (Spanish/Hispanic Origin). The computer-derived ethnicity may be different from the ethnicity reported by registries in item 190 (Spanish/Hispanic Origin) as code 7 (Spanish Surname Only), because that field may include manual review. This field shows the results of computer-derived ethnicity only.

Codes

- 0 No match was run (for 1994 and later cases)
- 1 Non-Hispanic last name and non-Hispanic maiden name
- 2 Non-Hispanic last name, did not check maiden name or patient was male
- 3 Non-Hispanic last name, missing maiden name
- 4 Hispanic last name, non-Hispanic maiden name
- 5 Hispanic last name, did not check maiden name or patient was male
- 6 Hispanic last name, missing maiden name
- 7 Hispanic Maiden name (females only) (regardless of last name)
- Blank 1993 and earlier cases, no match was run

Note: For SEER, blank is allowed only for cases diagnosed in 1993 and earlier. For SEER, all cases diagnosed before 1994 must be blank. Other registries may have computed this item for earlier years.

Note: NAACCR recognizes that available definitions and abstracting instructions for the data items Name--Last and Name--Maiden may be inadequate for describing names used in some cultures, including Hispanic cultures. Explicit instructions have not been provided for entering compound names, with or without hyphens or "De." Order of names, use of maternal and paternal names, and use of hyphens can vary across cultures. It is likely, too, that abstracting and coding practice for these items varies across registries. For purposes of the fields Spanish/Hispanic Origin and Computed Ethnicity, "Last Name" means the name entered in the field Name--Last (item 2230), and "Maiden Name" means the name entered in the field Name--Maiden (item 2390). Limitations inherent in these definitions should be kept in mind in any use of the data.

COMPUTED ETHNICITY SOURCE

Alternate Name	Item #	Length	Source of Standard	Column #
	210	1	NAACCR	117-117

Description

Code identifying the method used to determine ethnicity as recorded in item 200 (Computed Ethnicity).

Codes

- 0 No match was run, for 1994 and later cases
- 1 Census Bureau list of Spanish surnames, NOS
- 2 1980 Census Bureau list of Spanish surnames
- 3 1990 Census Bureau list of Spanish surnames
- 4 GUESS Program
- 5 Combination list including South Florida names
- 6 Combination of Census and other locally generated list
- 7 Combination of Census and GUESS, with or without other lists
- 8 Other type of match
- 9 Unknown type of match
- Blank 1993 and earlier cases, no match was run

Note: For SEER, blank is allowed only for cases diagnosed in 1993 and earlier. For SEER, all cases diagnosed before 1994 must be blank. Other registries may have computed this item for earlier years.

COUNTY AT DX

Alternate Name	Item #	Length	Source of Standard	Column #
County (pre-96 SEER/COC)	90	3	FIPS/SEER	83-85
County at Diagnosis (COC)				

Description

Code for the county of the patient's residence at the time the tumor was diagnosed. For U.S. residents, standard codes are those of the FIPS publication "Counties and Equivalent Entities of the United States, Its Possessions, and Associated Areas." If the patient has multiple tumors, the county codes may be different for each tumor.

COC uses the geocodes for residents of other countries.

Detailed standards have not been set for Canadian provinces/territories. Use code 998 for Canadian residents.

Note: The standard of using FIPS codes for this item has not been adopted by all states. Some states use their own codes for this data item. See Chapter V, Unresolved Issues, for further information.

Note: See Appendix A for standard FIPS county codes. See EDITS Table BPLACE.DBF in Appendix B for geocodes used by COC.

Note: SEER does not use code 998, as it does not collect cases if the county is unknown. COC uses country geocodes for nonresidents of the United States (see Appendix B) and 998 for residents of other states.

Codes (in addition to FIPS and Geocodes)

- 998 Known town, city, state, or country of residence but county code not known AND a resident outside of the state of reporting institution (must meet all criteria)
- 999 County unknown

COUNTY--CURRENT

Alternate Name	Item #	Length	Source of Standard	Column #
	1840	3	COC	1338-1340

Description

Code for county of patient's current residence. See Chapter V, Unresolved Issues, for further discussion.

Note: This item was used by COC only. COC recommended use of FIPS codes (see Appendix A). The *ROADS Manual* also provided for use of geocodes for countries of residence outside the United States and Canada to be used in the county fields.

Rationale

This item may be used in administrative reports to define a referral area.

Codes (in addition to FIPS and geocodes)

- 998* Known town, city, state, or country of residence but county code not known AND a resident outside of the state of reporting institution (must meet all criteria)
- 999 County unknown

**Note:* Code 998 was not used by COC for non-U.S. residents. COC used geocodes for county as described above.

Note: Beginning January 1, 2003, COC will no longer support this data item.

CRC CHECKSUM

Alternate Name	Item #	Length	Source of Standard	Column #
	2081	10	NAACCR	1164-1173

Description

Cyclic Redundancy Code (CRC) CHECKSUM for the NAACCR record in which it resides. A unique value is calculated for each unique record in a NAACCR file. The value is calculated by applying a CRC algorithm to all data fields of the NAACCR record (excluding the CRC CHECKSUM field). Following a transmission, the CRC CHECKSUM can be recalculated and compared with the transmitted CHECKSUM. Identical values indicate an error-free transmission; differing values indicate an error in transmission.

Users must provide recipients of the data with the algorithm used to create the data transmission file. Otherwise, the item should be left blank.

Rationale

The CHECKSUM can be used to determine if a record-level error occurred during transmission and can also be used to correct any such errors. Record-level CRC CHECKSUMs also allow portions of a NAACCR file to be salvaged in the event of a transmission error.

Note: The algorithm recommended by NAACCR is on the NAACCR Web Site at: <http://www.naacr.org>.

CS EXTENSION**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2810	2	AJCC	632-633

Description

This belongs to the set of Collaborative Staging (CS) data items. It is based on and replaces EOD--Extension (790) and EOD--Extension Prost Path (800). This modification for CS is collapsible into AJCC T code. "CS Extension" identifies the primary tumor growth within the organ of origin or its extension into neighboring organs.

Site-specific codes provide extensive detail describing disease extent. "CS Extension" is used to derive the AJCC Stage Grouping, SEER Summary 1977, and SEER Summary 2000 codes.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes (in addition to Site-Specific Codes)

- 00 *In situ*; noninvasive.
- 80 Further contiguous extension
- 95 No evidence of primary tumor
- 99 Unknown extension; primary tumor cannot be assessed; not stated in patient record

Note: See the *Collaborative Staging Manual and Coding Instructions, Version 1.0* for site-specific codes and coding rules.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naacr.org for the latest information.

CS LYMPH NODES**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
CS Lymph Nodes (SEER EOD)	2830	2	AJCC	635-636

Description

This belongs to the set of Collaborative Staging (CS) data items. It replaces EOD--Lymph Node Involvement (810). "CS Lymph Nodes" is site-specific and identifies the regional lymph nodes involved with cancer at the time of diagnosis. Site-specific codes provide extensive detail describing disease extent. "CS Lymph Nodes" is used to derive the AJCC Stage Grouping, SEER Summary 1977, and SEER Summary 2000 codes.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes (in addition to Site-Specific codes)

- 00 None; no regional lymph node involvement
- 80 Lymph nodes, NOS
- 90 Unknown; regional lymph nodes cannot be assessed; not stated in patient record

Note: See the *Collaborative Staging Manual and Coding Instructions, Version 1.0* for site-specific codes and coding rules.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

CS METS AT DX**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
CS Metastasis at Diagnosis	2850	2	AJCC	638-639

Description

This belongs to the set of Collaborative Staging (CS) data items and is part of the detailed site-specific codes for anatomic EOD. It replaces data items 1090, 1100, and 1110. “CS Metastasis at Diagnosis” identifies the site(s) of metastatic involvement at time of diagnosis.

This item allows the data to be collapsed into different staging schemes for EOD, AJCC, SEER Summary 1977, and SEER Summary 2000 fields.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes (in addition to Site-Specific codes)

- 00 No; none
- 10 Distant lymph node(s)
- 40 Distant metastases except distant lymph node(s) (code 10). Distant metastasis, NOS. Carcinomatosis.
- 50 (40) + (10)
- 99 Unknown; distant metastasis cannot be assessed; not stated in patient record

Note: See the *Collaborative Staging Manual and Coding Instructions, Version 1.0* for site-specific codes and coding rules.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

CS METS EVAL

(New)

Alternate Name	Item #	Length	Source of Standard	Column #
CS Metastasis Evaluation	2860	1	AJCC	640-640

Description

This belongs to the set of Collaborative Staging (CS) data items. “CS Metastasis Evaluation” records the validity of the classification of the item “CS Metastasis at Diagnosis” (NAACCR Item #2850) *only* according to the diagnostic methods employed.

This data item is used in CS to identify whether the M (of AJCC TNM) was clinically or pathologically diagnosed and by what methods, based upon modified “certainty factors” from *UICC TNM Classification of Malignant Tumors, Fifth Edition* (pp12-13).

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes

0, 1, 2, 3, 5, 6, 8, 9

Note: See the *Collaborative Staging Manual and Coding Instructions, Version 1.0* for codes and coding rules.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

CS REG NODE EVAL

(New)

Alternate Name	Item #	Length	Source of Standard	Column #
CS Regional Lymph Nodes Evaluation	2840	1	AJCC	637-637

Description

This belongs to the set of Collaborative Staging (CS) data items. “CS Regional Nodes Evaluation” records the validity of the classification of the item “CS Lymph Nodes” (NAACCR Item #2830) *only* according to the diagnostic methods employed.

This data item is used in CS to identify whether the N (of AJCC TNM) was clinically or pathologically diagnosed and by what methods, based upon modified “certainty factors” from *UICC TNM Classification of Malignant Tumors, Fifth Edition* (pp12-13).

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes

0, 1, 2, 3, 5, 6, 8, 9

Note: See the *Collaborative Staging Manual and Coding Instructions, Version 1.0* for codes and coding rules.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

CS SITE-SPECIFIC FACTOR 1

(New)

Alternate Name	Item #	Length	Source of Standard	Column #
	2880	3	AJCC	641-643

Description

This belongs to the set of Collaborative Staging (CS) data items. The “CS Site-Specific Factor” items (1-6) assist in validating the EOD at diagnosis. Site-specific changes that were recorded in “CS Tumor Size” (NAACCR Item #2800) (melanoma--Breslow’s Thickness; lymphoma--HIV/AIDS status) will be recorded in “CS Site-Specific Factor” items along with additional prognostic factors.

Rationale

This item allows changes in AJCC editions to be captured outside TNM. Breslow’s Thickness for melanoma and HIV/AIDS status for lymphoma will be recorded in “CS Site-Specific Factor” items (1-6) to allow “CS Tumor Size” (NAACCR Item #2800) to reflect only true tumor size.

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes (in addition to Site-Specific codes)

000 None
888 Not applicable for this site
999 Unknown; [site-specific title] cannot be assessed; not documented in patient record

Note: See the *Collaborative Staging Manual and Coding Instructions, Version 1.0* for site-specific codes.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

CS SITE-SPECIFIC FACTOR 2**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2890	3	AJCC	644-646

Description

This belongs to the set of Collaborative Staging (CS) data items. The “CS Site-Specific Factor” items (1-6) assist in validating the EOD at diagnosis. Site-specific changes that were recorded in “CS Tumor Size” (NAACCR Item #2800) (melanoma--Breslow’s Thickness; lymphoma--HIV/AIDS status) will be recorded in “CS Site-Specific Factor” items along with additional prognostic factors.

Rationale

This item allows changes in AJCC editions to be captured outside TNM. Breslow’s Thickness for melanoma and HIV/AIDS status for lymphoma will be recorded in “CS Site-Specific Factor” items (1-6) to allow “CS Tumor Size” (NAACCR Item #2800) to reflect only true tumor size.

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes (in addition to Site-Specific codes)

000 None
888 Not applicable for this site
999 Unknown; [site-specific title] cannot be assessed; not documented in patient record

Note: See the *Collaborative Staging Manual and Coding Instructions, Version 1.0* for site-specific codes.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naacr.org for the latest information.

CS SITE-SPECIFIC FACTOR 3**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2900	3	AJCC	647-649

Description

This belongs to the set of Collaborative Staging (CS) data items. The “CS Site-Specific Factor” items (1-6) assist in validating the EOD at diagnosis. Site-specific changes that were recorded in “CS Tumor Size” (NAACCR Item #2800) (melanoma--Breslow’s Thickness; lymphoma--HIV/AIDS status) will be recorded in “CS Site-Specific Factor” items along with additional prognostic factors.

Rationale

This item allows changes in AJCC editions to be captured outside TNM. Breslow’s Thickness for melanoma and HIV/AIDS status for lymphoma will be recorded in “CS Site-Specific Factor” items (1-6) to allow “CS Tumor Size” (NAACCR Item #2800) to reflect only true tumor size.

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes (in addition to Site-Specific codes)

000 None
888 Not applicable for this site
999 Unknown; [site-specific title] cannot be assessed; not documented in patient record

Note: See the *Collaborative Staging Manual and Coding Instructions, Version 1.0* for site-specific codes.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

CS SITE-SPECIFIC FACTOR 4**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2910	3	AJCC	650-652

Description

This belongs to the set of Collaborative Staging (CS) data items. The “CS Site-Specific Factor” items (1-6) assist in validating the EOD at diagnosis. Site-specific changes that were recorded in “CS Tumor Size” (NAACCR Item #2800) (melanoma--Breslow’s Thickness; lymphoma--HIV/AIDS status) will be recorded in “CS Site-Specific Factor” items along with additional prognostic factors.

Rationale

This item allows changes in AJCC editions to be captured outside TNM. Breslow’s Thickness for melanoma and HIV/AIDS status for lymphoma will be recorded in “CS Site-Specific Factor” items (1-6) to allow “CS Tumor Size” (NAACCR Item #2800) to reflect only true tumor size.

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes (in addition to Site-Specific codes)

000 None
888 Not applicable for this site
999 Unknown; [site-specific title] cannot be assessed; not documented in patient record

Note: See the *Collaborative Staging Manual and Coding Instructions, Version 1.0* for site-specific codes.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naacr.org for the latest information.

CS SITE-SPECIFIC FACTOR 5**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2920	3	AJCC	653-655

Description

This belongs to the set of Collaborative Staging (CS) data items. The “CS Site-Specific Factor” items (1-6) assist in validating the EOD at diagnosis. Site-specific changes that were recorded in “CS Tumor Size” (NAACCR Item #2800) (melanoma--Breslow’s Thickness; lymphoma--HIV/AIDS status) will be recorded in “CS Site-Specific Factor” items along with additional prognostic factors.

Rationale

This item allows changes in AJCC editions to be captured outside TNM. Breslow’s Thickness for melanoma and HIV/AIDS status for lymphoma will be recorded in “CS Site-Specific Factor” items (1-6) to allow “CS Tumor Size” (NAACCR Item #2800) to reflect only true tumor size.

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes (in addition to Site-Specific codes)

000 None

888 Not applicable for this site

999 Unknown; [site-specific title] cannot be assessed; not documented in patient record

Note: See the *Collaborative Staging Manual and Coding Instructions, Version 1.0* for site-specific codes.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

CS SITE-SPECIFIC FACTOR 6**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2930	3	AJCC	656-658

Description

This belongs to the set of Collaborative Staging (CS) data items. The “CS Site-Specific Factor” items (1-6) assist in validating the EOD at diagnosis. Site-specific changes that were recorded in “CS Tumor Size” (NAACCR Item #2800) (melanoma--Breslow’s Thickness; lymphoma--HIV/AIDS status) will be recorded in “CS Site-Specific Factor” items along with additional prognostic factors.

Rationale

This item allows changes in AJCC editions to be captured outside TNM. Breslow’s Thickness for melanoma and HIV/AIDS status for lymphoma will be recorded in “CS Site-Specific Factor” items (1-6) to allow “CS Tumor Size” (NAACCR Item #2800) to reflect only true tumor size.

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes (in addition to Site-Specific codes)

000 None
888 Not applicable for this site
999 Unknown; [site specific title] cannot be assessed; not documented in patient record

Note: See the *Collaborative Staging Manual and Coding Instructions, Version 1.0* for site-specific codes.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naacr.org for the latest information.

CS TUMOR SIZE**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2800	3	AJCC	629-631

Description

This item belongs to the set of Collaborative Staging (CS) data items. For most sites, CS Tumor Size is used to record the largest dimension, or the diameter of the primary tumor in millimeters (for example: 1 mm = 001, 1 cm = 010). See the CS schemes for site-specific variants. For many sites, the CS algorithm uses this data item to generate AJCC TNM-T.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes (in addition to Site-Specific codes)

000	Indicates no mass or no tumor found; that is, when a tumor of a stated primary site is not found, but the tumor has metastasized
001-988	Exact size in millimeters
989	989 millimeters or larger
990	Microscopic focus or foci only; no size is given
999	Unknown; size not stated; not stated in patient record

Note: See the *Collaborative Staging Manual and Coding Instructions, Version 1.0* for site-specific codes and coding rules.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

CS TUMOR SIZE/EXT EVAL**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
CS Tumor Size/Extension Evaluation	2820	1	AJCC	634-634

Description

This belongs to the set of Collaborative Staging (CS) data items. “CS Tumor Size/Ext Eval” records the validity of the classification of the items “CS Tumor Size” (NAACCR Item #2800) and “CS Extension” (NAACCR Item #2810) *only* according to the diagnostic methods employed. This data item is used in CS to identify whether the T (of AJCC TNM) was clinically or pathologically diagnosed and by what methods, based upon modified “certainty factors” from *UICC TNM Classification of Malignant Tumors, Fifth Edition* (pp12-13).

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes

0, 1, 2, 3, 5, 6, 8, 9

Note: See the *Collaborative Staging Manual and Coding Instructions, Version 1.0* for codes and coding rules.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

DATE CASE COMPLETED

Alternate Name	Item #	Length	Source of Standard	Column #
	2090	8	Varies	1174-1181

Description

The date that: (1) the abstractor decided that the case report was complete, and (2) the case passed all edits that were applied. Definitions may vary among registries and software providers. This is a local use field. The format for all dates is numeric (MMDDCCYY), with 99 for unknown day or month and 9999 for unknown year (i.e., 1899 = year 1899, 9999 = year unknown). Standard edits check that no dates are later than the current date.

DATE CASE LAST CHANGED

Alternate Name	Item #	Length	Source of Standard	Column #
	2100	8	Varies	1182-1189

Description

Local use field. The format for all dates is numeric (MMDDCCYY), with 99 for unknown day or month and 9999 for unknown year (i.e., 1899 = year 1899, 9999 = year unknown). Standard edits check that no dates are later than the current date. Definitions may vary among areas.

DATE CASE REPORT EXPORTED

Alternate Name	Item #	Length	Source of Standard	Column #
Date Case Transmitted (pre-98 NAACCR)	2110	8	NAACCR	1190-1197

Description

Date the reporting facility exports the electronic abstract to a file for transmission to the central registry via diskette or other electronic medium.

This item is not yet well defined for use when a central registry is creating a transmission record for a consolidated tumor record from multiple source records. NAACCR committees will continue to refine the definitions.

The format for all dates is numeric (MMDDCCYY), with 99 for unknown day or month and 9999 for unknown year (i.e., 1899 = year 1899, 9999 = year unknown). Standard edits check that no dates are later than the current date. Definitions may vary among registries and software providers.

DATE CASE REPORT LOADED

Alternate Name	Item #	Length	Source of Standard	Column #
	2112	8	NAACCR	1227-1234

Description

Date the case report is loaded into a central registry computerized processing file for initiation of quality control activities (e.g., visual editing, application of computerized edits, etc.).

This item is not yet well defined for use when a central registry is creating a transmission record for a consolidated tumor record from multiple source records. NAACCR committees will continue to refine the definitions.

DATE CASE REPORT RECEIVED

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	2111	8	NAACCR	1219-1226

Description

Date the electronic or paper abstract (or source record) is received by the central cancer registry for the respective tumor. If multiple reports are received from two or more sources and if a single date is needed, use the date the first abstract (or source record) was received from any source.

Rationale

This item is used to assess and monitor the timeliness of reporting. Timeliness of abstracting (and reporting) is a concern for all standard-setting organizations and consequently, timeliness standards have been established. This item can be used with the Date of 1st Contact [580] or the Path--Date of Specimen Collection [7320] to measure timeliness of reporting by individual reporting facilities to central cancer registries. This data item also can be used with the Date Tumor Record Available [2113] to measure timeliness of processing within the central cancer registry.

DATE OF 1ST CONTACT

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
Date of Adm/1st Contact	580	8	NAACCR	416-423

Description

Date of first patient contact, as inpatient or outpatient, with the respective facility for the diagnosis and/or treatment of the tumor. The date may represent the date of an outpatient visit for a biopsy, x-ray, scan, or laboratory test.

When Class of Case 7 (pathology-specimen-only) cases are collected, the Path--Date of Specimen Collection [7320] from the pathology report should be used for the Date of 1st Contact. If a pathology-specimen-only case is followed by a patient contact with the facility for the diagnosis and/or treatment of the respective tumor, the Date of 1st Contact is not changed. The date of the initial pathology laboratory specimen collection remains the Date of 1st Contact.

Rationale

This item is used to assess and monitor the timeliness of reporting. Timeliness of abstracting (and reporting) is a concern for all standard-setting organizations and consequently, timeliness standards have been established. This item can be used in conjunction with the Date Case Report Received [2111] to measure timeliness of reporting by individual facilities to central cancer registries.

DATE OF 1ST CRS RX--COC

Alternate Name	Item #	Length	Source of Standard	Column #
Date of First Course Treatment (COC) Date Started (pre-96 COC)	1270	8	COC	843-850

Description

Date of initiation of the first cancer-directed therapy for the cancer being reported, using the COC definition of first course. The date of first treatment includes the date a decision was made not to treat the patient. See *FORDS* for details. See Chapter V, Unresolved Issues for further discussion of the difference between SEER and COC items.

Clarification of NPCR Required Status

Central registries funded by NPCR are required to collect either Data Item 1260 - Date of Initial RX--SEER or Data Item 1270 - Date of 1st Crs RX--COC.

Codes (in addition to valid dates)

99999999 When it is unknown whether any treatment was administered to the patient, the date is unknown or the case was identified by death certificate-only.

DATE OF 1ST POSITIVE BX

Alternate Name	Item #	Length	Source of Standard	Column #
Date of First Positive Biopsy (COC)	1080	8	COC	610-617

Description

Date of first positive tissue biopsy/positive histology.

Codes (in addition to valid dates)

00000000 Positive biopsy never obtained

Note: Beginning January 1, 2003, COC will no longer support this data item.

DATE OF CA CONFERENCE

Alternate Name	Item #	Length	Source of Standard	Column #
Date of Cancer Conference (COC)	660	8	COC	449-456

Description

Date on which the case was first presented at cancer conference at the reporting facility.

Rationale

Collection of this item and item 650 (Presentation at CA Conf) allows preparation of reports on the contents of cancer conferences: sites presented, types of presentation for administrative use, quality control, and survey preparation.

Special Codes (in addition to valid dates)

00000000 Case was never presented at cancer conference
99999999 Unknown

Note: Beginning January 1, 2003, COC will no longer support this data item.

DATE OF DIAGNOSIS

Alternate Name	Item #	Length	Source of Standard	Column #
Date of Initial Diagnosis (COC)	390	8	SEER/COC	283-290

Description

Date of initial diagnosis by a recognized medical practitioner for the cancer being reported. For more discussion on determining date of diagnosis, consult the *SEER Program Manual* or *COC FORDS Manual*.

DATE OF INITIAL RX--SEER

Alternate Name	Item #	Length	Source of Standard	Column #
Date Therapy Initiated (SEER)	1260	8	SEER	835-842
Date Started (SEER)				

Description

Date of initiation of the first cancer-directed therapy for the cancer being reported, using the SEER definition of first course. See also item 1270 (Date of 1st Crs RX--COC). See Chapter V, Unresolved Issues, for further discussion of the difference between SEER and COC items.

Codes (in addition to valid dates)

00000000 No cancer-directed therapy
99999999 Unknown if any cancer-directed therapy was administered

Clarification of NPCR Required Status

Central registries funded by NPCR are required to collect either Data Item 1260 - Date of Initial RX--SEER or Data Item 1270 - Date of 1st Crs RX--COC.

DATE OF INPATIENT ADM

Alternate Name	Item #	Length	Source of Standard	Column #
Date of Inpatient Admission (COC)	590	8	COC	424-431

Description

Date of the inpatient admission to the reporting facility for the most definitive surgery. In the absence of surgery, use date of inpatient admission for any other cancer-directed therapy. In the absence of cancer-directed therapy, use date of inpatient admission for diagnostic evaluation.

Codes (in addition to a valid date)

00000000 Patient was never an inpatient at the reporting facility
99999999 Unknown

Note: Beginning January 1, 2003, COC will no longer support this data item.

DATE OF INPATIENT DISCH

Alternate Name	Item #	Length	Source of Standard	Column #
Date of Inpatient Discharge (COC)	600	8	COC	432-439

Description

Date of the inpatient discharge from the reporting facility after the most definitive surgery. In the absence of surgery, use date of inpatient discharge for other cancer-directed therapy. In the absence of cancer-directed therapy, use date of inpatient discharge for diagnostic evaluation. This discharge date corresponds to the admission date described by item 590, Date of Inpatient Adm.

Note: This item is not the same as the old NAACCR item, Date of Discharge, which has been deleted from the NAACCR layout.

Special Codes (in addition to a valid date)

00000000 Patient was never an inpatient at the reporting hospital
99999999 Unknown

Note: Beginning January 1, 2003, COC will no longer support this data item.

DATE OF LAST CONTACT

Alternate Name	Item #	Length	Source of Standard	Column #
Date of Last Contact or Death (COC) Date of Last Follow-Up or of Death (SEER)	1750	8	SEER/COC	1294-1301

Description

Date of last contact with the patient, or date of death.

Rationale

Used for Date of Last Contact from active or passive follow-up. Used to record date of death.

DATE TUMOR RECORD AVAILBL**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2113	8	NAACCR	1235-1242

Description

Date the demographic and cancer identification information on a single primary cancer/reportable neoplasm, compiled from one or more source records, from one or more facilities, is available in the central cancer registry database to be counted as an incident case. Cancer identification information includes, at a minimum, site, histology, laterality, behavior, and date of diagnosis.

Rationale

This item is used to assess and monitor the timeliness of reporting. Timeliness of abstracting (and reporting) is a concern for all standard-setting organizations and consequently, timeliness standards have been established. This data item can be used with the Date Case Report Received [2111] to measure timeliness of processing within the central cancer registry. This item also can be used with the Date of 1st Contact [580] or the Path--Date of Specimen Collection [7320] to measure overall timeliness.

DC STATE

Alternate Name	Item #	Length	Source of Standard	Column #
Item deleted, Item number retired	2370	0		

See item 1940 (Place of Death).

DC STATE FILE NUMBER

Alternate Name	Item #	Length	Source of Standard	Column #
	2380	6	State	2278-2283

Description

Death certificate identification number as assigned by the vital statistics office in the place recorded in item 1940 (Place of Death).

DERIVED AJCC M**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Derived M	2980	2	AJCC	665-666

Description

This item is the derived “M” from coding fields using the CS algorithm.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form and adds several additional fields. When CS data items are coded, a computer algorithm provided by the Task Force allows generation of AJCC Sixth Edition TNM stage, Summary Stage 1977, and Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

The Storage Code column is the value to be stored in the fields in the NAACCR record. The 2-character numeric Storage Codes are designed for analysis purposes. The Display String is the corresponding label that should be displayed on the screen or in a report. The meaning of these strings is explained for each site in the AJCC Manual.

Codes

M Storage Codes	Display String
99	MX
00	M0
10	M1
11	M1a
12	M1b
13	M1c
88	NA

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific categories.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

DERIVED AJCC M DESCRIPTOR

(New)

Alternate Name	Item #	Length	Source of Standard	Column #
Derived M Descriptor	2990	1	AJCC	667-667

Description

This item is the derived “M Descriptor” from coded fields using the CS algorithm.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

This derived output records a “c,” “p,” “a,” or “y” for “clinical,” “pathological,” “autopsy only,” or “y prefix,” respectively. For those cases in which AJCC TNM classification is performed during or following initial multimodality therapy, the category is identified by a “y prefix” to be derived from the computerized algorithm.

Codes

c Clinical stage
p Pathologic stage
a Autopsy stage
y Pathologic examination of metastatic tissue performed **after** presurgical systemic treatment or radiation, and extension based on pathologic evidence

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific definitions.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

DERIVED AJCC N**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Derived N	2960	2	AJCC	662-663

Description

This item is the derived “N” from coded fields using the CS algorithm.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

The Storage Code column is the value to be stored in the fields in the NAACCR record. The 2-character numeric Storage Codes are designed for analysis purposes. The Display String is the corresponding label that should be displayed on the screen or in a report. The meaning of these strings is explained for each site in the AJCC Manual.

N Storage Code	Display String
99	NX
00	N0
09	N0NOS
01	N0(i-)
02	N0(i+)
03	N0(mol-)
04	N0(mol+)
10	N1
19	N1NOS
11	N1a
12	N1b
13	N1c
15	N1 (i+)
17	N1mi
18	N1mi (i+)
20	N2
29	N2NOS
21	N2a
22	N2b
23	N2c
30	N3
39	N3NOS
31	N3a
32	N3b

33	N3c
88	NA

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific categories.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

DERIVED AJCC N DESCRIPTOR

(New)

Alternate Name	Item #	Length	Source of Standard	Column #
Derived N Descriptor	2970	1	AJCC	664-664

Description

This item is the derived “N Descriptor” from coded fields using the CS algorithm.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

This derived output records a “c,” “p,” “a,” or “y” for “clinical,” “pathological,” “autopsy only,” or “y prefix”, respectively. For those cases in which AJCC TNM classification is performed during or following initial multimodality therapy, the category is identified by a “y prefix” to be derived from the computerized algorithm.

Codes

c Clinical stage
 p Pathologic stage
 a Autopsy stage
 y Lymph nodes removed for examination **after** presurgical systemic treatment or radiation, and lymph node evaluation based on pathologic evidence

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific definitions.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

DERIVED AJCC STAGE GROUP**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Derived Stage Group	3000	2	AJCC	668-669

Description

This item is the derived Stage Group from the detailed site-specific codes using the CS from the CS algorithm.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes

AJCC Storage Code	Display String
00	0
01	0A
02	0IS
10	I
19	INOS
11	IA
12	IA1
13	IA2
14	IB
15	IB1
16	IB2
17	IC
18	IS
20	II
29	IINOS
21	IIA
22	IIB
23	IIC
30	III
39	IIINOS
31	IIIA
32	IIIB
33	IIIC
40	IV
49	IVNOS
41	IVA
42	IVB
43	IVC

88	NA
90	OCCULT
99	UNK

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific categories.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

DERIVED AJCC T

(New)

Alternate Name	Item #	Length	Source of Standard	Column #
Derived T	2940	2	AJCC	659-660

Description

This item is the derived “T” from coded fields using the CS algorithm.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

The Storage Code column is the value to be stored in the fields in the NAACCR record. The 2-character numeric Storage Codes are designed for analysis purposes. The Display String is the corresponding label that should be displayed on the screen or in a report. The meaning of these strings is explained for each site in the AJCC Manual.

Codes

T Storage Code	Display String
99	TX
90	T0
01	Ta
05	Tis
06	Tispu
07	Tispd
10	T1
11	T1mic
19	T1NOS
12	T1a
13	T1a1
14	T1a2
15	T1b
16	T1b1

17	T1b2
18	T1c
20	T2
29	T2NOS
21	T2a
22	T2b
23	T2c
30	T3
39	T3NOS
31	T3a
32	T3b
33	T3c
40	T4
49	T4NOS
41	T4a
42	T4b
43	T4c
44	T4d
88	NA

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific categories.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

DERIVED AJCC T DESCRIPTOR**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Derived T Descriptor	2950	1	AJCC	661-661

Description

This item is the derived “T Descriptor” from coded fields using the CS algorithm.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

This derived output records a “c,” “p,” “a,” or “y” for “clinical,” “pathological,” “autopsy only,” or “y prefix”, respectively. For those cases in which AJCC TNM classification is performed during or following initial multimodality therapy, the category is identified by a “y prefix” to be derived from the computerized algorithm.

Codes

c	Clinical stage
p	Pathologic stage
a	Autopsy stage
y	Surgical resection performed after presurgical systemic treatment or radiation; tumor size/extension based on pathologic evidence

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific definitions.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

DERIVED AJCC--FLAG**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
AJCC Conversion Flag	3030	1	AJCC	672-672

Description

Flag to indicate whether AJCC stage was coded directly or was derived from CS or EOD codes.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes

Blank Not derived

- 1 AJCC Sixth Edition derived from *Collaborative Staging Manual and Coding Instructions, Version 1.0*
- 2 AJCC Sixth Edition derived from EOD (prior to 2003)

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

DERIVED SS1977**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Derived General Summary Stage (SEER) 1977	3010	1	AJCC	670-670

Description

This item is the derived “SEER Summary Stage 1977” from the CS algorithm.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes

0	<i>In situ</i>
1	Localized
2	Regional, direct extension only
3	Regional, regional lymph nodes only
4	Regional, direct extension and regional lymph nodes
5	Regional, NOS
7	Distant
8	Not applicable
9	Unstaged, unknown
Blank	Not derived

Note: See the *SEER Summary Staging Guide, 1977* for site-specific categories.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naacr.org for the latest information.

DERIVED SS1977--FLAG

(New)

Alternate Name	Item #	Length	Source of Standard	Column #
SS 1977 Conversion Flag	3040	1	AJCC	673-673

Description

Flag to indicate where SEER Summary Stage 1977 was coded directly or was derived from CS or EOD codes.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes

Blank Not derived

- 1 SS1977 derived from *Collaborative Staging Manual and Coding Instructions, Version 1.0*
- 2 SS1977 derived from EOD (prior to 2003)

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

DERIVED SS2000**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Derived SEER Summary Stage 2000	3020	1	AJCC	671-671

Description

This item is the derived “SEER Summary Stage 2000” from the CS algorithm.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/ stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes

0	<i>In situ</i>
1	Localized
2	Regional, direct extension only
3	Regional, regional lymph nodes only
4	Regional, direct extension and regional lymph nodes
5	Regional, NOS
7	Distant
8	Not applicable
9	Unstaged, unknown
Blank	Not derived

Note: See the *SEER Summary Staging Manual, 2000* for site-specific categories.

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

DERIVED SS2000--FLAG**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
SS 2000 Conversion Flag	3050	1	AJCC	674-674

Description

Flag to indicate where SEER Summary Stage 2000 was coded directly or was derived from CS or EOD codes.

Rationale

CS is a group of data items set up by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC, designed to provide a single uniform set of codes and rules for coding EOD/stage information to meet the needs of all of the participating standard setters. CS incorporates all of the fields from SEER 10-digit EOD, in a modified form, and adds several additional fields. When CS data items are coded, a computer algorithm allows generation of AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER Summary Stage 2000. Separate CS fields are provided in the NAACCR record for these outputs.

Codes

Blank Not derived

- 1 SS2000 derived from *Collaborative Staging Manual and Coding Instructions, Version 1.0*
- 2 SS2000 derived from EOD (prior to 2003)

Note: At the time this volume went to press, it was not known whether CS would be implemented with 2003 or 2004 diagnoses. See www.naaccr.org for the latest information.

DIAGNOSTIC CONFIRMATION

Alternate Name	Item #	Length	Source of Standard	Column #
	490	1	SEER/COC	311-311

Description

Code for the best method of diagnostic confirmation of the cancer being reported at any time in the patient's history.

Rationale

Diagnostic confirmation is useful to calculate rates based on microscopically confirmed cancers. Full incidence calculations must also include cases that are only confirmed clinically. The percentage of cases that are clinically diagnosed only is an indication of whether case finding is including sources outside of pathology reports.

Codes

- 1 Positive histology
- 2 Positive cytology, no positive histology
- 4 Positive microscopic confirmation, method not specified
- 5 Positive laboratory test/marker study
- 6 Direct visualization without microscopic confirmation
- 7 Radiography and other imaging techniques without microscopic confirmation
- 8 Clinical diagnosis only (other than 5, 6, or 7)
- 9 Unknown whether or not microscopically confirmed

DIAGNOSTIC PROC 73-87

Alternate Name	Item #	Length	Source of Standard	Column #
Diagnostic Procedures (1973-87 SEER)	2200	2	SEER	1217-1218

Description

Data item required by SEER for cases of certain sites for the years 1973-87. This item is no longer collected. See Appendix D of the *SEER Program Code Manual* for details.

EOD--EXTENSION

Alternate Name	Item #	Length	Source of Standard	Column #
Extension (pre-96 SEER/COC) Extension (SEER EOD) (96 COC)	790	2	SEER	534-535

Description

Part of the 10-digit EOD (item 779). Detailed site-specific codes for anatomic EOD used by SEER for cases diagnosed from 1988 forward.

Codes were revised effective January 1, 1998, to reflect changes in the *AJCC Cancer Staging Manual*, Fifth Edition.

Rationale

Site-specific EOD codes provide extensive detail describing disease extent. The EOD codes can be grouped into different stage categories for analysis (e.g., historical summary stage categories consistent with those used in published SEER data since 1973, or more recently, AJCC stage groupings). The codes are updated as needed, but updates are usually backward compatible with old categories. See *Comparative Staging Guide for Cancer*.

Codes

See *SEER Extent of Disease, 1988: Codes and Coding Instructions*, Third Edition for site-specific codes and coding rules for all EOD fields.

EOD--EXTENSION PROST PATH

Alternate Name	Item #	Length	Source of Standard	Column #
	800	2	SEER	536-537

Description

Part of the 10-digit EOD (item 779). Detailed site-specific codes for anatomic EOD used by SEER for cases diagnosed from 1988 forward.

Codes were revised effective January 1, 1998, to reflect changes in the *AJCC Cancer Staging Manual*, Fifth Edition.

Rationale

Site-specific EOD codes provide extensive detail describing disease extent. The EOD codes can be grouped into different stage categories for analysis (e.g., historical summary stage categories consistent with those used in published SEER data since 1973, or more recently, AJCC stage groupings). The codes are updated as needed, but updates are usually backward compatible with old categories. See *Comparative Staging Guide for Cancer*.

EOD--Extension Prost Path is an additional field for prostate cancer only to reflect information from radical prostatectomy, effective with 1995 diagnoses. The field is left blank for all other primaries.

Codes

See *SEER Extent of Disease, 1988: Codes and Coding Instructions*, Third Edition, for site-specific codes and coding rules for all EOD fields.

EOD--LYMPH NODE INVOLV

Alternate Name	Item #	Length	Source of Standard	Column #
Lymph Nodes (pre-96-SEER/COC) Lymph Nodes (SEER EOD) (96 COC)	810	1	SEER	538-538

Description

Part of the 10-digit EOD (item 779). Detailed site-specific codes for anatomic EOD used by SEER for cases diagnosed from 1988 forward.

Codes were revised effective January 1, 1998, to reflect changes in the *AJCC Cancer Staging Manual*, Fifth Edition.

Rationale

Site-specific EOD codes provide extensive detail describing disease extent. The EOD codes can be grouped into different stage categories for analysis (e.g., historical summary stage categories consistent with those used in published SEER data since 1973, or more recently, AJCC stage groupings). The codes are updated as needed, but updates are usually backward compatible with old categories. See *Comparative Staging Guide for Cancer*.

Codes

See *SEER Extent of Disease, 1988: Codes and Coding Instructions*, Third Edition for site-specific codes and coding rules for all EOD fields. Codes for Tumor Size, Regional Nodes Positive, and Regional Nodes Examined also are in the *COC ROADS Manual*.

EOD--OLD 13 DIGIT

Alternate Name	Item #	Length	Source of Standard	Column #
13-Digit (Expanded) Site-Specific Extent of Disease (SEER) SEER EEOD (SEER)	840	13	SEER	543-555

Description

Detailed site-specific codes for EOD used by SEER for selected sites of cancer for cases diagnosed 1973-1982, except death-certificate-only cases.

Codes

See *Extent of Disease: Codes and Coding Instructions* (SEER 1977) for codes.

EOD--OLD 2 DIGIT

Alternate Name	Item #	Length	Source of Standard	Column #
2-Digit Nonspecific and 2-Digit Site-Specific Extent of Disease (1973-1982 SEER)	850	2	SEER	556-557

Description

Site-specific codes for EOD used by SEER for cases diagnosed from January 1, 1973, to December 31, 1982, for cancer sites that did not have a 13-digit scheme (see item 840).

Codes

See *Extent of Disease: Codes and Coding Instructions* (SEER 1977) for codes.

EOD--OLD 4 DIGIT

Alternate Name	Item #	Length	Source of Standard	Column #
4-Digit Extent of Disease (1983-1987 SEER)	860	4	SEER	558-561

Description

Codes for site-specific EOD used by SEER for cases diagnosed from January 1, 1983, to December 31, 1987, for all cancer sites.

Codes

See *SEER Extent of Disease: New 4-Digit Schemes: Codes and Coding Instructions* for codes.

EOD--TUMOR SIZE

Alternate Name	Item #	Length	Source of Standard	Column #
Size of Primary Tumor (SEER) Size of Tumor (COC)	780	3	SEER/COC	531-533

Description

Part of the 10-digit EOD (item 779). Detailed site-specific codes for anatomic EOD used by SEER for cases diagnosed from 1988 forward.

This field is included in the COC dataset, separate from EOD.

Codes were revised effective January 1, 1998, to reflect changes in the *AJCC Cancer Staging Manual*, Fifth Edition.

Rationale

Site-specific EOD codes provide extensive detail describing disease extent. The EOD codes can be grouped into different stage categories for analysis (e.g., historical summary stage categories consistent with those used in published SEER data since 1973, or more recently, AJCC stage groupings). The codes are updated as needed, but updates are usually backward compatible with old categories. See *Comparative Staging Guide for Cancer*.

Codes

See *SEER Extent of Disease, 1988: Codes and Coding Instructions*, Third Edition, for site-specific codes and coding rules for all EOD fields. The COC codes for Tumor Size are in the *FORDS Manual*.

Note: See Chapter V, Unresolved Issues, for a discussion of coding differences between COC and SEER.

EXTENT OF DISEASE 10-DIG [779]

The name for a group of subfields that contain detailed site-specific codes for the anatomic EOD. SEER uses the subfields for cases diagnosed from 1988 forward.

Subfields

EOD--Tumor Size [780]

EOD--Extension [790]

EOD--Extension Prost Path [800]

EOD--Lymph Node Involv [810]

Regional Nodes Positive [820]

Regional Nodes Examined [830]

Note: Group names appear only in the data dictionary and in Appendix E.

FAMILY HISTORY OF CANCER

Alternate Name	Item #	Length	Source of Standard	Column #
	360	1	Varies	226-226

Description

NAACCR has not adopted standards for this item.

FIN CODING SYSTEM**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	35	1	NAACCR	11-11

Description

The FIN coding system is a generated code that identifies the coding system used for individual facilities (hospital, clinics, or other providers) submitting data to a registry. This field identifies the coding system used for facilities in the following seven fields of the NAACCR layout:

Registry ID [40] (when Registry Type [30] = 3)
 Reporting Hospital [540]
 Institution Referred From [2410]
 Institution Referred To [2420]
 Last Follow-Up Hospital [2430]
 Following Registry [2440]
 Archive FIN [3100]

Within a single NAACCR record, all of these fields must be coded using the same FIN coding system.

Instructions for Coding

COC maintains the codes, including those for non-hospital sources of reporting.

For facilities with 7-digit FINs, consisting of a constant “6” followed by 6-digit facility-specific codes in the range of 6020009-6953290 that were assigned by COC before January 1, 2001: Enter all FIN codes of this type as 3 zeroes, followed by the constant “6” and the 6-digit facility-specific codes.

For facilities with FINs greater than or equal to 10000000 that were assigned by COC after January 1, 2001: Enter FIN codes of this type as 2 zeroes followed by the full 8-digit code. These sometimes are called COC FIN 10-digit codes.

Codes

- 1 COC 7-digit codes (assigned by COC until the end of 2000)
- 2 COC FIN 10-digit codes (assigned 2001+)
- 3 NPI 8-digit codes
- 9 Unknown

Note: Code 4-15-digit codes has been deleted.

FIRST COURSE CALC METHOD

Alternate Name	Item #	Length	Source of Standard	Column #
	1500	1	NAACCR	894-894

Description

Codes indicating the time interval for defining the first course of therapy.

Codes

- 1 COC definitions
- 2 SEER definitions
- 9 Other, unknown

FOLLOWING REGISTRY

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	2440	10	NAACCR	2475-2484

Description

Records registry responsible for following the patient.

Rationale

Each FIN is unique. The number is essential to NCDB for monitoring data submissions, ensuring the accuracy of data, and identifying areas for special studies. Efforts are underway at the federal level to establish uniform national provider ID numbers. COC and NAACCR committees will consider adoption of any federal standards when they become available.

Instructions for Coding

COC maintains the codes, including those for non-hospital sources of reporting.

For facilities with 7-digit FINs, consisting of a constant “6” followed by 6-digit facility-specific codes in the range of 6020009-6953290 that were assigned by COC before January 1, 2001: Enter all FIN codes of this type as 3 zeroes, followed by the constant “6” and the 6-digit facility-specific codes.

For facilities with FINs greater than or equal to 10000000 that were assigned by COC after January 1, 2001: Enter FIN codes of this type as 2 zeroes followed by the full 8-digit code. These sometimes are called COC FIN 10 digit codes.

Codes (in addition to COC assigned codes)

- 0000000000 Case not reported by a facility
- 0099999999 Case reported, but facility number is unknown

Note: When this special code is being used, the length in 9s should correspond to the length indicated by the code in item 35 (FIN coding system). The 9s must be right justified in the field, and the remaining spaces should be filled with leading zeroes to a total length of 10.

FOLLOW-UP CONTACT--CITY

Alternate Name	Item #	Length	Source of Standard	Column #
	1842	20	NAACCR	1357-1376

Description

Name of the city of the follow-up contact's current usual residence. If the patient has multiple tumors, the follow-up contact city of residence should be the same for all tumors.

FOLLOW-UP CONTACT--NAME

Alternate Name	Item #	Length	Source of Standard	Column #
	2394	30	NAACCR	2284-2313

Description

First and last name, in natural order, of a person, other than the patient or a physician, who can be contacted to obtain follow-up information for the patient. See item 1842 (Follow-Up Contact--City) for further explanation.

Note: The Patient-Confidential Section contains fields that can be used to identify the individual. This includes the patient's name and identifying numbers, and also the most specific parts of the address at diagnosis and the follow-up contact address. The other fields needed to complete the addresses are in the Demographic Section or the Follow-Up/Recurrence Section.

FOLLOW-UP CONTACT--NO&ST

Alternate Name	Item #	Length	Source of Standard	Column #
	2392	40	NAACCR	2314-2353

Description

The number and street address or the rural mailing address of the follow-up contact's current usual residence. This can be used to generate a follow-up inquiry, and must correspond to the other fields in the follow-up contact address. If the patient has multiple tumors, Follow-Up Contact--No&St should be the same. See item 1842 (Follow-Up Contact--City) for rationale and further description.

U.S. addresses should conform to the USPS Postal Addressing Standards. These standards are referenced in USPS Pub. 28, November 2000, *Postal Addressing Standards*. Canadian addresses should conform to the *Canada Postal Guide*.

Rationale

Addresses that are formatted to conform to USPS Postal Addressing Standards can be more properly geocoded by GIS software and vendors to the correct census tract, which is required by NPCR and SEER registries. The USPS Standards also address a number of issues that are problematic in producing precise addresses, including the use of punctuation, abbreviations, and proper placement of address elements, such as street direction, apartment and suite numbers, and unusual addressing situations. Spanish-language addresses also are covered by the USPS Standard.

Coding Instructions (summary of USPS guidelines)

The address should be fully spelled out with standardized use of abbreviations and punctuation per USPS postal addressing standards (USPS Postal Addressing Standards, Pub. 28, November 2000). Upper case is recommended. Mixed case allowed.

Abbreviations should be limited to those recognized by the Postal Service standard abbreviations. These include but are not limited to: AVE (avenue), BLVD (boulevard), CIR (circle), CT (court), DR (drive), PLZ (plaza), PARK (park), PKWY (parkway), RD (road), SQ (square), ST (street), APT (apartment), BLDG (building), FL (floor), STE (suite), UNIT (unit), RM (room), DEPT (department), N (north), NE (northeast), NW (northwest), S (south), SE (southeast), SW (southwest), E (east), and W (west). A complete list of recognized street abbreviations is provided in Appendix C of USPS Pub. 28.

Punctuation marks should be avoided except when punctuation is necessary to convey the meaning. Punctuation is normally limited to periods when the period carries meaning (e.g., 39.2 RD), slashes for fractional addresses (e.g., 101 1/2 MAIN ST), and hyphens when the hyphen carries meaning (e.g., 289-01 MONTGOMERY AVE). Use of the pound sign (#) to designate address units should be avoided whenever possible. The preferred notation is as follows: 102 MAIN ST APT 101. If a pound sign is used, there must be a space between the pound sign and the secondary number (e.g., 425 FLOWER BLVD # 72).

Note: Prior to Version 5, Follow-Up Contact fields may have been used for patient current address in the NAACCR record layout.

Note: The current USPS Pub. 28 may be found and downloaded from the following Web Site:
<http://pe.usps.gov/cpim/ftp/pubs/Pub28/pub28.pdf>.

Note: The current Canadian Postal Address standards may be found at the following Web Site:
<http://www.canadapost.ca/tools/pg/manual/b03-e.asp#top>.

FOLLOW-UP CONTACT--POSTAL

Alternate Name	Item #	Length	Source of Standard	Column #
	1846	9	NAACCR	1379-1387

Description

Postal code for the address of the follow-up contact's current usual residence. If the patient has multiple tumors, the follow-up contact postal codes should be the same for all tumors. For U.S. residents, use either the 5-digit or the extended 9-digit ZIP code. Blanks follow the 5-digit code. For Canadian residents, use the 6-character, alphanumeric postal code. Blanks follow the 6-character code. When available, enter postal code for other countries.

Codes (in addition to U.S., Canadian, and foreign postal codes)

888888888 Resident of country other than the United States (including its possessions, etc.) or Canada, **and** postal code **unknown**
999999999 Resident of the United States (including its possessions, etc.) or Canada, **and** postal code **unknown**

FOLLOW-UP CONTACT--STATE

Alternate Name	Item #	Length	Source of Standard	Column #
	1844	2	NAACCR	1377-1378

Description

USPS abbreviation for the state (including U.S. territories, commonwealths, or possessions), or Canada Post abbreviation for the Canadian province/territory of the follow-up contact's current usual residence. If the patient has multiple tumors, the follow-up contact state should be the same for all tumors.

Codes (in addition to USPS and Canadian Postal Service abbreviations)

- XX Resident of country other than the United States (including its territories, commonwealths, or possessions) or Canada, and country is known
- YY Resident of country other than the United States (including its territories, commonwealths, or possessions) or Canada, and country is unknown
- ZZ Resident of the United States, NOS (including its territories, commonwealths, or possessions); Canada, NOS; residence unknown

FOLLOW-UP CONTACT--SUPPL**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2393	40	NAACCR	2354-2393

Description

This data item provides the ability to store additional address information such as the name of a place or facility, a nursing home, or the name of an apartment complex. It can be used to generate a follow-up inquiry, and must correspond to the other fields in the follow-up contact address. If the patient has multiple tumors, Follow-Up Contact--Suppl should be the same. See item 1842 (Follow-Up Contact--City) for rationale and further description.

U.S. addresses should conform to the USPS Postal Addressing Standards. These standards are referenced in USPS Pub. 28, November 2000, *Postal Addressing Standards*. Canadian addresses should conform to the *Canada Postal Guide*.

Rationale

Sometimes the registry receives the name of a facility instead of a proper street address containing the street number, name, direction, and other elements necessary to locate an address on a street file for the purpose of geocoding. By having a second street address field to hold address information, the registry can look up and store the street address and not lose the facility name due to a shortage of space. The presence of a second street address field to hold additional address information also aids in follow-up.

Addresses that are formatted to conform to USPS Postal Addressing Standards can be more properly geocoded by GIS software and vendors to the correct census tract, which is required by NPCR and SEER registries. The USPS Standards also address a number of issues that are problematic in producing precise addresses, including the use of punctuation, abbreviations, and proper placement of address elements, such as street direction, apartment and suite numbers, and unusual addressing situations. Spanish-language addresses also are covered by the USPS Standard. Upper case recommended. Mixed case allowed.

Coding Instructions (summary of USPS guidelines)

The address should be fully spelled out with standardized use of abbreviations and punctuation per USPS postal addressing standards (USPS Postal Addressing Standards, Pub. 28, November 2000).

Abbreviations should be limited to those recognized by the Postal Service standard abbreviations, these include but are not limited to:

APT (apartment)	N (north)
BLDG (building)	NE (northeast)
FL (floor)	NW (northwest)
STE (suite)	S (south)
UNIT (unit)	SE (southeast)
RM (room)	SW (southwest)
DEPT (department)	E (east)
	W (west)

A complete list of recognized abbreviations is provided in Appendix C of USPS Pub. 28.

Note: The current USPS Pub. 28 may be found and downloaded from the following Web Site:
<http://e.usps.gov/cpim/ftp/pubs/Pub28/pub28.pdf>.

Note: The current *Canada Postal Guide* may be found at the following Web Site:
<http://www.canadapost.ca/tools/pg/manual/b03-e.asp#top>.

FOLLOW-UP SOURCE

Alternate Name	Item #	Length	Source of Standard	Column #
Follow-Up Method (pre-96 COC)	1790	1	COC	1305-1305

Description

Records the source from which the latest follow-up information was obtained.

Rationale

For registries performing follow-up, this field helps evaluate the success rates of various methods of follow-up. It also can be used to report to institutions the source of follow-up information that is sent to them. When there is a conflict in follow-up information, knowing the source can help resolve the inconsistency.

Codes

- 0 Reported hospitalization
- 1 Readmission (inpatient or outpatient)
- 2 Physician
- 3 Patient
- 4 Department of Motor Vehicles
- 5 Medicare/Medicaid file
- 7 Death certificate
- 8 Other
- 9 Unknown

FUTURE USE TIMELINESS 1

Alternate Name	Item #	Length	Source of Standard	Column #
	2114	8		1148-1155

Description

Reserved for future use for storing date of a central registry processing milestone. No standards have been adopted for this item.

FUTURE USE TIMELINESS 2

Alternate Name	Item #	Length	Source of Standard	Column #
	2115	8		1156-1163

Description

Reserved for future use for storing date of a central registry processing milestone. No standards have been adopted for this item.

GRADE

Alternate Name	Item #	Length	Source of Standard	Column #
Grade, Differentiation, or Cell Indicator (SEER)	440	1	SEER/COC	306-306
Grade/Differentiation (COC)				

Description

Code for the grade or degree of differentiation of the reportable tumor. For lymphomas and leukemias, field also is used to indicate T-, B-, Null-, or NK-cell origin.

Note: Code 8 was adopted for use with lymphoma cases diagnosed in 1995 and later.

Codes

See the grade tables on page 67 of ICD-O-3.¹⁴ See also the COC *FORDS Manual* and *The SEER Program Code Manual*, Third Edition, for site-specific coding rules and conversions.

- 1 Grade I
- 2 Grade II
- 3 Grade III
- 4 Grade IV
- 5 T-cell
- 6 B-cell
- 7 Null cell
- 8 NK (natural killer) cell
- 9 Grade/differentiation unknown, not stated, or not applicable

GRADE (73-91) ICD-O-1

Alternate Name	Item #	Length	Source of Standard	Column #
	1973	1	SEER	1146-1146

Description

Area for retaining the grade portion (1 digit) of the ICD-O-1 or field trial grade code entered before a conversion to ICD-O-2. See grouped data item Morph (73-91) ICD-O-1 [1970] in Appendix E. The item name includes years 1973-91. However, some states may have used the codes for cases before 1973.

Codes

For cases diagnosed before 1992, contains the ICD-O-1 or field trial 1-digit grade code as originally coded, if available.

HISTOLOGIC TYPE ICD-O-3

Alternate Name	Item #	Length	Source of Standard	Column #
	522	4	SEER/COC	301-304

Description

Codes for the histologic type of the tumor being reported using ICD-O-3. NAACCR adopted ICD-O-3 as the standard coding system for cases diagnosed in 2001 and later, and recommended that prior cases be converted from ICD-O-2.

Note: See Histology (92-00) ICD-O-2, item 420, for ICD-O-2 codes.

Codes

See ICD-O-3¹⁴, Morphology Section.

Clarification of Required Status

This data item is required by all standard-setting organizations for cancer cases diagnosed on or after January 1, 2001, and recommended (by conversion from ICD-O-2 codes when conversion algorithms and tables are available) for cases diagnosed before 2001.

When the histologic type is coded according to ICD-O-3, the histology code must be reported in Data Item 522 - Histologic Type ICD-O-3, with behavior coded in Data Item 523 - Behavior Code ICD-O-3.

For information on required status for related data items for histologic type and behavior when coded according to ICD-O-2, see Data Item 420 - Histology (92-00) ICD-O-2 and Data Item 430 - Behavior (92-00) ICD-O-2.

HISTOLOGY (73-91) ICD-O-1

Alternate Name	Item #	Length	Source of Standard	Column #
	1971	4	SEER	1141-1144

Description

Area for retaining the histology portion (4 digits) of the ICD-O-1 or field trial morphology codes entered before a conversion to ICD-O-2. See grouped data item [1970] Morph (73-91) ICD-O-1, in Appendix E. The item name includes years 1973-91. However, some states may have used the codes for cases before 1973.

Codes

For cases diagnosed before 1992, contains the ICD-O-1 or field trial 4-digit histology code as originally coded, if available. Blank for cases coded directly into ICD-O-2 (i.e., 1992 and later cases).

HISTOLOGY (92-00) ICD-O-2

Alternate Name	Item #	Length	Source of Standard	Column #
Histology (COC)	420	4	SEER/COC	296-299

Description

Codes for the histologic type of the tumor being reported using ICD-O-2. NAACCR adopted ICD-O-2 as the standard coding system for cases diagnosed in 1992 and later and recommended that prior cases be converted to ICD-O-2.

Note: See Histology (73-91) ICD-O-1, item 1971, for ICD-O-1 and field trial codes.

Codes

See ICD-O-2,¹⁵ Morphology Section.

Clarification of Required Status

This data item is required by all standard-setting organizations for cancer cases diagnosed from January 1, 1992 through December 31, 2000, and recommended for cases diagnosed before 1992.

When the histologic type is coded according to ICD-O-2, the histology code must be reported in Data Item 420 - Histology (92-00) ICD-O-2, with behavior coded in Data Item 430 - Behavior (92-00) ICD-O-2.

For information on required status for related data items for histologic type and behavior when coded according to ICD-O-3, see Data Item 522 - Histologic Type ICD-O-3 and Data Item 523 - Behavior Code ICD-O-3.

ICD REVISION NUMBER

Alternate Name	Item #	Length	Source of Standard	Column #
ICD Code Revision Used for Cause of Death (SEER)	1920	1	SEER/COC	1392-1392

Description

Indicator for the coding scheme used to code the cause of death.

Codes

- 0 Patient alive at last follow-up
- 1 ICD-10
- 7 ICD-7
- 8 ICDA-8
- 9 ICD-9

ICD-O-2 CONVERSION FLAG

Alternate Name	Item #	Length	Source of Standard	Column #
Review Flag for 1973-91 Cases (SEER)	1980	1	SEER	1147-1147

Description

Code specifying how the conversion of site and morphology codes from ICD-O-1 and the field trial editions to ICD-O-2 was accomplished. The item names include years 1973-91. However, some states may have used the codes for cases before 1973. The code also covers morphology conversions from ICD-O-3 to ICD-O-2.

Codes

- 0 Primary site and morphology originally coded in ICD-O-2
- 1 Primary site and morphology converted without review
- 2 Primary site converted with review; morphology machine-converted without review
- 3 Primary site machine-converted without review, morphology converted with review
- 4 Primary site and morphology converted with review
- 5 Morphology converted from ICD-O-3 without review
- 6 Morphology converted from ICD-O-3 with review

ICD-O-3 CONVERSION FLAG

Alternate Name	Item #	Length	Source of Standard	Column #
	2116	1	SEER/COC	1243-1243

Description

Code specifying how the conversion of site and morphology codes from ICD-O-2 to ICD-O-3 was accomplished.

Codes

Blank Not converted

0 Morphology (Morph--Type&Behav ICD-O-3, item 521) originally coded in ICD-O-3

1 Morphology (Morph--Type&Behav ICD-O-3, item 521) converted from (Morph--Type&Behav ICD-O-2, item 419) without review

3 Morphology (Morph--Type&Behav ICD-O-3, item 521) converted from (Morph--Type&Behav ICD-O-2, item 419) with review

INDUSTRY CODE--CENSUS**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	280	3	Census/NPCR	138-140

Description

Code for the patient's usual industry, using U.S. Census Bureau codes (2000 Census²⁶ is preferable) according to coding procedures recommended for death certificates.²⁵ This data item applies only to patients who are age 14 years or older at the time of diagnosis.

Note: Occupation/industry coding should NOT be performed by reporting facilities. This is a central cancer registry data item (i.e., codes should be applied by a central or regional registry rather than collected from reporting facilities). Specially trained and qualified personnel should perform coding.

Note: 2000 Census codes for occupation and industry are recommended for cancers diagnosed on or after January 1, 2003.²⁶ The 1990 Census codes are recommended for cancers diagnosed before January 1, 2003.²⁴ For more information, see the U.S. Census Bureau Web Site at: <http://www.census.gov/hhes/www/ioindex/overview.html>.

Rationale

Use of the Census Bureau classification system improves consistency of data collected from multiple sources. The Census Bureau industrial classification system is used for coding industry information from death certificates and from the U.S. Census of Population. The system includes specific coding rules.²²⁻²⁷

Codes

For the 1990 Census codes see Instructional Manual Part 19: *Industry and Occupation Coding for Death Certificates*, 1999²³ and related materials in the reference list, Chapter VII. A similar instruction manual for the 2000 Census codes has not been developed. Software for automated coding of occupation and industry is available from the Division of Safety Research, National Institute for Occupational Safety and Health, CDC. Contact Suzanne Marsh at (304) 285-6009 or at smm2@cdc.gov.

INDUSTRY SOURCE**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	300	1	NPCR	142-142

Description

Code that best describes the source of industry information provided on this patient. This is a central cancer registry data item (i.e., codes should be applied by a central or regional registry rather than collected from reporting facilities).

Rationale

Industry information may come from a variety of sources. The most valid and reliable source of industry information for cancer patients has not yet been determined.

Codes

- 0 Unknown industry/no industry available
- 1 Reporting facility records
- 2 Death certificate
- 3 Interview
- 7 Other source
- 8 Not applicable, patient less than 14 years of age at diagnosis
- 9 Unknown source
- Blank Not collected

INPATIENT/OUTPT STATUS

Alternate Name	Item #	Length	Source of Standard	Column #
Inpatient/Outpatient Status (COC)	640	1	COC	447-447

Description

Access point from which the patient first entered the hospital system for either the initial diagnosis or treatment.

Codes

- 1 Inpatient only
- 2 Outpatient only
- 3 In- and outpatient*
- 8 Other, including physician's office
- 9 Unknown

**Note:* This applies to patients who entered the institution as outpatients and were admitted as inpatients on the same day as well as on different dates.

Note: Beginning January 1, 2003, COC will no longer support this data item.

INSTITUTION REFERRED FROM

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
Facility Referred From	2410	10	NAACCR	2485-2494

Description

Identifies the facility that referred the patient to the reporting hospital.

Rationale

Each facility's FIN is unique. The number is essential to NCDB for monitoring data submissions, ensuring the accuracy of data, and identifying areas for special studies.

Efforts are underway at the level to establish uniform national provider ID numbers. COC and NAACCR committees will consider adoption of any federal standards, when they become available.

Instructions for Coding

COC maintains the codes, including those for non-hospital sources of reporting.

For facilities with 7-digit FINs, consisting of a constant "6" followed by 6-digit facility-specific codes in the range of 6020009-6953290 that were assigned by COC before January 1, 2001: Enter all FIN codes of this type as 3 zeroes, followed by the constant "6" and the 6-digit facility-specific codes.

For facilities with FINs greater than or equal to 10000000 that were assigned by COC after January 1, 2001: Enter FIN codes of this type as 2 zeroes followed by the full 8-digit code. These sometimes are called COC FIN 10-digit codes.

Codes (in addition to COC assigned codes)

0000000000 Case not referred from a facility

0099999999 Case referred from a facility, but facility number is unknown

Note: When this special code is being used, the length in 9s should correspond to the length indicated by the code in item 35 (FIN coding system). The 9s must be right justified in the field, and the remaining spaces should be filled with leading zeroes to a total length of 10.

INSTITUTION REFERRED TO

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
Facility Referred To	2420	10	NAACCR	2495-2504

Description

Identifies the facility to which the patient was referred for further care after discharge from the reporting facility.

Rationale

Each facility's FIN is unique. The number is essential to NCDB for monitoring data submissions, ensuring the accuracy of data, and identifying areas for special studies.

Efforts are underway at the level to establish uniform national provider ID numbers. COC and NAACCR committees will consider adoption of any federal standards, when they become available.

Instructions for Coding

COC maintains the codes, including those for non-hospital sources of reporting.

For facilities with 7-digit FINs, consisting of a constant "6" followed by 6-digit facility-specific codes in the range of 6020009-6953290 that were assigned by COC before January 1, 2001: Enter all FIN codes of this type as 3 zeroes, followed by the constant "6" and the 6-digit facility-specific codes.

For facilities with FINs greater than or equal to 10000000 that were assigned by COC after January 1, 2001: Enter FIN codes of this type as 2 zeroes followed by the full 8-digit code. These sometimes are called COC FIN 10-digit codes.

Codes (in addition to COC assigned codes)

0000000000 Case not referred to a facility

0099999999 Case referred to a facility, but facility number is unknown

Note: When this special code is being used, the length in 9s should correspond to the length indicated by the code in item 35 (FIN coding system). The 9s must be right justified in the field, and the remaining spaces should be filled with leading zeroes to a total length of 10.

LAST FOLLOW-UP HOSPITAL**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2430	10	NAACCR	2465-2474

Description

Records facility where the patient was last followed.

Rationale

Each facility's FIN is unique. The number is essential to NCDB for monitoring data submissions, ensuring the accuracy of data, and identifying areas for special studies.

Efforts are underway at the federal level to establish uniform national provider ID numbers. COC and NAACCR committees will consider adoption of any federal standards, when they become available.

Instructions for Coding

COC maintains the codes, including those for non-hospital sources of reporting.

For facilities with 7-digit FINs, consisting of a constant "6" followed by 6-digit facility-specific codes in the range of 6020009-6953290 that were assigned by COC before January 1, 2001: Enter all FIN codes of this type as 3 zeroes, followed by the constant "6" and the 6-digit facility-specific codes.

For facilities with FINs greater than or equal to 10000000 that were assigned by COC after January 1, 2001: Enter FIN codes of this type as 2 zeroes followed by the full 8-digit code. These sometimes are called COC FIN 10-digit codes.

Codes (in addition to COC assigned codes)

0000000000 Case not reported by a facility
0099999999 Case reported, but facility number is unknown

Note: When this special code is being used, the length in 9s should correspond to the length indicated by the code in item 35 (FIN coding system). The 9s must be right justified in the field, and the remaining spaces should be filled with leading zeroes to a total length of 10.

LATERALITY

Alternate Name	Item #	Length	Source of Standard	Column #
Laterality at Diagnosis (SEER)	410	1	SEER/COC	295-295

Description

Code for the side of a paired organ, or the side of the body on which the reportable tumor originated.

Codes

- 0 Not a paired site
- 1 Right: origin of primary
- 2 Left: origin of primary
- 3 Only one site involved, right or left origin unspecified
- 4 Bilateral involvement, lateral origin unknown; stated to be single primary; including both ovaries involved simultaneously, single histology; bilateral retinoblastomas; bilateral Wilms' tumors
- 9 Paired site, but no information concerning laterality, midline tumor

LATITUDE**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2352	10	NAACCR	2394-2403

Description

Cancer Registry spatial data for a case record represents the point location of the individual's residence on the Earth's surface. The point location is expressed as a coordinate pair of latitude and longitude values determined by any one of several methods: for example, geocoding, address matching, global positioning satellite (GPS) readings, and interpolation from paper or electronic maps. Most of the time this information is provided by a geocoding vendor service. Alternatively, a central registry staff manually assigns the code. This item is not coded by the hospital.

Rationale

Decimal degree coordinate data can be thought of as the universal "currency" of exchange for spatial data to be used (projected or not projected) in GIS. Data in this format can be used by any GIS software and projected for the appropriate area of interest, and would be consistent with formats of data obtained from other sources. Users may not necessarily need to project their data unless they need to preserve properties of area, shape, distance, or direction. Different projections provide one or more of these properties. Some projections are used simply for presentation purposes because they make the map "look" better. Displaying a large area such as a state or province/territory using an unprojected rectangular latitude/longitude decimal degree grid may make the area appear distorted, especially in far northern latitudes.

Allowable values and format

Projection and Units -- Spatial data will be exchanged in "unprojected" latitude and longitude coordinates. The data units will be in decimal degrees (and not in degrees, minutes, seconds).

Correct:	Latitude:	41.890949
	Longitude:	-71.128943
Not this:	Latitude:	41 deg 53' 27"
	Longitude:	-71 deg 7' 44"

The latitude field is a 10-byte numeric field, right justified. This coordinate may be carried out to 6 decimal places with an explicit decimal point. It has the following format: **x12.345678**, where "x" is reserved for a negative sign if the coordinate represents a location south of the equator.

Codes

Latitude and longitude data shall always be stored and exchanged as numeric values. Latitude north of the equator is positive. Longitude west of 0 degrees (the Prime Meridian) and east of 180 degrees (approximately the International Date Line) is negative—this applies to the entire North American continent with the exception of the tip of the Aleutian Islands in Alaska.

Note: The **datum** of the decimal degree data shall be North American Datum of 1983 (NAD 83). Data in NAD 27 shall be converted to NAD 83 prior to data exchange.

LOC/REG/DISTANT STAGE

Alternate Name	Item #	Length	Source of Standard	Column #
	770	1	Varies	530-530

Description

For use if no other staging is available. Use may not be consistent among registries.

Note: This is not the same as SEER historic stage. See the *Comparative Staging Guide for Cancer*.

Codes

0	<i>In situ</i>
1	Local
2	Regional
3	Distant
9	Unstaged

LONGITUDE**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2354	11	NAACCR	2404-2414

Description

Cancer Registry spatial data for a case record represents the point location of the individual's residence on the Earth's surface. The point location is expressed as a coordinate pair of latitude and longitude values determined by any one of several methods: for example, geocoding, address matching, GPS readings, and interpolation from paper or electronic maps. Most of the time this information is provided by a geocoding vendor service. Alternatively, a central registry staff manually assigns the code. This item is not coded by the hospital.

Rationale

Decimal degree coordinate data can be thought of as the universal "currency" of exchange for spatial data to be used (projected or not projected) in GIS. Data in this format can be used by any GIS software and projected for the appropriate area of interest, and would be consistent with formats of data obtained from other sources. Users may not necessarily need to project their data unless they need to preserve properties of area, shape, distance, or direction. Different projections provide one or more of these properties. Some projections are used simply for presentation purposes because they make the map "look" better. Displaying a large area such as a state or province/territory using an unprojected rectangular latitude/longitude decimal degree grid may make the area appear distorted, especially in far northern latitudes.

Allowable values and format

Projection and Units -- Spatial data will be exchanged in "unprojected" latitude and longitude coordinates. The data units will be in decimal degrees (and not in degrees, minutes, seconds).

Correct:	Latitude:	41.890949
	Longitude:	-71.128943
Not this:	Latitude:	41 deg 53' 27"
	Longitude:	-71 deg 7' 44"

The longitude field is an 11-byte numeric field, right justified. This coordinate may be carried out to 6 decimal places with an explicit decimal point. It has the following format: **x123.456789**, where "x" is reserved for a negative sign if the coordinate represents a location west of 0 degrees (Prime Meridian) and east of 180 degrees.

Codes

Latitude and longitude data shall always be stored and exchanged as numeric values. Latitude north of the equator is positive. Longitude west of 0 degrees (the Prime Meridian) and east of 180 degrees (approximately the International Date Line) is negative—this applies to the entire North American continent with the exception of the tip of the Aleutian Islands in Alaska.

Note: The **datum** of the decimal degree data shall be NAD 83. Data in NAD 27 shall be converted to NAD 83 prior to data exchange.

MARITAL STATUS AT DX

Alternate Name	Item #	Length	Source of Standard	Column #
Marital Status at Diagnosis (SEER/COC) Marital Status at Initial Diagnosis (pre-96 COC)	150	1	SEER/COC	102-102

Description

Code for the patient's marital status at the time of diagnosis for the reportable tumor. If the patient has multiple tumors, marital status may be different for each tumor.

Rationale

Marital status is linked to sexual activity and to hormonal status as a surrogate for parity. Incidence and survival with certain cancers vary by marital status. The item also helps in patient identification.

Codes

- 1 Single (never married)
- 2 Married (including common law)
- 3 Separated
- 4 Divorced
- 5 Widowed
- 9 Unknown

MEDICAL RECORD NUMBER

Alternate Name	Item #	Length	Source of Standard	Column #
	2300	11	NAACCR	2086-2096

Description

Records medical record number used by the facility to identify the patient. The COC *FORDS Manual* instructs registrars to record numbers assigned by the facility's Health Information Management (HIM) Department only, not department-specific numbers.

Rationale

This number identifies the patient in a facility. It can be used by a central registry to point back to the patient record, and it helps identify multiple reports on the same patient.

Codes (in addition to the medical record number)

UNK Medical record number **unknown**
RT Radiation therapy department patient without HIM number
SU 1-day surgery clinic patient without HIM number

Note: Other standard abbreviations may be used to indicate departments within the facility for patients without HIM numbers assigned.

Note: The Patient-Confidential Section contains fields that can be used to identify the individual. This includes the patient's name and identifying numbers, and also the most specific parts of the address at diagnosis and the follow-up contact address. The other fields needed to complete the addresses are in the Demographic Section and the Follow-Up/Recurrence Section.

MILITARY RECORD NO SUFFIX

Alternate Name	Item #	Length	Source of Standard	Column #
Military Medical Record Number Suffix (COC)	2310	2	COC	2097-2098

Description

Patient identifier used by military hospitals to record relationship of the patient to the sponsor.

Codes

Blank Not applicable, medical record number **not** from a military hospital

01-19 Child

20 Sponsor

30-39 Spouse

40-44 Mother

45-49 Father

50-54 Mother-in-law

55-59 Father-in-law

60-69 Other eligible dependents

98 Civilian emergency (Air Force/Navy)

99 Not classified elsewhere/stillborn

Note: The Patient-Confidential Section contains fields that can be used to identify the individual. This includes the patient's name and identifying numbers, and also the most specific parts of the address at diagnosis and the follow-up contact address. The other fields needed to complete the addresses are in the Demographic Section and the Follow-Up/Recurrence Section.

MORPH (73-91) ICD-O-1 [1970]

The name for a group of subfields describing the type and behavior of the tumor being reported using ICD-O-1 codes.

Subfields

Histology (73-91) ICD-O-1 [1971]

Behavior (73-91) ICD-O-1 [1972]

Grade (73-91) ICD-O-1 [1973]

Note: Group names appear only in the data dictionary and Appendix E.

MORPH CODING SYS--CURRENT

Alternate Name	Item #	Length	Source of Standard	Column #
	470	1	NAACCR	309-309

Description

Code that best describes how morphology is currently coded. If converted, this field shows the system it is converted to.

Codes

- 1 ICD-O, First Edition
- 2 ICD-O, 1986 Field Trial
- 3 ICD-O, 1988 Field Trial
- 4 ICD-O, Second Edition
- 5 ICD-O, Second Edition, plus REAL lymphoma codes effective 1/1/95
- 6 ICD-O, Second Edition, plus FAB codes effective 1/1/98
- 7 ICD-O-3
- 9 Other

| *Note:* The note was deleted.

MORPH CODING SYS--ORIGINL

Alternate Name	Item #	Length	Source of Standard	Column #
	480	1	NAACCR	310-310

Description

Code that best describes how morphology was originally coded. If later converted, this field shows the original codes used.

Codes

- 1 ICD-O, First Edition
- 2 ICD-O, 1986 Field Trial
- 3 ICD-O, 1988 Field Trial
- 4 ICD-O Second Edition
- 5 ICD-O, Second Edition, plus REAL lymphoma codes effective 1/1/95
- 6 ICD-O, Second Edition, plus FAB codes effective 1/1/98
- 7 ICD-O-3
- 9 Other

MORPH--TYPE&BEHAV ICD-O-2 [419]

The name for a group of subfields describing the type and behavior of the tumor being reported using ICD-O-2 codes.

Subfields

Histology (92-00) ICD-O-2 [420]

Behavior (92-00) ICD-O-2 [430]

Note: Group names appear only in the data dictionary and Appendix E.

MORPH--TYPE&BEHAV ICD-O-3 [521]

The name for a group of subfields describing the type and behavior of the tumor being reported using ICD-O-3 codes.

Subfields

Histologic Type ICD-O-3 [522]

Behavior Code ICD-O-3 [523]

Note: Group names appear only in the data dictionary and Appendix E.

Revision Note: This data item was missing in Version 9.

NAACCR RECORD VERSION

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	50	1	NAACCR	19-19

Description

This item applies only to record types I, C, A and M. Code the NAACCR record version used to create the record.

Note: The correction record (U) has its own record version data item.

Codes

Blank September 1989 Version
 1 1992-1994 Version (Version 2 and Version 3)
 4 1995 Version (Version 4.0)
 5 1996 and 1997 Version (Version 5.0 or Version 5.1)
 6 1998 Version (Version 6)
 7 1999 Version (Version 7)
 8 2000 Version (Version 8)
 9 2001 and 2002 Version (Version 9 and 9.1)
 A 2003 Version (Version 10)

Note: Code 4 was assigned to the 1995 Version to synchronize the document version and the layout version numbers. Layout document Versions 2 and 3 are coded as 1.

NAME--ALIAS

Alternate Name	Item #	Length	Source of Standard	Column #
Alias (COC)	2280	15	COC	2006-2020

Description

Records an alternate name or “AKA” (also known as) used by the patient, if known. Note that maiden name is entered in item 2390.

Note: The Patient-Confidential Section contains fields that can be used to identify the individual. This includes the patient’s name and identifying numbers, and also the most specific parts of the address at diagnosis and the follow-up contact address. The other fields needed to complete the addresses are in the Demographic Section and the Follow-Up/Recurrence Section.

NAME--FIRST

Alternate Name	Item #	Length	Source of Standard	Column #
First Name (COC)	2240	14	NAACCR	1972-1985

Description

First name of the patient.

Note: The COC *FORDS Manual* allows this field to be blank. If facilities with COC-approved cancer programs submit blanks to the central registry, it is suggested that the central registry devise procedures for completing the last and first name with text, such as “Unknown” or “John Doe,” after verifying with the hospital that the field was left intentionally blank.

Note: The Patient-Confidential Section contains fields that can be used to identify the individual. This includes the patient’s name and identifying numbers, and also the most specific parts of the address at diagnosis and the follow-up contact address. The other fields needed to complete the addresses are in the Demographic Section and the Follow-Up/Recurrence Section.

NAME--LAST

Alternate Name	Item #	Length	Source of Standard	Column #
Last Name (COC)	2230	25	NAACCR	1947-1971

Description

Last name of the patient.

Note: From *FORDS* Edits: Last Name is required. The last name of the patient must be entered left justified with trailing blanks. Mixed case is allowed. Blanks, spaces, hyphens, apostrophes, and punctuation marks are allowed. The field may not be completely blank. If the last name is unknown, enter "Unknown."

Note: The Patient-Confidential Section contains fields that can be used to identify the individual. This includes the patient's name and identifying numbers, and also the most specific parts of the address at diagnosis and the follow-up contact address. The other fields needed to complete the addresses are in the Demographic Section and the Follow-Up/Recurrence Section.

NAME--MAIDEN

Alternate Name	Item #	Length	Source of Standard	Column #
Maiden Name (COC)	2390	15	NAACCR	2021-2035

Description

Maiden name of female patients who are or have been married.

Rationale

This is used to link reports on a woman who changed her name between reports. It also is critical when using Spanish surname algorithms to categorize ethnicity.

Note: See Chapter V, Unresolved Issues, for discussion of hyphenated maiden name.

Note: The Patient-Confidential Section contains fields that can be used to identify the individual. This includes the patient's name and identifying numbers, and also the most specific parts of the address at diagnosis and the follow-up contact address. The other fields needed to complete the addresses are in the Demographic Section and the Follow-Up/Recurrence Section.

NAME--MIDDLE

Alternate Name	Item #	Length	Source of Standard	Column #
Middle Name (COC)	2250	14	COC	1986-1999
Middle Initial (pre-96 COC)				

Description

Middle name or, if middle name is unavailable, middle initial of the patient.

Note: The Patient-Confidential Section contains fields that can be used to identify the individual. This includes the patient's name and identifying numbers, and also the most specific parts of the address at diagnosis and the follow-up contact address. The other fields needed to complete the addresses are in the Demographic Section and the Follow-Up/Recurrence Section.

NAME--PREFIX

Alternate Name	Item #	Length	Source of Standard	Column #
Name Prefix (COC)	2260	3	COC	2000-2002

Description

Abbreviated title that precedes name in a letter (e.g., "Rev.," Ms.).

Note: The Patient-Confidential Section contains fields that can be used to identify the individual. This includes the patient's name and identifying numbers, and also the most specific parts of the address at diagnosis and the follow-up contact address. The other fields needed to complete the addresses are in the Demographic Section and the Follow-Up/Recurrence Section.

NAME--SPOUSE/PARENT

Alternate Name	Item #	Length	Source of Standard	Column #
	2290	50	Varies	2036-2085

Description

NAACCR has not adopted standards for this item. Use varies by area.

Note: The Patient-Confidential Section contains fields that can be used to identify the individual. This includes the patient's name and identifying numbers, and also the most specific parts of the address at diagnosis and the follow-up contact address. The other fields needed to complete the addresses are in the Demographic Section and the Follow-Up/Recurrence Section.

NAME--SUFFIX

Alternate Name	Item #	Length	Source of Standard	Column #
Name Suffix (COC)	2270	3	COC	2003-2005

Description

Title that follows a patient's last name, such as a generation order or credential status (e.g., "MD," "Jr.").

Note: The Patient-Confidential Section contains fields that can be used to identify the individual. This includes the patient's name and identifying numbers, and also the most specific parts of the address at diagnosis and the follow-up contact address. The other fields needed to complete the addresses are in the Demographic Section and the Follow-Up/Recurrence Section.

NEXT FOLLOW-UP SOURCE

Alternate Name	Item #	Length	Source of Standard	Column #
Next Follow-Up Method (pre-96 COC)	1800	1	COC	1306-1306

Description

Identifies the method planned for the next follow-up.

Codes

- 0 Chart requisition
- 1 Physician letter
- 2 Contact letter
- 3 Phone call
- 4 Other hospital contact
- 5 Other, NOS
- 8 Foreign residents (not followed)
- 9 Not followed

OCCUP/IND CODING SYSTEM

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	330	1	NPCR	223-223

Description

Code that identifies coding system used for occupation and industry. This is a central cancer registry data item (i.e., codes should be applied by a central or regional registry rather than collected from reporting facilities).

Codes

1 1970 Census
2 1980 Census
3 1990 Census
4 2000 Census
7 Other coding system
9 Unknown coding system
Blank Not collected

Note: 2000 Census codes for occupation and industry are recommended for cancers diagnosed on or after January 1, 2003.²⁶ The 1990 Census codes are recommended for cancers diagnosed before January 1, 2003.²⁴ For more information, see the U.S. Bureau of the Census Web Site at: <http://www.census.gov/hhes/www/ioindex/overview.html>.

OCCUPATION CODE--CENSUS

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	270	3	Census/NPCR	135-137

Description

Code for the patient's usual occupation, using U.S. Census Bureau codes (2000 Census²⁶ is preferable) according to coding procedures recommended for death certificates.²⁵ This data item applies only to patients who are age 14 years or older at the time of diagnosis.

Note: Occupation/industry coding should NOT be performed by reporting facilities. This is a central registry data item (i.e., codes should be applied by a central or regional registry rather than collected from reporting facilities). Specially trained and qualified personnel should perform coding.

Note: 2000 Census codes for occupation and industry are recommended for cancers diagnosed on or after January 1, 2003.²⁶ The 1990 Census codes are recommended for cancers diagnosed before January 1, 2003.²⁴ For more information, see the U.S. Bureau of the Census Web Site at: <http://www.census.gov/hhes/www/ioindex/overview.html>.

Rationale

Use of the Census Bureau classification system improves consistency of data collected from multiple sources. The Census Bureau occupation classification system is used for coding occupation information from death certificates and from the U.S. Census of Population. The system includes specific coding rules.²²⁻²⁷

Codes

For the 1990 Census codes, see Instructional Manual Part 19: *Industry and Occupation Coding for Death Certificates*, 1999,²³ and related materials in the reference list, Chapter VII. A similar instruction manual for the 2000 Census codes has not been developed. Software for automated coding of occupation and industry is available from the Division of Safety Research, National Institute for Occupational Safety and Health, CDC. Contact Suzanne Marsh at (304) 285-6009 or at mmm2@cdc.gov.

OCCUPATION SOURCE**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	290	1	NPCR	141-141

Description

Code that best describes the source of occupation information provided on this patient. This is a central cancer registry data item (i.e., codes should be applied by a central or regional registry rather than collected from reporting facilities).

Rationale

Occupation information may come from a variety of sources. The most valid and reliable source of occupation information for cancer patients has not yet been determined.

Codes

0 Unknown occupation/no occupation available
1 Reporting facility records
2 Death certificate
3 Interview
7 Other source
8 Not applicable, patient less than 14 years of age at diagnosis
9 Unknown source
Blank Not collected

OTHER STAGING SYSTEM

Alternate Name	Item #	Length	Source of Standard	Column #
	1070	15	COC	595-609

Description

Field for collecting additional staging classifications (e.g., Dukes, AUA). Text field. User defined.

Note: Beginning January 1, 2003, COC will no longer support this data item.

OVER-RIDE ACSN/CLASS/SEQ

Alternate Name	Item #	Length	Source of Standard	Column #
Over-ride Accession/Class of Case/Sequence	1985	1	NAACCR	1119-1119

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edit in the NAACCR Metafile of the EDITS software: Accession Number, Class of Case, Seq Number (COC).

See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed
1 Reviewed

OVER-RIDE AGE/SITE/MORPH

Alternate Name	Item #	Length	Source of Standard	Column #
Age/Site/Histology Interfield Review (Interfield Edit 15) (SEER #3)	1990	1	SEER	1124-1124

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- Age, Primary Site, Morphology (COC)
- Age, Primary Site, Morphology (NAACCR IF15)
- Age, Primary Site, Morphology (SEER IF15)
- Age, Primary Site, Morphology ICDO3 (COC)
- Age, Primary Site, Morphology ICDO3 (NAACCR IF15)
- Age, Primary Site, Morphology ICDO3 (SEER IF15)

In the *SEER Program Code Manual*, Third Edition, this over-ride is referred to as the “Age/Site/Histology Interfield Review (Interfield Edit 15).” See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed
1 Reviewed: An unusual occurrence of a particular age/site/histology combination for a given age group has been reviewed

OVER-RIDE COC-SITE/TYPE

Alternate Name	Item #	Length	Source of Standard	Column #
	1987	1	NAACCR	1121-1121

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Primary Site, Morphology-Type Check (COC)

Primary Site, Morphology-Type Check ICDO3 (COC)

See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed

OVER-RIDE HISTOLOGY

Alternate Name	Item #	Length	Source of Standard	Column #
Histology/Behavior Interfield Review (Field Item Edit Morph) (SEER #2)	2040	1	SEER	1129-1129

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- Diagnostic Confirmation, Behavior Code (COC)
- Diagnostic Confirmation, Behavior Code (SEER IF31)
- Diagnostic Confirmation, Behavior ICDO3 (COC)
- Diagnostic Confirmation, Behavior ICDO3 (SEER IF31)
- Morph (1973-91) ICD-O-1 (SEER OMORPhos)
- Morphology--Type&Behavior (COC)
- Morphology--Type&Behavior (SEER MORPH)
- Morphology--Type&Behavior ICDO3 (COC)
- Morphology--Type&Behavior ICDO3 (SEER MORPH)

In the *SEER Program Code Manual*, Third Edition, this over-ride is referred to as the “Histology/Behavior Interfield Review (Field Item Edit MORPH).” See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

- 1 Reviewed: The behavior code of the histology is designated as “benign” or “uncertain” in ICD-O-2 or ICD-O-3, and the pathologist states the primary to be “*in situ*” or “malignant” (flag for a “Morphology Type & Behavior” edit)
- 2 Reviewed: The behavior code is “*in situ*,” but the case is not microscopically confirmed (flag for a “Diagnostic Confirmation, Behavior Code” edit)
- 3 Reviewed: Conditions 1 and 2 above both apply

OVER-RIDE HOSPSEQ/DXCONF

Alternate Name	Item #	Length	Source of Standard	Column #
Over-ride Hospital Sequence/Diagnostic Confirmation	1986	1	NAACCR	1120-1120

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edit in the NAACCR Metafile of the EDITS software:
Diagnostic Confirm, Seq Num--Hosp (COC)

See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed
1 Reviewed

OVER-RIDE HOSPSEQ/SITE

Alternate Name	Item #	Length	Source of Standard	Column #
Over-ride Hospital Sequence/Site	1988	1	NAACCR	1122-1122

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:
Seq Num--Hosp, Primary Site, Morph (COC)
Seq Num--Hosp, Primary Site, Morph ICDO3 (COC)

See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed
1 Reviewed

OVER-RIDE ILL-DEFINE SITE

Alternate Name	Item #	Length	Source of Standard	Column #
Sequence Number/Ill-defined Site Interfield Review (Interfield Edit 22) (SEER #8)	2060	1	SEER	1131-1131

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- Seq Num--Central, Primary Site, Morph (NAACCR IF22)
- Seq Num--Central, Primary Site, Morph (SEER IF22)
- Seq Num--Central, Prim Site, Morph ICDO3 (NAACCR)
- Seq Num--Central, Prim Site, Morph ICDO3 (SEER IF22)

In the *SEER Program Code Manual*, Third Edition, this over-ride is referred to as the “Sequence Number/Ill-defined Site Interfield Review (Interfield Edit 22).” See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed: A second or subsequent primary reported with an ill-defined primary site (C76.0-C76.8, C80.9) has been reviewed and is an independent primary

OVER-RIDE LEUK, LYMPHOMA

Alternate Name	Item #	Length	Source of Standard	Column #
Leukemia or Lymphoma/Diagnostic Confirmation Interfield Review (Interfield Edit 48) (SEER #9)	2070	1	SEER	1132-1132

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- Diagnostic Confirmation, Histol Typ (COC)
- Diagnostic Confirmation, Histologic Typ (SEER IF48)
- Diagnostic Confirmation, Histol Typ ICDO3 (COC)
- Diagnostic Confirmation, Histology ICDO3 (SEER IF48)

In the *SEER Program Code Manual*, Third Edition, this over-ride is referred to as the “Leukemia or Lymphoma/Diagnostic Confirmation Interfield Review (Interfield Edit 48).” See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed: A patient was diagnosed with leukemia or lymphoma and the diagnosis was not microscopically confirmed

OVER-RIDE REPORT SOURCE

Alternate Name	Item #	Length	Source of Standard	Column #
Type of Reporting Source/Sequence Number Interfield Review (Interfield Edit 04) (Seer #7)	2050	1	SEER	1130-1130

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Type of Report Srce(DC),Seq Num--Cent (NAACCR IF04)

Type of Report Srce(DC),Seq Num--Central (SEER IF04)

Type of Rep Srce(DC),Seq Num--Cent, ICDO3 (NAACCR)

Type of Rep Srce(DC),Seq Num--Cent, ICDO3 (SEER IF04)

In the *SEER Program Code Manual*, Third Edition, this over-ride is referred to as the “Type of Reporting Source/Sequence Number Interfield Review (Interfield Edit 04).” See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed: A second or subsequent primary with a reporting source of death certificate only has been reviewed and is indeed an independent primary

OVER-RIDE SEQNO/DXCONF

Alternate Name	Item #	Length	Source of Standard	Column #
Sequence Number/Diagnostic Confirmation Interfield Review (Interfield Edit 23) (SEER #4)	2000	1	SEER	1125-1125

Description:

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Diagnostic Confirm, Seq Num--Central (NAACCR IF23)

Diagnostic Confirm, Seq Num--Central (SEER IF23)

In the *SEER Program Code Manual*, Third Edition, this over-ride is referred to as the “Sequence Number/Diagnostic Confirmation Interfield Review (Interfield Edit 23).” See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed: Multiple primaries of special sites in which at least one diagnosis has not been microscopically confirmed have been reviewed

OVER-RIDE SITE/BEHAVIOR

Alternate Name	Item #	Length	Source of Standard	Column #
Over-ride Flag for Site/Behavior (IF39) (SEER #11)	2071	1	SEER	1133-1133

Description:

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- Primary Site, Behavior Code (COC)
- Primary Site, Behavior Code (SEER IF39)
- Primary Site, Behavior Code ICDO3 (COC)
- Primary Site, Behavior Code ICDO3 (SEER IF39)

In the *SEER Program Code Manual*, Third Edition, this over-ride is referred to as the “Over-ride Flag for Site/Behavior (IF39).” See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed: A patient has an *in situ* cancer of a nonspecific site and no further information about the primary site is available

Note: The IF 39 edit does not allow *in situ* cases of nonspecific sites, such as gastrointestinal tract, NOS; uterus, NOS; female genital tract, NOS; male genital organs, NOS; and others. The over-ride indicates that the conflict has been reviewed.

OVER-RIDE SITE/EOD/DX DT

Alternate Name	Item #	Length	Source of Standard	Column #
Over-ride Flag for Site/EOD/Diagnosis Date (IF40) (SEER #13)	2072	1	SEER	1134-1134

Description:

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Primary Site, EOD (SEER IF40)

Primary Site, EOD, ICDO3 (SEER IF40)

In the *SEER Program Code Manual*, Third Edition, this over-ride is referred to as the “Over-ride Flag for Site/EOD/Diagnosis Date (IF40).” See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed: A patient had “localized” disease with a nonspecific site and no further information about the primary site is available

Note: The IF40 edit does not allow “localized” disease with nonspecific sites, such as mouth, NOS; colon, NOS (except histology 8220); bone, NOS; female genital system, NOS; male genital organs, NOS; and others. This over-ride indicates that the conflict has been reviewed.

OVER-RIDE SITE/LAT/EOD

Alternate Name	Item #	Length	Source of Standard	Column #
Over-ride Flag for Site/Laterality/EOD (IF41) (SEER #12)	2073	1	SEER	1135-1135

Description:

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Primary Site, Laterality, EOD (SEER IF41)

Primary Site, Laterality, EOD, ICDO3 (SEER IF41)

In the *SEER Program Code Manual*, Third Edition, this over-ride is referred to as the “Over-ride Flag for Site/Laterality/EOD (IF41).” See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed: A patient had laterality coded nonspecifically and EOD coded specifically

Note: The IF41 edit for paired organs does not allow EOD to be specified as *in situ*, localized, or regional by direct extension if laterality is coded as “bilateral, site unknown,” or “laterality unknown.” This over-ride indicates that the conflict has been reviewed.

OVER-RIDE SITE/LAT/MORPH

Alternate Name	Item #	Length	Source of Standard	Column #
Over-ride Flag for Site/Laterality/Morphology (IF42) (SEER #13)	2074	1	SEER	1136-1136

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- Laterality, Primary Site, Morphology (NAACCR IF42)
- Laterality, Primary Site, Morphology SEER IF42)
- Laterality, Primary Site, Morph ICDO3 (NAACCR IF42)
- Laterality, Primary Site, Morph ICDO3 (SEER IF42)

In the *SEER Program Code Manual*, Third Edition, this over-ride is referred to as the “Over-ride Flag for Site/Laterality/Morphology (IF42).” See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed: A patient had behavior code of “*in situ*” and laterality is not stated as “right: origin of primary;” “left: origin of primary;” or “only one side involved, right or left origin not specified”

Note: The IF 42 edit does not allow behavior code of “*in situ*” with nonspecific laterality codes. This over-ride indicates that the conflict has been reviewed.

OVER-RIDE SITE/LAT/SEQNO

Alternate Name	Item #	Length	Source of Standard	Column #
Site/Histology/Laterality/Sequence Number Interrecord Review (Interrecord Edit 09) (SEER #5)	2010	1	SEER	1126-1126

Description:

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following Interrecord Edit from the SEER Program:

Verify Same Primary Not Reported Twice for a Person (SEER IR09)

In the *SEER Program Code Manual*, Third Edition, this over-ride is referred to as the “Site/Histology/Laterality/Sequence Interrecord Review (Interrecord Edit 09).” Presently, documentation on interrecord edits is not included in the EDITS software. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed: Multiple primaries of the same histology (3 digit) in the same primary site group have been reviewed

OVER-RIDE SITE/TNM-STGGRP

Alternate Name	Item #	Length	Source of Standard	Column #
	1989	1	NAACCR	1123-1123

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is available for future use in the NAACCR Metafile of the EDITS software. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed

OVER-RIDE SITE/TYPE

Alternate Name	Item #	Length	Source of Standard	Column #
Site/Type Interfield Review (Interfield Edit 25) (SEER #1)	2030	1	SEER	1128-1128

Description:

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Primary Site, Morphology-Type Check (SEER IF25)

Primary Site, Morphology-Type Check ICDO3 (SEER IF25)

In the *SEER Program Code Manual*, Third Edition, this over-ride is referred to as the “Site/Type Interfield Review (Interfield Edit 25).” See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed: The coding of an unusual combination of primary site and histologic type has been reviewed

OVER-RIDE SS/DISMET1

Alternate Name	Item #	Length	Source of Standard	Column #
Over-ride Summary Stage/Distant Metastasis 1	1984	1	NAACCR	1118-1118

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Summary Stage, Site Dist Met 1 (NAACCR)

Summary Stage 2000, Site Dist Met 1 (NAACCR)

See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed

OVER-RIDE SS/NODESPOS

Alternate Name	Item #	Length	Source of Standard	Column #
Over-ride Summary Stage/Nodes Positive	1981	1	NAACCR	1115-1115

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Summary Stage, Regional Nodes Pos (NAACCR)

Summary Stage 2000, Regional Nodes Pos (NAACCR)

See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed

OVER-RIDE SS/TNM-M

Alternate Name	Item #	Length	Source of Standard	Column #
Over-ride Summary Stage/TNM-M	1983	1	NAACCR	1117-1117

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Summary Stage, TNM-M (NAACCR)

Summary Stage 2000, TNM-M (NAACCR)

See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed

1 Reviewed

OVER-RIDE SS/TNM-N

Alternate Name	Item #	Length	Source of Standard	Column #
Over-ride Summary Stage/TNM-N	1982	1	NAACCR	1116-1116

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Summary Stage, TNM-N (NAACCR)
Summary Stage 2000, TNM-N (NAACCR)

See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed
1 Reviewed

OVER-RIDE SURG/DXCONF

Alternate Name	Item #	Length	Source of Standard	Column #
Surgery/Diagnostic Confirmation Interfield Review (Interfield Edit 46) (SEER #6)	2020	1	SEER	1127-1127

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

RX Summ--Surg Prim Site, Diag Conf (NAACCR IF76)
RX Summ--Surg Prim Site, Diag Conf (SEER IF76)
RX Summ--Surgery Type, Diag Conf (SEER IF46)

In the *SEER Program Code Manual*, Third Edition, this over-ride is referred to as the “Surgery/Diagnostic Confirmation Interfield Review (Interfield Edit 46).” See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Codes

Blank Not reviewed
1 Reviewed: A patient who had (cancer-directed) surgery, but the tissue removed was not sufficient for microscopic confirmation

PAIN ASSESSMENT**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
	3260	1	COC	872-872

Description

Records whether or not a pain assessment was performed to determine the need for palliative care.

Rationale

Information about pain assessment and pain management is necessary to evaluate the quality of care given to a patient. Palliative care includes pain and symptom management during active cancer treatment (i.e., surgery, radiation, chemotherapy) as well as care given at end of life when active treatment of cancer may have ceased.

Codes

- 0 No pain assessment
- 1 Pain assessment was performed and did not indicate a need for palliative care
- 2 Pain assessment was performed and did indicate a need for palliative care;
no referral for care was made
- 3 Pain assessment was performed and did indicate a need for palliative care; referral was made
- 9 Unknown if pain assessment was performed

PATIENT ID NUMBER

Alternate Name	Item #	Length	Source of Standard	Column #
	20	8	Reporting Registry	2-9

Description

Unique number assigned to an individual patient by the central registry. The central registry will assign this same number to all of the patient's subsequent tumors (records).

"Patient ID Number" will only differ when multiple central registries accession the same patient. Each central registry will assign their unique "Patient ID Number."

NAACCR recommends that the registry should not reissue or reuse this number when a patient's record is deleted from the files.

In the transmit file (data exchange) this number will be the "Patient ID Number" assigned by the sending registry as defined in item 40, "Registry ID."

Rationale

Provides the central registry with a unique identification number that will link all records (multiple tumors) for the same patient. The unique number also allows the central registry to identify the patient when there are multiple reports from different hospitals.

PEDIATRIC STAGE

Alternate Name	Item #	Length	Source of Standard	Column #
	1120	2	COC	621-622

Description

Code for stage of pediatric cancer case in an AJCC stage scheme, a pediatric intergroup study scheme, or a pediatric cooperative group scheme.

Rationale

Staging of pediatric cancers requires very different schemes from those used to stage adult tumors.

Codes

See the *ROADS Manual* for allowable codes for this field.

| *Note:* Beginning January 1, 2003, COC will no longer support this data item.

PEDIATRIC STAGED BY

Alternate Name	Item #	Length	Source of Standard	Column #
Staged By (Pediatric Stage) (COC)	1140	1	COC	625-625

Description

Code for person who documented the pediatric staging system and stage.

Codes

- 0 Not staged
- 1 Managing physician
- 2 Pathologist
- 3 Other physician
- 4 Any combination of 1, 2, or 3
- 5 Registrar
- 6 Any combination of 5 with 1, 2, or 3
- 7 Other
- 8 Staged, individual not specified
- 9 Unknown if staged

| *Note:* Beginning January 1, 2003, COC will no longer support this data item.

PEDIATRIC STAGING SYSTEM

Alternate Name	Item #	Length	Source of Standard	Column #
Type of Staging System (Pediatric) (COC)	1130	2	COC	623-624

Description

Staging system used to assign the Pediatric Stage.

Rationale

Staging of pediatric cancers requires very different schemes from those used to stage adult tumors.

Codes

00	None
01	AJCC
02	Ann Arbor
03	Children's Cancer Group (CCG)
04	Evans
05	General Summary
06	Intergroup Ewings
07	Intergroup Hepatoblastoma
08	Intergroup Rhabdomyosarcoma
09	International System
10	Murphy
11	NCI (pediatric oncology)
12	National Wilms's Tumor Study
13	Pediatric Oncology Group (POG)
14	Reese-Ellsworth
15	SEER Extent of Disease
88	Not applicable (not pediatric case)
97	Other
99	Unknown

Note: Beginning January 1, 2003, COC will no longer support this data item.

PHYSICIAN 3

Alternate Name	Item #	Length	Source of Standard	Column #
Physician #3 (COC)	2490	8	COC	2579-2586
Other Physician (pre-96 COC)				

Description

Code for another physician involved in the care of the patient. Registry may use physicians' medical license numbers or may create individual numbering systems. See *FORDS Manual* for suggested use of this item and detailed instructions.

Codes (in addition to medical license numbers or facility-generated codes)

99999999 Physician 3 unknown or ID number not assigned

PHYSICIAN 4

Alternate Name	Item #	Length	Source of Standard	Column #
Physician #4 (COC)	2500	8	COC	2587-2594
Other Physician (pre-96 COC)				

Description

Code for another physician involved in the care of the patient. Registry may use physicians' medical license numbers or may create individual numbering systems. See *FORDS Manual* for suggested use of this item and detailed instructions.

Codes (in addition to medical license numbers or facility-generated codes)

99999999 Physician 4 unknown or ID number not assigned

PHYSICIAN--FOLLOW-UP

Alternate Name	Item #	Length	Source of Standard	Column #
Following Physician (COC)	2470	8	COC	2563-2570
Follow-Up Physician (pre-96 COC)				

Description

Code for the physician currently responsible for the patient's medical care. Registry may use physicians' medical license numbers or may create individual numbering systems.

Codes (in addition to medical license numbers or facility-generated codes)

99999999 Follow-up physician unknown or ID number not assigned

PHYSICIAN--MANAGING

Alternate Name	Item #	Length	Source of Standard	Column #
Managing Physician (COC)	2460	8	COC	2555-2562
Attending Physician (pre-96 COC)				

Description

Code for the physician who is responsible for the overall management of the patient during diagnosis and/or treatment for this cancer. Registry may use physicians' medical license numbers or may create individual numbering systems.

Codes (in addition to medical license numbers or facility-generated codes)

99999999 Managing physician unknown or ID number not assigned

PHYSICIAN--PRIMARY SURG

Alternate Name	Item #	Length	Source of Standard	Column #
Primary Surgeon (COC)	2480	8	COC	2571-2578

Description

Code for physician who performed the most definitive surgical procedure. Registry may use physician's medical license numbers or may create individual numbering systems.

Codes (in addition to medical license numbers or facility-generated codes)

88888888 Physician who performed a surgical procedure was not a surgeon (i.e., radiation oncologist, diagnostic radiologist, or general practitioner)
99999999 Primary Surgeon unknown or ID number not assigned

PLACE OF DEATH

Alternate Name	Item #	Length	Source of Standard	Column #
	1940	3	NAACCR	1394-1396

Description

State or country where the patient died and where certificate of death is filed.

Rationale

This field also helps carry out death clearance. When a hospital reports a place of death, the information can help in death certificate matching. It can also signal an out-of-state death for which the death certificate is to be requested.

Codes (in addition to geocodes)

997 Not applicable, patient alive
999 Place of death unknown

Note: See Appendix B of the SEER Program Code Manual or the COC *ROADS Manual*, Appendix C.

PLACE OF DIAGNOSIS

Alternate Name	Item #	Length	Source of Standard	Column #
	2690	50	NAACCR	5875-5924

Description

Text area for information about the facility, city, state, or county where the diagnosis was made.

PRESENTATION AT CA CONF

Alternate Name	Item #	Length	Source of Standard	Column #
Presentation at Cancer Conference (COC)	650	1	COC	448-448

Description

Documents presentation of the case at a cancer conference at the reporting facility and the type or format of the presentation.

Rationale

Collection of this item and item 660 (Date of CA Conference) allows preparation of reports on the number of cancer conferences, sites presented and types of presentation for administrative use, quality control, and survey preparation.

Codes

- 0 Not presented
- 1 Prospective presentation (diagnostic)
- 2 Prospective presentation (treatment)
- 3 Prospective presentation (follow-up care)
- 4 Prospective presentation (combinations of 1, 2, or 3)
- 5 Prospective, NOS
- 6 Retrospective presentation
- 7 Follow-up presentation
- 8 Presentation, NOS
- 9 Unknown

| *Note:* Beginning January 1, 2003, COC will no longer support this data item.

PRIMARY PAYER AT DX

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
Primary Payer at Diagnosis (COC)	630	2	COC	445-446

Description

Primary payer/insurance carrier at the time of initial diagnosis and/or treatment.

Rationale

This item is used in financial analysis and as an indicator for quality and outcome analyses. The Joint Commission on Accreditation of Healthcare Organizations requires the patient admission page document the type of insurance or payment structure that will cover the patient while being cared for at the hospital.

Codes

- 01 Not insured. Patient has no insurance and facility has declared a charity write-off.
- 02 Not insured, self-pay. Patient has no insurance and patient has been declared responsible for charges.
- 10 Insurance, NOS. Type of insurance unknown or other than the types listed in codes 20, 31, 35, 36, and 50-56.
- 20 Managed care (health maintenance organization [HMO], preferred provider organization [PPO]), an organized system of prepaid care for a group of enrollees, usually with a defined geographic area. Generally formed as one of four types: a group model, independent physician association (IPA), network, or staff model. "Gate-keeper model" is another term for describing this type of insurance.
- 31 State government-administered insurance for persons who are uninsured, below the poverty level, or covered under entitlement programs. Medicaid other than those described in codes 35 and 36.
- 35 State government-administered insurance through a managed care plan. State government insurance that is administered through a commercial managed care plan such as an HMO or PPO for persons who are uninsured, below the poverty level, or covered under entitlement programs.
- 36 State government-administered Medicaid insurance with federal Medicare supplement.
- 50 Medicare. Federal government insurance for persons who are retired or disabled. Medicare other than those described in codes 51 and 52.
- 51 Medicare with supplement. Patient has Medicare and another insurance to pay costs not covered by Medicare.
- 52 Federal government Medicare insurance with state Medicaid-administered supplement.
- 53 TRICARE. Department of Defense program providing supplementary civilian-sector hospital and medical services beyond a military treatment facility to military personnel, retirees, and their dependents. Formally CHAMPUS (Civilian Health and Medical Program of the Uniformed Services).
- 54 Military. Military personnel or their dependents that are treated at a military facility.
- 55 Veterans Administration. Veterans who are treated in Veterans Administration facilities.
- 56 Indian/Public Health Service. Patient who receives care at an Indian Health Service facility or at another facility, and the medical costs are reimbursed by the Indian Health Service. Patient receives care at a Public Health Service facility or at another facility, and the costs are reimbursed by the Public Health Service.
- 99 Insurance status unknown. It is unknown from the patient's admission page whether or not the patient is insured.

PRIMARY SITE

Alternate Name	Item #	Length	Source of Standard	Column #
	400	4	SEER/COC	291-294

Description

Code for the primary site of the tumor being reported using either ICD-O-2 or ICD-O-3. NAACCR adopted ICD-O-2 as the standard coding system for cases diagnosed beginning January 1, 1992. In addition, NAACCR recommended that cases diagnosed prior to 1992 be converted to ICD-O-2. The topography (primary site) codes have not changed between ICD-O-2 and ICD-O-3.

Codes

See ICD-O-2,¹⁴ or ICD-O-3,¹³ Topography Section, for the codes for primary site.

Note: See Site (73-91) ICD-O-1, item 1960, for ICD-O-1 cases.

PROTOCOL ELIGIBILITY STAT

Alternate Name	Item #	Length	Source of Standard	Column #
Protocol Eligibility Status (COC)	1470	1	COC	890-890

Description

Code for eligibility status of patient to be entered into a protocol.

Codes

- 0 Protocol not available
- 1 On protocol
- 2 Patient ineligible (age, stage, etc.)
- 3 Patient ineligible (comorbidity, pre-existing condition)
- 4 Patient entered but withdrawn from study
- 6 Patient eligible, but not entered, reason not specified
- 7 Patient eligible, patient or patient's guardian refused
- 8 Protocol not recommended
- 9 Unknown if on protocol

| *Note:* Beginning January 1, 2003, COC will no longer support this data item.

PROTOCOL PARTICIPATION

Alternate Name	Item #	Length	Source of Standard	Column #
	1480	2	COC	891-892

Description

Code indicating agency or group that established the protocol in which the patient is participating.

Codes

00 Not on/not applicable

National Protocols:

01 NSABP

02 GOG

03 RTOG

04 SWOG

05 ECOG

06 POG

07 CCG

08 CALGB

09 NCI

10 ACS

11 National protocol, NOS

12 ACOS-OG

13-50 National trials

51-98 Locally defined trials

99 Unknown

Note: Beginning January 1, 2003, COC will no longer support this data item.

QUALITY OF SURVIVAL

Alternate Name	Item #	Length	Source of Standard	Column #
	1780	1	COC	1304-1304

Description

Records patient's ability to carry on the activities of daily living at the date of last contact.

Codes

0 Normal activity

1 Symptomatic and ambulatory

2 Ambulatory more than 50 percent of the time, occasionally needs assistance

3 Ambulatory less than 50 percent of the time, nursing care needed

4 Bedridden, may require hospitalization

8 Not applicable, dead

9 Unknown or unspecified

Note: Beginning January 1, 2003, COC will no longer support this data item.

RACE 1

Alternate Name	Item #	Length	Source of Standard	Column #
Race	160	2	SEER/COC	103-104

Description

Code the patient's race. Race is coded separately from item 190 (Spanish/Hispanic Origin). All tumors for the same patient should have the same race code. If the patient is multiracial, code all races using items 161 (RACE 2) through item 164 (RACE 5).

Rationale

Because race has a significant association with cancer rates and outcomes, a comparison between areas with different racial distributions may require an analysis of race to interpret the findings. The race codes listed correspond closely to race categories used by the U.S. Census Bureau to allow calculation of race-specific incidence rates. The full coding system should be used to allow accurate national comparison and collaboration, even if the state population does not include many of the race categories.

Codes

01	White
02	Black
03	American Indian, Aleutian, or Eskimo
04	Chinese
05	Japanese
06	Filipino
07	Hawaiian
08	Korean
09	Asian Indian, Pakistani
10	Vietnamese
11	Laotian
12	Hmong
13	Kampuchean
14	Thai
20	Micronesian, NOS
21	Chamorroan
22	Guamanian, NOS
25	Polynesian, NOS
26	Tahitian
27	Samoan
28	Tongan
30	Melanesian, NOS
31	Fiji Islander
32	New Guinean
96	Other Asian, including Asian, NOS and Oriental, NOS
97	Pacific Islander, NOS
98	Other
99	Unknown

Note: Codes 20-97 were adopted for use effective with 1991 diagnoses. Code 14 was adopted for use effective with 1994 diagnoses.

RACE 2

Alternate Name	Item #	Length	Source of Standard	Column #
	161	2	SEER/COC	105-106

Description

Code the patient's race. Race is coded separately from item 190 (Spanish/Hispanic Origin). All tumors for the same patient should have the same race code. If the patient is multiracial, code all races using items 161 (RACE 2) through item 164 (RACE 5).

Rationale

Because race has a significant association with cancer rates and outcomes, a comparison between areas with different racial distributions may require an analysis of race to interpret the findings. The race codes listed correspond closely to race categories used by the U.S. Census Bureau to allow calculation of race-specific incidence rates. The full coding system should be used to allow accurate national comparison and collaboration, even if the state population does not include many of the race categories.

Note: If any race code (Race 2, 3, 4, and 5) is blank, all subsequent race codes must be blank. If more than the Race 1 code is entered, and if any race equals 99, then all race codes (Race 1, 2, 3, 4, and 5) must be 99. If more than the Race 1 code is entered, and if any race codes (for Race 2, 3, 4, and 5) are 88 (no further race documented), then all subsequent race codes also must be 88.

Codes

01	White
02	Black
03	American Indian, Aleutian, or Eskimo
04	Chinese
05	Japanese
06	Filipino
07	Hawaiian
08	Korean
09	Asian Indian, Pakistani
10	Vietnamese
11	Laotian
12	Hmong
13	Kampuchean
14	Thai
20	Micronesian, NOS
21	Chamorroan
22	Guamanian, NOS
25	Polynesian, NOS
26	Tahitian
27	Samoan
28	Tongan
30	Melanesian, NOS

31	Fiji Islander
32	New Guinean
88	No further race documented
96	Other Asian, including Asian, NOS and Oriental, NOS
97	Pacific Islander, NOS
98	Other
99	Unknown

Note: Codes 20-97 were adopted for use effective with 1991 diagnoses. Code 14 was adopted for use effective with 1994 diagnoses. Code 88 was adopted for use effective with 2000 diagnoses.

RACE 3

Alternate Name	Item #	Length	Source of Standard	Column #
	162	2	SEER/COC	107-108

Description

Code the patient's race. Race is coded separately from item 190 (Spanish/Hispanic Origin). All tumors for the same patient should have the same race code. If the patient is multiracial, code all races using items 161 (RACE 2) through item 164 (RACE 5).

Rationale

Because race has a significant association with cancer rates and outcomes, a comparison between areas with different racial distributions may require an analysis of race to interpret the findings. The race codes listed correspond closely to race categories used by the U.S. Census Bureau to allow calculation of race-specific incidence rates. The full coding system should be used to allow accurate national comparison and collaboration, even if the state population does not include many of the race categories.

Note: If any race code (Race 2, 3, 4, and 5) is blank, all subsequent race codes must be blank. If more than the Race 1 code is entered, and if any race equals 99, then all race codes (Race 1, 2, 3, 4, and 5) must be 99. If more than the Race 1 code is entered, and if any race codes (for Race 2, 3, 4, and 5) are 88 (no further race documented), then all subsequent race codes also must be 88.

Codes

01	White
02	Black
03	American Indian, Aleutian, or Eskimo
04	Chinese
05	Japanese
06	Filipino
07	Hawaiian
08	Korean
09	Asian Indian, Pakistani
10	Vietnamese
11	Laotian
12	Hmong
13	Kampuchean
14	Thai

20	Micronesian, NOS
21	Chamorroan
22	Guamanian, NOS
25	Polynesian, NOS
26	Tahitian
27	Samoan
28	Tongan
30	Melanesian, NOS
31	Fiji Islander
32	New Guinean
88	No further race documented
96	Other Asian, including Asian, NOS and Oriental, NOS
97	Pacific Islander, NOS
98	Other
99	Unknown

Note: Codes 20-97 were adopted for use effective with 1991 diagnoses. Code 14 was adopted for use effective with 1994 diagnoses. Code 88 was adopted for use effective with 2000 diagnoses.

RACE 4

Alternate Name	Item #	Length	Source of Standard	Column #
	163	2	SEER/COC	109-110

Description

Code the patient's race. Race is coded separately from item 190 (Spanish/Hispanic Origin). All tumors for the same patient should have the same race code. If the patient is multiracial, code all races using items 161 (RACE 2) through item 164 (RACE 5).

Rationale

Because race has a significant association with cancer rates and outcomes, a comparison between areas with different racial distributions may require an analysis of race to interpret the findings. The race codes listed correspond closely to race categories used by the U.S. Census Bureau to allow calculation of race-specific incidence rates. The full coding system should be used to allow accurate national comparison and collaboration, even if the state population does not include many of the race categories.

Note: If any race code (Race 2, 3, 4, and 5) is blank, all subsequent race codes must be blank. If more than the Race 1 code is entered, and if any race equals 99, then all race codes (Race 1, 2, 3, 4, and 5) must be 99. If more than the Race 1 code is entered, and if any race codes (for Race 2, 3, 4, and 5) are 88 (no further race documented), then all subsequent race codes also must be 88.

Codes

01	White
02	Black
03	American Indian, Aleutian, or Eskimo
04	Chinese
05	Japanese
06	Filipino

07	Hawaiian
08	Korean
09	Asian Indian, Pakistani
10	Vietnamese
11	Laotian
12	Hmong
13	Kampuchean
14	Thai
20	Micronesian, NOS
21	Chamorroan
22	Guamanian, NOS
25	Polynesian, NOS
26	Tahitian
27	Samoan
28	Tongan
30	Melanesian, NOS
31	Fiji Islander
32	New Guinean
88	No further race documented
96	Other Asian, including Asian, NOS and Oriental, NOS
97	Pacific Islander, NOS
98	Other
99	Unknown

Note: Codes 20-97 were adopted for use effective with 1991 diagnoses. Code 14 was adopted for use effective with 1994 diagnoses. Code 88 was adopted for use effective with 2000 diagnoses.

RACE 5

Alternate Name	Item #	Length	Source of Standard	Column #
	164	2	SEER/COC	111-112

Description

Code the patient's race. Race is coded separately from item 190 (Spanish/Hispanic Origin). All tumors for the same patient should have the same race code. If the patient is multiracial, code all races using items 161 (RACE 2) through item 164 (RACE 5).

Rationale

Because race has a significant association with cancer rates and outcomes, a comparison between areas with different racial distributions may require an analysis of race to interpret the findings. The race codes listed correspond closely to race categories used by the U.S. Census Bureau to allow calculation of race-specific incidence rates. The full coding system should be used to allow accurate national comparison and collaboration, even if the state population does not include many of the race categories.

Note: If any race code (Race 2, 3, 4, and 5) is blank, all subsequent race codes must be blank. If more than the Race 1 code is entered, and if any race equals 99, then all race codes (Race 1, 2, 3, 4, and 5) must be 99. If more than the Race 1 code is entered, and if any race codes (for Race 2, 3, 4, and 5) are 88 (no further race documented), then all subsequent race codes also must be 88.

Codes

01	White
02	Black
03	American Indian, Aleutian, or Eskimo
04	Chinese
05	Japanese
06	Filipino
07	Hawaiian
08	Korean
09	Asian Indian, Pakistani
10	Vietnamese
11	Laotian
12	Hmong
13	Kampuchean
14	Thai
20	Micronesian, NOS
21	Chamorroan
22	Guamanian, NOS
25	Polynesian, NOS
26	Tahitian
27	Samoan
28	Tongan
30	Melanesian, NOS
31	Fiji Islander
32	New Guinean
88	No further race documented
96	Other Asian, including Asian, NOS and Oriental, NOS

- 97 Pacific Islander, NOS
- 98 Other
- 99 Unknown

Note: Codes 20-97 were adopted for use effective with 1991 diagnoses. Code 14 was adopted for use effective with 1994 diagnoses. Code 88 was adopted for use effective with 2000 diagnoses.

RACE CODING SYS--CURRENT

Alternate Name	Item #	Length	Source of Standard	Column #
	170	1	NAACCR	113-113

Description

Code describes how race currently is coded. If the data have been converted, this field shows the system to which it has been converted.

Rationale

Race codes (item 160 through item 164) have changed over time. To be able to accurately group and analyze the data, it is necessary to record the system used to record the race codes.

Codes

- 1 4-value coding: 1 = White, 2 = Black, 3 = Other, 9 = Unknown
- 2 SEER < 1988 (1-digit)
- 3 1988+ SEER & COC (2-digit)
- 4 1991+ SEER & COC (added codes 20-97, additional Asian and Pacific Islander codes)
- 5 1994+ SEER & COC (added code 14, Thai)
- 6 2000+ SEER & COC*
- 9 Other

**Note:* Code 88, No further race documented, was added. Race 2 (item 161), Race 3 (item 162), Race 4 (item 163), and Race 5 (item 164) were added.

RACE CODING SYS--ORIGINAL

Alternate Name	Item #	Length	Source of Standard	Column #
	180	1	NAACCR	114-114

Description

Code that best describes how item 160 (Race) originally was coded. If data have been converted, this field identifies the coding system originally used to code the case.

Rationale

Race codes (item 160) have changed over time. Identifying both original and current coding systems used to code race promotes accurate data grouping and analysis.

Codes

- 1 4-value coding: 1 = White, 2 = Black, 3 = Other, 9 = Unknown
- 2 SEER < 1988 (1-digit)
- 3 1988+ SEER & COC (2-digit)
- 4 1991+ SEER & COC (added codes 20-97, additional Asian and Pacific Islander codes)
- 5 1994+ SEER & COC (added code 14, Thai)
- 6 2000+ SEER & COC*
- 9 Other

*Note: Code 88, No further race documented, was added. Race 2 (item 161), Race 3 (item 162), Race 4 (item 163), and Race 5 (item 164) were added.

RAD--BOOST DOSE CGY**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Boost Radiation Dose: cGY	3210	5	COC	913-917

Description

Records the additional dose delivered to that part of the treatment volume encompassed by the boost fields or devices. The unit of measure is centiGray (cGy).

Rationale

To evaluate patterns of radiation oncology care, it is necessary to describe the prescribed boost radiation dose. As in chemotherapy, outcomes are strongly related to the dose delivered.

Codes (in addition to value dose)

- (Fill blanks) Record the actual boost dose delivered
- 00000 Boost radiation therapy was not administered
- 99999 Boost radiation therapy administered, boost dose unknown

Note: Codes should be right justified, zero filled.

Note: See the COC *FORDS Manual*.

RAD--BOOST RX MODALITY**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Boost Radiation Treatment Modality	3200	2	COC	911-912

Description

Records the radiation treatment—boost modality used to deliver the most clinically significant dose to the primary volume of interest during the first course of treatment. This is accomplished with external beam fields of reduced size (relative to the regional treatment fields), implants, stereotactic radiosurgery, conformal therapy, or intensity-modulated radiation therapy. External beam boosts may consist of two or more successive phases with progressively smaller fields, and they are generally coded as a single entity. This field is used with Rad--Regional RX Modality Item #1570.

Rationale

Radiation treatment frequently is delivered in two or more phases that can be summarized as regional and boost treatments. For outcomes analysis, the modalities used for each of these phases can be very important.

Codes

00	No radiation treatment
20	External beam, NOS
21	Orthovoltage
22	Cobalt-60, Cesium-137
23	Photons (2-5 MV)
24	Photons (6-10 MV)
25	Photons (11-19 MV)
26	Photons (> 19 MV)
27	Photons (mixed energies)
28	Electrons
29	Photons and electrons mixed
30	Neutrons, with or without photons/electrons
31	IMRT
32	Conformal or 3-D therapy
40	Protons
41	Stereotactic radiosurgery, NOS
42	Linac radiosurgery
43	Gamma Knife
50	Brachytherapy, NOS
51	Brachytherapy, Intracavitary, LDR
52	Brachytherapy, Intracavitary, HDR
53	Brachytherapy, Interstitial, LDR
54	Brachytherapy, Interstitial, HDR
55	Radium
60	Radio-isotopes, NOS
61	Strontium - 89
62	Strontium - 90
98	Other, NOS
99	Unknown

RAD--ELAPSED RX DAYS

Alternate Name	Item #	Length	Source of Standard	Column #
Radiation Elapsed Treatment Time (Days) (COC)	1530	3	COC	902-904

Description

Actual number of radiation treatment days during first course of treatment, including weekend days and intervals of rest. See also item 1360 (RX Summ--Radiation).

Special codes

- 000 No radiation therapy administered
- 999 Radiation therapy administered, but number of treatment days is unknown; unknown if radiation therapy given

Note: Beginning January 1, 2003, COC will no longer support this data item.

RAD--INTENT OF TREATMENT

Alternate Name	Item #	Length	Source of Standard	Column #
Intent of Treatment (Radiation) (COC)	1560	1	COC	908-908

Description

Code for intent of radiation treatment during first course of therapy. See also item 1360 (RX Summ--Radiation).

Codes

- 0 No radiation treatment
- 1 Curative (primary)
- 2 Curative (adjuvant)
- 4 Palliative (pain control)
- 5 Palliative (other, cosmetic)
- 6 Prophylactic (no symptoms, preventive)
- 8 Other, NOS
- 9 Intent unknown; unknown if radiation therapy given

Note: Beginning January 1, 2003, COC will no longer support this data item.

RAD--LOCAL CONTROL STATUS

Alternate Name	Item #	Length	Source of Standard	Column #
Radiation Therapy Local Control Status (Irradiated Volume) (COC)	1590	1	COC	919-919

Description

Code for results of radiation therapy during first course of therapy in terms of disease control within the irradiated volume. See also item 1360 (RX Summ--Radiation).

Codes

- 0 No radiation treatment
- 1 Tumor control status not evaluable
- 2 Tumor/symptoms controlled
- 3 Tumor/symptoms have returned
- 4 Tumor/symptoms never adequately controlled
- 8 Other, NOS
- 9 Status unknown; unknown if radiation therapy given

| *Note:* Beginning January 1, 2003, COC will no longer support this data item.

RAD--LOCATION OF RX

Alternate Name	Item #	Length	Source of Standard	Column #
Location of Radiation Treatment (COC)	1550	1	COC	907-907

Description

Code for location where radiation treatment was administered during first course of therapy. See also item 1360 (RX Summ--Radiation).

Codes

- 0 No radiation treatment
- 1 All radiation treatment at this facility
- 2 Regional treatment at this facility, boost elsewhere
- 3 Boost radiation at this facility, regional elsewhere
- 4 All radiation treatment elsewhere
- 8 Other, NOS
- 9 Location unknown; unknown if radiation therapy given

RAD--NO OF TREATMENT VOL

Alternate Name	Item #	Length	Source of Standard	Column #
Number of Treatments to this Volume (COC)	1520	2	COC	900-901

Description

Records the actual number of radiation therapy treatment sessions in first course of therapy. See also item 1360 (RX Summ--Radiation).

Codes

00 No radiation therapy administered.
 01-98 Number of treatments. Total number of treatment sessions administered to the patient.
 99 Unknown. Radiation therapy was administered, but the number of treatments is unknown.

RAD--REGIONAL DOSE: CGY

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
Regional Dose: cGy (COC)	1510	5	COC	895-899

Description

Dominant or most clinically significant radiation dose actually delivered in the first course of therapy, in cGy. See also item 1570 Rad--Regional RX Modality.

Codes (in addition to actual doses)

(Fill blanks) Record the actual regional dose delivered
 00000 Radiation therapy was not administered
 99999 Radiation therapy was administered, but the dose is unknown

RAD--REGIONAL RX MODALITY**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Regional Treatment Modality (COC)	1570	2	COC	909-910

Description

Records the dominant modality of radiation therapy used to deliver the clinically most significant regional dose to the primary volume of interest during the first course of treatment.

Rationale

Radiation treatment frequently is delivered in two or more phases that can be summarized as regional and boost treatments. To evaluate patterns of radiation oncology care, it is necessary to know which radiation resources were employed in the delivery of therapy. For outcomes analysis, the modalities used for each of these phases can be very important.

Codes

00	No radiation treatment
20	External beam, NOS
21	Orthovoltage
22	Cobalt-60, Cesium-137
23	Photons (2-5 MV)
24	Photons (6-10 MV)
25	Photons (11-19 MV)
26	Photons (> 19 MV)
27	Photons (mixed energies)
28	Electrons
29	Photons and electrons mixed
30	Neutrons, with or without photons/electrons
31	IMRT
32	Conformal or 3-D therapy
40	Protons
41	Stereotactic radiosurgery, NOS
42	Linac radiosurgery
43	Gamma Knife
50	Brachytherapy, NOS
51	Brachytherapy, Intracavitary, Low Dose Rate (LDR)
52	Brachytherapy, Intracavitary, High Dose Rate (HDR)
53	Brachytherapy, Interstitial, Low Dose Rate (LDR)
54	Brachytherapy, Interstitial, High Dose Rate (HDR)
55	Radium
60	Radio-isotopes, NOS
61	Strontium - 89
62	Strontium - 90
80	Combination of beam with radioactive implants or radioisotopes, NOS
85	Other combinations of treatment modalities, NOS
98	Other, NOS
99	Unknown

RAD--RX COMPLETION STATUS

Alternate Name	Item #	Length	Source of Standard	Column #
Radiation Treatment Completion Status (COC)	1580	1	COC	918-918

Description

Code indicating whether or not the patient's radiation therapy was completed as outlined in the initial treatment plan. See also item 1360 (RX Summ--Radiation).

Codes

- 0 No radiation treatment
- 1 Treatment completed
- 2 Radiation not complete, patient health
- 3 Radiation not complete, patient expired
- 4 Radiation not complete, patient choice
- 5 Radiation not complete, family choice
- 6 Radiation not complete, complications
- 7 Radiation not complete, cytopenia
- 8 Radiation not complete, other reason
- 9 Radiation not complete, reason unknown; unknown if radiation therapy given

Note: Beginning January 1, 2003, COC will no longer support this data item.

RAD--TREATMENT VOLUME**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Radiation Treatment Volume (COC)	1540	2	COC	905-906

Description

Identifies the volume or anatomic target of the most clinically significant regional radiation therapy delivered to the patient during the first course of therapy. See also item 1570 (Rad--Regional RX Modality).

Code

00	No radiation therapy, not applicable
01	Eye/orbit
02	Pituitary
03	Brain (NOS)
04	Brain (limited)
05	Head and neck (NOS)
06	Head and neck (limited)
07	Glottis
08	Sinuses
09	Parotid
10	Chest/lung (NOS)
11	Lung (limited)
12	Esophagus
13	Stomach
14	Liver
15	Pancreas
16	Kidney
17	Abdomen (NOS)
18	Breast
19	Breast/lymph nodes
20	Chest wall
21	Chest wall/lymph nodes
22	Mantle, mini-mantle
23	Lower extended field
24	Spine
25	Skull
26	Ribs
27	Hip
28	Pelvic bones
29	Pelvis (NOS)
30	Skin
31	Soft tissue
32	Hemibody
33	Whole body
34	Bladder and pelvis
35	Prostate and pelvis
36	Uterus and Cervix
37	Shoulder

- 38 Extremities bone, NOS
- 39 Inverted Y
- 40 Spinal cord
- 41 Prostate
- 50 Thyroid
- 60 Lymph node region, NOS
- 98 Other volume
- 99 Unknown volume; unknown if radiation therapy given

READM SAME HOSP 30 DAYS

(New)

Alternate Name	Item #	Length	Source of Standard	Column #
Readmission to the Same Hospital Within 30 Days of Surgical Discharge	3190	1	COC	938-938

Description

Records a readmission to the same hospital within 30 days of discharge following hospitalization for surgical resection of the primary site.

Rationale

This data item provides information related to the quality-of-care. A patient may have a readmission if he/she was discharged too soon and then needed to return for problems or complications. A patient also may need to be readmitted if discharge planning and/or follow-up instructions were ineffective. It is important to distinguish a planned from an unplanned readmission, because a planned readmission is not an indicator of quality problems.

Codes

- 0 No surgical procedure of the primary site was performed. Patient not readmitted to the same hospital within 30 days of discharge.
- 1 Patient was surgically treated and was then readmitted to the same hospital within 30 days of being discharged. This readmission was unplanned.
- 2 Patient was surgically treated and was then readmitted to the same hospital within 30 days of being discharged. This readmission was planned (chemotherapy port insertion, revision of colostomy, etc.).
- 3 Patient was surgically treated and, within 30 days of being discharged, had both a planned and an unplanned readmission to the same hospital.
- 9 It is unknown whether surgery of the primary site was recommended or performed. It is unknown whether the patient was readmitted to the same hospital within 30 days of discharge. Death certificate only.

REASON FOR NO CHEMO

Alternate Name	Item #	Length	Source of Standard	Column #
Reason for No Chemotherapy (COC)	1440	1	COC	886-886

Description

Code for reason patient did not receive chemotherapy as part of first course of therapy. See also item 1390 (RX Summ--Chemo).

Codes

- 0 Chemotherapy administered
- 1 Chemotherapy not recommended
- 2 Chemotherapy contraindicated because of other conditions; autopsy-only case
- 6 Reason unknown for no chemotherapy
- 7 Patient or patient's guardian refused chemotherapy
- 8 Chemotherapy recommended, unknown if administered
- 9 Unknown if chemotherapy recommended or performed; death certificate-only case

Note: Beginning January 1, 2003, COC will no longer support this data item.

REASON FOR NO HORMONE

Alternate Name	Item #	Length	Source of Standard	Column #
Reason for No Hormone Therapy (COC)	1450	1	COC	887-887

Description

Code for reason patient did not receive hormone therapy as part of first course of therapy. See also item 1400 (RX Summ--Hormone).

Codes

- 0 Hormone therapy administered
- 1 Hormone therapy not recommended
- 2 Hormone therapy contraindicated because of other conditions; autopsy-only case
- 6 Reason unknown for no hormone therapy
- 7 Patient or patient's guardian refused hormone therapy
- 8 Hormone therapy recommended, unknown if administered
- 9 Unknown if hormone therapy recommended or performed; death-certificate-only case

Note: Beginning January 1, 2003, COC will no longer support this data item.

REASON FOR NO RADIATION**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Reason for No Regional Radiation Therapy	1430	1	COC	885-885

Description

Code the reason the patient did not receive radiation treatment as part of first course of therapy. See also item 1570 (RX--Regional RX Modality).

Codes

- 0 Radiation therapy was administered.
- 1 Radiation therapy was not administered because it was not part of the planned first-course treatment.
- 2 Radiation therapy was not administered because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, etc).
- 5 Radiation therapy was not administered because the patient died prior to planned or recommended treatment.
- 6 Radiation therapy was not administered; it was recommended by the patient's physician, but was not performed as part of the first-course therapy. No reason was noted in the patient's record.
- 7 Radiation therapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in the patient record.
- 8 Radiation therapy was recommended, but it is unknown if it was performed.
- 9 It is unknown if radiation therapy was recommended or performed. Death-certificate-only cases and autopsy-only cases.

REASON FOR NO SURGERY**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Reason for No Cancer-Directed Surgery (SEER)	1340	1	SEER/COC	868-868
Reason for No CA Dir Surgery (COC)				
Reason for No Surgery of the Primary Site				

Description

Records the reason that no surgery was performed on the primary site.

Coding Instructions

- If “Surgical Procedure of Primary Site” (NAACCR Item #1290) is coded 00 or 98, then record the reason based on documentation in the patient record.
- Code 1 if the treatment plan offered multiple options and the patient selected treatment that did not include surgery of the primary site.
- Code 7 if the patient refused recommended surgical treatment or made a blanket refusal of all recommended treatment.
- Cases coded 8 should be followed and updated to a more definitive code as appropriate.
- Code 9 if the treatment plan offered multiple choices, but it is unknown which treatment, if any, was provided.

Codes

- 0 Surgery of the primary site was performed.
- 1 Surgery of the primary site was not performed because it was not part of the planned first-course treatment.
- 2 Surgery of the primary site was not recommended/performed because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, etc.).
- 5 Surgery of the primary site was not performed because the patient died prior to planned or recommended surgery.
- 6 Surgery of the primary site was not performed; it was recommended by the patient’s physician, but was not performed as part of the first-course therapy. No reason was noted in the patient’s record.
- 7 Surgery of the primary site was not performed; it was recommended by the patient’s physician, but this treatment was refused by the patient, the patient’s family member, or the patient’s guardian. The refusal was noted in the patient record.
- 8 Surgery of the primary site was recommended, but it is unknown if it was performed. Further follow-up is recommended.
- 9 It is unknown if surgery of the primary site was recommended or performed. Death certificate-only cases and autopsy-only cases.

RECORD TYPE**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	10	1	NAACCR	1-1

Description

Generated field that identifies which of the five NAACCR data exchange record types is being used in a file of data exchange records. A file should have records of only one type.

Codes

I	Incidence-only record type (nonconfidential coded data) Length = 1946	
C	Confidential record type (incidence record plus confidential data) Length = 2644	
A	Full case Abstract record type (incidence and confidential data plus text summaries; used for reporting to central registries) Length = 6694	
U	Correction/Update record type (short format record used to submit corrections to data already submitted) Length = 850	
R	Analysis/Research record type (incidence record plus appended error flags and recoded values) Length = 2215	
M	Record Modified since previous submission to central registry (identical in format to the “A” record type) Length = 6694	

RECURRENCE DATE--1ST

Alternate Name	Item #	Length	Source of Standard	Column #
Date of First Recurrence (COC)	1860	8	COC	1342-1349

Description

The date of the first recurrence of this tumor.

RECURRENCE DISTANT SITE 1

Alternate Name	Item #	Length	Source of Standard	Column #
	1871	1	COC	1350-1350

Description

Code for the distant site or sites in which the tumor has recurred.

Codes

0	None or none known
1	Peritoneum
2	Lung
3	Pleura
4	Liver
5	Bone
6	Central nervous system
7	Skin
8	Lymph nodes (distant)
9	Other, generalized, NOS, carcinomatosis

Note: When carcinomatosis is present, all three fields—Recurrence Distant Site 1, 2, and 3—are coded 9.

Note: Beginning January 1, 2003, COC will no longer support this data item.

RECURRENCE DISTANT SITE 2

Alternate Name	Item #	Length	Source of Standard	Column #
	1872	1	COC	1351-1351

Description

Code for the distant site or sites in which the tumor has recurred.

Codes

0	None or none known
1	Peritoneum
2	Lung
3	Pleura
4	Liver
5	Bone
6	Central nervous system
7	Skin
8	Lymph nodes (distant)
9	Other, generalized, NOS, carcinomatosis

Note: When carcinomatosis is present, all three fields—Recurrence Distant Site 1, 2, and 3—are coded 9. If Recurrence Distant Site 1 (item 1871) is coded to 0, then this field also must be coded to 0.

Note: Beginning January 1, 2003, COC will no longer support this data item.

RECURRENCE DISTANT SITE 3

Alternate Name	Item #	Length	Source of Standard	Column #
	1873	1	COC	1352-1352

Description

Code for the distant site or sites in which the tumor has recurred.

Codes

- 0 None or none known
- 1 Peritoneum
- 2 Lung
- 3 Pleura
- 4 Liver
- 5 Bone
- 6 Central nervous system
- 7 Skin
- 8 Lymph nodes (distant)
- 9 Other, generalized, NOS, carcinomatosis

Note: When carcinomatosis is present, all three fields—Recurrence Distant Site 1, 2, and 3—are coded 9. If Recurrence Distant Site 1 (Item # 1871) is coded to 0, then this field also must be coded to 0.

Note: Beginning January 1, 2003, COC will no longer support this data item.

RECURRENCE DISTANT SITES [1870]

(Retired)

The name for a group of subfields that describe a distant site or sites in which a tumor has recurred. The subfields are edited as three separate 1-digit fields and as a single field.

Subfields

- Recurrence Distant Site 1 [1871]
- Recurrence Distant Site 2 [1872]
- Recurrence Distant Site 3 [1873]

Note: Group names appear only in the data dictionary and Appendix E .

Note: Only the group item has retired. The subfields are not retired.

RECURRENCE TYPE--1ST

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
Type of First Recurrence (COC)	1880	2	COC	1353-1354

Description

Code for the type of first recurrence.

Codes

- 00 Patient became disease-free after treatment and has not had a recurrence.
- 04 *In situ* recurrence of an invasive tumor.
- 06 *In situ* recurrence of an *in situ* tumor.
- 10 Local recurrence and there is insufficient information available to code to 13-17. Recurrence is confined to the remnant of the organ of origin; to the organ of origin; to the anastomosis; or to scar tissue where the organ previously existed.
- 13 Local recurrence of an invasive tumor.
- 14 Trocar recurrence of an invasive tumor. Includes recurrence in the trocar path or entrance site following prior surgery.
- 15 Both local and trocar recurrence of an invasive tumor (both 13 and 14)
- 16 Local recurrence of an *in situ* tumor.
- 17 Both local and trocar recurrence of an *in situ* tumor.
- 20 Regional recurrence, and there is insufficient information available to code to 21-27.
- 21 Recurrence of an invasive tumor in adjacent tissue or organ(s) only.
- 22 Recurrence of an invasive tumor in regional lymph nodes only.
- 25 Recurrence of an invasive tumor in adjacent tissue or organs(s) and in regional lymph nodes (both 21 and 22) at the same time.
- 26 Regional recurrence of an *in situ* tumor, NOS.
- 27 Recurrence of an *in situ* tumor in adjacent tissue or organ(s) and in regional lymph nodes at the same time.
- 30 Both regional recurrence of an invasive tumor in adjacent tissue or organ(s) and/or regional lymph nodes (20-25) **and** local and/or trocar recurrence (10, 13, 14, or 15).
- 36 Both regional recurrence of an *in situ* tumor in adjacent tissue or organ(s) and/or regional lymph nodes (26 or 27) and local and/or trocar recurrence (16 or 17).
- 40 Distant recurrence and there is insufficient information available to code to 46-62.
- 46 Distant recurrence of an *in situ* tumor.
- 51 Distant recurrence of an invasive tumor in the peritoneum only. Peritoneum includes peritoneal surfaces of all structures within the abdominal cavity and/or positive ascitic fluid.
- 52 Distant recurrence of an invasive tumor in the lung only. Lung includes the visceral pleura.
- 53 Distant recurrence of an invasive tumor in the pleura only. Pleura includes the pleural surface of all structures within the thoracic cavity and/or positive pleural fluid.
- 54 Distant recurrence of an invasive tumor in the liver only.
- 55 Distant recurrence of an invasive tumor in bone only. This includes bones other than the primary site.
- 56 Distant recurrence of an invasive tumor in the CNS only. This includes the brain and spinal cord, but not the external eye.
- 57 Distant recurrence of an invasive tumor in the skin only. This includes skin other than the primary site.
- 58 Distant recurrence of an invasive tumor in lymph node only. Refer to the staging scheme for a description of lymph nodes that are distant for a particular site.

- 59 Distant systemic recurrence of an invasive tumor only. This includes leukemia, bone marrow metastasis, carcinomatosis, and generalized disease.
- 60 Distant recurrence of an invasive tumor in a single distant site (51-58) and local, trocar, and/or regional recurrence (10-15, 20-25, or 30).
- 62 Distant recurrence of an invasive tumor in multiple sites (recurrences that can be coded to more than one category 51-59).
- 70 Since diagnosis, patient has never been disease-free. This includes cases with distant metastasis at diagnosis, systemic disease, unknown primary, or minimal disease that is not treated.
- 88 Disease has recurred, but the type of recurrence is unknown.
- 99 It is unknown whether the disease has recurred or if the patient was ever disease-free.

***Exception:** Code leukemias that are in remission 00. If the patient relapses, code recurrence status as 59.

RECURRENCE TYPE--1ST--OTH

Alternate Name	Item #	Length	Source of Standard	Column #
Other Type of First Recurrence (COC)	1890	2	COC	1355-1356

Description

Code for an additional type of first recurrence. If more than one type of first recurrence, code one in item 1880 (Recurrence Type--1st), and one in this field. Otherwise, this field is coded 00.

Codes

- 00 None, disease free
 - 01 *In situ*
 - 06 *In situ* recurrence following diagnosis of an *in situ* lesion of the same site
- 10 Local
 - 11 Trochar site
 - 15 Combination of 10 and 11
 - 16 Local recurrence following an *in situ* lesion of the same site
 - 17 Combination of 16 with 10, 11, and/or 15
- 20 Regional, NOS
 - 21 Regional Tissue
 - 22 Regional lymph nodes
 - 25 Combination of 21 and 22
 - 26 Regional recurrence following an *in situ* lesion of the same site
 - 27 Combination of 26 with 21, 22, and/or 25
- 30 Any combination of 10 and/or 11 and 20, 21, or 22
- 36 Any combination of recurrence following an *in situ* lesion of the same site with 10, 11, 20, 21, or 22
- 40 Distant
- 46 Distant recurrence following an *in situ* lesion of the same site
- 70 Never disease free
- 88 Recurred, site unknown
- 99 Unknown if recurred

Note: Beginning January 1, 2003, COC will no longer support this data item.

REFERRAL TO SUPPORT SERV

Alternate Name	Item #	Length	Source of Standard	Column #
Referral to Support Services (COC)	1490	1	COC	893-893

Description

Code for whether or not patient was referred to any specified support services.

Codes

0 No
1 Yes
9 Unknown, not specified

Note: Beginning January 1, 2003, COC will no longer support this data item.

REGIONAL NODES EXAMINED

Alternate Name	Item #	Length	Source of Standard	Column #
Number of Regional Lymph Nodes Examined (SEER) Pathologic Review of Regional Lymph Nodes (SEER)	830	2	SEER/C0C	541-542

Description

Part of the 10-digit EOD (item 779), detailed site-specific codes for anatomic EOD used by SEER for cases diagnosed from 1988 forward.

This field is included in the COC dataset, separate from EOD.

Codes were revised effective January 1, 1998, to reflect changes in the *AJCC Cancer Staging Manual*, Fifth Edition.

Rationale

Site-specific EOD codes provide extensive detail describing disease extent. The EOD codes can be grouped into different stage categories for analysis (e.g., historical summary stage categories consistent with those used in published SEER data since 1973, or more recently, AJCC stage groupings). The codes are updated as needed, but updates are usually backward compatible with old categories. See *Comparative Staging Guide for Cancer*.

Codes

See *SEER Extent of Disease, 1988: Codes and Coding Instructions*, Third Edition, 1998 for site-specific codes and coding rules for all EOD fields. COC codes for Regional Nodes Examined are in the *FORDS Manual*.

Note: See Chapter V, Unresolved Issues, for a discussion of coding differences between COC and SEER.

REGIONAL NODES POSITIVE

Alternate Name	Item #	Length	Source of Standard	Column #
Number of Positive Regional Lymph Nodes (SEER) Pathologic Review of Regional Lymph Nodes (SEER)	820	2	SEER/COC	539-540

Description

Part of the 10-digit EOD (item 779), detailed site-specific codes for anatomic EOD used by SEER for cases diagnosed from 1988 forward.

This field is included in the COC dataset, separate from EOD.

Codes were revised effective January 1, 1998 to reflect changes in the *AJCC Cancer Staging Manual*, Fifth Edition.

Rationale

Site-specific EOD codes provide extensive detail describing disease extent. The EOD codes can be grouped into different stage categories for analysis (e.g., historical summary stage categories consistent with those used in published SEER data since 1973, or more recently, AJCC stage groupings). The codes are updated as needed, but updates are usually backward compatible with old categories. See *Comparative Staging Guide for Cancer*.

Codes

See *SEER Extent of Disease, 1988: Codes and Coding Instructions*, Third Edition, 1998 for site-specific codes and coding rules for all EOD fields. COC codes for Regional Nodes Positive are in the *FORDS Manual*.

Note: See Chapter V, Unresolved Issues, for a discussion of coding differences between COC and SEER.

REGISTRY ID**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	40	10	NAACCR	20-29

Description

A unique code assigned to each data source identifying who is sending the record and what population it is based on. If the registry type is 1 (central registry), refer to REGID.DBF, Appendix B of this volume. If the registry type is 2 or 3, refer to FIN codes maintained by COC.

Rationale

For registry types 2 and 3, each facility's FIN is unique. The number is essential to NCDB for monitoring data submissions, ensuring the accuracy of data, and identifying areas for special studies.

For Registry Type 1, the number notes which central registry generated the record transmission of data.

Instructions for Coding

COC maintains the codes for Registry Types 2 and 3, including those for non-hospital sources of reporting.

For facilities with 7-digit FINs, consisting of a constant "6" followed by 6-digit facility-specific codes in the range of 6020009-6953290 that were assigned by COC before January 1, 2001. Enter all FIN codes of this type as 3 zeroes, followed by the constant "6" and the 6-digit facility-specific codes.

For facilities with FINs greater than or equal to 10000000 that were assigned by COC after January 1, 2001: Enter FIN codes of this type as 2 zeroes followed by the full 8-digit code. These sometimes are called COC FIN 10-digit codes.

For Registry Type 1, NAACCR maintains the codes for REGID.DBF.

Codes (in addition to COC assigned codes or NAACCR assigned codes)

0000000000 Case not reported by a facility

0099999999 Case reported, but facility number is unknown.

Note: When this special code is being used, the length in 9s should correspond to the length indicated by the code in item 35 (FIN coding system). The 9s must be right justified in the field, and the remaining spaces should be filled with leading zeroes to a total length of 10.

REGISTRY TYPE

Alternate Name	Item #	Length	Source of Standard	Column #
	30	1	NAACCR	10-10

Description

A computer-generated code that best describes the type of registry generating the record; used when cases are pooled from multiple registries (a hospital-based registry reporting to a state should have a “3” in this field).

Rationale

Allows the data from multiple registries to be pooled.

Codes

- 1 Central registry (population-based)
- 2 Central registry or hospital consortium (not population-based)
- 3 Single hospital/freestanding center

RELIGION

Alternate Name	Item #	Length	Source of Standard	Column #
	260	2	Varies	133-134

Description

NAACCR has not adopted standards for this item.

REPORTING HOSPITAL**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Institution ID Number (COC)	540	10	COC	382-391
Facility Identification Number (COC)				

Description

Code for the facility reporting the case.

Rationale

Each facility's FIN is unique. The number is used to identify a reporting facility in the central registry database and is useful in monitoring data submission, ensuring the accuracy of data and identifying areas for special studies. The codes for this item are assigned by COC.

Instructions for Coding

COC maintains the codes, including those for non-hospital sources of reporting.

For facilities with 7-digit FINs, consisting of a constant "6" followed by 6-digit facility-specific codes in the range of 6020009-6953290 that were assigned by COC before January 1, 2001: Enter all FIN codes of this type as 3 zeroes, followed by the constant "6" and the 6-digit facility-specific codes.

For facilities with 8-digit FINs greater than or equal to 10000000 that were assigned by COC after January 1, 2001: Enter FIN codes of this type as 2 zeroes followed by the full 8-digit code.

Codes (in addition to COC assigned codes)

0000000000 Case not reported by a facility
 0099999999 Case reported, but facility number is unknown

Note: When this special code is being used, the length in 9s should correspond to the length indicated by the code in item 35 (FIN coding system). The 9s must be right justified in the field, and the remaining spaces should be filled with leading zeroes to a total length of 10.

REPORTING HOSPITAL FAN

Alternate Name	Item #	Length	Source of Standard	Column #
	538	10	COC	372-381

Description

The facility association number (FAN) identifies country/state (3 characters), type of institution (2 characters), and facility “ownership” (5 characters).

Codes

COC maintains the codes. The number is entered without dashes. When used, the number reads similar to a social security number with dashes (000-00-00000), for ease of generating reports.

Rationale

Data can be grouped for reporting from country/state, type of institution (freestanding surgery center, pathology laboratory, hospital), or institution group ID code (Kaiser, Humana, Columbia, etc.).

Note: This data item was added to the dataset in 1998, but was never used.

Note: Beginning January 1, 2003, COC will no longer support this data item.

RESERVED 00

Alternate Name	Item #	Length	Source of Standard	Column #
	37	7		12-18

RESERVED 01

Alternate Name	Item #	Length	Source of Standard	Column #
	370	20		32-51

RESERVED 02

Alternate Name	Item #	Length	Source of Standard	Column #
	530	50		231-280

RESERVED 03

Alternate Name	Item #	Length	Source of Standard	Column #
	680	50		322-371

RESERVED 04

Alternate Name	Item #	Length	Source of Standard	Column #
	750	50		478-527

RESERVED 05

Alternate Name	Item #	Length	Source of Standard	Column #
	1180	50		705-754

RESERVED 06

Alternate Name	Item #	Length	Source of Standard	Column #
	1190	49		939-987

RESERVED 07

Alternate Name	Item #	Length	Source of Standard	Column #
	1300	50		1065-1114

RESERVED 08

Alternate Name	Item #	Length	Source of Standard	Column #
	1650	50		1244-1293

RESERVED 09

Alternate Name	Item #	Length	Source of Standard	Column #
	1740	50		1397-1446

RESERVED 10

Alternate Name	Item #	Length	Source of Standard	Column #
	1835	50		2415-2464

RESERVED 11

Alternate Name	Item #	Length	Source of Standard	Column #
	1900	50		2505-2554

RESERVED 12

Alternate Name	Item #	Length	Source of Standard	Column #
	1950	50		2595-2644

RESERVED 13

Alternate Name	Item #	Length	Source of Standard	Column #
	2080	0	Retired	Retired

RESERVED 14

Alternate Name	Item #	Length	Source of Standard	Column #
	2210	0		Retired

RESERVED 16

Alternate Name	Item #	Length	Source of Standard	Column #
	2400	0		Retired

RESERVED 17

Alternate Name	Item #	Length	Source of Standard	Column #
	2450	0		Retired

RESERVED 19

Alternate Name	Item #	Length	Source of Standard	Column #
	2700	770		5925-6694

RESERVED 20

Alternate Name	Item #	Length	Source of Standard	Column #
	2161	0		Retired

RESERVED 21

Alternate Name	Item #	Length	Source of Standard	Column #
	2371	0		Retired

RURALURBAN CONTINUUM 1993**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Beale Code	3300	2	NAACCR	227-228

Description

The “RuralUrban Continuum 1993” code, often referred to as the “Beale Code,” is generated programmatically using Addr at DX--State [80] and County at DX [90]. It contains the Rural-Urban Continuum code as provided by the Office of Management and Budget (OMB) in 1993.

The code is a 10-point continuum (00-09) measuring urban-rural status. Abstractors do not enter these codes.

The code has been expanded to 2 digits to accommodate areas that are not included in the Rural Urban Continuum code table, such as Canadian provinces/territories and U.S. territories. These areas will be coded with a value of 98. Records for nonresidents of the state of reporting institution (County at DX = 998) also will be coded 98. If Addr at DX--State is XX, YY, or ZZ, the Rural Urban Continuum 93 code will be coded as 99. If County at DX equals 999, the Rural Urban Continuum 1993 code will be coded as 99. Note that counties created after 1993 will not be listed in the 1993 Rural Urban Continuum code table and will be assigned a code of 98.

Rationale

RuralUrban Continuum 1993 codes are provided for each county by the OMB and consist of a 1-character rural-urban status, which is very useful for incidence and mortality data analysis

Codes**Metropolitan Counties (00-03)**

- 00 Central counties of metropolitan areas of 1 million population or more
- 01 Fringe counties of metropolitan areas of 1 million population or more
- 02 Counties in metropolitan areas of 250,000-1,000,000 population
- 03 Counties in metropolitan areas of less than 250,000 population

Nonmetropolitan Counties (04-09)

- 04 Urban population of 20,000 or more, adjacent to a metropolitan area
- 05 Urban population of 20,000 or more, not adjacent to a metropolitan area
- 06 Urban population of 2,500-19,999, adjacent to a metropolitan area
- 07 Urban population of 2,500-19,999, not adjacent to a metropolitan area
- 08 Completely rural (no places with a population of 2,500 or more) adjacent to a metropolitan area
- 09 Completely rural (no places with a population of 2,500 or more) not adjacent to a metropolitan area
- 98 Program run, but: (1) area is not included in Rural-Urban Continuum code table, or (2) record is for resident outside of state of reporting institution
- 99 Unknown
- Blank Program not run; record not coded

RURALURBAN CONTINUUM 2000**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Beale Code	3310	2	NAACCR	229-230

Description

The “RuralUrban Continuum 2000” code, often referred to as the “Beale Code,” is generated programmatically using Addr at DX--State [80] and County at DX [90]. It contains the Rural-Urban Continuum code as provided by OMB based on the 2000 Census.

The code is a 10-point continuum (00-09) measuring urban-rural status. Abstractors do not enter these codes.

The code has been expanded to 2 digits to accommodate areas that are not included in Rural Urban Continuum code table, such as Canadian provinces/territories and U.S. territories. These areas will be coded with a value of 98. Records for nonresidents of the state of reporting institution (County at DX = 998) will also be coded 98. If Addr at DX--State is XX, YY, or ZZ, the Rural Urban Continuum 93 code will be coded as 99. If County at DX equals 999, the Rural Urban Continuum 2000 code will be coded as 99.

Rationale

RuralUrban Continuum 2000 codes are provided for each county by OMB and consist of a 1-character rural-urban status, which is very useful for incidence data analysis.

Codes**Metropolitan Counties (00-03)**

- 00 Central counties of metropolitan areas of 1 million population or more
- 01 Fringe counties of metropolitan areas of 1 million population or more
- 02 Counties in metropolitan areas of 250,000-1,000,000 population
- 03 Counties in metropolitan areas of less than 250,000 population

Nonmetropolitan Counties (04-09)

- 04 Urban population of 20,000 or more, adjacent to a metropolitan area
- 05 Urban population of 20,000 or more, not adjacent to a metropolitan area
- 06 Urban population of 2,500-19,999, adjacent to a metropolitan area
- 07 Urban population of 2,500-19,999, not adjacent to a metropolitan area
- 08 Completely rural (no places with a population of 2,500 or more) adjacent to a metropolitan area
- 09 Completely rural (no places with a population of 2,500 or more) not adjacent to a metropolitan area
- 98 Program run, but: (1) area is not included in Rural-Urban Continuum code table, or (2) record is for resident outside of state of reporting institution
- 99 Unknown
- Blank Program not run; record not coded

RX CODING SYSTEM--CURRENT**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1460	2	NAACCR	888-889

Description

Code describing how treatment for this case now is coded.

Codes

00	Treatment data not coded/transmitted (i.e., all treatment fields [items 1200-1450 and 1500-1645] blank*)
01	Treatment data coded using 1-digit surgery codes (obsolete)
02	Treatment data coded according to 1983-1992 SEER manuals and 1983-1995 COC manuals
03	Treatment data coded according to 1996 <i>ROADS Manual</i>
04	Treatment data coded according to 1998 <i>ROADS Supplement</i>
05	Treatment data coded according to 1998 SEER Manual
06	Treatment data coded according to <i>FORDS Manual</i>
99	Other coding, including partial or nonstandard coding

*Note: Treatment text fields, items 2610-2670, may be completed although treatment is not coded.

RX DATE--BRM

Alternate Name	Item #	Length	Source of Standard	Column #
Date Immunotherapy Started (COC)	1240	8	COC	819-826

Description

Date of initiation for immunotherapy that is part of the first course of treatment. See also item 1410 (RX Summ--BRM).

Rationale

The dates on which different treatment modalities were started are used to evaluate whether the treatments were part of first course of therapy and to reconstruct the sequence of first-course treatment modes.

Codes (in addition to valid dates)

00000000	No immunotherapy administered; autopsy-only case
99999999	Unknown if any immunotherapy administered; date unknown, or death certificate-only case

Note: Beginning January 1, 2003, the COC will no longer support this data item.

RX DATE--CHEMO

Alternate Name	Item #	Length	Source of Standard	Column #
Date Chemotherapy Started (COC)	1220	8	COC	803-810

Description

Date of initiation of chemotherapy that is part of the first course of treatment. See also item 1390 (RX Summ--Chemo).

Rationale

The dates on which different treatment modalities were started are used to evaluate whether the treatments were part of first-course therapy and to reconstruct the sequence of first-course treatment modes.

Codes (in addition to valid dates)

00000000 No chemotherapy administered; autopsy-only case

99999999 Unknown if any chemotherapy administered; date unknown, or death certificate only-case.

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX DATE--DX/STG PROC**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Date of Noncancer-Directed Surgery (COC)	1280	8	COC	851-858
Date of Diagnostic, Staging or Palliative Procedures (1996-2002)				
Date of Surgical Diagnostic and Staging Procedure (COC)				

Description

Records the date on which the surgical diagnostic and/or staging procedure was performed.

Rationale

It is useful to record separately the dates on which different treatment modalities were started. It helps when evaluating whether a treatment was a part of first course of therapy.

Codes (in addition to valid dates)

00000000 No diagnostic or staging procedure performed; autopsy-only case

99999999 Unknown if any diagnostic or staging procedure performed; date unknown, or death certificate-only case

Note: This is a COC item and for cases diagnosed from January 1, 1996, through December 31, 2002, may describe the date on which diagnostic, staging, and palliative procedures were performed. Beginning with cases diagnosed on or after January 1, 2003, palliative procedures are collected in items 3270 and 3280 (RX Summ--Palliative Proc and RX Hosp--Palliative Proc).

RX DATE--HORMONE

Alternate Name	Item #	Length	Source of Standard	Column #
Date Hormone Therapy Started (COC)	1230	8	COC	811-818

Description

Date of initiation for hormone therapy that is part of the first course of treatment. See also item 1400 (RX Summ--Hormone).

Rationale

The dates on which different treatment modalities were started are used to evaluate whether the treatments were part of first-course therapy and to reconstruct the sequence of first-course treatment modes.

Codes (in addition to valid dates)

00000000 No hormone therapy administered; autopsy-only case

99999999 Unknown if any hormone therapy administered; date unknown, or death certificate-only case

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX DATE--MOST DEFIN SURG**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Date Most Definitive Surgery of Primary Site	3170	8	COC	763-770

Description

Date of most definitive surgical resection of the primary site performed as part of the first course of treatment.

Rationale

This item is used to measure lag time between diagnosis and the most definitive surgery of the primary site or survival following the procedure. It also is used in conjunction with "Date of Surgical Discharge" NAACCR item #3180 to calculate the duration of hospitalization following the most definitive primary site surgical procedure to evaluate treatment efficacy.

Special Codes (in addition to valid dates)

00000000 When no surgical resection of the primary site is performed and for cases. Diagnosed at autopsy.

99999999 When it is unknown if any surgical procedure of the primary site was performed, the date is unknown or the case was identified by death certificate-only.

RX DATE--OTHER

Alternate Name	Item #	Length	Source of Standard	Column #
Date Other Treatment Started (COC)	1250	8	COC	827-834

Description

Date of initiation for other treatment that is part of the first course of treatment at any facility.

Rationale

The dates on which different treatment modalities were started are used to evaluate whether the treatments were part of first-course therapy and to reconstruct the sequence of first-course treatment modes.

Codes (in addition to valid dates)

00000000 No other treatment administered; autopsy-only case

99999999 Unknown if any other treatment administered; date unknown, or death certificate-only case

RX DATE--RADIATION

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
Date Radiation Started (COC)	1210	8	COC	779-786

Description

Records the date on which radiation therapy began at any facility that is part of the first course of treatment.

Rationale

The dates on which different treatment modalities were started are used to evaluate whether the treatments were part of first-course therapy and to reconstruct the sequence of first-course treatment modes.

Codes (in addition to valid dates)

00000000 No radiation therapy administered; autopsy-only case.

88888888 When radiation therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up. The date should be revised at the next follow-up.

99999999 When it is unknown whether any radiation therapy was administered; the date is unknown, or the case was identified by death certificate-only.

RX DATE--RADIATION ENDED**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Date Radiation Ended	3220	8	COC	787-794

Description

Date of last radiation treatment at any facility (first course of treatment only).

Rationale

The length of time over which radiation therapy is administered to a patient is a factor in tumor control and treatment morbidity. It is useful in evaluating the quality-of-care and the success of patient support programs designed to maintain continuity of treatment.

Codes (in addition to valid dates)

- 00000000 Radiation therapy was not administered or case diagnosed at autopsy
- 88888888 Radiation was administered and was ongoing at the time of most recent follow-up. The date should be revised at the next follow-up.
- 99999999 Unknown if radiation therapy was administered, or the date radiation ended is unknown. Death certificate-only cases.

RX DATE--SURGERY

Alternate Name	Item #	Length	Source of Standard	Column #
Date of Cancer-Directed Surgery (COC)	1200	8	COC	755-762
Date of Surgery				
Date of First Surgical Procedure				

Description

Date the first surgery of the type described under Surgery of Primary Site, Scope of Regional Lymph Node Surgery, or Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Nodes was performed. See also items 1290 (RX Summ--Surg Prim Site), 1292 (RX Summ--Scope Reg LN Sur), and 1294 (RX Summ--Surg Oth Reg/Dis).

Rationale

The dates on which different treatment modalities were started are used to evaluate whether the treatments were part of first-course therapy and to reconstruct the sequence of first-course treatment modes.

Codes (in addition to valid dates)

- 00000000 No cancer-directed surgery performed; autopsy-only case
- 99999999 When it is unknown if any surgical procedure of the primary site was performed, the date is unknown or the case was identified by death certificate-only

RX DATE--SURGICAL DISCH**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Date of Surgical Discharge	3180	8	COC	771-778

Description

Records the date the patient was discharged following primary site surgery. The date corresponds to the event recorded in “Surgical Procedure of Primary Site” (NAACCR Item #1290), and “Date of Most Definitive Surgical Resection” (NAACCR Item #3170).

Rationale

Length of stay is an important quality-of-care and financial measure among hospital administrations, those who fund public and private health care, and public health users. This date, in conjunction with the data item “Date of Most Definitive Surgical Resection” (NAACCR Item #3170), will allow for the calculation of a patient’s length of hospitalization associated with primary site surgery.

Special Codes (in addition to valid dates)

00000000 When no surgical treatment of the primary site was performed. Diagnosed at autopsy.

99999999 When it is unknown whether surgical treatment was performed, the date is unknown or the case was identified by death certificate only.

RX DATE--SYSTEMIC**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Date Systemic Therapy Started	3230	8	COC	795-802

Description

Date of initiation of systemic therapy that is part of the first course of treatment. Systemic therapy includes the administration of chemotherapy agents, hormone agents, biological response modifiers, bone marrow transplants, stem cell harvests, and surgical and/or radiation endocrine therapy.

Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Codes (in addition to valid dates)

00000000 When no systemic therapy was administered, or the case was diagnosed at autopsy.

88888888 When systemic therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up. The date should be revised at the next follow-up.

99999999 When it is unknown if any systemic therapy was administered, the date is unknown, or the case was identified by death certificate-only.

RX HOSP--BRM**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Immunotherapy at this Facility (COC)	720	2	COC	468-469

Description

Records whether immunotherapeutic agents (biologic response modifiers) were administered as first-course treatment at this facility or the reason they were not given. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host's response to tumor cells.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of immunotherapeutic agents as part of the first course of therapy.

If central registries wish to study the treatment given at particular hospitals, the hospital-level treatment fields must be used. The summary treatment fields, conversely, combine information across all hospitals that provide first course of treatment for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing what part of the treatment was given at a particular hospital also helps resolve coding issues.

Codes

- 00 None, immunotherapy was not part of the first course of therapy; not customary therapy for this cancer.
- 01 Immunotherapy.
- 82 Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, etc.).
- 85 Immunotherapy was not administered because the patient died prior to planned or recommended therapy.
- 86 Immunotherapy was not administered; it was recommended by the patient's physician, but was not administered as part of first-course therapy. No reason was noted in the patient record.
- 87 Immunotherapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in the patient record.
- 88 Immunotherapy was recommended, but it is unknown if it was administered.
- 99 It is unknown if immunotherapy was recommended or administered; death certificate-only cases.

Note: See the COC *FORDS Manual*, Immunotherapy at this Facility.

Note: For cases diagnosed on or after January 1, 2003, information on bone marrow transplants and stem cell transplants should be coded in the new field, item 3250 (RX SUMM--Transplnt/Endocr). Codes 02-06 should not be used for cases diagnosed on or after January 1, 2003.

RX HOSP--CHEMO**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Chemotherapy at this Facility (COC)	700	2	COC	464-465

Description

Defines the type of chemotherapy the patient received as a part of the initial treatment for the reportable tumor at the reporting facility or the reason chemotherapy was not given.

Rationale

If central registries wish to study the treatment given at particular hospitals, the hospital-level treatment fields must be used. The summary treatment fields, conversely, combine information across all hospitals that provide first course of treatment for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing what part of the treatment was given at a particular hospital also helps resolve coding issues.

Codes

- 00 None, chemotherapy was not part of the first course of therapy; not customary therapy for this cancer.
- 01 Chemotherapy, NOS.
- 02 Chemotherapy, single agent.
- 03 Chemotherapy, multiple agents.
- 82 Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, etc.).
- 85 Chemotherapy was not administered because the patient died prior to planned or recommended therapy.
- 86 Chemotherapy was not administered; it was recommended by the patient's physician, but was not administered as part of first-course therapy. No reason was noted in the patient record.
- 87 Chemotherapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in the patient record.
- 88 Chemotherapy was recommended, but it is unknown if it was administered.
- 99 It is unknown if chemotherapy was recommended or administered; death certificate-only cases.

Note: See the COC *FORDS Manual*.

RX HOSP--DX/STG/ PROC**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Noncancer-Directed Surgery at this Facility (COC) Surgical Diagnostic & Staging Procedure at this Facility (1996-2002)	740	2	COC	471-472

Description

Identifies the surgical procedure(s) performed in an effort to diagnose and/or stage disease at this facility. Used for cases diagnosed in 1996 and later. Earlier data may be converted into this field. See also item 670, RX Hosp--Surg Prim Site.

Rationale

If central registries wish to study the procedures given at particular hospitals, the hospital-level fields must be used. The summary fields, conversely, combine information across all hospitals that provide for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing what part of the treatment was given at a particular hospital also helps resolve coding issues.

Codes

- 00 No surgical diagnostic or staging procedure was performed.
- 01 A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done.
- 02 A biopsy (incisional, needle, or aspiration) was done of the primary site.
- 03 A surgical exploratory only. The patient was not biopsied or treated.
- 04 A surgical procedure with a bypass was performed, but no biopsy was done.
- 05 An exploratory procedure was performed, and a biopsy of either the primary site or another site was done.
- 06 A bypass procedure was performed, and a biopsy of either the primary site or another site was done.
- 07 A procedure was done, but the type of procedure is unknown.
- 09 No information about whether a diagnostic or staging procedure was performed.

Note: See the COC *FORDS Manual*.

Note: This item has been used for cases diagnosed in 1996 and later. For cases diagnosed before 1996, this item may have been converted, and cases with cancer-directed surgery would have been converted to 09 in this field. For cases diagnosed between 1996 and 2002, this field may have described palliative care. For cases diagnosed on or after January 1, 2003 palliative care is coded in a new field, item 3280 (RX Hosp--Palliative Proc).

RX HOSP--HORMONE

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
Hormone Therapy at this Facility (COC)	710	2	COC	466-467

Description

Records whether systemic hormonal agents were administered as first-course treatment at this facility or the reason they were not given. Hormone therapy consists of a group of drugs that may affect the long-term control of a cancer's growth. It is not usually used as a curative measure.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of hormonal agents as part of the first course of therapy. If central registries wish to study the treatment given at particular hospitals, the hospital-level treatment fields must be used. The summary treatment fields, conversely, combine information across all hospitals that provide first course of treatment for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing what part of the treatment was given at a particular hospital also helps resolve coding issues.

Codes

- 00 None, hormone therapy was not part of the first course of therapy; not customary therapy for this cancer.
- 01 Hormone therapy.
- 82 Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, etc.).
- 85 Hormone therapy was not administered because the patient died prior to planned or recommended therapy.
- 86 Hormone therapy was not administered; it was recommended by the patient's physician, but was not administered as part of first-course therapy. No reason was noted in the patient record.
- 87 Hormone therapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in the patient record.
- 88 Hormone therapy was recommended, but it is unknown if it was administered.
- 99 It is unknown if hormone therapy was recommended or administered; death certificate-only cases.

Note: See the COC *FORDS Manual*.

Note: Any therapy codes 02-03 should have been converted to the appropriate code in the new field, item 3250 (RX SUMM--Transplnt/Endocr). Codes 02-03 should not be used for cases diagnosed on or after January 1, 2003.

RX HOSP--OTHER**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Other Treatment at this Facility (COC)	730	1	COC	470-470

Description

Identifies other treatment given at this facility that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual. Treatment for reportable hematopoietic diseases can be supportive care, observation, or any treatment that does not meet the usual definition in which treatment modifies, controls, removes, or destroys proliferating cancer tissue. Such treatments include phlebotomy, transfusions, and aspirin.

Rationale

Information on other therapy is used to describe and evaluate the quality-of-care and treatment practices. If central registries wish to study the treatment given at particular hospitals, the hospital-level treatment fields must be used. The summary treatment fields, conversely, combine information across all hospitals that provide first course of treatment for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing what part of the treatment was given at a particular hospital also helps resolve coding issues.

Codes

- 0 None, all cancer treatment was coded to other modalities.
- 1 Other. Cancer treatment that cannot be appropriately assigned to other treatment modalities. Used for hematopoietic diseases (M-9950-9989) treated by aspirin, phlebotomy, or transfusions (see notes below).
- 2 Other Experimental, code not defined. It may be used to record participation in institution-based clinical trials.
- 3 Other-Double Blind, a patient is involved in a double-blind clinical trial. Code the treatment actually administered when the trial code is broken.
- 6 Other-Unproven, cancer treatments administered by nonmedical personnel.
- 7 Refusal. The patient or patient's guardian refused treatment, which would have been coded as 1, 2, or 3.
- 8 Recommended; unknown if administered. Other treatment was recommended, but it is unknown whether it was administered.
- 9 Unknown; it is unknown whether other treatment was recommended or administered, and there is no information in the medical record to confirm the recommendation or administration of other treatment.

Note: Aspirin (also known as acetylsalicylic acid [ASA] or by a brand name) is used as a treatment for essential thrombocythemia. Record ONLY aspirin therapy to thin the blood for symptomatic control of thrombocythemia. To determine whether aspirin is administered for pain, cardiovascular protection, or thinning of platelets in the blood, use the following general guideline:

- Pain control is approximately 325-1,000mg every 3-4 hours.
- Cardiovascular protection starts at about 160 mg/day.
- Aspirin treatment for essential thrombocythemia is low dose, approximately 70-100 mg/day.

Phlebotomy may be called blood removal, bloodletting, or venisection. Transfusions may include whole blood, red blood cells, platelets, plateletpheresis, fresh frozen plasma, plasmapheresis, and cryoprecipitate.

RX HOSP--PALLIATIVE PROC

(New)

Alternate Name	Item #	Length	Source of Standard	Column #
Palliative Procedure at this Facility	3280	1	COC	473-473

Description

Identifies any procedure performed at the reporting facility in an effort to palliate or alleviate symptoms. Palliative procedures are performed to relieve symptoms and may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or pain management therapy.

Rationale

This data item allows reporting facilities to track the use of procedures that are considered palliative rather than therapeutic, diagnostic, or staging.

Codes

- 0 No palliative care provided
- 1 Surgery (which may involve a bypass procedure) performed to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made
- 2 Radiation therapy given to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made
- 3 Chemotherapy, hormone therapy, or other systemic drugs given to alleviate symptoms, but no attempt to diagnose, stage or treat the primary tumor is made
- 4 Pain management therapy with no other palliative care
- 5 Any combination of codes 1, 2, and/or 3 without code 4
- 6 Any combination of codes 1, 2 and/or 3 with code 4
- 7 Palliative care was performed, but no information on the type of procedure is available in the patient record
- 9 Unknown if palliative care was performed; not stated in patient record.

RX HOSP--RADIATION

Alternate Name	Item #	Length	Source of Standard	Column #
Radiation at this Facility (COC)	690	1	SEER	463-463

Description

Defines the type of radiation therapy the patient received as a part of the initial treatment for the reportable tumor at the reporting facility.

Rationale

If central registries wish to study the treatment given at particular hospitals, the hospital-level treatment fields must be used. The summary treatment fields, conversely, combine information across all hospitals that provide first course of treatment for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing what part of the treatment was given at a particular hospital also helps resolve coding issues.

Codes

- 0 None
- 1 Beam radiation
- 2 Radioactive implants
- 3 Radioisotopes
- 4 Combination of 1 with 2 or 3
- 5 Radiation, NOS—method or source not specified
- 9 Unknown if radiation therapy administered

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX HOSP--REG LN REMOVED

Alternate Name	Item #	Length	Source of Standard	Column #
Number of Regional Lymph Nodes Examined at this Facility (COC) RX Hosp--Reg LN Examined	676	2	COC	461-462

Description

Describes number of regional lymph nodes removed as part of the first course of treatment. This item reflects that portion of the first course of treatment given at the reporting facility.

Rationale

If central registries wish to study the treatment given at particular hospitals, the hospital-level treatment fields must be used. The summary treatment fields, conversely, combine information across all hospitals that provide first course of treatment for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing the extent of treatment given at a particular hospital also helps resolve coding issues.

Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph node(s) removed, but aspiration of regional lymph node(s) was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as a dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed, but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate-only

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX HOSP--SCOPE REG LN SUR**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Scope of Regional Lymph Node Surgery at this Facility (COC)	672	1	COC	459-459

Description

Describes the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event at the reporting facility.

Rationale

In evaluating quality of care and treatment practices it is important to identify the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event.

If central registries wish to study the treatment given at particular hospitals, the hospital-level treatment fields must be used. The summary treatment fields, conversely, combine information across all hospitals that provide first course of treatment for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing the extent of treatment given at a particular hospital also helps resolve coding issues.

Coding Instructions

- The scope of regional lymph node surgery is collected for each surgical event even if surgery of the primary site was not performed.
- Codes 0–7 are hierarchical. If only one procedure can be recorded, code the procedure that is numerically higher.
- For primaries of the meninges, brain, spinal cord, cranial nerves, and other parts of the central nervous system (C70.0–C70.9, C71.0–C71.9, C72.0–C72.9), code 9.
- For lymphomas (M-9590–9596, 9650–9719, 9727–9729) with a lymph node primary site (C77.0–77.9), code 9.
- For an unknown or ill-defined primary (C76.0–76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9720, 9722–23, 9731–34, 9740–42, 9750–58, 9760–69, 9800–9941, 9945–46, 9948, 9950–89), code 9.
- Do not code *distant* lymph nodes removed during surgery to the primary site for this data item. Distant nodes are coded in the data field “Surgical Procedure/Other Site” (NAACCR item #1294).

Codes

- | | |
|---|---|
| 0 | No regional lymph nodes removed |
| 1 | Biopsy or aspiration of regional lymph node, NOS |
| 2 | Sentinel lymph node biopsy |
| 3 | Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS |
| 4 | 1 to 3 regional lymph nodes removed |
| 5 | 4 or more regional lymph nodes removed |
| 6 | Sentinel node biopsy and code 3, 4, or 5 at same time or timing not stated |
| 7 | Sentinel node biopsy and code 3, 4, or 5 at different times |
| 9 | Unknown or not applicable |

Note: See the COC *FORDS Manual*.

Note: One important use of registry data is the tracking of treatment patterns over time. To compare contemporary treatment to previously published treatment based on former codes, or to data unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. However, it is very important to note that the distinction between codes 4 and 5 is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than 4 nodes was not reflected in surgery codes. It is not intended to reflect clinical significance when applied to a particular surgical procedure. It is important to *avoid inferring, by data presentation or other methods, that one category is preferable to another within the intent of these items.*

RX HOSP--SCREEN/BX PROC1

Alternate Name	Item #	Length	Source of Standard	Column #
Diagnostic and Staging Procedures (pre-2001 COC) RX Hosp--Diag/Stage Proc1 (pre-2001) Screening or Biopsy Procedures (COC)	742	1	COC	474-474

Description

Site-specific field with codes for primary site biopsy procedures.

Rationale

If central registries wish to study the treatment given at particular hospitals, the hospital-level treatment fields must be used. The summary treatment fields, conversely, combine information across all hospitals that provide first course of treatment for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing what part of the treatment was given at a particular hospital also helps resolve coding issues.

Codes

For all cases other than breast and prostate:

0 Not applicable

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX HOSP--SCREEN/BX PROC2

Alternate Name	Item #	Length	Source of Standard	Column #
Diagnostic and Staging Procedures (pre-2001 COC) RX Hosp--Diag/Stage Proc2 (pre-2001) Screening or Biopsy Procedures (COC)	743	1	COC	475-475

Description

Site-specific field with codes for use of guidance procedures for the primary site biopsy.

Rationale

If central registries wish to study the treatment given at particular hospitals, the hospital-level treatment fields must be used. The summary treatment fields, conversely, combine information across all hospitals that provide first course of treatment for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing what part of the treatment was given at a particular hospital also helps resolve coding issues.

Codes

For all cases other than breast and prostate:

0 Not applicable

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX HOSP--SCREEN/BX PROC3

Alternate Name	Item #	Length	Source of Standard	Column #
Diagnostic and Staging Procedures (pre-2001 COC) RX Hosp--Diag/Stage Proc3 (pre-2001) Screening or Biopsy Procedures (COC)	744	1	COC	476-476

Description

Site-specific field with codes for palpability of a breast primary or the approach for a prostate primary site biopsy.

Rationale

If central registries wish to study the treatment given at particular hospitals, the hospital-level treatment fields must be used. The summary treatment fields, conversely, combine information across all hospitals that provide first course of treatment for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing what part of the treatment was given at a particular hospital also helps resolve coding issues.

Codes

For all cases other than breast and prostate:

0 Not applicable

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX HOSP--SCREEN/BX PROC4

Alternate Name	Item #	Length	Source of Standard	Column #
Diagnostic and Staging Procedures (pre-2001 COC) RX Hosp--Diag/Stage Proc4 (pre-2001) Screening or Biopsy Procedures (COC)	745	1	COC	477-477

Description

Site-specific field with codes for first detection of a breast primary or a non-primary site biopsy for a prostate primary.

Rationale

If central registries wish to study the treatment given at particular hospitals, the hospital-level treatment fields must be used. The summary treatment fields, conversely, combine information across all hospitals that provide first course of treatment for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing what part of the treatment was given at a particular hospital also helps resolve coding issues.

Codes

For all cases other than breast and prostate:

0 Not applicable

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX HOSP--SURG OTH REG/DIS**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s) at this Facility (COC)	674	1	COC	460-460
Surgical Procedure/Other Site at this Facility				

Description

Records the surgical removal of *distant* lymph nodes or other tissue(s)/organ(s) beyond the primary site at this facility.

Rationale

The removal of non-primary tissue documents the extent of surgical treatment and is useful in evaluating the extent of metastatic involvement. If central registries wish to study the treatment given at particular hospitals, the hospital-level treatment fields must be used. The summary treatment fields, conversely, combine information across all hospitals that provide first course of treatment for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing what part of the treatment was given at a particular hospital also helps resolve coding issues.

Codes

- 0 None
- 1 Non-primary surgical procedure performed
- 2 Non-primary surgical procedure to other regional sites
- 3 Non-primary surgical procedure to distant lymph node(s)
- 4 Non-primary surgical procedure to distant site
- 5 Any combination of codes 2, 3, or 4
- 9 Unknown

Note: See COC *FORDS Manual*.

RX HOSP--SURG PRIM SITE**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Cancer-Directed Surgery at this Facility (pre-96 COC) RX Hosp--CA Dir Surgery (pre-96 NAACCR) Surgical Procedure of Primary Site	670	2	COC	457-458

Description

Describes surgical procedures used to treat the primary site of the reportable tumor. This item records that portion of the first course of treatment given at the reporting facility. See Chapter V, Unresolved Issues, for a discussion of differences in treatment coding among groups and over time.

Rationale

If central registries wish to study the treatment given at particular hospitals, the hospital-level treatment fields must be used. The summary treatment fields, conversely, combine information across all hospitals that provide first course of treatment for the tumor. Hospital-specific fields allow studies of detailed referral patterns and treatment by type of hospital. Knowing what part of the treatment was given at a particular hospital also helps resolve coding issues.

Codes (in addition to the site-specific codes)

- 00 None. No surgical procedure of primary site. Autopsy only.
- 10-19 Site-specific codes. Tumor destruction; no pathologic specimen produced.
- 20-80 Site-specific codes. Resection. Path specimen produced.
- 90 Surgery, NOS.
- 98 Special codes for hematopoietic/reticuloendothelial/immunoproliferative/myeloproliferative disease, ill-defined site, and unknown primaries (see site-specific codes for site/histologies included). Code 98 takes precedence over Code 00.
- 99 Unknown. Patient record does not state whether a surgical procedure of the primary site was performed and no information is available. Death certificate-only.

Note: See COC *FORDS Manual*.

RX SUMM--BRM**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Immunotherapy (SEER/COC) Biological Response Modifiers (pre-96 SEER)	1410	2	SEER/COC	882-883

Description

Records whether immunotherapeutic (biologic response modifiers) agents were administered as first-course treatment at this facility or the reason they were not given. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host's response to tumor cells.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of immunotherapeutic agents as part of the first course of therapy.

Codes

- 00 None, immunotherapy was not part of the first course of therapy; not customary therapy for this cancer.
- 01 Immunotherapy.
- 82 Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, etc.).
- 85 Immunotherapy was not administered because the patient died prior to planned or recommended therapy.
- 86 Immunotherapy was not administered; it was recommended by the patient's physician, but was not administered as part of first-course therapy. No reason was noted in the patient record.
- 87 Immunotherapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in the patient record.
- 88 Immunotherapy was recommended, but it is unknown if it was administered.
- 99 It is unknown if immunotherapy was recommended or administered; death certificate-only cases.

Instructions for Storing/Converting Historical Codes

SEER recommends that the 1-digit historical codes be stored in the second character position preceded by a zero. COC recommends that the historic codes be converted to the current codes, using the algorithm it has developed.

Historically (before 2003), this was a 1-character field with the following codes:

- 0 None
- 1 Biological response modifier
- 2 Bone marrow transplant--autologous
- 3 Bone marrow transplant--allogeneic
- 4 Bone marrow transplant, NOS
- 5 Stem cell transplant
- 6 Combination of 1 and any 2, 3, 4 or 5
- 7 Patient or patient's guardian refused
- 8 Biological response modifier recommended, unknown if administered
- 9 Unknown if immunotherapy given

Note: See the COC *FORDS Manual*, and the *SEER Program Code Manual*.

Note: For cases diagnosed on or after January 1, 2003, information on bone marrow transplants and stem cell transplants should be coded in the new field, item 3250 (RX SUMM--Transplnt/Endocr). The COC standards for hospitals do not allow use of codes 02-06 in cases diagnosed on or after January 1, 2003.

RX SUMM--CHEMO

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
Chemotherapy (SEER/COC)	1390	2	SEER/COC	878-879

Description

Codes for chemotherapy given as part of the first course of treatment or the reason chemotherapy was not given. Includes treatment given at all facilities as part of the first course.

Codes

- 00 None, chemotherapy was not part of the first course of therapy; not customary therapy for this cancer.
- 01 Chemotherapy, NOS.
- 02 Chemotherapy, single agent.
- 03 Chemotherapy, multiple agents.
- 82 Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, etc.).
- 85 Chemotherapy was not administered because the patient died prior to planned or recommended therapy.
- 86 Chemotherapy was not administered; it was recommended by the patient's physician, but was not administered as part of first-course therapy. No reason was noted in the patient record.
- 87 Chemotherapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in the patient record.
- 88 Chemotherapy was recommended, but it is unknown if it was administered.
- 99 It is unknown if chemotherapy was recommended or administered; death certificate-only cases.

Note: See the COC *FORDS Manual*.

Instructions for Storing/Converting Historical Codes

SEER recommends that the 1-digit historical codes be stored in the second character position preceded by a zero. COC recommends that the historic codes be converted to the current codes, using the algorithm it has developed.

Historically (before 2003), this was a 1-character field with the following codes:

- 0 None
- 1 Chemotherapy, NOS
- 2 Chemotherapy, single agent
- 3 Chemotherapy, multiple agents (combination regimen)
- 7 Patient or patient's guardian refused
- 8 Chemotherapy recommended, unknown if administered
- 9 Unknown if chemotherapy administered; death certificate-only

RX SUMM--DX/STG PROC**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Non Cancer-Directed Surgery (COC) Surgical, Diagnostic and Staging Procedure (1996-2002)	1350	2	COC	869-870

Description

Identifies the surgical procedure(s) performed in an effort to diagnose and/or stage disease. COC recommends this item for cases diagnosed 1996 and forward. For cases diagnosed before 1996, this item may have been converted, and cases with cancer-directed surgery would have been converted to 09 in this field. See also items 1290 (RX Summ--Surg Prim Site) and 1330 (RX Summ--Reconstruct 1st). For SEER and pre-1996 COC, see item 1640 (RX Summ--Surgery Type).

Codes

- 00 No surgical diagnostic or staging procedure was performed.
- 01 A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done.
- 02 A biopsy (incisional, needle, or aspiration) was done of the primary site.
- 03 A surgical exploratory only. The patient was not biopsied or treated.
- 04 A surgical procedure with a bypass was performed, but no biopsy was done.
- 05 An exploratory procedure was performed, and a biopsy of either the primary site or another site was done.
- 06 A bypass procedure was performed, and a biopsy of either the primary site or another site was done.
- 07 A procedure was done, but the type of procedure is unknown.
- 09 No information about whether a diagnostic or staging procedure was performed.

Note: See the COC *FORDS Manual*.

Note: This item has been used for cases diagnosed in 1996 and later. For cases diagnosed before 1996, cases with cancer-directed surgery would have been converted to 09 in this field. For cases diagnosed between 1996 and 2002 this field may have described palliative care. For cases diagnosed on or after January 1, 2003 palliative care is coded in a new field, item 3270 (RX Summ--Palliative Proc).

RX SUMM--HORMONE**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Hormone Therapy (SEER/COC) Endocrine (Hormone/Steroid) Therapy (pre-96 SEER)	1400	2	SEER/COC	880-881

Description

Records whether systemic hormonal agents were administered as first-course treatment at any facility, or the reason they were not given. Hormone therapy consists of a group of drugs that may affect the long-term control of a cancer's growth. It is not usually used as a curative measure.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of hormonal agents as part of the first course of therapy.

Codes

- 00 None, hormone therapy was not part of the first course of therapy; not customary therapy for this cancer.
- 01 Hormone therapy.
- 82 Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, etc.).
- 85 Hormone therapy was not administered because the patient died prior to planned or recommended therapy.
- 86 Hormone therapy was not administered; it was recommended by the patient's physician, but was not administered as part of first-course therapy. No reason was noted in the patient record.
- 87 Hormone therapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in the patient record.
- 88 Hormone therapy was recommended, but it is unknown if it was administered.
- 99 It is unknown if hormone therapy was recommended or administered; death certificate-only cases.

Instructions for Storing/Converting Historical Codes

SEER recommends that the 1-digit historical codes be stored in the second character position preceded by a zero. COC recommends that the historic codes be converted to the current codes, using the algorithm it has developed.

Historically (before 2003), this was a 1-character field with the following codes:

- 0 None
- 1 Hormone therapy
- 2 Endocrine surgery and/or endocrine radiation (if cancer is of another site)
- 3 Combination of 1 and 2
- 7 Patient or patient's guardian refused*
- 8 Hormonal therapy recommended, unknown if administered*
- 9 Unknown if hormonal therapy administered; death certificate-only

**Note:* For COC, codes 7 and 8 were used for cases diagnosed before 1996, but should have been converted to 0 in this field and to the appropriate code in the new field, item 1450 (Reason for No Hormone). The COC standards for hospitals do not allow use of codes 7 and 8 in 1996 and later. SEER continues to use codes 7 and 8 for all years. See Chapter V, Unresolved Issues, for further discussion.

Note: See the COC *FORDS Manual*, and the *SEER Program Code Manual*.

Note: For cases diagnosed on or after January 1, 2003, information on endocrine surgery and/or endocrine radiation should be coded in the new field, item 3250 (RX Summ--Transplnt/Endocr). The COC standards for hospitals do not allow use of codes 02-03 in cases diagnosed on or after January 1, 2003.

RX SUMM--OTHER**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Other Treatment (COC) Other Cancer-Directed Therapy (SEER/pre-96 COC)	1420	1	SEER/COC	884-884

Description

Identifies other treatment given at this facility that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual. Treatment for reportable hematopoietic diseases can be supportive care, observation, or any treatment that does not meet the usual definition in which treatment modifies, controls, removes, or destroys proliferating cancer tissue. Such treatments include phlebotomy, transfusions, and aspirin.

Rationale

Information on other therapy is used to describe and evaluate the quality-of-care and treatment practices.

Codes

- 0 None, all cancer treatment was coded to other modalities.
- 1 Other, cancer treatment that cannot be appropriately assigned to other treatment modalities. Used for hematopoietic diseases (M-9950-9989) treated by aspirin, phlebotomy, or transfusions (see notes below).
- 2 Other Experimental, code not defined. It may be used to record participation in institution-based clinical trials.
- 3 Other-Double Blind, a patient is involved in a double-blind clinical trial. Code the treatment actually administered when the trial code is broken.
- 6 Other-Unproven, cancer treatments administered by nonmedical personnel.
- 7 Refusal, the patient or patient's guardian refused treatment that would have been coded as 1, 2, or 3.
- 8 Recommended; unknown if administered. Other treatment was recommended, but it is unknown whether it was administered.
- 9 Unknown; it is unknown whether other treatment was recommended or administered, and there is no information in the medical record to confirm the recommendation or administration of other treatment.

Note: See the COC FORDS Manual

Note: Aspirin (also known as acetylsalicylic acid [ASA] or by a brand name) is used as a treatment for essential thrombocythemia. Record ONLY aspirin therapy to thin the blood for symptomatic control of thrombocythemia. To determine whether aspirin is administered for pain, cardiovascular protection, or thinning of platelets in the blood, use the following general guideline:

- Pain control is approximately 325-1,000 mg every 3-4 hours.
- Cardiovascular protection starts at about 160 mg/day.
- Aspirin treatment for essential thrombocythemia is low dose, approximately 70-100 mg/day.

Phlebotomy may be called blood removal, bloodletting, or venisection. Transfusions may include whole blood, red blood cells, platelets, plateletpheresis, fresh frozen plasma, plasmapheresis, and cryoprecipitate.

RX SUMM--PALLIATIVE PROC**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Palliative Procedure	3270	1	COC	871-871

Description

Identifies any procedure performed in an effort to palliate or alleviate symptoms. Palliative procedures are performed to relieve symptoms and may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or pain management therapy.

Rationale

This data item allows the tracking of the use of procedures that are considered palliative rather than therapeutic, diagnostic, or staging.

Codes

- 0 No palliative care provided.
- 1 Surgery (which may involve a bypass procedure) performed to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
- 2 Radiation therapy given to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
- 3 Chemotherapy, hormone therapy, or other systemic drugs given to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
- 4 Pain management therapy with no other palliative care.
- 5 Any combination of codes 1, 2, and/or 3 without code 4.
- 6 Any combination of codes 1, 2 and/or 3 with code 4.
- 7 Palliative care was performed, but no information on the type of procedure is available in the patient record.
- 9 Unknown if palliative care was performed; not stated in patient record.

RX SUMM--RAD TO CNS

Alternate Name	Item #	Length	Source of Standard	Column #
Radiation Therapy to CNS (COC) Radiation to the Brain and/or Central Nervous System (SEER)	1370	1	SEER/COC	874-874

Description

For lung and leukemia cases only, codes for radiation given to the brain or central nervous system. Includes treatment given at all facilities as part of the first course. See Chapter V, Unresolved Issues, for more information.

Note: SEER does not collect this data item beginning with 1998 cases. They retain the codes for older cases in this field, and they have also recoded radiation coded here as radiation in item 1360 (RX Summ--Radiation). COC does not collect this data item beginning with 1996 cases.

Codes

For Lung and Leukemia Cases only:

- 0 No radiation to the brain and/or central nervous system
- 1 Radiation
- 7 Patient or patient's guardian refused
- 8 Radiation recommended, unknown if administered
- 9 Unknown

For all other cases (primaries other than lung or leukemia):

- 9 Not applicable

RX SUMM--RADIATION

Alternate Name	Item #	Length	Source of Standard	Column #
Radiation (SEER/COC) Radiation Therapy (pre-96 COC)	1360	1	SEER	873-873

Description

Codes for the type of radiation therapy performed as part of the first course of treatment. Includes treatment given at all facilities as part of first course.

Note: Radiation to brain and central nervous system for leukemia and lung cases is coded as radiation in this field.

Codes

- 0 None
- 1 Beam radiation
- 2 Radioactive implants
- 3 Radioisotopes
- 4 Combination of 1 with 2 or 3
- 5 Radiation, NOS—method or source not specified
- 7 Patient or patient's guardian refused*
- 8 Radiation recommended, unknown if administered*
- 9 Unknown if radiation administered

**Note:* For COC, codes 7 and 8 were used for cases diagnosed before 1996, but should have been converted to 0 in this field and to the appropriate code in the new field, item 1430 (Reason for No Radiation). The COC standards for hospitals do not allow use of codes 7 and 8 in 1996 and later. SEER continues to use codes 7 and 8 for all years. See Chapter V, Unresolved Issues, for further discussion.

RX SUMM--RECONSTRUCT 1ST

Alternate Name	Item #	Length	Source of Standard	Column #
Reconstruction--First Course (SEER) Reconstruction/Restoration-First Course (COC)	1330	1	COC	867-867

Description

Codes for surgical procedures done to reconstruct, restore, or improve the shape and appearance or function of body structures that are missing, defective, damaged, or misshapen by cancer or cancer-directed therapies. Reconstructive/restorative procedures are coded here when started during the first course of cancer-directed therapy.

COC introduced site-specific codes for this item in the COC *ROADS Manual* 1998 Supplement. Item 1460 (RX Coding System--Current) identifies which coding system applies.

SEER collects reconstructive procedures for breast cancer cases only.

For reconstructive/restorative procedures performed later, see item 1741 (Subseq RX--Reconstruct Del). See also item 1640 (RX Summ--Surgery Type).

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX SUMM--REG LN EXAMINED

Alternate Name	Item #	Length	Source of Standard	Column #
Number of Regional Lymph Nodes Examined (SEER/COC)	1296	2	SEER/COC	863-864
Number of Regional Lymph Nodes Removed (COC)				

Description

Codes for the number of regional lymph nodes examined in conjunction with surgery performed as part of the first-course treatment. This includes treatment given at all facilities as part of the first course of treatment. See also item 1292 (RX Summ--Scope Reg LN Sur).

Codes

00	No regional lymph nodes examined
01	One regional lymph node examined
02	Two regional lymph nodes examined
..	
..	
90	90 or more regional lymph nodes examined
..	
95	No regional lymph node(s) removed, but aspiration of regional lymph node(s) was performed
96	Regional lymph node removal documented as sampling, and number of lymph nodes unknown/not stated
97	Regional lymph node removal documented as a dissection, and number of lymph nodes unknown/not stated
98	Regional lymph nodes surgically removed, but number of lymph nodes unknown/not stated and not documented as sampling or dissection
99	Unknown; not stated; death certificate-only

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX SUMM--SCOPE REG LN SUR**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Scope of Regional Lymph Node Surgery (SEER/COC)	1292	1	SEER/COC	861-861

Description

Describes the removal, biopsy or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event at all facilities.

Rationale

In evaluating quality-of-care and treatment practices it is important to identify the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event.

Coding Instructions

- The scope of regional lymph node surgery is collected for each surgical event even if surgery of the primary site was not performed.
- Codes 0–7 are hierarchical. If only one procedure can be recorded, code the procedure that is numerically higher.
- For primaries of the meninges, brain, spinal cord, cranial nerves, and other parts of the central nervous system (C70.0–C70.9, C71.0–C71.9, C72.0–C72.9), code 9.
- For lymphomas (M-9590–9596, 9650–9719, 9727–9729) with a lymph node primary site (C77.0–77.9), code 9.
- For an unknown or ill-defined primary (C76.0–76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9720, 9722–23, 9731–34, 9740–42, 9750–58, 9760–69, 9800–9941, 9945–46, 9948, 9950–89), code 9.
- Do not code *distant* lymph nodes removed during surgery to the primary site for this data item. Distant nodes are coded in the data field “Surgical Procedure/Other Site” (NAACCR item #1294).

Codes

- 0 No regional lymph nodes removed
- 1 Biopsy or aspiration of regional lymph node, NOS
- 2 Sentinel lymph node biopsy
- 3 Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS
- 4 1 to 3 regional lymph nodes removed
- 5 4 or more regional lymph nodes removed
- 6 Sentinel node biopsy and code 3, 4, or 5 at same time or timing not noted.
- 7 Sentinel node biopsy and code 3, 4, or 5 at different times
- 9 Unknown

Note: See the COC *FORDS Manual* and *SEER Program Code Manual*.

Note: One important use of registry data is the tracking of treatment patterns over time. To compare contemporary treatment to previously published treatment based on former codes, or to data unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. However, it is very important to note that the distinction between codes 4 and 5 is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than 4 nodes was not reflected in surgery

codes. It is not intended to reflect clinical significance when applied to a particular surgical procedure. It is important to *avoid inferring, by data presentation or other methods, that one category is preferable to another within the intent of these items.*

RX SUMM--SCREEN/BX PROC1

Alternate Name	Item #	Length	Source of Standard	Column #
Diagnostic and Staging Procedures (pre-2001 COC) RX Summ--Diag/Stage Proc1 (pre-2001) Screening or Biopsy Procedures (COC)	1642	1	COC	934-934

Description

Site-specific field with codes for primary site biopsy procedure.

Codes

For detailed site-specific 1-digit codes for each field for breast and prostate cases, see the *COC ROADS Manual*, 1998 Supplement.

For all cases other than breast and prostate

0 Not applicable

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX SUMM--SCREEN/BX PROC2

Alternate Name	Item #	Length	Source of Standard	Column #
Diagnostic and Staging Procedures (pre-2001 COC) RX Summ—Diag/Stage Proc2 (pre-2001) Screening or Biopsy Procedures (COC)	1643	1	COC	935-935

Description

Site-specific field with codes for use of guidance procedures for the primary site biopsy.

Codes

For detailed site-specific 1-digit codes for each field for breast and prostate cases, see the *COC ROADS Manual*, 1998 Supplement.

For all cases other than breast and prostate

0 Not applicable

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX SUMM--SCREEN/BX PROC3

Alternate Name	Item #	Length	Source of Standard	Column #
Diagnostic and Staging Procedures (pre-2001 COC) RX Summ--Diag/Stage Proc3 (pre-2001) Screening or Biopsy Procedures (COC)	1644	1	COC	936-936

Description

Site-specific field with codes for palpability of a breast primary or the approach for a prostate primary site biopsy.

Codes

For detailed site-specific 1-digit codes for each field for breast and prostate cases, see the *COC ROADS Manual*, 1998 Supplement.

For all cases other than breast and prostate

0 Not applicable

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX SUMM--SCREEN/BX PROC4

Alternate Name	Item #	Length	Source of Standard	Column #
Diagnostic and Staging Procedures (pre-2001 COC) RX Summ--Diag/Stage Proc4 (pre-2001) Screening or Biopsy Procedures (COC)	1645	1	COC	937-937

Description

Site-specific field with codes for first detection of a breast primary or a non-primary site biopsy for a prostate primary.

Codes

For detailed site-specific 1-digit codes for each field for breast and prostate cases, see the *COC ROADS Manual*, 1998 Supplement.

For all cases other than breast and prostate

0 Not applicable

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX SUMM--SURG OTH REG/DIS**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Nodes (SEER/COC)	1294	1	SEER/COC	862-862
Surgical Procedure/Other Site				

Description

Records the surgical removal of *distant* lymph nodes or other tissue(s)/organ(s) beyond the primary site.

Rationale

The removal of non-primary tissue documents the extent of surgical treatment and is useful in evaluating the extent of metastatic involvement.

Codes

- 0 None
- 1 Non-primary surgical procedure performed
- 2 Non-primary surgical procedure to other regional sites
- 3 Non-primary surgical procedure to distant lymph node(s)
- 4 Non-primary surgical procedure to distant site
- 5 Any combination of codes 2, 3, or 4
- 9 Unknown

Note: See the COC *FORDS Manual*, and the *SEER Program Code Manual*.

RX SUMM--SURG PRIM SITE**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Cancer-Directed Surgery (pre-96 COC)	1290	2	SEER/COC	859-860
Surgery of Primary Site (SEER/COC)				

Description

Site-specific codes for the type of surgery to the primary site performed as part of the first course of treatment. This includes treatment given at all facilities as part of the first course of treatment.

Codes (in addition to the site-specific codes)

- 00 None. No surgical procedure of primary site. Autopsy only.
- 10-19 Site-specific codes. Tumor destruction; no pathologic specimen produced.
- 20-80 Site-specific codes. Resection. Pathologic specimen produced.
- 90 Surgery, NOS.
- 98 Special codes for hematopoietic /reticuloendothelial/immunoproliferative/myeloproliferative disease, ill-defined site and unknown primaries (see site-specific codes for site/histologies included). Code 98 takes precedence over Code 00.
- 99 Unknown. Patient record does not state whether a surgical procedure of the primary site was performed and no information is available. Death certificate-only.

Note: See the COC *FORDS Manual*, and the *SEER Program Code Manual*, for site-specific codes.

RX SUMM--SURG/RAD SEQ

Alternate Name	Item #	Length	Source of Standard	Column #
Radiation Sequence with Surgery (pre-96 SEER/COC) Radiation/Surgery Sequence (COC)	1380	1	SEER/COC	875-875

Description

Codes for the sequencing of radiation and cancer-directed surgery given as part of the first course of treatment. Includes treatment given at all facilities as part of the first course. See also items 1290 (RX Summ--Surg Prim Site) and 1360 (RX Summ--Radiation).

Codes

- 0 No radiation and/or no cancer-directed surgery
- 2 Radiation before surgery
- 3 Radiation after surgery
- 4 Radiation both before and after surgery
- 5 Intraoperative radiation
- 6 Intraoperative radiation with other radiation given before or after surgery
- 9 Sequence unknown, but both surgery and radiation were given

RX SUMM--SURGERY TYPE

Alternate Name	Item #	Length	Source of Standard	Column #
Site--Specific Surgery (pre-98 SEER)	1640	2	SEER	932-933

Description

Field for pre-1996 surgery codes for COC and pre-1998 surgery codes for SEER. Surgery codes used 1998 and later can be backward converted into the older codes and the converted value can be stored in this field. See Chapter V, Unresolved Issues, for discussion of COC/SEER differences in coding treatment.

RX SUMM--SURGICAL APPROCH

Alternate Name	Item #	Length	Source of Standard	Column #
Surgical Approach (COC)	1310	1	COC	865-865

Description

Codes for method used to approach the surgical field for the primary site. COC requires coding for cases diagnosed 1996 and forward. COC introduced site-specific codes for this item in the COC *ROADS Manual* 1998 Supplement. See also item 1290 (RX Summ--Surg Prim Site).

Codes

See the COC *ROADS Manual*, 1998 Supplement, for site-specific codes.

Note: Beginning January 1, 2003, COC will no longer support this data item.

RX SUMM--SURGICAL MARGINS**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Surgical Margins (COC) Residual Primary Tumor Following Cancer-Directed Surgery (pre-96 COC)	1320	1	COC	866-866

Description

Codes describe the final status of surgical margins after resection of the primary tumor. See also item 1290 (RX Summ--Surg Prim Site).

Rationale

This item serves as a quality measure for pathology reports, is used for staging, and may be a prognostic factor in recurrence. This item is not limited to cases that have been staged. It applies to all cases that have a surgical procedure of the primary site.

Coding Instructions

- Codes 0–3 are hierarchical; if two codes describe the margin status, use the numerically higher code.
- If no surgery of the primary site was performed, code 8.
- For lymphomas (M– 9590–96, 9650–9719, 9727–29) with a lymph node primary site (C77.0– C77.9), code 9.
- For an unknown or ill-defined primary (C76.0–C76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4, or M–9720, 9722–23, 9731–34, 9740–42, 9750–58, 9760–69, 9800–9941, 9945–46, 9948, 9950–89), code 9.

Codes

- 0 No residual tumor; all margins are grossly and microscopically negative.
- 1 Residual tumor, NOS; involvement is indicated, but not otherwise specified.
- 2 Microscopic residual tumor is present but cannot be seen by the naked eye.
- 3 Macroscopic residual tumor. Gross tumor of the primary site, which is visible to the naked eye.
- 7 Margins not evaluable.
- 8 No primary site surgery. No surgical procedure of the primary site. Diagnosed at autopsy.
- 9 Unknown or not applicable. It is unknown whether a surgical procedure to the primary site was performed; for lymphomas with a lymph node primary site; an unknown or ill-defined primary; or for hematopoietic, reticuloendothelial, immunoproliferative or myeloproliferative disease; death certificate-only.

Note: Codes were site specific (1998-2002), and have been changed to be generic across all disease sites.

Note: See the COC *FORDS Manual*.

RX SUMM--TRANSPLNT/ENDOCR**(New)**

Alternate Name	Item #	Length	Source of Standard	Column #
Hematologic Transplant and Endocrine Procedures	3250	2	COC	876-877

Description

Identifies systemic therapeutic procedures administered as part of the first course of treatment at this facility and all other facilities or the reason they were not used. These include bone marrow transplants, stem cell harvests, and surgical and radiation endocrine therapy.

Rationale

This data item allows the evaluation of patterns of treatment, which involve the alteration of the immune system or change the patient's response to tumor cells but do not involve the administration of antineoplastic agents.

Codes

- 00 None, transplant procedure or endocrine therapy was not part of the first course of therapy; not customary therapy for this cancer.
- 10 Bone marrow transplant, NOS. A bone marrow transplant procedure was administered, but the type was not specified.
- 11 Bone marrow transplant—autologous.
- 12 Bone marrow transplant—allogeneic.
- 20 Stem cell harvest.
- 30 Endocrine surgery and/or endocrine radiation therapy.
- 40 Combination of a transplant procedure with endocrine surgery and/or radiation (code 30 in combination with 10, 11, 12 or 20).
- 82 Transplant procedure and/or endocrine therapy was not recommended/administered because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, etc.).
- 85 Transplant procedure and/or endocrine therapy was not administered because the patient died prior to planned or recommended therapy.
- 86 Transplant procedure and/or endocrine therapy was not administered; it was recommended by the patient's physician, but was not administered as part of first-course therapy. No reason was noted in the patient record.
- 87 Transplant procedure and/or endocrine therapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in the patient record.
- 88 Transplant procedure and/or endocrine therapy was recommended, but it is unknown if it was administered.
- 99 It is unknown if a transplant procedure or endocrine surgery and/or radiation were recommended or administered. Death certificate-only cases and autopsy-only cases.

Note: See the COC *FORDS Manual*.

RX TEXT--BRM

Alternate Name	Item #	Length	Source of Standard	Column #
	2660	100	NAACCR	5325-5424

Description

Text area for information about biological response modifier treatment.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

RX TEXT--CHEMO

Alternate Name	Item #	Length	Source of Standard	Column #
	2640	200	NAACCR	4925-5124

Description

Text area for information about chemotherapy treatment.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

RX TEXT--HORMONE

Alternate Name	Item #	Length	Source of Standard	Column #
	2650	200	NAACCR	5125-5324

Description

Text area for information about hormonal cancer-directed treatment.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

RX TEXT--OTHER

Alternate Name	Item #	Length	Source of Standard	Column #
	2670	100	NAACCR	5425-5524

Description

Text area for information about other cancer-directed treatment.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

RX TEXT--RADIATION (BEAM)

Alternate Name	Item #	Length	Source of Standard	Column #
	2620	150	NAACCR	4625-4774

Description

Text area for information about beam radiation given for cancer treatment.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

RX TEXT--RADIATION OTHER

Alternate Name	Item #	Length	Source of Standard	Column #
	2630	150	NAACCR	4775-4924

Description

Text area for information about nonbeam radiation given for cancer treatment.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

RX TEXT--SURGERY

Alternate Name	Item #	Length	Source of Standard	Column #
	2610	150	NAACCR	4475-4624

Description

Text area for information about surgical procedures performed as part of treatment.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

SCREENING DATE

Alternate Name	Item #	Length	Source of Standard	Column #
	510	8	COC	313-320

Description

Most recent date on which the patient participated in a screening program related to this primary cancer.

Codes (in addition to appropriate dates)

00000000 Patient did not participate in screening program related to this primary cancer

99999999 Patient participated in screening program related to this primary cancer; date is unknown

Note: Beginning January 1, 2003, COC will no longer support this data item.

SCREENING RESULT

Alternate Name	Item #	Length	Source of Standard	Column #
	520	1	COC	321-321

Description

Code the findings from screening recorded in item 510 (Screening Date).

Codes

- 0 Within normal limits
- 1 Abnormal/not suggestive of cancer
- 2 Abnormal/suggestive of cancer
- 3 Equivocal/no follow-up necessary
- 4 Equivocal/evaluation recommended
- 8 Not applicable
- 9 Unknown, result not specified

| *Note:* Beginning January 1, 2003, COC will no longer support this data item.

SEER CODING SYS--CURRENT**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	2120	1	NAACCR	1198-1198

Description

This shows the SEER coding system best describing the majority of SEER items as they are in the record (after conversion).

Codes

- 0 No SEER coding
- 1 1987 SEER Coding Manual
- 2 May 1988 SEER Coding Manual
- 3 January 1989 SEER Coding Manual
- 4 January 1992 SEER Coding Manual
- 5 January 1998 SEER Coding Manual
- | 6 January 2003 SEER Coding Manual

SEER CODING SYS--ORIGINAL

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	2130	1	NAACCR	1199-1199

Description

This shows the SEER coding system best describing the way the majority of SEER items in the record were originally coded.

Codes

- 0 No SEER coding
- 1 1987 SEER Coding Manual
- 2 May 1988 SEER Coding Manual
- 3 January 1989 SEER Coding Manual
- 4 January 1992 SEER Coding Manual
- 5 January 1998 SEER Coding Manual
- 6 January 2003 SEER Coding Manual

SEER RECORD NUMBER

Alternate Name	Item #	Length	Source of Standard	Column #
Record Number (SEER)	2190	2	SEER	1215-1216

Description

A unique sequential number assigned by the SEER participant to each record for the person for each submission. The number may change from submission to submission. See also item 60 (Tumor Record Number).

Codes

- 01 One or first of more than one record for person
- 02 Second record for person
- ..
- ..
- nn Last of nn records for person

SEER SUMMARY STAGE 1977

Alternate Name	Item #	Length	Source of Standard	Column #
General Summary Stage (SEER/COC)	760	1	SEER	529-529

Description

Code for summary stage at the initial diagnosis or treatment of the reportable tumor. This has traditionally been used by central registries to monitor time trends. For hospital registries, COC requires its use in the absence of a defined AJCC classification. For site-specific definitions of categories, see the *SEER Summary Staging Guide*.

SEER Summary Stage 1977 is limited to information available within 2 months of the date of diagnosis. NAACCR approved extension of this time period to 4 months for prostate cancer cases diagnosed beginning January 1, 1995.

Rationale

Stage information is important when evaluating the effects of cancer control programs. It is crucial for understanding whether changes over time in incidence rates or outcomes are due to earlier detection of the cancers. In addition, cancer treatment cannot be studied without knowing the stage at diagnosis.

To study historical trends in stage, the coding system must be relatively unchanged (stable) over time. AJCC's TNM system is updated periodically to maintain clinical relevance with changes in diagnosis and treatment. The surveillance registries often rely on the Summary Stage, which they consider to be more "stable." Summary Stage has been in widespread use, either as the primary staging scheme or a secondary scheme, in most central and hospital registries since 1977.

Codes

0	<i>In situ</i>
1	Localized
2	Regional, direct extension only
3	Regional, regional lymph nodes only
4	Regional, direct extension and regional lymph nodes
5	Regional, NOS
7	Distant
9	Unstaged

Clarification of NAACCR and NPCR Required Status

Summary stage is required. The correct data item to use (and corresponding code manual) is determined by the year in which the cancer was diagnosed. Cancers diagnosed on or after January 1, 2003, should be assigned a summary stage based upon the Collaborative Stage data item algorithms and retained in Data Item 3020, Derived SS2000. Cancers diagnosed in 2001 and 2002 should be assigned a summary stage according to the *SEER Summary Staging Manual 2000*, and the code should be reported in Data Item 759, SEER Summary Stage 2000. Cancers diagnosed before January 1, 2001, should be assigned a summary stage according to *SEER Summary Stage Guide 1977*, and the code should be reported in Data Item 760, SEER Summary Stage 1977.

SEER SUMMARY STAGE 2000**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	759	1	SEER	528-528

Description

Code for summary stage at the initial diagnosis or treatment of the reportable tumor. For hospital registries, COC requires its use in the absence of a defined AJCC classification. For site-specific definitions of categories, see *SEER Summary Staging Manual 2000*.

Summary stage should include all information available through completion of surgery(ies) in the first course of treatment or within 4 months of diagnosis in the absence of disease progression, whichever is longer.

Rationale

Stage information is important when evaluating the effects of cancer control programs. It is crucial in understanding whether changes over time in incidence rates or outcomes are due to earlier detection of the cancers. In addition, cancer treatment cannot be studied without knowing the stage at diagnosis.

Codes

0	<i>In situ</i>
1	Localized
2	Regional, direct extension only
3	Regional, regional lymph nodes only
4	Regional, direct extension and regional lymph nodes
5	Regional, NOS
7	Distant
9	Unstaged

Clarification of NAACCR and NPCR Required Status

Summary stage is required. The correct data item to use (and corresponding code manual) is determined by the year in which the cancer was diagnosed. Cancers diagnosed on or after January 1, 2003, should be assigned a summary stage based upon the Collaborative Stage data item algorithms and retained in Data Item 3020, Derived SS2000. Cancers diagnosed in 2001 and 2002 should be assigned a summary stage according to the *SEER Summary Staging Manual 2000*, and the code should be reported in Data Item 759, SEER Summary Stage 2000. Cancers diagnosed before January 1, 2001, should be assigned a summary stage according to *SEER Summary Stage Guide 1977*, and the code should be reported in Data Item 760, SEER Summary Stage 1977.

SEER TYPE OF FOLLOW-UP

Alternate Name	Item #	Length	Source of Standard	Column #
Type of Follow-Up (SEER)	2180	1	SEER	1214-1214

Description

Codes for the type of follow-up expected for a SEER case.

Codes

- 1 “Autopsy-Only” or “Death Certificate-Only” case
- 2 Active follow-up case
- 3 *In situ* cancer of the cervix uteri only
- 4 Case not originally in active follow-up, but in active follow-up now (San Francisco-Oakland only)

SEQUENCE NUMBER--CENTRAL**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Sequence Number (pre-96 SEER)	380	2	NAACCR	281-282

Description

Code indicates the sequence of all reportable neoplasms over the lifetime of the person. This data item differs from Sequence Number--Hospital [560], because the definitions of reportable neoplasms often vary between a hospital and a central registry. Each neoplasm is assigned a different number. Sequence Number 00 indicates that the person has only one reportable neoplasm in his lifetime (regardless of central registry reference date). Sequence Number 01 indicates the first of two or more reportable neoplasms, while 02 indicates the second of two or more reportable neoplasms, and so on. Because the time period of Sequence Number is a person's lifetime, reportable neoplasms not included in the central registry (those that occur outside the registry catchment area or before the reference date) also are allotted a sequence number. For example, a registry may contain a single record for a patient with a sequence number of 02 because the first reportable neoplasm preceded the central registry's reference date.

Reporting Requirements: Nationally Required and State Defined

The national (SEER and/or NPCR) standard defining which neoplasms are reportable is described in Chapter III, Standards For Case Inclusion and Reportability; it is assumed that this common standard is the “minimum” definition of reportability. Individual central cancer registries may define additional neoplasms as reportable.

Numeric codes in the 00-35 range indicate reportable neoplasms of malignant or *in situ* behavior, which national standards require to be reported. Codes between 60 and 87 indicate other neoplasms that the state registry has defined as reportable, primarily of benign/borderline behavior. The neoplasms required by SEER and/or NPCR are sequenced completely independently of this other category.

Some examples of neoplasms that could be required by the state cancer registry include benign brain tumors, borderline ovarian tumors, squamous cell and basal cell carcinomas of the skin, prostatic intraepithelial neoplasia grade III (PIN III), or cervix carcinoma *in situ*/cervical intraepithelial neoplasia grade III (cervix CIS/CIN III) (see table at the end of this description). The state registry-defined reportable sequence codes do not affect the nationally required sequence numbers. The two notational systems are independent. For example, if a patient is assigned a sequence number of 00 for a nationally required reportable neoplasm and is

later diagnosed with a state registry-reportable neoplasm, the sequencing for the nationally required neoplasm does not change.

Timing Rule

The sequence number may change over the lifetime of the patient. Thus, an individual previously diagnosed with one reportable neoplasm may be diagnosed with a second reportable neoplasm, in which case the first neoplasm code changes from 00 to 01. A registry could also discover that an individual with one or more known neoplasms had an earlier reportable neoplasm that had been unknown to the registry. Typically, a re-evaluation of all related sequence numbers is required whenever an additional neoplasm is identified. If a registry collects any of the state registry-defined neoplasms, the codes 60-87 should be used. Timing rules for these neoplasms are analogous to the timing rules for nationally required neoplasms.

If two or more reportable neoplasms are diagnosed at the same time, the lowest sequence number will be assigned to the diagnosis with the worst prognosis. If no difference in prognosis is evident, the decision is arbitrary.

Rationale

The purpose of sequencing based on the patient's lifetime is to truly identify the 00s or the people who only had one malignant primary in their lifetimes for survival analysis. If a central registry sequences by just what is reportable to them, then it will be unclear whether 00 means the person only had one malignant primary in his lifetime or the person had one malignant primary since the central registry started collecting data.

Codes

Nationally Required:

- 00 One primary only in the patient's lifetime
- 01 First of two or more primaries
- 02 Second of two or more primaries
- ..
- .. (Actual number of this primary)
- ..
- 35 Thirty-fifth of thirty-five or more primaries
- 99 Unspecified nationally required sequence number or unknown

State Registry-Defined:

- 60 Only one state registry-defined neoplasm
- 61 First of two or more state registry-defined neoplasms
- 62 Second of two or more state registry-defined neoplasms
- ..
- 88 Unspecified number of state registry-defined neoplasms

The table below shows which sequence number series to use by type of neoplasm.

<u>Neoplasm</u>	<u>SeqNum-Central</u>
Nationally Required (SEER and NPCR)	(Numeric Series)
<i>In Situ</i> (behavior code = 2) (Cervix CIS/CIN III, Diagnosis Year before 1996) (includes VIN III, VAIN III, AIN III)	00 - 35
Malignant (behavior code = 3)	00 - 35
Juvenile Astrocytoma, Diagnosis Year 2001+ (*)	00 - 35
Invasive following <i>In Situ</i> —New primary as defined by COC	00 - 35
Invasive following <i>In Situ</i> —New primary as defined by SEER	00 - 35

Unspecified Nationally Required Sequence Number or Unknown	99
State Registry-Defined	
<u>Examples:</u>	
Benign Brain	60 - 87
Borderline Ovarian, Diagnosis Year 2001+	60 - 87
Other Borderline/Benign	60 - 87
Skin SCC/BCC	60 - 87
PIN III	60 - 87
Cervix CIS/CIN III, Diagnosis Year 1996+	60 - 87
Unspecified State Registry-Defined Sequence Number	88

* Juvenile astrocytomas should be reported as 9421/3.

Note: See the section on Sequence Number—Central in *The SEER Program Code Manual*.

SEQUENCE NUMBER--HOSPITAL

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
Sequence Number (COC)	560	2	COC	411-412

Description

Code indicates the sequence of all reportable neoplasms over the lifetime of the patient. This item differs from the Sequence Number--Central [380] because the definitions of reportable neoplasms often vary between a hospital and a central registry. Each neoplasm is assigned a different number. Sequence Number 00 indicates that the person has only one reportable malignant neoplasm in his lifetime (regardless of hospital registry reference date). Sequence Number 01 indicates the first of two or more reportable malignant neoplasms, while 02 indicates the second of two or more reportable malignant neoplasm, and so on. Because the time period of Sequence Number is a person's lifetime, reportable neoplasms not included in the hospital registry are also allotted a sequence number. For example, a registry may contain a single record for a patient with a sequence number of 02 because the first reportable neoplasm occurred before the hospital registry's reference date.

Reporting Requirements: COC, State, and The Hospital Cancer Committee

The COC standard defining which neoplasms are reportable is described in Chapter III, Standards For Case Inclusion and Reportability; it is assumed that this standard is the "minimum" definition of reportability. In addition to the COC-required reportable neoplasms, hospital cancer registries have to meet the reporting requirements of the state cancer registry and the hospital cancer committee. These neoplasms often are called "reportable by agreement" in COC publications.

Numeric codes in the 00-35 range indicate reportable neoplasms of malignant or *in situ* behavior, which COC requires to be reported. Codes between 60 and 87 indicate other neoplasms that the state registry or the hospital cancer committee has defined as reportable. The COC-required neoplasms are sequenced completely independently of this other category.

Some examples of neoplasms that the state cancer registry or hospital cancer committee may define as reportable neoplasms include benign brain tumors, borderline ovarian tumors, squamous cell and basal cell carcinoma of the skin, prostatic intraepithelial neoplasia grade III (PIN III), or cervix carcinoma *in situ*/cervical intraepithelial neoplasia, grade III (cervix CIS/CIN III). In addition, state cancer registries require the collection

of vulvar intraepithelial neoplasia grade III (VIN III), vaginal intraepithelial neoplasia grade III (VAIN III), anal intraepithelial neoplasia grade III (AIN III), and the “Invasive following *In Situ*—New primary as defined by SEER.” These neoplasms are not required by COC (see Chapter III, Multiple Primary Rules and table at the end of this description).

The state registry/cancer committee-reportable sequence code does not affect the COC-required sequence numbers. The two notational systems are independent. For example, if a patient is assigned a sequence number of 00 for a COC-reportable neoplasm and is later diagnosed with a state registry/cancer committee-reportable neoplasm, the sequencing for the COC-required neoplasm does not change.

Timing Rule

The sequence number may change over the lifetime of the patient. Thus, an individual previously diagnosed with one reportable neoplasm may be diagnosed with a second reportable neoplasm, in which case the first neoplasm code changes from 00 to 01. A registry could also discover that an individual with one or more known neoplasms had an earlier reportable neoplasm that had been unknown to the registry. Typically, a re-evaluation of all related sequence numbers is required whenever an additional neoplasm is identified. When a registry collects any of the state registry/cancer committee reportable neoplasms, the codes 60-87 should be used. Timing rules for these neoplasms are analogous to the timing rules for the COC-required neoplasms.

If two or more reportable neoplasms are diagnosed at the same time, the lowest sequence number will be assigned to the diagnosis with the worst prognosis. If no difference in prognosis is evident, the decision is arbitrary.

Codes

COC Required:

- 00 One primary only in the patient’s lifetime
- 01 First of two or more primaries
- 02 Second of two or more primaries
- ..
- .. (Actual number of this primary)
- ..
- 35 Thirty-fifth of thirty-five primaries
- 99 Unspecified COC-required sequence number or unknown

State Registry/Cancer Committee Reportable:

- 60 Only one neoplasm required by the state or the hospital cancer committee but not by COC
- 61 First of two or more neoplasms in this category
- 62 Second of two or more neoplasms in this category
- ..
- 88 Unspecified number of neoplasms in this category

The table below shows which sequence number series to use by type of neoplasm.

<u>Neoplasm</u>	<u>SeqNum-Hospital</u>
COC Required	<u>(code range)</u>
<i>In Situ</i> (behavior code = 2) (Cervix CIS/CIN III, Diagnosis Year before 1996) (excludes VIN III, VAIN III, AIN III)	00 - 35
Invasive (behavior code = 3)	00 - 35
Juvenile Astrocytoma, Diagnosis Year 2001+ (*)	00 - 35
Invasive following <i>In Situ</i> —New primary as defined by COC	00 - 35

Unspecified <i>In Situ</i> /Invasive Sequence Number or Unknown	99
State Registry Required	
VIN III, VAIN III, AIN III	60 - 87
Invasive following <i>In Situ</i> —New primary as defined by SEER	60 - 87
<u>State Registry/Cancer Committee Reportable</u>	
<u>Examples:</u>	
Benign Brain	60 - 87
Borderline Ovarian, Diagnosis Year 2001+	60 - 87
Other Borderline/Benign	60 - 87
Skin SCC/BCC	60 - 87
Skin SCC/BCC Gr. III, Diagnosis Year 2003+	60 - 87
PIN III	60 - 87
Cervix CIS/CIN III (1996+)	60 - 87
Unspecified State Registry/Cancer Committee-Reportable SeqNumber	88

* Juvenile astrocytomas should be reported as 9421/3.

Note: See the section on Sequence Number in COC (*FORDS*) Manual.

SEX

Alternate Name	Item #	Length	Source of Standard	Column #
	220	1	SEER/COC	118-118

Description

Code for the sex of the patient.

Codes

- 1 Male
- 2 Female
- 3 Other (hermaphrodite)
- 4 Transsexual
- 9 Not stated/Unknown

SITE (73-91) ICD-O-1

Alternate Name	Item #	Length	Source of Standard	Column #
Primary Site (1973-81) (SEER)	1960	4	SEER	1137-1140

Description

Area for retaining the ICD-O-1 primary site code entered before conversion to ICD-O-2. The item name includes years 1973-91. However, some states may have used the codes for cases before 1973.

Codes

For cases diagnosed before 1992, contains the ICD-O-1 site code as originally coded, if available. Blank for cases coded directly into ICD-O-2 (i.e., 1992 and later cases).

SITE CODING SYS--CURRENT

Alternate Name	Item #	Length	Source of Standard	Column #
	450	1	NAACCR	307-307

Description

Code that best describes how the primary site currently is coded. If converted, this field shows the system to which it is converted.

Codes

- 1 ICD-8 and MOTNAC
- 2 ICD-9
- 3 ICD-O, First Edition
- 4 ICD-O, Second Edition
- 5 ICD-O, Third Edition
- 6 ICD-10
- 9 Other

Note: The note was deleted.

SITE CODING SYS--ORIGINAL

Alternate Name	Item #	Length	Source of Standard	Column #
	460	1	NAACCR	308-308

Description

Code that best describes how primary site was originally coded. If converted, this field shows the original coding system used.

Codes

- 1 ICD-8 and MOTNAC
- 2 ICD-9
- 3 ICD-O, First Edition
- 4 ICD-O, Second Edition
- 5 ICD-O, Third Edition
- 6 ICD-10
- 9 Other

SITE OF DISTANT MET 1

Alternate Name	Item #	Length	Source of Standard	Column #
Site of Distant Metastasis #1 (COC)	1090	1	COC	618-618

Description

Codes for a site of distant metastasis at initial diagnosis. There are three individual fields, each with a 1-digit code for a site of metastasis.

Codes

0	None
1	Peritoneum
2	Lung
3	Pleura
4	Liver
5	Bone
6	Central nervous system
7	Skin
8	Lymph nodes (distant)
9	Other, generalized, carcinomatosis, disseminated, not specified, unknown

Note: Beginning January 1, 2003, COC will no longer support this data item.

SITE OF DISTANT MET 2

Alternate Name	Item #	Length	Source of Standard	Column #
Site of Distant Metastasis #2 (COC)	1100	1	COC	619-619

Description

Codes for a site of distant metastasis at initial diagnosis. There are three individual fields, each with a 1-digit code for a site of metastasis.

Codes

0	None
1	Peritoneum
2	Lung
3	Pleura
4	Liver
5	Bone
6	Central nervous system
7	Skin
8	Lymph nodes (distant)
9	Other, generalized, carcinomatosis, disseminated, not specified, unknown

Note: Beginning January 1, 2003, COC will no longer support this data item.

SITE OF DISTANT MET 3

Alternate Name	Item #	Length	Source of Standard	Column #
Site of Distant Metastasis #3 (COC)	1110	1	COC	620-620

Description

Codes for a site of distant metastasis at initial diagnosis. There are three individual fields, each with a 1-digit code for a site of metastasis.

Codes

0	None
1	Peritoneum
2	Lung
3	Pleura
4	Liver
5	Bone
6	Central nervous system
7	Skin
8	Lymph nodes (distant)
9	Other, generalized, carcinomatosis, disseminated, not specified, unknown

Note: Beginning January 1, 2003, COC will no longer support this data item.

SOCIAL SECURITY NUMBER

Alternate Name	Item #	Length	Source of Standard	Column #
	2320	9	COC	2099-2107

Description

Records patient's social security number. The number is entered without dashes and without any letter suffix. This is not always identical to the Medicare claim number.

Codes (in addition to social security number)

999999999 Unknown

Note: The Patient-Confidential Section contains fields that can be used to identify the individual. This includes the patient's name and identifying numbers, and also the most specific parts of the address at diagnosis and the follow-up contact address. The other fields needed to complete the addresses are in the Demographic Section and the Follow-Up/Recurrence Section.

SPANISH/HISPANIC ORIGIN

Alternate Name	Item #	Length	Source of Standard	Column #
Spanish Origin--All Sources (96 COC)	190	1	SEER/COC	115-115
Spanish Surname or Origin (SEER)				

Description

Code identifying persons of Spanish or Hispanic origin. This code is used by hospital and central registries to show the “best guess” as to whether or not the person should be classified as Hispanic for purposes of calculating cancer rates. If the patient has multiple tumors, all records should have the same code.

All information resources should be used to determine the correct code, including:

- Stated ethnicity in the medical record
- Stated Hispanic origin on the death certificate
- Birthplace
- Information about life history and/or language spoken found during the abstracting process
- Patient’s last name (item 2230) or maiden name (item 2390) found on a list of Hispanic names.

Some registries code the information from the medical record, others code ethnicity based on Spanish names, and others use a combination of methods.

Persons of Spanish or Hispanic origin may be of any race, but these categories generally are not used for Native Americans, Filipinos, etc., who may have Spanish names. If a patient has an Hispanic name, but there is reason to believe they are not Hispanic (e.g., the patient is Filipino, or the patient is a woman known to be non-Hispanic who has a Hispanic married name), the code in this field should be 0 (non-Spanish, non-Hispanic). The code in item 200 (Computed Ethnicity), however, would reflect the Hispanic name.

Assign code 7 if Hispanic ethnicity is based strictly on a computer list or algorithm (unless contrary evidence is available) and also code in item 200 (Computed Ethnicity).

See also item 200 (Computed Ethnicity).

Note: NAACCR recognizes that available definitions and abstracting instructions for the items 2230 (Name--Last) and 2390 (Name--Maiden) may be inadequate for describing names used in some cultures, including Hispanic cultures. Explicit instructions have not been provided for entering compound names, with or without hyphens or “De.” Order of names, use of maternal and paternal names, and use of hyphens can vary across cultures. It is likely that abstracting and coding practice for these items varies across registries. For purposes of the fields Spanish/Hispanic Origin and Computed Ethnicity, “last name” means the name entered into item 2230 (Name--Last) and “maiden name” means the name entered in item 2390 (Name--Maiden). Limitations inherent in these definitions should be kept in mind when using the data.

Rationale

See the rationales for the items 160-164 (Race) and 200 (Computed Ethnicity). Ethnic origin has a significant association with cancer rates and outcomes. Hispanic populations have different patterns of occurrence of cancer from other populations that may be included in the “white” category of item 160 (Race).

Codes

- 0 Non-Spanish; non-Hispanic
- 1 Mexican (includes Chicano)
- 2 Puerto Rican
- 3 Cuban
- 4 South or Central American (except Brazil)
- 5 Other specified Spanish/Hispanic origin (includes European)
- 6 Spanish, NOS
Hispanic, NOS
Latino, NOS
There is evidence, other than surname or maiden name, that the person is Hispanic, but he/she cannot be assigned to any of the categories 1-5
- 7 Spanish surname only
The only evidence of the person's Hispanic origin is the surname or maiden name and there is no contrary evidence that the patient is not Hispanic
- 9 Unknown whether Spanish or not

Note: Code 7 was adopted for use effective with 1994 diagnosis and modified December 1994.

STATE/REQUESTOR ITEMS

Alternate Name	Item #	Length	Source of Standard	Column #
	2220	500	Varies	1447-1946

Description

Old fields, Site-Specific Studies, and State-Specific Items were combined into this area and renamed. The area also was expanded. Reserved for use by special studies, or for items defined in individual states or central registries. COC uses this area for Patient Care Evaluation Studies.

SUBSQ RX 2ND COURSE BRM

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	1675	1	COC	1001-1001

Description

Codes for the type of biological response modifier therapy given as part of the second course of treatment. The codes are the same as those for Immunotherapy, *1998 ROADS Manual*, p. 243. See also item 1500 (First Course Calc Method).

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 2ND COURSE CHEMO**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1673	1	COC	999-999

Description

Codes for the type of chemotherapy given as part of the second course of treatment. The codes are the same as those for Chemotherapy, *1998 ROADS Manual*, p. 228. See also item 1500 (First Course Calc Method).

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 2ND COURSE CODES [1670]

The name for a group of subfields that describe the second course or set of subsequent therapy. Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

Subfields

Subsq RX 2nd Course Surg [1671]
 Subsq RX 2nd Course Rad [1672]
 Subsq RX 2nd Course Chemo [1673]
 Subsq RX 2nd Course Horm [1674]
 Subsq RX 2nd Course BRM [1675]
 Subsq RX 2nd Course Oth [1676]

Note: Group names appear only in the data dictionary and Appendix E.

SUBSQ RX 2ND COURSE DATE

Alternate Name	Item #	Length	Source of Standard	Column #
Second Course of Therapy-Date Started (pre-96 COC)	1660	8	COC	988-995

Description

Date of initiation of second-course treatment.

Codes (in addition to valid dates)

00000000 No subsequent therapy
 99999999 Unknown if any subsequent therapy

SUBSQ RX 2ND COURSE HORM**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1674	1	COC	1000-1000

Description

Codes for the type of hormonal therapy given as part of the second course of treatment. The codes are the same as those for Hormone Therapy, *1998 ROADS Manual*, p. 238. See also item 1500 (First Course Calc Method).

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 2ND COURSE OTH**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1676	1	COC	1002-1002

Description

Codes for the type of other treatment given as part of the second course of treatment. The codes are the same as those for Other Treatment, *1998 ROADS Manual*, p. 246. See also item 1500 (First Course Calc Method).

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 2ND COURSE RAD**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1672	1	COC	998-998

Description

Codes for the type of radiation given as part of the second course of treatment. The codes are the same as those for Radiation, *1998 ROADS Manual*, p. 199. See also item 1500 (First Course Calc Method).

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 2ND COURSE SURG**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1671	2	COC	996-997

Description

Codes for the type of primary site surgery given as part of the second course of treatment. The codes are the same as those for Surgery of Primary Site, *1998 ROADS Manual*, p. 187. See also item 1500 (First Course Calc Method).

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 2ND--REG LN REM**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1679	2	COC	1050-1051

Description

Codes for the number of regional lymph nodes removed as part of the second course of treatment. The codes are the same as those for Number of Regional Lymph Nodes Removed, *1998 ROADS Manual*, p. 193. See also item 1500 (First Course Calc Method).

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 2ND--SCOPE LN SU**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1677	1	COC	1048-1048

Description

Codes for the type of surgery performed to remove regional lymph nodes as part of the second course of treatment. The codes are the same as those for Scope of Regional Lymph Node Surgery, *1998 ROADS Manual*, p. 192. See also item 1500 (First Course Calc Method).

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 2ND--SURG OTH

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	1678	1	COC	1049-1049

Description

Codes for the type of surgery performed on tissue or organs other than the primary site and regional lymph nodes as part of the second course of treatment. The codes are the same as those for Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Node(s), *1998 ROADS Manual*, p. 194. See also item 1500 (First Course Calc Method).

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 3RD COURSE BRM

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	1695	1	COC	1016-1016

Description

Codes for the type of biological response modifier therapy given as part of the second course of treatment. The codes are the same as those for Immunotherapy, *1998 ROADS Manual*, p. 243

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 3RD COURSE CHEMO

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	1693	1	COC	1014-1014

Description

Codes for the type of chemotherapy given as part of the third course of treatment. The codes are the same as those for Chemotherapy, *1998 ROADS Manual*, p. 228.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 3RD COURSE CODES [1690]

The name for a group of subfields that describe the third course or set of subsequent therapy. Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

Subfields

Subsq RX 3rd Course Surg [1691]
Subsq RX 3rd Course Rad [1692]
Subsq RX 3rd Course Chemo [1693]
Subsq RX 3rd Course Horm [1694]
Subsq RX 3rd Course BRM [1695]
Subsq RX 3rd Course Oth [1696]

Note: Group names appear only in the data dictionary and Appendix E .

SUBSQ RX 3RD COURSE DATE

Alternate Name	Item #	Length	Source of Standard	Column #
	1680	8	COC	1003-1010

Description

Date of initiation of third course of treatment.

Codes (in addition to valid dates)

00000000 No subsequent therapy
99999999 Unknown if any subsequent therapy

SUBSQ RX 3RD COURSE HORM

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	1694	1	COC	1015-1015

Description

Codes for the type of hormonal therapy given as part of the third course of treatment. The codes are the same as those for Hormone Therapy, *1998 ROADS Manual*, p. 238.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 3RD COURSE OTH**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1696	1	COC	1017-1017

Description

Codes for the type of other treatment given as part of the third course of treatment. The codes are the same as those for Other Treatment, *1998 ROADS Manual*, p. 246.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 3RD COURSE RAD**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1692	1	COC	1013-1013

Description

Codes for the type of radiation given as part of the third course of treatment. The codes are the same as those for Radiation, *1998 ROADS Manual*, p. 1999.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 3RD COURSE SURG**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1691	2	COC	1011-1012

Description

Codes for the type of primary site surgery given as part of the third course of treatment. The codes are the same as those for Surgery of Primary Site, *1998 ROADS Manual*, p. 187.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 3RD--REG LN REM**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1699	2	COC	1054-1055

Description

Codes for the number of regional lymph nodes removed as part of the third course of treatment. The codes are the same as those for Number of Regional Lymph Nodes Removed, *1998 ROADS Manual*, p. 193.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 3RD--SCOPE LN SU**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1697	1	COC	1052-1052

Description

Codes for the type of surgery performed to remove regional lymph nodes as part of the third course of treatment. The codes are the same as those for Scope of Regional Lymph Node Surgery, *1998 ROADS Manual*, p. 192.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 3RD--SURG OTH**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1698	1	COC	1053-1053

Description

Codes for the type of surgery performed on tissue or organs other than the primary site and regional lymph nodes as part of the third course of treatment. The codes are the same as those for Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Node(s), *1998 ROADS Manual*, p. 194.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 4TH COURSE BRM**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1715	1	COC	1031-1031

Description

Codes for the type of biological response modifier therapy given as part of the second course of treatment. The codes are the same as those for Immunotherapy, *1998 ROADS Manual*, p. 243.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 4TH COURSE CHEMO**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1713	1	COC	1029-1029

Description

Codes for the type of chemotherapy given as part of the fourth course of treatment. The codes are the same as those for Chemotherapy, *1998 ROADS Manual*, p. 228.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 4TH COURSE CODES [1710]

The name for a group of subfields that describe the fourth course or set of subsequent therapy. Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

Subfields

Subsq RX 4th Course Surg [1711]
Subsq RX 4th Course Rad [1712]
Subsq RX 4th Course Chemo [1713]
Subsq RX 4th Course Horm [1714]
Subsq RX 4th Course BRM [1715]
Subsq RX 4th Course Oth [1716]

Note: Group names appear only in the data dictionary and Appendix E.

SUBSQ RX 4TH COURSE DATE

Alternate Name	Item #	Length	Source of Standard	Column #
	1700	8	COC	1018-1025

Description

Date of initiation of the fourth course of treatment.

Codes (in addition to valid dates)

00000000 No subsequent therapy
99999999 Unknown if any subsequent therapy

SUBSQ RX 4TH COURSE HORM

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	1714	1	COC	1030-1030

Description

Codes for the type of hormonal therapy given as part of the fourth course of treatment. The codes are the same as those for Hormone Therapy, *1998 ROADS Manual*, p. 238.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 4TH COURSE OTH**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1716	1	COC	1032-1032

Description

Codes for the type of other treatment given as part of the fourth course of treatment. The codes are the same as those for Other Treatment, *1998 ROADS Manual*, p. 246.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 4TH COURSE RAD**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1712	1	COC	1028-1028

Description

Codes for the type of radiation given as part of the fourth course of treatment. The codes are the same as those for Radiation, *1998 ROADS Manual*, p. 199.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 4TH COURSE SURG**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1711	2	COC	1026-1027

Description

Codes for the type of primary site surgery given as part of the fourth course of treatment. The codes are the same as those for Surgery of Primary Site, *1998 ROADS Manual*, p. 187.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 4TH--REG LN REM**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1719	2	COC	1058-1059

Description

Codes for the number of regional lymph nodes removed as part of the fourth course of treatment. The codes are the same as those for Number of Regional Lymph Nodes Removed, *1998 ROADS Manual*, p. 193.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 4TH--SCOPE LN SU**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1717	1	COC	1056-1056

Description

Codes for the type of surgery performed to remove regional lymph nodes as part of the fourth course of treatment. The codes are the same as those for Scope of Regional Lymph Node Surgery, *1998 ROADS Manual*, p. 192.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 4TH--SURG OTH**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1718	1	COC	1057-1057

Description

Codes for the type of surgery performed on tissue or organs other than the primary site and regional lymph nodes as part of the fourth course of treatment. The codes are the same as those for Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Node(s), *1998 ROADS Manual*, p. 194.

Note: Beginning January 1, 2003, COC will no longer support Subsequent Therapy data items.

SUBSQ RX 5TH COURSE BRM**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1735	1	NAACCR	1046-1046

Description

Codes for the type of biological response modifier therapy given as part of the second course of treatment. The codes are the same as those for Immunotherapy, *1998 ROADS Manual*, p. 243.

Note: The COC *ROADS Manual* does not include fifth course of treatment.

SUBSQ RX 5TH COURSE CHEMO**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1733	1	NAACCR	1044-1044

Description

Codes for the type of chemotherapy given as part of the fifth course of treatment. The codes are the same as those for Chemotherapy, *1998 ROADS Manual*, p. 228.

Note: The COC *ROADS Manual* does not include fifth course of treatment.

SUBSQ RX 5TH COURSE CODES [1730]

The name for a group of subfields that describe the fifth course or set of subsequent therapy.

Subfields

Subsq RX 5th Course Surg [1731]
Subsq RX 5th Course Rad [1732]
Subsq RX 5th Course Chemo [1733]
Subsq RX 5th Course Horm [1734]
Subsq RX 5th Course BRM [1735]
Subsq RX 5th Course Oth [1736]

Note: Group names appear only in the data dictionary and Appendix E.

SUBSQ RX 5TH COURSE DATE

Alternate Name	Item #	Length	Source of Standard	Column #
	1720	8	NAACCR	1033-1040

Description

Date of initiation of fifth course of treatment.

The COC *ROADS Manual* does not include fifth course of treatment.

Codes (in addition to valid dates)

00000000 No subsequent therapy
99999999 Unknown if any subsequent therapy

SUBSQ RX 5TH COURSE HORM

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	1734	1	NAACCR	1045-1045

Description

Codes for the type of hormonal therapy given as part of the fifth course of treatment. The codes are the same as those for Hormone Therapy, 1998 *ROADS Manual*, p. 238

The COC *ROADS Manual* does not include fifth course of treatment.

SUBSQ RX 5TH COURSE OTH**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1736	1	NAACCR	1047-1047

Description

Codes for the type of other treatment given as part of the fifth course of treatment. The codes are the same as those for Other Treatment, *1998 ROADS Manual*, p. 246.

The COC *ROADS Manual* does not include fifth course of treatment.

SUBSQ RX 5TH COURSE RAD**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1732	1	NAACCR	1043-1043

Description

Codes for the type of radiation therapy given as part of the fifth course of treatment. The codes are the same as those for Radiation, *1998 ROADS Manual*, p. 199.

The COC *ROADS Manual* does not include fifth course of treatment.

SUBSQ RX 5TH COURSE SURG**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1731	2	NAACCR	1041-1042

Description

Codes for the type of primary site surgery given as part of the fifth course of treatment. The codes are the same as those for Surgery of Primary Site, *1998 ROADS Manual* p. 187.

The COC *ROADS Manual* does not include fifth course of treatment.

SUBSQ RX 5TH--REG LN REM**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1739	2	NAACCR	1062-1063

Description

Codes for the number of regional lymph nodes removed as part of the fifth course of treatment. The codes are the same as those for Number of Regional Lymph Nodes Removed, *1998 ROADS Manual*, p. 193.

The COC *ROADS Manual* does not include fifth course of treatment.

SUBSQ RX 5TH--SCOPE LN SU**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1737	1	NAACCR	1060-1060

Description

Codes for the type of surgery performed to remove regional lymph nodes as part of the fifth course of treatment. The codes are the same as those for Scope of Regional Lymph Node Surgery, *1998 ROADS Manual*, p. 192.

The COC *ROADS Manual* does not include fifth course of treatment.

SUBSQ RX 5TH--SURG OTH**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1738	1	NAACCR	1061-1061

Description

Codes for the type of surgery performed on tissue or organs other than the primary site and regional lymph nodes as part of the fifth course of treatment. The codes are the same as those for Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Node(s), *1998 ROADS Manual*, p. 194.

The COC *ROADS Manual* does not include fifth course of treatment.

SUBSQ REPORT FOR PRIMARY

Alternate Name	Item #	Length	Source of Standard	Column #
Item deleted, Item number retired	2160	0	NAACCR	

SUBSQ RX--RECONSTRUCT DEL

Alternate Name	Item #	Length	Source of Standard	Column #
Reconstruction/Restoration--Delayed (COC)	1741	1	COC	1064-1064

Description

Code for surgical procedure done to reconstruct, restore, or improve shape and appearance or function of body structures that are missing, defective, damaged, or misshapen by cancer or cancer-directed therapies. Reconstructive/restorative procedures are coded here when started after the first course of cancer-directed therapy. For reconstructive/restorative procedures started during the first course of therapy, see item 1330 (RX Summ--Reconstruct 1st). See also item 1640 (RX Summ--Surgery Type).

Codes

See the COC *ROADS Manual*, 1998 Supplement, for site-specific codes.

Note: Beginning January 1, 2003, COC will no longer support this data item.

TELEPHONE

Alternate Name	Item #	Length	Source of Standard	Column #
	2360	10	COC	2268-2277

Description

Current telephone number with area code for the patient. Number is entered without dashes.

Codes (in addition to valid telephone number)

0000000000 Patient does not have a telephone
9999999999 Telephone number unavailable or unknown

Note: The Patient-Confidential Section contains fields that can be used to identify the individual. This includes the patient's name and identifying numbers, and also the most specific parts of the address at diagnosis and the follow-up contact address. The other fields needed to complete the addresses are in the Demographic Section and the Follow-Up/Recurrence Section.

Note: Prior to Version 5, Follow-Up Contact fields may have been used for patient current telephone in the NAACCR record layout.

TEXT--DX PROC--LAB TESTS

Alternate Name	Item #	Length	Source of Standard	Column #
	2550	250	NAACCR	3345-3594

Description

Text area for information from laboratory examinations other than cytology or histopathology.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

TEXT--DX PROC--OP

Alternate Name	Item #	Length	Source of Standard	Column #
	2560	250	NAACCR	3595-3844

Description

Text area for information from operative reports.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

TEXT--DX PROC--PATH

Alternate Name	Item #	Length	Source of Standard	Column #
	2570	250	NAACCR	3845-4094

Description

Text area for information from cytology and histopathology reports.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

TEXT--DX PROC--PE

Alternate Name	Item #	Length	Source of Standard	Column #
	2520	200	NAACCR	2645-2844

Description

Text area for information from history and physical examinations.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

TEXT--DX PROC--SCOPES

Alternate Name	Item #	Length	Source of Standard	Column #
	2540	250	NAACCR	3095-3344

Description

Text area for information from endoscopic examinations.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

TEXT--DX PROC--X-RAY/SCAN

Alternate Name	Item #	Length	Source of Standard	Column #
	2530	250	NAACCR	2845-3094

Description

Text area for information from diagnostic imaging reports.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, the NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

TEXT--HISTOLOGY TITLE

Alternate Name	Item #	Length	Source of Standard	Column #
	2590	40	NAACCR	4135-4174

Description

Text area for information of histologic type, behavior, and grade in natural language.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

TEXT--PRIMARY SITE TITLE

Alternate Name	Item #	Length	Source of Standard	Column #
	2580	40	NAACCR	4095-4134

Description

Text area for information of primary site in natural language.

Rationale

Text is needed to justify the codes selected for the data items and to allow recording information that is not coded at all. It is a component of a complete electronic abstract, and allows for the full abstract to be printed or reviewed on the screen as needed. The text is used for quality control and special studies. As the purpose of text information is to provide an opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should not be generated electronically from coded values.

Note: For systems that allow unlimited text, NAACCR recommends that it be indicated to abstractors in reporting facilities how much of the text will be transmitted in a data exchange record so that they can prioritize data entry to ensure that the most important information is sent to the central registry.

TEXT--REMARKS

Alternate Name	Item #	Length	Source of Standard	Column #
	2680	350	NAACCR	5525-5874

Description

Text area for information not elsewhere provided for and for overflow from other text areas.

TEXT--STAGING

Alternate Name	Item #	Length	Source of Standard	Column #
	2600	300	NAACCR	4175-4474

Description

Additional text area for staging information not already entered in the Text--DX Proc areas.

TEXT--USUAL INDUSTRY**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	320	40	NPCR	183-222

Description

Text area for information about the patient's usual industry, also known as usual kind of business/industry.

Rationale

Used to identify new work-related health hazards; serves as an additional measure of socioeconomic status; identifies industrial groups or worksite-related groups in which cancer screening or prevention activities may be beneficial.

The data item "usual industry" is defined identically as on death certificates and conforms to the 1989 revision of the U.S. Standard Certificate of Death.²⁵ See related materials in reference list, Chapter VII.

Abstracting Instructions

Record the primary type of activity carried on by the business/industry at the location where the patient was employed for the most number of years before diagnosis of this tumor. Be sure to distinguish among "manufacturing," "wholesale," "retail," and "service" components of an industry that performs more than one of these components.

If the primary activity carried on at the location where the patient worked is unknown, it may be sufficient for facility registrars to record the name of the company (with city or town) in which the patient performed his/her usual industry. In these situations, if resources permit, a central or regional registry may be able to use the employer name and city/town to determine the type of activity conducted at that location.

As noted in the Text--Usual Occupation [310] section, in those situations where the usual occupation is not available or is unknown, the patient's current or most recent occupation is recorded, if available. The information for industry should be based upon the information in occupation. Therefore, if current or most recent occupation rather than usual occupation was recorded, record the patient's current or most recent business/industry.

If later documentation in the patient's record provides an industry that is more likely to be the usual industry than what was originally recorded, facility registrars are encouraged to update the case abstract with the new information. However, it is **not** the responsibility of the facility registrars to update abstracts with industry information provided on death certificates. Comparison with death certificate information should be the function of a central or regional registry.

There should be an entry for Text--Usual Industry if any occupation is recorded. If no information is available regarding the industry in which the reported occupation was carried out, record "unknown." If the patient was not a student or housewife and had never worked, record "never worked" as the usual industry. This data item usually is collected only for patients who are age 14 years or older at the time of diagnosis.

TEXT--USUAL OCCUPATION

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
	310	40	NPCR	143-182

Description

Text area for information about the patient's usual occupation, also known as usual type of job or work.

Rationale

Used to identify new work-related health hazards; serves as an additional measure of socioeconomic status; identifies occupational groups in which cancer screening or prevention activities may be beneficial.

The data item "usual occupation" is defined identically as on death certificates and conforms to the 1989 revision of the U.S. Standard Certificate of Death.²⁵ See related materials in reference list, Chapter VII.

Abstracting Instructions

Record the patient's usual occupation (i.e., the kind of work performed during most of the patient's working life before diagnosis of this tumor). Do **not** record "retired." If usual occupation is not available or is unknown, record the patient's current or most recent occupation, or any available occupation.

If later documentation in the patient's record provides an occupation that is more likely to be the usual occupation than what was originally recorded, facility registrars are encouraged to update the case abstract with the new information. However, it is **not** the responsibility of the facility registrars to update abstracts with occupation information provided on death certificates. Comparison with death certificate information should be the function of a central or regional registry.

If the patient was a househusband/housewife and also worked outside the home during most of his/her adult life, record the usual occupation outside the home; if the patient was a househusband/housewife and did not work outside the home for most of his/her adult life, record "househusband" or "housewife." If the patient was not a student or housewife and had never worked, record "never worked" as the usual occupation.

If no information is available, record "unknown."

This data item usually is collected only for patients who are age 14 years or older at the time of diagnosis.

TNM CLIN DESCRIPTOR

Alternate Name	Item #	Length	Source of Standard	Column #
Clinical Stage (Prefix/Suffix) Descriptor (COC)	980	1	COC	581-581

Description

Identifies the AJCC clinical stage (prefix/suffix) descriptor as recorded by the physician. AJCC stage descriptors identify special cases that need separate data analysis. The descriptors are adjuncts to and do not change the stage group.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout. COC defines a descriptor and “Staged By” item for each of these three areas.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes

- 0 None
- 1 E (Extranodal, lymphomas only)
- 2 S (Spleen, lymphomas only)
- 3 M (Multiple primary tumors in a single site)
- 4 Y (Classification during or after initial multimodality therapy)—pathologic staging only
- 5 E & S (Extranodal and spleen)
- 6 M & Y (Multiple primary tumors and initial multimodality therapy)
- 9 Unknown

TNM CLIN M**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Clinical M (COC)	960	2	AJCC	577-578

Description

Detailed site-specific codes for the clinical metastases (M) as defined by AJCC and recorded by the physician.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the *AJCC Cancer Staging Manual*)

88 Not applicable

This field can be left blank if a physician did not record the stage element.

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific categories for the TNM elements and stage groups. See the *FORDS Manual* for specifications for codes and data entry rules.

TNM CLIN N**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Clinical N (COC)	950	2	AJCC	575-576

Description

Detailed site-specific codes for the clinical nodes (N) as defined by AJCC and recorded by the physician.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the *AJCC Cancer Staging Manual*)

88 Not applicable

This field can be left blank if a physician did not record the stage element.

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific categories for the TNM elements and stage groups. See the *FORDS Manual* for specifications for codes and data entry rules.

TNM CLIN STAGE GROUP

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
Clinical Stage Group (COC)	970	2	AJCC	579-580

Description

Detailed site-specific codes for the clinical stage group as defined by AJCC and recorded by the physician.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the *AJCC Cancer Staging Manual*)

- 88 Not applicable
- 99 Unknown, not staged

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific categories for the TNM elements and stage groups. See the *FORDS Manual* for specifications for codes and data entry rules.

TNM CLIN STAGED BY**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Staged By (Clinical Stage) (COC)	990	1	COC	582-582

Description

Identifies the person who recorded the clinical AJCC staging elements and the stage group in the patient's medical record.

Rationale

Data captured in this field can be used to evaluate the accuracy and completeness of physician staging and form the basis for quality management and improvement studies. This item is used to monitor compliance with the COC Staging Standard. The medical record contains the AJCC stage assigned/initialed by the managing physician.

Instructions for Coding:

Record the person who documented the AJCC staging elements and the stage group in the medical record. The staging elements (T, N, M) and the stage group must be recorded. The managing physician must stage all analytic cases in the medical record. A pathologist may contribute to staging by recording the appropriate T and/or N elements following evaluation of a resected specimen. The managing physician, however, must record the M element and stage group.

Codes

- 0 Not staged. Staging was not assigned.
- 1 Managing physician. The managing physician assigned staging.
- 2 Pathologist. Staging was assigned by the pathologist only.
- 3 Pathologist and managing physician. The pathologist and the managing physician assigned staging.
- 4 Cancer Committee chair, cancer liaison physician, or registry physician advisor. The Cancer Committee chair, cancer liaison physician, or the registry physician advisor assigned staging during a quality control review.
- 5 Cancer registrar. Staging was assigned by the cancer registrar only.
- 6 Cancer registrar and physician. Staging was assigned by the cancer registrar and any of the physicians specified in 1-4.
- 7 Staging assigned at another facility. A physician at another facility assigned staging.
- 8 Case is not eligible for staging. An AJCC staging scheme has not been developed for this site. The histology is excluded from the AJCC scheme.
- 9 Unknown; not stated in patient record. It is unknown whether or not the case was staged.

TNM CLIN T**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Clinical T (COC)	940	2	AJCC	573-574

Description

Detailed site-specific codes for the clinical tumor (T) as defined by AJCC and recorded by the physician.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the *AJCC Cancer Staging Manual*)

88 Not applicable

This field can be left blank if a physician did not record the stage element.

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific categories for the TNM elements and stage groups. See the *FORDS Manual* for specifications for codes and data entry rules.

TNM EDITION NUMBER**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	1060	2	COC	593-594

Description

A code that indicates the edition of the AJCC manual used to stage the case. This applies to the manually coded AJCC fields. It does not apply to the Derived AJCC T, N, M and AJCC Stage Group fields (items 2940, 2960, 2980, and 3000).

Rationale

TNM codes have changed over time and conversion is not always simple. Therefore, a case-specific indicator is needed to allow grouping of cases for comparison.

Codes

00 Not staged (cases that have AJCC staging scheme and staging was not done)
 03 First Edition
 02 Second Edition Second Edition (published 1983)
 03 Third Edition (published 1988)
 04 Fourth Edition (published 1992), recommended for use for cases diagnosed 1993-1997
 05 Fifth Edition (published 1997), recommended for use for cases diagnosed 1998-2002
 06 Sixth Edition (published 2002), recommended for use for cases diagnosed 2003+
 88 Not applicable (cases that do not have an AJCC staging scheme)
 99 Edition Unknown

TNM OTHER DESCRIPTOR

Alternate Name	Item #	Length	Source of Standard	Column #
Other Stage (Prefix/Suffix) Descriptor (COC)	1050	1	COC	592-592

Description

AJCC stage descriptors identify special cases that need separate data analysis. The descriptors are adjuncts to and do not change the stage group.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout. COC defines a descriptor and “Staged By” item for each of these three areas.

The “other” TNM components and Stage group allow collection of retreatment staging. They also may be used for historic data such as the surgical TNM and stage group items. The “other” categories may be used for converted data if the staging basis is not identified.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes

- 0 None
- 1 E (Extranodal, lymphomas only)
- 2 S (Spleen, lymphomas only)
- 3 M (Multiple primary tumors in a single site)
- 4 Y (Classification during or after initial multimodality therapy)
- 5 E & S (Extranodal and spleen)
- 6 M & Y (Multiple primary tumors and initial multimodality therapy)
- 9 Unknown

| *Note:* Beginning January 1, 2003, COC will no longer support this data item.

TNM OTHER M

Alternate Name	Item #	Length	Source of Standard	Column #
Other M (COC)	1020	2	AJCC	587-588

Description

Detailed site-specific codes for the other metastases (M) as defined by AJCC.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout.

The “other” TNM components and Stage group allow collection of retreatment staging. They also may be used for historic data such as the surgical TNM and stage group items. The “other” categories may be used for converted data if the staging basis is not identified.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the *AJCC Cancer Staging Manual*)

88 Not applicable

Note: See the *AJCC Cancer Staging Manual*, Fifth Edition for site-specific categories for the TNM elements and stage groups. See the *ROADS Manual*, 1998 Supplement, for specifications for codes and data entry rules.

Note: Beginning January 1, 2003, COC will no longer support this data item.

TNM OTHER N

Alternate Name	Item #	Length	Source of Standard	Column #
Other N (COC)	1010	2	AJCC	585-586

Description

Detailed site-specific codes for the other nodes (N) as defined by AJCC.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout.

The “other” TNM components and Stage group allow collection of retreatment staging. They also may be used for historic data such as the surgical TNM and stage group items. The “other” categories may be used for converted data if the staging basis is not identified.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the *AJCC Cancer Staging Manual*)

88 Not applicable

Note: See the *AJCC Cancer Staging Manual*, Fifth Edition for site-specific categories for the TNM elements and stage groups. See the *ROADS Manual*, 1998 Supplement, for specifications for codes and data entry rules.

| *Note:* Beginning January 1, 2003, COC will no longer support this data item.

TNM OTHER STAGE GROUP

Alternate Name	Item #	Length	Source of Standard	Column #
Other Stage Group (COC)	1030	2	AJCC	589-590

Description

Detailed site-specific codes for the other stage group as defined by AJCC.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout.

The “other” TNM components and Stage group allow collection of retreatment staging. They also may be used for historic data such as the surgical TNM and stage group items. The “other” categories may be used for converted data if the staging basis is not identified.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the *AJCC Cancer Staging Manual*)

88 Not applicable

99 Unknown, not staged

Note: See the *AJCC Cancer Staging Manual*, Fifth Edition for site-specific categories for the TNM elements and stage groups. See the *ROADS Manual*, 1998 Supplement, for specifications for codes and data entry rules.

Note: Beginning January 1, 2003, COC will no longer support this data item.

TNM OTHER STAGED BY

Alternate Name	Item #	Length	Source of Standard	Column #
Staged By (Other Stage) (COC)	1040	1	COC	591-591

Description

AJCC “Staged By” fields identify the person who documented the AJCC staging elements and stage group. COC requires analytic cases to be staged by the managing physician.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout. COC defines a descriptor and “Staged By” item for each of these three areas.

The “other” TNM components and Stage group allow collection of retreatment staging. They also may be used for historic data such as the surgical TNM and stage group items. The “other” categories may be used for converted data if the staging basis is not identified.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes

0	Not staged
1	Managing physician
2	Pathologist
3	Other physician
4	Any combination of 1, 2, or 3
5	Registrar
6	Any combination of 5 with 1, 2, or 3
7	Other
8	Staged, individual not specified
9	Unknown if staged

| *Note:* Beginning January 1, 2003, COC will no longer support this data item.

TNM OTHER T

Alternate Name	Item #	Length	Source of Standard	Column #
Other T (COC)	1000	2	AJCC	583-584

Description

Detailed site-specific codes for the other tumor (T) as defined by AJCC.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout.

The “other” TNM components and Stage group allow collection of retreatment staging. They also may be used for historic data such as the surgical TNM and stage group items. The “other” categories may be used for converted data if the staging basis is not identified.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the *AJCC Cancer Staging Manual*)

88 Not applicable

Note: See the *AJCC Cancer Staging Manual*, Fifth Edition for site-specific categories for the TNM elements and stage groups. See the *ROADS Manual*, 1998 Supplement, for specifications for codes and data entry rules.

Note: Beginning January 1, 2003, COC will no longer support this data item. |

TNM PATH DESCRIPTOR

Alternate Name	Item #	Length	Source of Standard	Column #
Pathologic Stage (Prefix/Suffix) Descriptor (COC)	920	1	AJCC	571-571

Description

Identified the AJCC clinical stage (prefix/suffix) descriptor as recorded by the physician. AJCC stage descriptors identify special cases that need separate data analysis. The descriptors are adjuncts to and do not change the stage group.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout. COC defines a descriptor and “Staged By” item for each of these three areas.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes

- 0 None
- 1 E (Extranodal, lymphomas only)
- 2 S (Spleen, lymphomas only)
- 3 M (Multiple primary tumors in a single site)
- 4 Y (Classification during or after initial multimodality therapy)—pathologic staging only
- 5 E & S (Extranodal and spleen)
- 6 M & Y (Multiple primary tumors and initial multimodality therapy)
- 9 Unknown

TNM PATH M**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Pathologic M (COC)	900	2	AJCC	567-568

Description

Detailed site-specific codes for the pathologic metastases (M) as defined by AJCC and recorded by the physician.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the *AJCC Cancer Staging Manual*)

88 Not applicable

This field can be left blank if a physician did not record the stage element.

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific categories for the TNM elements and stage groups. See the *FORDS Manual* for specifications for codes and data entry rules.

TNM PATH N**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Pathologic N (COC)	890	2	AJCC	565-566

Description

Detailed site-specific codes for the pathologic nodes (N) as defined by AJCC and recorded by physician.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the *AJCC Cancer Staging Manual*)

88 Not applicable

This field can be left blank if a physician did not record the stage element.

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific categories for the TNM elements and stage groups. See the *FORDS Manual* for specifications for codes and data entry rules.

TNM PATH STAGE GROUP**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Pathologic Stage Group (COC)	910	2	AJCC	569-570

Description

Detailed site-specific codes for the pathologic stage group as defined by AJCC and recorded by the physician.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the *AJCC Cancer Staging Manual*)

88 Not applicable

99 Unknown, unstaged

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific categories for the TNM elements and stage groups. See the *FORDS Manual* for specifications for codes and data entry rules.

TNM PATH STAGED BY

(Revised)

Alternate Name	Item #	Length	Source of Standard	Column #
Staged By (Pathologic Stage) (COC)	930	1	COC	572-572

Description

Identifies the person who recorded the pathologic AJCC staging elements and the stage group in the patient's medical record.

Rationale

Data captured in this field can be used to evaluate the accuracy and completeness of physician staging and form the basis for quality management and improvement studies. This item is used to monitor compliance with the COC Staging Standard. The medical record contains the AJCC stage assigned/initialed by the managing physician.

Instructions for Coding

Record the person who documented the AJCC staging elements and the stage group in the medical record. The staging elements (T, N, M) and the stage group must be recorded. The managing physician must stage all analytic cases in the medical record. A pathologist may contribute to staging by recording the appropriate T and/or N elements following evaluation of a resected specimen. The managing physician, however, must record the M element and stage group.

Codes

- 0 Not staged. Staging was not assigned.
- 1 Managing physician. The managing physician assigned staging.
- 2 Pathologist. Staging was assigned by the pathologist only.
- 3 Pathologist and managing physician. The pathologist and the managing physician assigned staging.
- 4 Cancer Committee chair, cancer liaison physician, or registry physician advisor. The Cancer Committee chair, cancer liaison physician, or the registry physician advisor assigned staging during a quality control review.
- 5 Cancer registrar. Staging was assigned by the cancer registrar only.
- 6 Cancer registrar and physician. Staging was assigned by the cancer registrar and any of the physicians specified in 1-4.
- 7 Staging assigned at another facility. A physician at another facility assigned staging.
- 8 Case is not eligible for staging. An AJCC staging scheme has not been developed for this site. The histology is excluded from the AJCC scheme.
- 9 Unknown; not stated in patient record. It is unknown whether or not the case was staged.

TNM PATH T**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
Pathologic T (COC)	880	2	AJCC	563-564

Description

Detailed site-specific codes for the pathologic tumor (T) as defined by AJCC and recorded by the physician.

Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout.

Rationale

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the *AJCC Cancer Staging Manual*)

88 Not applicable

This field can be left blank if a physician did not record the stage element.

Note: See the *AJCC Cancer Staging Manual*, current edition for site-specific categories for the TNM elements and stage groups. See the *FORDS Manual* for specifications for codes and data entry rules.

TOBACCO HISTORY

Alternate Name	Item #	Length	Source of Standard	Column #
	340	1	Varies	224-224

Description

NAACCR has not adopted standards for this item.

TUMOR MARKER 1

Alternate Name	Item #	Length	Source of Standard	Column #
Tumor Marker One (COC)	1150	1	SEER/COC	626-626

Description

Records prognostic indicators for specific sites or histologies. COC uses these codes for cases diagnosed 1996 and forward. See the COC *ROADS Manual*, 1998 Supplement, for a list of specific sites and histologies. For cases diagnosed before January 1, 1996, Tumor Marker 1 is coded only for estrogen receptor status of breast cancers.

For SEER requirements for the specific sites, histologies, and diagnosis years for which this item is coded, see the 1998 *SEER Program Code Manual*.

Codes

- 0 None done (SX)
- 1 Positive/elevated
- 2 Negative/normal; within normal limits (S0)
- 3 Borderline; undetermined whether positive/elevated or negative/normal

Three-tiered system:

- 4 Range 1 (S1)
- 5 Range 2 (S2)
- 6 Range 3 (S3)
- 8 Ordered, but results not in chart
- 9 Unknown or no information

For sites for which Tumor Marker 1 is not collected:

- 9 Not applicable

Note: Beginning January 1, 2003, COC will no longer support this data item.

TUMOR MARKER 2

Alternate Name	Item #	Length	Source of Standard	Column #
Tumor Marker Two (COC)	1160	1	SEER/COC	627-627

Description

Records prognostic indicators for specific sites or histologies. COC uses these codes for cases diagnosed 1996 and forward. See the COC *ROADS Manual*, 1998 Supplement, for a list of specific sites and histologies. For cases diagnosed before January 1, 1996, Tumor Marker 2 is coded only for progesterone receptor status of breast cancers.

For SEER requirements for the specific sites, histologies, and diagnosis years for which this item is coded, see the 1998 *SEER Program Code Manual*.

Codes

- 0 None done (SX)
- 1 Positive/elevated
- 2 Negative/normal; within normal limits (S0)
- 3 Borderline; undetermined whether positive/elevated or negative/normal

Three-tiered system:

- 4 Range 1 (S1)
- 5 Range 2 (S2)
- 6 Range 3 (S3)

- 8 Ordered, but results not in chart
- 9 Unknown or no information

For sites for which Tumor Marker 2 is not collected:

- 9 Not applicable

| *Note:* Beginning January 1, 2003, COC will no longer support this data item.

TUMOR MARKER 3

Alternate Name	Item #	Length	Source of Standard	Column #
Tumor Marker Three (COC)	1170	1	SEER/COC	628-628

Description

Records prognostic indicators for specific sites or histologies. COC uses these codes for cases diagnosed 1998 and forward. See the COC *ROADS Manual*, 1998 Supplement, for a list of specific sites and histologies.

For SEER requirements for the specific sites, histologies, and diagnosis years for which this item is coded, see the 1998 *SEER Program Code Manual*.

Codes

- 0 None done (SX)
- 1 Positive/elevated
- 2 Negative/normal; within normal limits (S0)
- 3 Borderline; undetermined whether positive/elevated or negative/normal

Three-Tiered System:

- 4 Range 1 (S1)
- 5 Range 2 (S2)
- 6 Range 3 (S3)
- 8 Ordered, but results not in chart
- 9 Unknown or no information

For sites for which Tumor Marker 3 is not collected:

- 9 Not applicable

Note: Beginning January 1, 2003, COC will no longer support this data item.

TUMOR RECORD NUMBER

Alternate Name	Item #	Length	Source of Standard	Column #
	60	2	NAACCR	30-31

Description

A system-generated number assigned to each tumor. The number should never change even if the tumor sequence is changed or a record (tumor) is deleted.

Rationale

This is a unique number that identifies a specific tumor so data can be linked. “Sequence Number” cannot be used as a link because the number is changed if a report identifies an earlier tumor or if a tumor record is deleted.

TYPE OF REPORTING SOURCE**(Revised)**

Alternate Name	Item #	Length	Source of Standard	Column #
	500	1	SEER	312-312

Description

Code identifying source documents used to abstract the cancer being reported. This may not be the source of original case finding (for example, if a case is identified through a pathology laboratory report review and all source documents used to abstract the case are from the physician's office, code this item 4).

Type of Reporting Source can be used in conjunction with item 610 (Class of Case). Class of case is designed to differentiate between analytic and non-analytic cases at the hospital level.

See Chapter V, Unresolved Issues, for a discussion of inadequacies in this item.

Rationale

The code in this field can be used to explain why information may be incomplete on a case. The field also is used to monitor the success of non-hospital case reporting and follow-back mechanisms. All population-based registries should have some death certificate-only cases where no hospital admission was involved, but too high a percentage can imply that follow-back to uncover missed hospital reports was not complete.

Codes

- 1 Hospital inpatient/outpatient or clinic
- 3 Laboratory only (hospital or private)
- 4 Physician's office/private medical practitioner (LMD)
- 5 Nursing/convalescent home/hospice
- 6 Autopsy only
- 7 Death certificate only

Note: Coding is hierarchical. Within codes 1-5, assign codes in the following priority: 1, 4, 5, 3.

UNUSUAL FOLLOW-UP METHOD

Alternate Name	Item #	Length	Source of Standard	Column #
	1850	1	COC	1341-1341

Description

User-defined numeric codes used to flag cases that need unusual follow-up methods.

Codes

User-defined

Note: Beginning January 1, 2003, COC will no longer support this data item.

VENDOR NAME

Alternate Name	Item #	Length	Source of Standard	Column #
	2170	10	NAACCR	1204-1213

Description

System-generated. Name of the computer services vendor who programmed the system submitting the data. Abbreviate as necessary and keep a consistent name throughout all submissions. Include software version number where available. Code is self-assigned by vendor.

Rationale

This is used to track which vendor and which software version submitted the case. It helps define the source and extent of a problem discovered in data submitted by a software provider.

VITAL STATUS

Alternate Name	Item #	Length	Source of Standard	Column #
	1760	1	SEER/COC	1302-1302

Description

Vital status of the patient as of the date entered in item 1750 (Date of Last Contact).

Codes

0 Dead (COC)
1 Alive
4 Dead (SEER)

YEAR FIRST SEEN THIS CA

Alternate Name	Item #	Length	Source of Standard	Column #
Accession Year (pre-96 COC) Year First Seen for this Primary (COC)	620	4	COC	441-444

Description

Year patient was first seen at the reporting institution for diagnosis and/or treatment of this primary, since the reference date of the registry. It is **not** the year that the registrar accessioned the case.

Rationale

This data item is used by hospital registries to organize their case reporting into individual years. It differs from the first 4 digits of the Accession Number, because this variable is case-specific rather than patient-specific, and from the diagnosis year because it relates to the specific facility and not the tumor. Central registries that wish to compare their data with hospital case lists can make use of this field to create equivalent reports.

Note: Beginning January 1, 2003, COC will no longer support this data item.

APPENDIX A

FIPS CODES FOR COUNTIES AND EQUIVALENT ENTITIES

[Ed. Note: The information in this table is from FIPS Publication Number 6-4, "Counties and Equivalent Entities of the United States, its Possessions, and Associated Areas," as reissued December 21, 1992, and made available electronically on the National Institute of Standards and Technology Web Site (<http://www.itl.nist.gov>). We compared two versions of the file against printed lists to reconcile apparent errors and discrepancies.]

STATE NAME:	085	Lowndes	070	Dillingham (C)	019	Pima	
ALABAMA	087	Macon	090	Fairbanks North Star	021	Pinal	
ALPHABETIC CODE:	089	Madison		(B)	023	Santa Cruz	
AL	091	Marengo	100	Haines (B)	025	Yavapai	
NUMERIC CODE: 01	093	Marion	110	Juneau (B)	027	Yuma	
	095	Marshall	122	Kenai Peninsula (B)			
CODE COUNTY NAME	097	Mobile	130	Ketchikan Gateway		La Paz was established from	
001	Auatauga	099	Monroe	(B)		part of Yuma (1/1/83).	
003	Baldwin	101	Montgomery	150			
005	Barbour	103	Morgan	164			
007	Bibb	105	Perry	(B)		STATE NAME:	
009	Blount	107	Pickens	170		ARKANSAS	
011	Bullock	109	Pike	(B)		ALPHABETIC CODE:	
013	Butler	111	Randolph	180		AR	
015	Calhoun	113	Russell	185		NUMERIC CODE: 05	
017	Chambers	115	St. Clair	188			
019	Cherokee	117	Shelby	(B)		CODE COUNTY NAME	
021	Chilton	119	Sumter	201		001	Arkansas
023	Choctaw	121	Talladega			003	Ashley
025	Clarke	123	Tallapoosa	220		005	Baxter
027	Clay	125	Tuscaloosa	232		007	Benton
029	Cleburne	127	Walker			009	Boone
031	Coffee	129	Washington	240		011	Bradley
033	Colbert	131	Wilcox	(C)		013	Calhoun
035	Conecuh	133	Winston	261		015	Carroll
037	Coosa			270		017	Chicot
039	Covington			280		019	Clark
041	Crenshaw	STATE NAME: ALASKA		(C)		021	Clay
043	Cullman	ALPHABETIC CODE:	282	Yakutat (B)		023	Cleburne
045	Dale	AK	290	Yukon-Koyukuk (C)		025	Cleveland
047	Dallas	NUMERIC CODE: 02				027	Columbia
049	DeKalb			STATE NAME:		029	Conway
051	Elmore	Note: The following is a		ARIZONA		031	Craighead
053	Escambia	complete list of all current		ALPHABETIC CODE:		033	Crawford
055	Etowah	Alaska county equivalents		AZ		035	Crittenden
057	Fayette	where (B) identifies a		NUMERIC CODE: 03		037	Cross
059	Franklin	borough and (C) identifies a				039	Dallas
061	Geneva	census area per FIPS		CODE COUNTY NAME		041	Desha
063	Greene	Publication Change Notice		001	Apache	043	Drew
065	Hale	(Reissue 12/21/92).		003	Cochise	045	Faulkner
067	Henry			005	Coconino	047	Franklin
069	Houston	CODE BOROUGH/		007	Gila	049	Fulton
071	Jackson	CENSUS AREA		009	Graham	051	Garland
073	Jefferson	013	Aleutians East (B)	011	Greenlee	053	Grant
075	Lamar	016	Aleutians West (C)	012	LaPaz	055	Greene
077	Lauderdale	020	Anchorage (B)	013	Maricopa	057	Hempstead
079	Lawrence	050	Bethel (C)	015	Mohave	059	Hot Spring
081	Lee	060	Bristol Bay (B)	017	Navajo	061	Howard
083	Limestone	068	Denali (B)			063	Independence

065 Izard	027 Inyo	019 Clear Creek	city legally in effect on November 15, 2001. To maintain alphanumeric sequences of counties, Broomfield County will have a code of 014 for FIPS 6-4.
067 Jackson	029 Kern	021 Conejos	
069 Jefferson	031 Kings	023 Costilla	
071 Johnson	033 Lake	025 Crowley	
073 Lafayette	035 Lassen	027 Custer	
075 Lawrence	037 Los Angeles	029 Delta	
077 Lee	039 Madera	031 Denver	
079 Lincoln	041 Marin	033 Dolores	
081 Little River	043 Mariposa	035 Douglas	
083 Logan	045 Mendocino	037 Eagle	
085 Lonoke	047 Merced	039 Elbert	STATE NAME: CONNECTICUT ALPHABETIC CODE: CT NUMERIC CODE: 09 CODE COUNTY NAME 001 Fairfield 003 Hartford 005 Litchfield 007 Middlesex 009 New Haven 011 New London 013 Tolland 015 Windham
087 Madison	049 Modoc	041 El Paso	
089 Marion	051 Mono	043 Fremont	
091 Miller	053 Monterey	045 Garfield	
093 Mississippi	055 Napa	047 Gilpin	
095 Monroe	057 Nevada	049 Grand	
097 Montgomery	059 Orange	051 Gunnison	
099 Nevada	061 Placer	053 Hinsdale	
101 Newton	063 Plumas	055 Huerfano	
103 Ouachita	065 Riverside	057 Jackson	
105 Perry	067 Sacramento	059 Jefferson	STATE NAME: DELAWARE ALPHABETIC CODE: DE NUMERIC CODE: 10 CODE COUNTY NAME 001 Kent 003 New Castle 005 Sussex
107 Phillips	069 San Benito	061 Kiowa	
109 Pike	071 San Bernardino	063 Kit Carson	
111 Poinsett	073 San Diego	065 Lake	
113 Polk	075 San Francisco	067 La Plata	
115 Pope	077 San Joaquin	069 Larimer	
117 Prairie	079 San Luis Obispo	071 Las Animas	
119 Pulaski	081 San Mateo	073 Lincoln	
121 Randolph	083 Santa Barbara	075 Logan	
123 St. Francis	085 Santa Clara	077 Mesa	
125 Saline	087 Santa Cruz	079 Mineral	STATE NAME: DISTRICT OF COLUMBIA ALPHABETIC CODE: DC NUMERIC CODE: 11 CODE SUBDIVISION NAME 001 District of Columbia
127 Scott	089 Shasta	081 Moffat	
129 Searcy	091 Sierra	083 Montezuma	
131 Sebastian	093 Siskiyou	085 Montrose	
133 Sevier	095 Solano	087 Morgan	
135 Sharp	097 Sonoma	089 Otero	
137 Stone	099 Stanislaus	091 Ouray	
139 Union	101 Sutter	093 Park	
141 Van Buren	103 Tehama	095 Phillips	
143 Washington	105 Trinity	097 Pitkin	
145 White	107 Tulare	099 Prowers	Name was reported incorrectly as "Washington" in FIPS PUB 6-3. The District has no first-order subdivisions, and therefore "District of Columbia" also serves as the county-equivalent entity.
147 Woodruff	109 Tuolumne	101 Pueblo	
149 Yell	111 Ventura	103 Rio Blanco	
	113 Yolo	105 Rio Grande	
	115 Yuba	107 Routt	
		109 Saguache	
		111 San Juan	
		113 San Miguel	
		115 Sedgwick	
		117 Summit	
		119 Teller	Broomfield County, Colorado, has been created from parts of Adams (001), Boulder (013), Jefferson (059) and Weld (123) counties effective November 15, 2001. The boundaries of Broomfield County reflect the boundaries of Broomfield
		121 Washington	
		123 Weld	
		125 Yuma	

STATE NAME:
CALIFORNIA
ALPHABETIC CODE: CA
NUMERIC CODE: 06

CODE COUNTY NAME

001 Alameda
003 Alpine
005 Amador
007 Butte
009 Calaveras
011 Colusa
013 Contra Costa
015 Del Norte
017 El Dorado
019 Fresno
021 Glenn
023 Humboldt
025 Imperial

STATE NAME:
COLORADO
ALPHABETIC CODE:
CO
NUMERIC CODE: 08

CODE COUNTY NAME

001 Adams
003 Alamosa
005 Arapahoe
007 Archuleta
009 Baca
011 Bent
013 Boulder
014 Broomfield
015 Chaffee
017 Cheyenne

Broomfield County, Colorado, has been created from parts of Adams (001), Boulder (013), Jefferson (059) and Weld (123) counties effective November 15, 2001. The boundaries of Broomfield County reflect the boundaries of Broomfield

STATE NAME: FLORIDA
ALPHABETIC CODE: FL
NUMERIC CODE: 12

CODE COUNTY NAME

001 Alachua
 003 Baker
 005 Bay
 007 Bradford
 009 Brevard
 011 Broward
 013 Calhoun
 015 Charlotte
 017 Citrus
 019 Clay
 021 Collier
 023 Columbia
 025 Miami-Dade County
 027 DeSoto
 029 Dixie
 031 Duval
 033 Escambia
 035 Flagler
 037 Franklin
 039 Gadsden
 041 Gilchrist
 043 Glades
 045 Gulf
 047 Hamilton
 049 Hardee
 051 Hendry
 053 Hernando
 055 Highlands
 057 Hillsborough
 059 Holmes
 061 Indian River
 063 Jackson
 065 Jefferson
 067 Lafayette
 069 Lake
 071 Lee
 073 Leon
 075 Levy
 077 Liberty
 079 Madison
 081 Manatee
 083 Marion
 085 Martin
 087 Monroe
 089 Nassau
 091 Okaloosa
 093 Okeechobee
 095 Orange
 097 Osceola
 099 Palm Beach
 101 Pasco
 103 Pinellas
 105 Polk
 107 Putnam
 109 St. Johns
 111 St. Lucie
 113 Santa Rosa
 115 Sarasota
 117 Seminole

119 Sumter
 121 Suwannee
 123 Taylor
 125 Union
 127 Volusia
 129 Wakulla
 131 Walton
 133 Washington

NAME:
GEORGIA
ALPHABETIC CODE:
GA
NUMERIC CODE: 13

CODE COUNTY NAME

001 Appling
 003 Atkinson
 005 Bacon
 007 Baker
 009 Baldwin
 011 Banks
 013 Barrow
 015 Bartow
 017 Ben Hill
 019 Berrien
 021 Bibb
 023 Bleckley
 025 Brantley
 027 Brooks
 029 Bryan
 031 Bulloch
 033 Burke
 035 Butts
 037 Calhoun
 039 Camden
 043 Candler
 045 Carroll
 047 Catoosa
 049 Charlton
 051 Chatham
 053 Chattahoochee
 055 Chattooga
 057 Cherokee
 059 Clarke
 061 Clay
 063 Clayton
 065 Clinch
 067 Cobb
 069 Coffee
 071 Colquitt
 073 Columbia
 075 Cook
 077 Coweta
 079 Crawford
 081 Crisp
 083 Dade
 085 Dawson
 087 Decatur
 089 DeKalb
 091 Dodge
 093 Dooley
 095 Dougherty

097 Douglas
 099 Early
 101 Echols
 103 Effingham
 105 Elbert
 107 Emanuel
 109 Evans
 111 Fannin
 113 Fayette
 115 Floyd
 117 Forsyth
 119 Franklin
 121 Fulton
 123 Gilmer
 125 Glascock
 127 Glynn
 129 Gordon
 131 Grady
 133 Greene
 135 Gwinnett
 137 Habersham
 139 Hall
 141 Hancock
 143 Haralson
 145 Harris
 147 Hart
 149 Heard
 151 Henry
 153 Houston
 155 Irwin
 157 Jackson
 159 Jasper
 161 Jeff Davis
 163 Jefferson
 165 Jenkins
 167 Johnson
 169 Jones
 171 Lamar
 173 Lanier
 175 Laurens
 177 Lee
 179 Liberty
 181 Lincoln
 183 Long
 185 Lowndes
 187 Lumpkin
 189 McDuffie
 191 McIntosh
 193 Macon
 195 Madison
 197 Marion
 199 Meriwether
 201 Miller
 205 Mitchell
 207 Monroe
 209 Montgomery
 211 Morgan
 213 Murray
 215 Muscogee
 217 Newton
 219 Oconee
 221 Oglethorpe
 223 Paulding
 225 Peach

227 Pickens
 229 Pierce
 231 Pike
 233 Polk
 235 Pulaski
 237 Putnam
 239 Quitman
 241 Rabun
 243 Randolph
 245 Richmond
 247 Rockdale
 249 Schley
 251 Screven
 253 Seminole
 255 Spalding
 257 Stephens
 259 Stewart
 261 Sumter
 263 Talbot
 265 Taliaferro
 267 Tattnall
 269 Taylor
 271 Telfair
 273 Terrell
 275 Thomas
 277 Tift
 279 Toombs
 281 Towns
 283 Treutlen
 285 Troup
 287 Turner
 289 Twiggs
 291 Union
 293 Upson
 295 Walker
 297 Walton
 299 Ware
 301 Warren
 303 Washington
 305 Wayne
 307 Webster
 309 Wheeler
 311 White
 313 Whitfield
 315 Wilcox
 317 Wilkes
 319 Wilkinson
 321 Worth

Muscogee was reported incorrectly as "Columbus (consolidated government)" (510) in FIPS PUB6-3.

STATE NAME: HAWAII
ALPHABETIC CODE: HI
NUMERIC CODE: 15

CODE COUNTY NAME

001 Hawaii
 003 Honolulu
 005 Kalawao
 007 Kauai
 009 Maui

Kalawao does not have its own local government; it is administered by the State of Hawaii. It may be included with Maui for statistical purposes.

STATE NAME: IDAHO
ALPHABETIC CODE: ID
NUMERIC CODE: 16

CODE COUNTY NAME

001 Ada
 003 Adams
 005 Bannock
 007 Bear Lake
 009 Benewah
 011 Bingham
 013 Blaine
 015 Boise
 017 Bonner
 019 Bonneville
 021 Boundary
 023 Butte
 025 Camas
 027 Canyon
 029 Caribou
 031 Cassia
 033 Clark
 035 Clearwater
 037 Custer
 039 Elmore
 041 Franklin
 043 Fremont
 045 Gem
 047 Gooding
 049 Idaho
 051 Jefferson
 053 Jerome
 055 Kootenai
 057 Latah
 059 Lemhi
 061 Lewis
 063 Lincoln
 065 Madison
 067 Minidoka
 069 Nez Perce
 071 Oneida
 073 Owyhee
 075 Payette
 077 Power
 079 Shoshone

081 Teton
 083 Twin Falls
 085 Valley
 087 Washington

STATE NAME: ILLINOIS
ALPHABETIC CODE: IL
NUMERIC CODE: 17

CODE COUNTY NAME

001 Adams
 003 Alexander
 005 Bond
 007 Boone
 009 Brown
 011 Bureau
 013 Calhoun
 015 Carroll
 017 Cass
 019 Champaign
 021 Christian
 023 Clark
 025 Clay
 027 Clinton
 029 Coles
 031 Cook
 033 Crawford
 035 Cumberland
 037 DeKalb
 039 De Witt
 041 Douglas
 043 DuPage
 045 Edgar
 047 Edwards
 049 Effingham
 051 Fayette
 053 Ford
 055 Franklin
 057 Fulton
 059 Gallatin
 061 Greene
 063 Grundy
 065 Hamilton
 067 Hancock
 069 Hardin
 071 Henderson
 073 Henry
 075 Iroquois
 077 Jackson
 079 Jasper

081 Jefferson
 083 Jersey
 085 Jo Daviess
 087 Johnson
 089 Kane
 091 Kankakee
 093 Kendall
 095 Knox
 097 Lake
 099 La Salle
 101 Lawrence
 103 Lee
 105 Livingston

107 Logan
 109 McDonough
 111 McHenry
 113 McLean
 115 Macon
 117 Macoupin
 119 Madison
 121 Marion
 123 Marshall
 125 Mason
 127 Massac
 129 Menard
 131 Mercer
 133 Monroe
 135 Montgomery
 137 Morgan
 139 Moultrie
 141 Ogle
 143 Peoria
 145 Perry
 147 Piatt
 149 Pike
 151 Pope
 153 Pulaski
 155 Putnam
 157 Randolph
 159 Richland
 161 Rock Island
 163 St. Clair
 165 Saline
 167 Sangamon
 169 Schuyler
 171 Scott
 173 Shelby
 175 Stark
 177 Stephenson
 179 Tazewell
 181 Union
 183 Vermilion
 185 Wabash
 187 Warren
 189 Washington
 191 Wayne
 193 White
 195 Whiteside
 197 Will
 199 Williamson
 201 Winnebago
 203 Woodford

STATE NAME: INDIANA
ALPHABETIC CODE: IN
NUMERIC CODE: 18

CODE COUNTY NAME

001 Adams
 003 Allen
 005 Bartholomew
 007 Benton
 009 Blackford
 011 Boone
 013 Brown
 015 Carroll

017 Cass
 019 Clark
 021 Clay
 023 Clinton
 025 Crawford
 027 Daviess
 029 Dearborn
 031 Decatur
 033 DeKalb
 035 Delaware
 037 Dubois
 039 Elkhart
 041 Fayette
 043 Floyd
 045 Fountain
 047 Franklin
 049 Fulton
 051 Gibson
 053 Grant
 055 Greene
 057 Hamilton
 059 Hancock
 061 Harrison
 063 Hendricks
 065 Henry
 067 Howard
 069 Huntington
 071 Jackson
 073 Jasper
 075 Jay
 077 Jefferson
 079 Jennings
 081 Johnson
 083 Knox
 085 Kosciusko
 087 Lagrange
 089 Lake
 091 LaPorte
 093 Lawrence
 095 Madison
 097 Marion
 099 Marshall
 101 Martin
 103 Miami
 105 Monroe
 107 Montgomery
 109 Morgan
 111 Newton
 113 Noble
 115 Ohio
 117 Orange
 119 Owen
 121 Parke
 123 Perry
 125 Pike
 127 Porter
 129 Posey
 131 Pulaski
 133 Putnam
 135 Randolph
 137 Ripley
 139 Rush
 141 St. Joseph
 143 Scott

145	Shelby	073	Greene	STATE NAME: KANSAS	117	Marshall
147	Spencer	075	Grundy	ALPHABETIC CODE:	119	Meade
149	Starke	077	Guthrie	KS	121	Miami
151	Steuben	079	Hamilton	NUMERIC CODE: 20	123	Mitchell
153	Sullivan	081	Hancock		125	Montgomery
155	Switzerland	083	Hardin	CODE COUNTY NAME	127	Morris
157	Tippecanoe	085	Harrison	001 Allen	129	Morton
159	Tipton	087	Henry	003 Anderson	131	Nemaha
161	Union	089	Howard	005 Atchison	133	Neosho
163	Vanderburgh	091	Humboldt	007 Barber	135	Ness
165	Vermillion	093	Ida	009 Barton	137	Norton
167	Vigo	095	Iowa	011 Bourbon	139	Osage
169	Wabash	097	Jackson	013 Brown	141	Osborne
171	Warren	099	Jasper	015 Butler	143	Ottawa
173	Warrick	101	Jefferson	017 Chase	145	Pawnee
175	Washington	103	Johnson	019 Chautauqua	147	Phillips
177	Wayne	105	Jones	021 Cherokee	149	Pottawatomie
179	Wells	107	Keokuk	023 Cheyenne	151	Pratt
181	White	109	Kossuth	025 Clark	153	Rawlins
183	Whitley	111	Lee	027 Clay	155	Reno
		113	Linn	029 Cloud	157	Republic
		115	Louisa	031 Coffey	159	Rice
		117	Lucas	033 Comanche	161	Riley
STATE NAME:		119	Lyon	035 Cowley	163	Rooks
IOWA		121	Madison	037 Crawford	165	Rush
ALPHABETIC CODE: IA		123	Mahaska	039 Decatur	167	Russell
NUMERIC CODE: 19		125	Marion	041 Dickinson	169	Saline
CODE COUNTY NAME		127	Marshall	043 Doniphan	171	Scott
001 Adair		129	Mills	045 Douglas	173	Sedgwick
003 Adams		131	Mitchell	047 Edwards	175	Seward
005 Allamakee		133	Monona	049 Elk	177	Shawnee
007 Appanoose		135	Monroe	051 Ellis	179	Sheridan
009 Audubon		137	Montgomery	053 Ellsworth	181	Sherman
011 Benton		139	Muscatine	055 Finney	183	Smith
013 Black Hawk		141	O'Brien	057 Ford	185	Stafford
015 Boone		143	Osceola	059 Franklin	187	Stanton
017 Bremer		145	Page	061 Geary	189	Stevens
019 Buchanan		147	Palo Alto	063 Gove	191	Sumner
021 Buena Vista		149	Plymouth	065 Graham	193	Thomas
023 Butler		151	Pocahontas	067 Grant	195	Trego
025 Calhoun		153	Polk	069 Gray	197	Wabaunsee
027 Carroll		155	Pottawattamie	071 Greeley	199	Wallace
029 Cass		157	Poweshiek	073 Greenwood	201	Washington
031 Cedar		159	Ringgold	075 Hamilton	203	Wichita
033 Cerro Gordo		161	Sac	077 Harper	205	Wilson
035 Cherokee		163	Scott	079 Harvey	207	Woodson
037 Chickasaw		165	Shelby	081 Haskell	209	Wyandotte
039 Clarke		167	Sioux	083 Hodgeman		
041 Clay		169	Story	085 Jackson		
043 Clayton		171	Tama	087 Jefferson	STATE NAME:	
045 Clinton		173	Taylor	089 Jewell	KENTUCKY	
047 Crawford		175	Union	091 Johnson	ALPHABETIC CODE:	
049 Dallas		177	Van Buren	093 Kearny	KY	
051 Davis		179	Wapello	095 Kingman	NUMERIC CODE: 21	
053 Decatur		181	Warren	097 Kiowa		
055 Delaware		183	Washington	099 Labette	CODE COUNTY NAME	
057 Des Moines		185	Wayne	101 Lane	001 Adair	
059 Dickinson		187	Webster	103 Leavenworth	003 Allen	
061 Dubuque		189	Winnebago	105 Lincoln	005 Anderson	
063 Emmet		191	Winneshie	107 Linn	007 Ballard	
065 Fayette		193	Woodbury	109 Logan	009 Barren	
067 Floyd		195	Worth	111 Lyon	011 Bath	
069 Franklin		197	Wright	113 McPherson	013 Bell	
071 Fremont				115 Marion	015 Boone	

017	Bourbon	145	McCracken	015	Bossier	CODE	COUNTY NAME
019	Boyd	147	McCreary	017	Caddo	001	Androscoggin
021	Boyle	149	McLean	019	Calcasieu	003	Aroostook
023	Bracken	151	Madison	021	Caldwell	005	Cumberland
025	Breathitt	153	Magoffin	023	Cameron	007	Franklin
027	Breckinridge	155	Marion	025	Catahoula	009	Hancock
029	Bullitt	157	Marshall	027	Claiborne	011	Kennebec
031	Butler	159	Martin	029	Concordia	013	Knox
033	Caldwell	161	Mason	031	DeSoto	015	Lincoln
035	Calloway	163	Meade	033	East Baton Rouge	017	Oxford
037	Campbell	165	Menifee	035	East Carroll	019	Penobscot
039	Carlisle	167	Mercer	037	East Feliciana	021	Piscataquis
041	Carroll	169	Metcalfe	039	Evangeline	023	Sagadahoc
043	Carter	171	Monroe	041	Franklin	025	Somerset
045	Casey	173	Montgomery	043	Grant	027	Waldo
047	Christian	175	Morgan	045	Iberia	029	Washington
049	Clark	177	Muhlenberg	047	Iberville	031	York
051	Clay	179	Nelson	049	Jackson		
053	Clinton	181	Nicholas	051	Jefferson		
055	Crittenden	183	Ohio	053	Jefferson Davis	STATE NAME:	
057	Cumberland	185	Oldham	055	Lafayette	MARYLAND	
059	Daviess	187	Owen	057	Lafourche	ALPHABETIC CODE:	
061	Edmonson	189	Owsley	059	La Salle	MD	
063	Elliott	191	Pendleton	061	Lincoln	NUMERIC CODE: 24	
065	Estill	193	Perry	063	Livingston		
067	Fayette	195	Pike	065	Madison	CODE	COUNTY NAME
069	Fleming	197	Powell	067	Morehouse	001	Allegany
071	Floyd	199	Pulaski	069	Natchitoches	003	Anne Arundel
073	Franklin	201	Roberston	071	Orleans	005	Baltimore
075	Fulton	203	Rockcastle	073	Ouachita	009	Calvert
077	Gallatin	205	Rowan	075	Plaquemines	011	Caroline
079	Garrard	207	Russell	077	Pointe Coupee	013	Carroll
081	Grant	209	Scott	079	Rapides	015	Cecil
083	Graves	211	Shelby	081	Red River	017	Charles
085	Grayson	213	Simpson	083	Richland	019	Dorchester
087	Green	215	Spencer	085	Sabine	021	Frederick
089	Greenup	217	Taylor	087	St. Bernard	023	Garrett
091	Hancock	219	Todd	089	St. Charles	025	Harford
093	Hardin	221	Trigg	091	St. Helena	027	Howard
095	Harlan	223	Trimble	093	St. James	029	Kent
097	Harrison	225	Union	095	St. John the Baptist	031	Montgomery
099	Hart	227	Warren	097	St. Landry	033	Prince George's
101	Henderson	229	Washington	099	St. Martin	035	Queen Anne's
103	Henry	231	Wayne	101	St. Mary	037	St. Mary's
105	Hickman	233	Webster	103	St. Tammany	039	Somerset
107	Hopkins	235	Whitley	105	Tangipahoa	041	Talbot
109	Jackson	237	Wolfe	107	Tensas	043	Washington
111	Jefferson	239	Woodford	109	Terbonne	045	Wicomico
113	Jessamine			111	Union	047	Worcester
115	Johnson			113	Vermilion		
117	Kenton	STATE NAME:		115	Vernon	CODE	
119	Knott	LOUISIANA		117	Washington	INDEPENDENT CITY	
121	Knox	ALPHABETIC CODE:		119	Webster	510	Baltimore (City)
123	Larue	LA		121	West Baton Rouge		
125	Laurel	NUMERIC CODE: 22		123	West Carroll		
127	Lawrence			125	West Feliciana	STATE NAME:	
129	Lee	CODE	COUNTY NAME	127	Winn	MASSACHUSETTS	
131	Leslie	001	Acadia			ALPHABETIC CODE:	
133	Letcher	003	Allen			MA	
135	Lewis	005	Ascension	STATE NAME: MAINE		NUMERIC CODE: 25	
137	Lincoln	007	Assumption	ALPHABETIC CODE:			
139	Livingston	009	Avoyelles	ME		CODE	COUNTY NAME
141	Logan	011	Beauregard	NUMERIC CODE: 23		001	Barnstable
143	Lyon	013	Bienville			003	Berkshire

005 Bristol
007 Dukes
009 Essex
011 Franklin
013 Hampden
015 Hampshire
017 Middlesex
019 Nantucket
021 Norfolk
023 Plymouth
025 Suffolk
027 Worcester

STATE NAME:**MICHIGAN****ALPHABETIC CODE:****MI****NUMERIC CODE: 26****CODE COUNTY NAME**

001 Alcona
003 Alger
005 Allegan
007 Alpena
009 Antrim
011 Arenac
013 Baraga
015 Barry
017 Bay
019 Benzie
021 Berrien
023 Branch
025 Calhoun
027 Cass
029 Charlevoix
031 Cheboygan
033 Chippewa
035 Clare
037 Clinton
039 Crawford
041 Delta
043 Dickinson
045 Eaton
047 Emmet
049 Genesee
051 Gladwin
053 Gogebic
055 Grand Traverse
057 Gratiot
059 Hillsdale
061 Houghton
063 Huron
065 Ingham
067 Ionia
069 Iosco
071 Iron
073 Isabella
075 Jackson
077 Kalamazoo
079 Kalkaska
081 Kent
083 Keweenaw
085 Lake

087 Lapeer
089 Leelanau
091 Lenawee
093 Livingston
095 Luce
097 Mackinac
099 Macomb
101 Manistee
103 Marquette
105 Mason
107 Mecosta
109 Menominee
111 Midland
113 Missaukee
115 Monroe
117 Montcalm
119 Montmorency
121 Muskegon
123 Newaygo
125 Oakland
127 Oceana
129 Ogemaw
131 Ontonagon
133 Osceola
135 Oscoda
137 Otsego
139 Ottawa
141 Presque Isle
143 Roscommon
145 Saginaw
147 St. Clair
149 St. Joseph
151 Sanilac
153 Schoolcraft
155 Shiawassee
157 Tuscola
159 Van Buren
161 Washtenaw
163 Wayne
165 Wexford

STATE NAME:**MINNESOTA****ALPHABETIC CODE:****MN****NUMERIC CODE: 27****CODE COUNTY NAME**

001 Aitkin
003 Anoka
005 Becker
007 Beltrami
009 Benton
011 Big Stone
013 Blue Earth
015 Brown
017 Carlton
019 Carver
021 Cass
023 Chippewa
025 Chisago
027 Clay
029 Clearwater

031 Cook
033 Cottonwood
035 Crow Wing
037 Dakota
039 Dodge
041 Douglas
043 Faribault
045 Fillmore
047 Freeborn
049 Goodhue
051 Grant
053 Hennepin
055 Houston
057 Hubbard
059 Isanti
061 Itasca
063 Jackson
065 Kanabec
067 Kandiyohi
069 Kittson
071 Koochiching
073 Lac qui Parle
075 Lake
077 Lake of the Woods
079 Le Sueur
081 Lincoln
083 Lyon
085 McLeod
087 Mahanomen
089 Marshall
091 Martin
093 Meeker
095 Mille Lacs
097 Morrison
099 Mower
101 Murray
103 Nicollet
105 Nobles
107 Norman
109 Olmsted
111 Otter Tail
113 Pennington
115 Pine
117 Pipestone
119 Polk
121 Pope
123 Ramsey
125 Red Lake
127 Redwood
129 Renville
131 Rice
133 Rock
135 Roseau
137 St. Louis
139 Scott
141 Sherburne
143 Sibley
145 Stearns
147 Steele
149 Stevens
151 Swift
153 Todd
155 Traverse
157 Wabasha

159 Wadena
161 Waseca
163 Washington
165 Watonwan
167 Wilkin
169 Winona
171 Wright
173 Yellow Medicine

STATE NAME:**MISSISSIPPI****ALPHABETIC CODE:****MS****NUMERIC CODE: 28****CODE COUNTY NAME**

001 Adams
003 Alcorn
005 Amite
007 Attala
009 Benton
011 Bolivar
013 Calhoun
015 Carroll
017 Chickasaw
019 Choctaw
021 Claiborne
023 Clarke
025 Clay
027 Coahoma
029 Copiah
031 Covington
033 DeSoto
035 Forrest
037 Franklin
039 George
041 Greene
043 Grenada
045 Hancock
047 Harrison
049 Hinds
051 Holmes
053 Humphreys
055 Issaquena
057 Itawamba
059 Jackson
061 Jasper
063 Jefferson
065 Jefferson Davis
067 Jones
069 Kemper
071 Lafayette
073 Lamar
075 Lauderdale
077 Lawrence
079 Leake
081 Lee
083 Leflore
085 Lincoln
087 Lowndes
089 Madison
091 Marion
093 Marshall

025	Cass	153	Sarpy	015	Rockingham	043	Sandoval
027	Cedar	155	Saunders	017	Strafford	045	San Juan
029	Chase	157	Scotts Bluff	019	Sullivan	047	San Miguel
031	Cherry	159	Seward			049	Santa Fe
033	Cheyenne	161	Sheridan			051	Sierra
035	Clay	163	Sherman		STATE NAME:	053	Socorro
037	Colfax	165	Sioux		NEW JERSEY	055	Taos
039	Cuming	167	Stanton		ALPHABETIC CODE: NJ	057	Torrance
041	Custer	169	Thayer		NUMERIC CODE: 34	059	Union
043	Dakota	171	Thomas			061	Valencia
045	Dawes	173	Thurston		CODE COUNTY NAME		
047	Dawson	175	Valley	001	Atlantic		Cibola was established from
049	Deuel	177	Washington	003	Bergen		part of Valencia (6/19/81).
051	Dixon	179	Wayne	005	Burlington		
053	Dodge	181	Webster	007	Camden		
055	Douglas	183	Wheeler	009	Cape May		STATE NAME:
057	Dundy	185	York	011	Cumberland		NEW YORK
059	Fillmore			013	Essex		ALPHABETIC CODE:
061	Franklin			015	Gloucester		NY
063	Frontier		STATE NAME: NEVADA	017	Hudson		NUMERIC CODE: 36
065	Furnas		ALPHABETIC CODE:	019	Hunterdon		
067	Gage		NV	021	Mercer		CODE COUNTY NAME
069	Garden		NUMERIC CODE: 32	023	Middlesex	001	Albany
071	Garfield			025	Monmouth	003	Allegany
073	Gosper		CODE COUNTY NAME	027	Morris	005	Bronx
075	Grant	001	Churchill	029	Ocean	007	Broome
077	Greeley	003	Clark	031	Passaic	009	Cattaraugus
079	Hall	005	Douglas	033	Salem	011	Cayuga
081	Hamilton	007	Elko	035	Somerset	013	Chautauqua
083	Harlan	009	Esmeralda	037	Sussex	015	Chemung
085	Hayes	011	Eureka	039	Union	017	Chenango
087	Hitchcock	013	Humboldt	041	Warren	019	Clinton
089	Holt	015	Lander			021	Columbia
091	Hooker	017	Lincoln		STATE NAME:	023	Cortland
093	Howard	019	Lyon		NEW MEXICO	025	Delaware
095	Jefferson	021	Mineral		ALPHABETIC CODE:	027	Dutchess
097	Johnson	023	Nye		NM	029	Erie
099	Kearney	027	Pershing		NUMERIC CODE: 35	031	Essex
101	Keith	029	Storey			033	Franklin
103	Keya Paha	031	Washoe		CODE COUNTY NAME	035	Fulton
105	Kimball	033	White Pine			037	Genesee
107	Knox			001	Bernalillo	039	Greene
109	Lancaster		CODE INDEPENDENT	003	Catron	041	Hamilton
111	Lincoln		CITY	005	Chaves	043	Herkimer
113	Logan	510	Carson City	006	Cibola	045	Jefferson
115	Loup			007	Colfax	047	Kings
117	McPherson		Carson City does not include	009	Curry	049	Lewis
119	Madison		a legal designation (such as	011	DeBaca	051	Livingston
121	Merrick		“city”).	013	Dona Ana	053	Madison
123	Morrill			015	Eddy	055	Monroe
125	Nance		STATE NAME:	017	Grant	057	Montgomery
127	Nemaha		NEW HAMPSHIRE	019	Guadalupe	059	Nassau
129	Nuckolls		ALPHABETIC CODE:	021	Harding	061	New York
131	Otoe		NH	023	Hidalgo	063	Niagara
133	Pawnee		NUMERIC CODE: 33	025	Lea	065	Oneida
135	Perkins			027	Lincoln	067	Onondaga
137	Phelps		CODE COUNTY NAME	028	Los Alamos	069	Ontario
139	Pierce	001	Belknap	029	Luna	071	Orange
141	Platte	003	Carroll	031	McKinley	073	Orleans
143	Polk	005	Cheshire	033	Mora	075	Oswego
145	Red Willow	007	Coos	035	Otero	077	Otsego
147	Richardson	009	Grafton	037	Quay	079	Putnam
149	Rock	011	Hillsborough	039	Rio Arriba	081	Queens
151	Saline	013	Merrimack	041	Roosevelt	083	Rensselaer

085	Richmond	071	Gaston	199	Yancey	STATE NAME: OHIO	
087	Rockland	073	Gates			ALPHABETIC CODE:	
089	St. Lawrence	075	Graham			OH	
091	Saratoga	077	Granville	STATE NAME: NORTH		NUMERIC CODE: 39	
093	Schenectady	079	Greene	DAKOTA			
095	Schoharie	081	Guilford	ALPHABETIC CODE:		CODE	COUNTY NAME
097	Schuyler	083	Halifax	ND		001	Adams
099	Seneca	085	Harnett	NUMERIC CODE: 38		003	Allen
101	Steuben	087	Haywood			005	Ashland
103	Suffolk	089	Henderson	CODE		007	Ashtabula
105	Sullivan	091	Hertford	COUNTY NAME		009	Athens
107	Tioga	093	Hoke	001	Adams	011	Auglaize
109	Tompkins	095	Hyde	003	Barnes	013	Belmont
111	Ulster	097	Iredell	005	Benson	015	Brown
113	Warren	099	Jackson	007	Billings	017	Butler
115	Washington	101	Johnston	009	Bottineau	019	Carroll
117	Wayne	103	Jones	011	Bowman	021	Champaign
119	Westchester	105	Lee	013	Burke	023	Clark
121	Wyoming	107	Lenoir	015	Burleigh	025	Clermont
123	Yates	109	Lincoln	017	Cass	027	Clinton
STATE NAME: NORTH		111	McDowell	019	Cavalier	029	Columbiana
CAROLINA		113	Macon	021	Dickey	031	Coshocton
ALPHABETIC CODE:		115	Madison	023	Divide	033	Crawford
NC		117	Martin	025	Dunn	035	Cuyahoga
NUMERIC CODE: 37		119	Mecklenburg	027	Eddy	037	Darke
CODE		121	Mitchell	029	Emmons	039	Defiance
COUNTY NAME		123	Montgomery	031	Foster	041	Delaware
001	Alamance	125	Moore	033	Golden Valley	043	Erie
003	Alexander	127	Nash	035	Grand Forks	045	Fairfield
005	Alleghany	129	New Hanover	037	Grant	047	Fayette
007	Anson	131	Northampton	039	Griggs	049	Franklin
009	Ashe	133	Onslow	041	Hettinger	051	Fulton
011	Avery	135	Orange	043	Kidder	053	Gallia
013	Beaufort	137	Pamlico	045	LaMoure	055	Geauga
015	Bertie	139	Pasquotank	047	Logan	057	Greene
017	Bladen	141	Pender	049	McHenry	059	Guernsey
019	Brunswick	143	Perquimans	051	McIntosh	061	Hamilton
021	Buncombe	145	Person	053	McKenzie	063	Hancock
023	Burke	147	Pitt	055	McLean	065	Hardin
025	Cabarrus	149	Polk	057	Mercer	067	Harrison
027	Caldwell	151	Randolph	059	Morton	069	Henry
029	Camden	153	Richmond	061	Mountrail	071	Highland
031	Carteret	155	Robeson	063	Nelson	073	Hocking
033	Caswell	157	Rockingham	065	Oliver	075	Holmes
035	Catawba	159	Rowan	067	Pembina	077	Huron
037	Chatham	161	Rutherford	069	Pierce	079	Jackson
039	Cherokee	163	Sampson	071	Ramsey	081	Jefferson
041	Chowan	165	Scotland	073	Ransom	083	Knox
043	Clay	167	Stanly	075	Renville	085	Lake
045	Cleveland	169	Stokes	077	Richland	087	Lawrence
047	Columbus	171	Surry	079	Rolette	089	Licking
049	Craven	173	Swain	081	Sargent	091	Logan
051	Cumberland	175	Transylvania	083	Sheridan	093	Lorain
053	Currituck	177	Tyrrell	085	Sioux	095	Lucas
055	Dare	179	Union	087	Slope	097	Madison
057	Davidson	181	Vance	089	Stark	099	Mahoning
059	Davie	183	Wake	091	Steele	101	Marion
061	Duplin	185	Warren	093	Stutsman	103	Medina
063	Durham	187	Washington	095	Towner	105	Meigs
065	Edgecombe	189	Watauga	097	Traill	107	Mercer
067	Forsyth	191	Wayne	099	Walsh	109	Miami
069	Franklin	193	Wilkes	101	Ward	111	Monroe
		195	Wilson	103	Wells	113	Montgomery
		197	Yadkin	105	Williams	115	Morgan

117 Morrow
119 Muskingum
121 Noble
123 Ottawa
125 Paulding
127 Perry
129 Pickaway
131 Pike
133 Portage
135 Preble
137 Putnam
139 Richland
141 Ross
143 Sandusky
145 Scioto
147 Seneca
149 Shelby
151 Stark
153 Summit
155 Trumbull
157 Tuscarawas
159 Union
161 VanWert
163 Vinton
165 Warren
167 Washington
169 Wayne
171 Williams
173 Wood
175 Wyandot

STATE NAME:**OKLAHOMA****ALPHABETIC CODE:****OK****NUMERIC CODE: 40****CODE COUNTY NAME**

001 Adair
003 Alfalfa
005 Atoka
007 Beaver
009 Beckham
011 Blaine
013 Bryan
015 Caddo
017 Canadian
019 Carter
021 Cherokee
023 Choctaw
025 Cimarron
027 Cleveland
029 Coal
031 Comanche
033 Cotton
035 Craig
037 Creek
039 Custer
041 Delaware
043 Dewey
045 Ellis
047 Garfield
049 Garvin

051 Grady
053 Grant
055 Greer
057 Harmon
059 Harper
061 Haskell
063 Hughes
065 Jackson
067 Jefferson
069 Johnston
071 Kay
073 Kingfisher
075 Kiowa
077 Latimer
079 Le Flore
081 Lincoln
083 Logan
085 Love
087 McClain
089 McCurtain
091 McIntosh
093 Major
095 Marshall
097 Mayes
099 Murray
101 Muskogee
103 Noble
105 Nowata
107 Okfushee
109 Oklahoma
111 Okmulgee
113 Osage
115 Ottawa
117 Pawnee
119 Payne
121 Pittsburg
123 Pontotoc
125 Pottawatomie
127 Pushmataha
129 Roger Mills
131 Rogers
133 Seminole
135 Sequoyah
137 Stephens
139 Texas
141 Tillman
143 Tulsa
145 Wagoneer
147 Washington
149 Washita
151 Woods
153 Woodward

STATE NAME:**OREGON****ALPHABETIC CODE:****OR****NUMERIC CODE: 41****CODE COUNTY NAME**

001 Baker
003 Benton
005 Clackamas

007 Clatsop
009 Columbia
011 Coos
013 Crook
015 Curry
017 Deschutes
019 Douglas
021 Gilliam
023 Grant
025 Harney
027 Hood River
029 Jackson
031 Jefferson
033 Josephine
035 Klamath
037 Lake
039 Lane
041 Lincoln
043 Linn
045 Malheur
047 Marion
049 Morrow
051 Multnomah
053 Polk
055 Sherman
057 Tillamook
059 Umatilla
061 Union
063 Wallowa
065 Wasco
067 Washington
069 Wheeler
071 Yamhill

STATE NAME:**PENNSYLVANIA****ALPHABETIC CODE:****PA****NUMERIC CODE: 42****CODE COUNTY NAME**

001 Adams
003 Allegheny
005 Armstrong
007 Beaver
009 Bedford
011 Berks
013 Blair
015 Bradford
017 Bucks
019 Butler
021 Cambria
023 Cameron
025 Carbon
027 Centre
029 Chester
031 Clarion
033 Clearfield
035 Clinton
037 Columbia
039 Crawford
041 Cumberland
043 Dauphin

045 Delaware
047 Elk
049 Erie
051 Fayette
053 Forest
055 Franklin
057 Fulton
059 Greene
061 Huntingdon
063 Indiana
065 Jefferson
067 Juniata
069 Lackawanna
071 Lancaster
073 Lawrence
075 Lebanon
077 Lehigh
079 Luzerne
081 Lycoming
083 McKean
085 Mercer
087 Mifflin
089 Monroe
091 Montgomery
093 Montour
095 Northampton
097 Northumberland
099 Perry
101 Philadelphia
103 Pike
105 Potter
107 Schuylkill
109 Snyder
111 Somerset
113 Sullivan
115 Susquehanna
117 Tioga
119 Union
121 Venango
123 Warren
125 Washington
127 Wayne
129 Westmoreland
131 Wyoming
133 York

STATE NAME: RHODE**ISLAND****ALPHABETIC CODE: RI****NUMERIC CODE: 44****CODE COUNTY NAME**

001 Bristol
003 Kent
005 Newport
007 Providence
009 Washington

**STATE NAME: SOUTH
CAROLINA**
ALPHABETIC CODE:
SC
NUMERIC CODE: 45

CODE COUNTY NAME

001	Abbeville
003	Aiken
005	Allendale
007	Anderson
009	Bamberg
011	Barnwell
013	Beaufort
015	Berkeley
017	Calhoun
019	Charleston
021	Cherokee
023	Chester
025	Chesterfield
027	Clarendon
029	Colleton
031	Darlington
033	Dillon
035	Dorchester
037	Edgefield
039	Fairfield
041	Florence
043	Georgetown
045	Greenville
047	Greenwood
049	Hampton
051	Horry
053	Jasper
055	Kershaw
057	Lancaster
059	Laurens
061	Lee
063	Lexington
065	McCormick
067	Marion
069	Marlboro
071	Newberry
073	Oconee
075	Orangeburg
077	Pickens
079	Richland
081	Saluda
083	Spartanburg
085	Sumter
087	Union
089	Williamsburg
091	York

**STATE NAME: SOUTH
DAKOTA**
ALPHABETIC CODE:
SD
NUMERIC CODE: 46

CODE COUNTY NAME

003	Aurora
005	Beadle

007	Bennett
009	Bon Homme
011	Brookings
013	Brown
015	Brule
017	Buffalo
019	Butte
021	Campbell
023	Charles Mix
025	Clark
027	Clay
029	Codington
031	Corson
033	Custer
035	Davison
037	Day
039	Deuel
041	Dewey
043	Douglas
045	Edmunds
047	Fall River
049	Faulk
051	Grant
053	Gregory
055	Haakon
057	Hamlin
059	Hand
061	Hanson
063	Harding
065	Hughes
067	Hutchinson
069	Hyde
071	Jackson
073	Jerauld
075	Jones
077	Kingsbury
079	Lake
081	Lawrence
083	Lincoln
085	Lyman
087	McCook
089	McPherson
091	Marshall
093	Meade
095	Mellette
097	Miner
099	Minnehaha
101	Moody
103	Pennington
105	Perkins
107	Potter
109	Roberts
111	Sanborn
113	Shannon
115	Spink
117	Stanley
119	Sully
121	Todd
123	Tripp
125	Turner
127	Union
129	Walworth
135	Yankton
137	Ziebach

STATE NAME:
TENNESSEE
ALPHABETIC CODE:
TN
NUMERIC CODE: 47

CODE COUNTY NAME

001	Anderson
003	Bedford
005	Benton
007	Bledsoe
009	Blount
011	Bradley
013	Campbell
015	Cannon
017	Carroll
019	Carter
021	Cheatham
023	Chester
025	Claiborne
027	Clay
029	Cocke
031	Coffee
033	Crockett
035	Cumberland
037	Davidson
039	Decatur
041	DeKalb
043	Dickson
045	Dyer
047	Fayette
049	Fentress
051	Franklin
053	Gibson
055	Giles
057	Grainger
059	Greene
061	Grundy
063	Hamblen
065	Hamilton
067	Hancock
069	Hardeman
071	Hardin
073	Hawkins
075	Haywood
077	Henderson
079	Henry
081	Hickman
083	Houston
085	Humphreys
087	Jackson
089	Jefferson
091	Johnson
093	Knox
095	Lake
097	Lauderdale
099	Lawrence
101	Lewis
103	Lincoln
105	Loudon
107	McMinn
109	McNairy
111	Macon
113	Madison

115	Marion
117	Marshall
119	Maury
121	Meigs
123	Monroe
125	Montgomery
127	Moore
129	Morgan
131	Obion
133	Overton
135	Perry
137	Pickett
139	Polk
141	Putnam
143	Rhea
145	Roane
147	Robertson
149	Rutherford
151	Scott
153	Sequatchie
155	Sevier
157	Shelby
159	Smith
161	Stewart
163	Sullivan
165	Sumner
167	Tipton
169	Trousdale
171	Unicoi
173	Union
175	Van Buren
177	Warren
179	Washington
181	Wayne
183	Weakley
185	White
187	Williamson
189	Wilson

STATE NAME: TEXAS
ALPHABETIC CODE:
TX
NUMERIC CODE: 48

CODE COUNTY NAME

001	Anderson
003	Andrews
005	Angelina
007	Aransas
009	Archer
011	Armstrong
013	Atascosa
015	Austin
017	Bailey
019	Bandera
021	Bastrop
023	Baylor
025	Bee
027	Bell
029	Bexar
031	Blanco
033	Borden
035	Bosque

037	Bowie	165	Gaines	293	Limestone	421	Sherman
039	Brazoria	167	Galveston	295	Lipscomb	423	Smith
041	Brazos	169	Garza	297	Live Oak	425	Somervell
043	Brewster	171	Gillespie	299	Llano	427	Starr
045	Briscoe	173	Glasscock	301	Loving	429	Stephens
047	Brooks	175	Goliad	303	Lubbock	431	Sterling
049	Brown	177	Gonzales	305	Lynn	433	Stonewall
051	Burleson	179	Gray	307	McCulloch	435	Sutton
053	Burnet	181	Grayson	309	McLennan	437	Swisher
055	Caldwell	183	Gregg	311	McMullen	439	Tarrant
057	Calhoun	185	Grimes	313	Madison	441	Taylor
059	Callahan	187	Guadalupe	315	Marion	443	Terrell
061	Cameron	189	Hale	317	Martin	445	Terry
063	Camp	191	Hall	319	Mason	447	Throckmorton
065	Carson	193	Hamilton	321	Matagorda	449	Titus
067	Cass	195	Hansford	323	Maverick	451	Tom Green
069	Castro	197	Hardeman	325	Medina	453	Travis
071	Chambers	199	Hardin	327	Menard	455	Trinity
073	Cherokee	201	Harris	329	Midland	457	Tyler
075	Childress	203	Harrison	331	Milam	459	Upshur
077	Clay	205	Hartley	333	Mills	461	Upton
079	Cochran	207	Haskell	335	Mitchell	463	Uvalde
081	Coke	209	Hays	337	Montague	465	Val Verde
083	Coleman	211	Hemphill	339	Montgomery	467	Van Zandt
085	Collin	213	Henderson	341	Moore	469	Victoria
087	Collingsworth	215	Hidalgo	343	Morris	471	Walker
089	Colorado	217	Hill	345	Motley	473	Waller
091	Comal	219	Hockley	347	Nacogdoches	475	Ward
093	Comanche	221	Hood	349	Navarro	477	Washington
095	Concho	223	Hopkins	351	Newton	479	Webb
097	Cooke	225	Houston	353	Nolan	481	Wharton
099	Coryell	227	Howard	355	Nueces	483	Wheeler
101	Cottle	229	Hudspeth	357	Ochiltree	485	Wichita
103	Crane	231	Hunt	359	Oldham	487	Wilbarger
105	Crockett	233	Hutchinson	361	Orange	489	Willacy
107	Crosby	235	Irion	363	Palo Pinto	491	Williamson
109	Culberson	237	Jack	365	Panola	493	Wilson
111	Dallam	239	Jackson	367	Parker	495	Winkler
113	Dallas	241	Jasper	369	Parmer	497	Wise
115	Dawson	243	Jeff Davis	371	Pecos	499	Wood
117	Deaf Smith	245	Jefferson	373	Polk	501	Yoakum
119	Delta	247	Jim Hogg	375	Potter	503	Young
121	Denton	249	Jim Wells	377	Presidio	505	Zapata
123	DeWitt	251	Johnson	379	Rains	507	Zavala
125	Dickens	253	Jones	381	Randall		
127	Dimmit	255	Karnes	383	Reagan		
129	Donley	257	Kaufman	385	Real		
131	Duval	259	Kendall	387	Red River		
133	Eastland	261	Kenedy	389	Reeves		
135	Ector	263	Kent	391	Refugio		
137	Edwards	265	Kerr	393	Roberts		
139	Ellis	267	Kimble	395	Robertson		
141	El Paso	269	King	397	Rockwall		
143	Erath	271	Kinney	399	Runnels		
145	Falls	273	Kleberg	401	Rusk		
147	Fannin	275	Knox	403	Sabine		
149	Fayette	277	Lamar	405	San Augustine		
151	Fisher	279	Lamb	407	San Jacinto		
153	Floyd	281	Lampasas	409	San Patricio		
155	Foard	283	La Salle	411	San Saba		
157	Fort Bend	285	Lavaca	413	Schleicher		
159	Franklin	287	Lee	415	Scurry		
161	Freestone	289	Leon	417	Shackleford		
163	Frio	291	Liberty	419	Shelby		

STATE NAME: UTAH
ALPHABETIC CODE:
UT
NUMERIC CODE: 49

CODE	COUNTY NAME
001	Beaver
003	Box Elder
005	Cache
007	Carbon
009	Daggett
011	Davis
013	Duchesne
015	Emery
017	Garfield
019	Grand
021	Iron
023	Juab

025 Kane	031 Campbell	167 Russell	and Charlotte Counties,
027 Millard	033 Caroline	169 Scott	reported respectively as 037
029 Morgan	035 Carroll	171 Shenandoah	and 039 in FIPS PUB 6-3,
031 Piute	036 Charles City	173 Smyth	have been corrected. The
033 Rich	037 Charlotte	175 Southampton	Bureau of Economic
035 Salt Lake	041 Chesterfield	177 Spotsylvania	Analysis, U.S. Department
037 San Juan	043 Clarke	179 Stafford	of Commerce has defined
039 Sanpete	045 Craig	181 Surry	codes in the 900 series to
041 Sevier	047 Culpeper	183 Sussex	represent county/independent
043 Summit	049 Cumberland	185 Tazewell	city combination in Virginia.
045 Tooele	051 Dickenson	187 Warren	
047 Uintah	053 Dinwiddie	191 Washington	The FIPS county code of 780
049 Utah	057 Essex	193 Westmoreland	for South Boston, VA, is
051 Wasatch	059 Fairfax	195 Wise	deleted. South Boston will
053 Washington	061 Fauquier	197 Wythe	be incorporated within
055 Wayne	063 Floyd	199 York	Halifax County rather than a
057 Weber	065 Fluvanna		separate county-equivalent
	067 Franklin	CODE	surrounded by Halifax
	069 Frederick	INDEPENDENT CITY	County.
STATE NAME:	071 Giles	510 Alexandria (city)	
VERMONT	073 Gloucester	515 Bedford (city)	
ALPHABETIC CODE:	075 Goochland	520 Bristol (city)	STATE NAME:
VT	077 Grayson	530 Buena Vista (city)	WASHINGTON
NUMERIC CODE: 50	079 Greene	540 Charlottesville (city)	ALPHABETIC CODE:
	081 Greensville	550 Chesapeake (city)	WA
CODE COUNTY NAME	083 Halifax	560 Clifton Forge (city)	NUMERIC CODE: 53
001 Addison	085 Hanover	570 Colonial Heights	
003 Bennington	087 Henrico	(city)	CODE COUNTY NAME
005 Caldeonia	089 Henry	580 Covington (city)	001 Adams
007 Chittenden	091 Highland	590 Danville (city)	003 Asotin
009 Essex	093 Isle of Wight	595 Emporia (city)	005 Benton
011 Franklin	095 James City	600 Fairfax (city)	007 Chelan
013 Grand Isle	097 King And Queen	610 Falls Church (city)	009 Clallam
015 Lamoille	099 King George	620 Franklin (city)	011 Clark
017 Orange	101 King William	630 Fredericksburg	013 Columbia
019 Orleans	103 Lancaster	(city)	015 Cowlitz
021 Rutland	105 Lee	640 Galax (city)	017 Douglas
023 Washington	107 Loudoun	650 Hampton (city)	019 Ferry
025 Windham	109 Louisa	660 Harrisonburg (city)	021 Franklin
027 Windsor	111 Lunenburg	670 Hopewell (city)	023 Garfield
	113 Madison	678 Lexington (city)	025 Grant
STATE NAME:	115 Mathews	680 Lynchburg (city)	027 Grays Harbor
VIRGINIA	117 Mecklenburg	683 Manassas (city)	029 Island
ALPHABETIC CODE:	119 Middlesex	685 Manassas Park (city)	031 Jefferson
VA	121 Montgomery	690 Martinsville (city)	033 King
NUMERIC CODE: 51	125 Nelson	700 Newport News	035 Kitsap
	127 New Kent	(city)	037 Kittitas
CODE COUNTY NAME	131 Northampton	710 Norfolk (city)	039 Klickitat
001 Accomack	133 Northumberland	720 Norton (city)	041 Lewis
003 Albermarle	135 Nottoway	730 Petersburg (city)	043 Lincoln
005 Alleghany	137 Orange	735 Poquoson (city)	045 Mason
007 Amelia	139 Page	740 Portsmouth (city)	047 Okanogan
009 Amherst	141 Patrick	750 Radford (city)	049 Pacific
011 Appomattox	143 Pittsylvania	760 Richmond (city)	051 Pend Oreille
013 Arlington	145 Powhatan	770 Roanoke (city)	053 Pierce
015 Augusta	147 Prince Edward	775 Salem (city)	055 San Juan
017 Bath	149 Prince George	790 Staunton (city)	057 Skagit
019 Bedford	153 Prince William	800 Suffolk (city)	059 Skamania
021 Bland	155 Pulaski	810 Virginia Beach	061 Snohomish
023 Botetourt	157 Rappahannock	(city)	063 Spokane
025 Brunswick	159 Richmond	820 Waynesboro (city)	065 Stevens
027 Buchanan	161 Roanoke	830 Williamsburg (city)	067 Thurston
029 Buckingham	163 Rockbridge	840 Winchester (city)	069 Wahkiakum
	165 Rockingham	The codes for Charles City	071 Walla Walla

073 Whatcom
075 Whitman
077 Yakima

STATE NAME: WEST VIRGINIA
ALPHABETIC CODE: WV
NUMERIC CODE: 54

CODE COUNTY NAME

001 Barbour
003 Berkeley
005 Boone
007 Braxton
009 Brooke
011 Cabell
013 Calhoun
015 Clay
017 Doddridge
019 Fayette
021 Gilmer
023 Grant
025 Greenbrier
027 Hampshire
029 Hancock
031 Hardy
033 Harrison
035 Jackson
037 Jefferson
039 Kanawha
041 Lewis
043 Lincoln
045 Logan
047 McDowell
049 Marion
051 Marshall
053 Mason
055 Mercer
057 Mineral
059 Mingo
061 Monongalia
063 Monroe
065 Morgan
067 Nicholas
069 Ohio
071 Pendleton
073 Pleasants
075 Pocahontas
077 Preston
079 Putnam
081 Raleigh
083 Randolph
085 Ritchie
087 Roane
089 Summers
091 Taylor
093 Tucker
095 Tyler
097 Upshur
099 Wayne
101 Webster
103 Wetzel

105 Wirt
107 Wood
109 Wyoming

STATE NAME: WISCONSIN
ALPHABETIC CODE: WI
NUMERIC CODE: 55

CODE COUNTY NAME

001 Adams
003 Ashland
005 Barron
007 Bayfield
009 Brown
011 Buffalo
013 Burnett
015 Calumet
017 Chippewa
019 Clark
021 Columbia
023 Crawford
025 Dane
027 Dodge
029 Door
031 Douglas
033 Dunn
035 Eau Claire
037 Florence
039 Fond du Lac
041 Forest
043 Grant
045 Green
047 Green Lake
049 Iowa
051 Iron
053 Jackson
055 Jefferson
057 Juneau
059 Kenosha
061 Kewaunee
063 La Crosse
065 Lafayette
067 Langlade
069 Lincoln
071 Manitowoc
073 Marathon
075 Marinette
077 Marquette
078 Menominee
079 Milwaukee
081 Monroe
083 Oconto
085 Oneida
087 Outagamie
089 Ozaukee
091 Pepin
093 Pierce
095 Polk
097 Portage
099 Price
101 Racine

103 Richland
105 Rock
107 Rusk
109 St. Croix
111 Sauk
113 Sawyer
115 Shawano
117 Sheboygan
119 Taylor
121 Trempealeau
123 Vernon
125 Vilas
127 Walworth
129 Washburn
131 Washington
133 Waukesha
135 Waupaca
137 Waushara
139 Winnebago
141 Wood

STATE NAME: WYOMING
ALPHABETIC CODE: WY
NUMERIC CODE: 56

CODE COUNTY NAME

001 Albany
003 Big Horn
005 Campbell
007 Carbon
009 Converse
011 Crook
013 Fremont
015 Goshen
017 Hot Springs
019 Johnson
021 Laramie
023 Lincoln
025 Natrona
027 Niobrara
029 Park
031 Platte
033 Sheridan
035 Sublette
037 Sweetwater
039 Teton
041 Uinta
043 Washakie
045 Weston

APPENDIX A

AREA NAME: AMERICAN SAMOA
ALPHABETIC CODE: AS
NUMERIC CODE: 60

CODE DISTRICT/ISLAND NAME
010 Eastern (District)

020 Manu'a (District)
030 Rose Island
040 Swains Island
050 Western (District)

"Island" is part of the name of Rose Island and Swains Island. The entities called "counties" in American Samoa are subdivisions of the districts, and therefore are second-order subdivisions of American Samoa.

AREA NAME: GUAM
ALPHABETIC CODE: GU
NUMERIC CODE: 66

CODE SUBDIVISION NAME
010 Guam

Guam has no first-order subdivisions, and therefore "Guam" also serves as the county-equivalent entity.

AREA NAME: NORTHERN MARINA ISLANDS
ALPHABETIC CODE: MP
NUMERIC CODE: 69

CODE MUNICIPALITY NAME
085 Northern Islands
100 Rota
110 Saipan
120 Tinian

AREA NAME: PALAU
ALPHABETIC CODE: PW
NUMERIC CODE: 70

CODE STATE NAME
002 Aimeliik
004 Airai
010 Angaur
050 Hatoboheit
100 Kayangel
150 Koror
212 Melekeok
214 Ngaraard
218 Ngarchelong
222 Ngardmau
224 Ngatpang
226 Ngchesar

227 Ngermlengui
228 Ngiwal
350 Peleliu
370 Sonsorol

Palau also is known as Beau, and may be referred to as the Republic of... Changes since recognition of Palau in Change Notice No. 9 to FIPS PUB 6-3. The first-order subdivisions of Palau have been revised from municipalities to states; the name of Melekeik has been revised to Melekeok; the name and code for Ngaremlengui (223) have been revised to Ngeremlengui (227); the name and code for Tobí (380) have been revised to Hatobohei (050); the Palau Islands (unorganized territory) (300) is no longer included because that area is part of Koror and Peleliu.

AREA NAME: PUERTO RICO
ALPHABETIC CODE: PR
NUMERIC CODE: 72

CODE
MUNICIPALITY NAME

001 Adjuntas
003 Aguada
005 Aguadilla
007 Aguas Buenas
009 Aibonito
011 Anasco
013 Arecibo
015 Arroyo
017 Barceloneta
019 Barranquitas
021 Bayamo'n
023 Cabo Rojo
025 Caguas
027 Camuy
029 Canovanas
031 Carolina
033 Catano
035 Cayey
037 Ceiba
039 Ciales
041 Cidra
043 Coamo
045 Comerio
047 Corozal
049 Culebra
051 Dorado
053 Fajardo

054 Florida
057 Guayama
059 Guayanilla
061 Guaynabo
063 Gurabo
065 Hatillo
067 Hormigueros
069 Humacao
071 Isabela
073 Jayuya
075 Juana Díaz
077 Juncos
079 Lajas
081 Lares
083 Las Marias
085 Las Piedras
087 Loiza
089 Luquillo
091 Manatí
093 Maricao
095 Maunabo
097 Mayaguez
099 Moca
101 Morovis
103 Naguabo
105 Naranjito
107 Orocovis
109 Patillas
111 Penuelas
113 Ponce
115 Quebradillas
117 Rincon
119 Río Grande
121 Sabana Grande
123 Salinas
125 San German
127 San Juan
129 San Lorenzo
131 San Sebastian
133 Santa Isabel
135 Toa Alta
137 Toa Baja
139 Trujillo Alto
141 Utuado
143 Vega Alta
145 Vega Baja
147 Vieques
149 Villalba
151 Yabucoa
153 Yauco

AREA NAME: U.S. OUTLYING ISLANDS
ALPHABETIC CODE: UM
NUMERIC CODE: 74

CODE ISLAND NAME

050 Baker Island
100 Howland Island
150 Jarvis Island
200 Johnston Island
250 Kingman Reef

300 Midway Islands
350 Navassa Island
400 Palmyra Atoll
450 Wake Island

An FIPS State numeric code is available for each area; FIPS PUB 5-2 identifies the codes and explains their usage. The State codes can be used in combination with the "county" codes listed here.

AREA NAME: VIRGIN ISLANDS OF THE UNITED STATES
ALPHABETIC CODE: VI
NUMERIC CODE: 78

CODE ISLAND NAME

010 St. Croix
020 St. John
030 St. Thomas

APPENDIX B

AREA NAME: FEDERATED STATES OF MICRONESIA
ALPHABETIC CODE: FM
NUMERIC CODE: 64

CODE STATE NAME

002 Chuuk
005 Kosrae
040 Pohnpei
060 Yap

The Federated States of Micronesia (FSM) became a freely associated state on 11/3/86. Its first-order subdivisions are called states. Changes since recognition of the FSM in Change Notice No. 9 to FIPS PUB 6-3. Ponape was renamed Pohnpei (11/8/84), and retained code 040; Truk (050) was renamed Chuuk (10/1/89).

AREA NAME: MARSHALL ISLANDS
ALPHABETIC CODE: MH
NUMERIC CODE: 68

CODE
MUNICIPALITY NAME

007 Ailinginae
010 Ailinglaplap
030 Ailuk
040 Arno
050 Aur
060 Bikar
070 Bikini
073 Bokak
080 Ebon
090 Enewetak
100 Erikub
110 Jabat
120 Jaluit
130 Jemo
140 Kili
150 Kwajalein
160 Lae
170 Lib
180 Likiep
190 Majuro
300 Maloelap
310 Mejit
320 Mili
330 Namorik
340 Namu
350 Rongelap
360 Rongrik
385 Toke
390 Ujae
400 Ujelang
410 Utrik
420 Wotho
430 Wotile

The Marshall Islands became a freely associated state on 11/3/86. Its first-order subdivisions also may be referred to as "islands" and "atolls." Since the recognition of the Marshall Islands in Change Notice No. 9, Jemo has been revised from Jemo Island to a municipality. Toke also may be spelled "Taka."

APPENDIX B

EDITS TABLES FOR SELECTED DATA ITEMS

Table Name: BPLACE.DBF (SEER GEOCODES FOR CODING PLACE OF BIRTH)

CONTINENTAL UNITED STATES AND HAWAII

000 United States

001 New England and New Jersey
 002 Maine
 003 New Hampshire
 004 Vermont
 005 Massachusetts
 006 Rhode Island
 007 Connecticut
 008 New Jersey

010 North Mid-Atlantic States
 011 New York
 014 Pennsylvania
 017 Delaware

020 South Mid-Atlantic States
 021 Maryland
 022 District of Columbia
 023 Virginia
 024 West Virginia
 025 North Carolina
 026 South Carolina

030 Southeastern States
 031 Tennessee
 033 Georgia
 035 Florida
 037 Alabama
 039 Mississippi

040 North Central States
 041 Michigan
 043 Ohio
 045 Indiana
 047 Kentucky

050 Northern Midwest States
 051 Wisconsin
 052 Minnesota
 053 Iowa
 054 North Dakota
 055 South Dakota
 056 Montana

060 Central Midwest States
 061 Illinois
 063 Missouri
 065 Kansas
 067 Nebraska

070 Southern Midwest States
 071 Arkansas
 073 Louisiana
 075 Oklahoma
 077 Texas

080 Mountain States
 081 Idaho
 082 Wyoming
 083 Colorado
 084 Utah
 085 Nevada
 086 New Mexico
 087 Arizona

090 Pacific Coast States
 091 Alaska
 093 Washington
 095 Oregon
 097 California
 099 Hawaii

UNITED STATES POSSESSIONS

When SEER geocodes were originally assigned during the 1970s, the United States owned or controlled islands in the Pacific. Since then, many of these islands have either been given their independence or had control turned over to another country. In order to maintain consistent information over time, these islands are still to be coded to the original codes. Earlier designations are listed in parentheses.

100 Atlantic/Caribbean Area
 101 Puerto Rico
 102 U.S. Virgin Islands
 109 Other Atlantic/Caribbean Area

110 Canal Zone

120 Pacific Area
 121 American Samoa
 122 Kiribati (Canton and Enderbury Islands, Gilbert Islands, Southern Line Islands, Phoenix Islands)
 123 Micronesia [Federated States of] (Caroline Islands, Trust Territory of Pacific Islands)
 124 Cook Islands (New Zealand)
 125 Tuvalu (Ellice Islands)
 126 Guam
 127 Johnston Atoll
 129 Mariana Islands (Trust Territory of Pacific Islands)
 131 Marshall Islands (Trust Territory Pacific Islands)
 132 Midway Islands
 133 Nampo-Shoto, Southern

- 134 Ryukyu Islands (Japan)
- 135 Swan Islands
- 136 Tokelau Islands (New Zealand)
- 137 Wake Island
- 139 Palau (Trust Territory of Pacific Islands)

NORTH AND SOUTH AMERICA, EXCLUSIVE OF THE UNITED STATES AND ITS POSSESSIONS

- 210 Greenland
- 220 Canada
 - 221 Labrador
 - Maritime provinces
 - New Brunswick
 - Newfoundland and Labrador
 - Nova Scotia
 - Prince Edward Island
 - 222 Quebec
 - 223 Ontario
 - 224 Prairie provinces
 - Alberta
 - Manitoba
 - Saskatchewan
 - 225 Northwest Territories
 - Yukon Territory
 - 226 British Columbia
 - 227 Nunavut (Nunavut became an official Territory of Canada on April 1, 1999.)
- 230 Mexico
- 240 North American Islands
 - 241 Cuba
 - 242 Haiti
 - 243 Dominican Republic
 - 244 Jamaica
 - 245 Other Caribbean Islands
 - Anguilla
 - Antigua and Barbuda
 - Barbados
 - British Virgin Islands
 - Cayman Islands
 - Dominica
 - Grenada
 - Guadeloupe
 - Martinique
 - Montserrat
 - Netherlands Antilles
 - St. Kitts and Nevis
 - St. Lucia
 - St. Vincent and the Grenadines
 - Trinidad and Tobago
 - Turks and Caicos
 - Antilles, NOS
 - British West Indies, NOS
 - Caribbean, NOS
 - Leeward islands, NOS
 - West Indies, NOS
 - Windward islands, NOS
 - 246 Bermuda
 - 247 Bahamas
 - 249 St. Pierre and Miquelon

- 250 Central America
 - 251 Guatemala
 - 252 Belize (British Honduras)
 - 253 Honduras
 - 254 El Salvador
 - 255 Nicaragua
 - 256 Costa Rica
 - 257 Panama

260 North America, NOS

265 Latin America, NOS

- 300 South America, NOS
 - 311 Colombia
 - 321 Venezuela
 - 331 Guyana (British Guiana)
 - 332 Suriname (Dutch Guiana)
 - 333 French Guiana
 - 341 Brazil
 - 345 Ecuador
 - 351 Peru
 - 355 Bolivia
 - 361 Chile
 - 365 Argentina
 - 371 Paraguay
 - 375 Uruguay

- 380 South American Islands
 - 381 Falkland Islands

EUROPE

Former or alternative names are in parentheses

Europe, NOS (See code 499) *

* *Effective cases diagnosed 1/1/92.*

- 400 United Kingdom, NOS
 - 401 England
 - Channel Islands
 - Isle of Man
 - 402 Wales
 - 403 Scotland
 - 404 Northern Ireland (Ulster)
- 410 Ireland (Eire)
 - Ireland, NOS
 - Republic of Ireland
- 420 Scandinavia
 - Lapland, NOS
 - 421 Iceland
 - 423 Norway
 - Svalbard
 - Jan Mayen
 - 425 Denmark
 - Faroe Islands
 - 427 Sweden
 - 429 Finland

- 430 Germanic countries
 - 431 Germany
 - (East Germany including East Berlin)
 - (West Germany including West Berlin)
 - 432 Netherlands
 - 433 Belgium
 - 434 Luxembourg
 - 435 Switzerland
 - 436 Austria
 - 437 Liechtenstein

- 440 Romance-language countries
 - 441 France
 - Corsica
 - Monaco
 - 443 Spain
 - Andorra
 - Balearic Islands
 - Canary Islands
 - 445 Portugal
 - Azores
 - Cape Verde Islands
 - Madeira Islands
 - 447 Italy
 - San Marino
 - Sardinia
 - Sicily
 - Vatican City (Holy See)
 - 449 Romania

- 450 Slavic countries
 - 451 Poland
 - 452 (former) Czechoslovakia region
 - Bohemia
 - Czech Republic
 - Moravia
 - Slovak Republic
 - Slovakia
 - 453 (former) Yugoslavia region
 - Bosnia-Herzegovina
 - Croatia
 - Dalmatia
 - Montenegro
 - Macedonia
 - Serbia
 - Slavonia
 - Slovenia
 - 454 Bulgaria
 - 455 Russia
 - Russian Federation
 - (former) U.S.S.R.
 - Russia, NOS
 - (Russian S.F.S.R.)
 - 456 Ukraine and Moldova
 - (Bessarabia)
 - Moldavia
 - (Moldavian S.S.R.)
 - (Ukrainian S.S.R.)
 - 457 Belarus
 - (Byelorussian S.S.R.)
 - (White Russia)
 - 458 Estonia (Estonian S.S.R.)
 - 459 Latvia (Latvian S.S.R.)
 - 461 Lithuania
 - (Lithuanian S.S.R.)

- 463 Baltic Republic(s), NOS
 - (Baltic States, NOS)
- 470 Other mainland Europe
 - 471 Greece
 - 475 Hungary
 - 481 Albania
 - 485 Gibraltar
- 490 Other Mediterranean islands
 - 491 Malta
 - 495 Cyprus
 - 499 Europe, NOS*
 - Central Europe, NOS
 - Eastern Europe, NOS
 - Northern Europe, NOS
 - Southern Europe, NOS
 - Western Europe, NOS

* *Effective cases diagnosed 1/1/92.*

AFRICA

- 500 Africa, NOS
 - Central Africa, NOS
 - Equatorial Africa, NOS
- 510 North Africa, NOS
 - 511 Morocco
 - 513 Algeria
 - 515 Tunisia
 - 517 Libya
 - (Cyrenaica)
 - (Tripoli)
 - (Tripolitania)
 - 519 Egypt (United Arab Republic)
- 520 Sudanese countries
 - Burkina Faso (Upper Volta)
 - Chad
 - Mali
 - Mauritania
 - Niger
 - Sudan (Anglo-Egyptian Sudan)
 - Western (Spanish) Sahara
- 530 West Africa, NOS
 - French West Africa, NOS
 - 531 Nigeria
 - 539 Other West African Countries
 - Benin (Dahomey)
 - Cameroon (Kameroun)
 - Central African Republic (French Equatorial Africa)
 - Cote d'Ivoire (Ivory Coast)
 - Congo (Congo-Brazzaville, French Congo)
 - Equatorial Guinea (Spanish Guinea) (Bioko [Fernando Poo], Rio Muni)
 - Gambia
 - Gabon
 - Ghana
 - Guinea
 - Guinea Bissau (Portuguese Guinea)
 - Liberia
 - Senegal
 - Sierra Leone
 - Togo

- 540 South Africa, NOS
 541 Zaire (Congo-Leopoldville, Belgian Congo, Congo/Kinshasa)
 543 Angola (Sao Tome, Principe, Cabinda)
 545 Republic of South Africa
 (Bophuthatswana, Cape Colony, Ciskei, Natal, Free State [Orange Free State], Transkei, Transvaal, Venda)
 Botswana (Bechuanaland)
 Lesotho (Basutoland)
 Namibia (South West Africa)
 Swaziland
 547 Zimbabwe (Rhodesia, Southern Rhodesia)
 549 Zambia (Northern Rhodesia)
 551 Malawi (Nyasaland)
 553 Mozambique
 555 Madagascar (Malagasy Republic)
- 570 East Africa
 571 Tanzania (Tanganyika, Tanzanyika, Zanzibar)
 573 Uganda
 575 Kenya
 577 Rwanda (Ruanda)
 579 Burundi (Urundi)
 581 Somalia (Somali Republic, Somaliland)
 583 Djibouti (French Territory of the Afars and Issas, French Somaliland)
 585 Ethiopia (Abyssinia)
 Eritrea
- 580 African Coastal Islands (previously included in 540)
 Comoros
 Mauritius
 Mayotte
 Reunion
 St. Helena
 Seychelles
- * Effective cases diagnosed 1/1/92*
- ASIA**
- 600 Asia, NOS*
- 610 Near East
 Mesopotamia, NOS
 611 Turkey
 Anatolia
 Asia Minor, NOS
- 620 Asian Arab Countries
 Iraq-Saudi Arabia Neutral Zone
 621 Syria
 623 Lebanon
 625 Jordan (Transjordan, former Arab Palestine)
 627 Iraq
 629 Arabian Peninsula
 Bahrain
 Kuwait
 Oman and Muscat
 Persian Gulf States, NOS
 Qatar
 Saudi Arabia
 United Arab Emirates (Trucial States)
 Yemen (Aden, People's Democratic Republic of Yemen, Southern Yemen)
- 631 Israel and former Jewish Palestine
 Gaza
 Palestine, NOS
 Palestine (Palestinian National Authority [PNA])
 West Bank
 633 Caucasian Republics of the former U.S.S.R.
 Armenia
 Azerbaijan (Nagorno-Karabakh)
 Georgia
 634 Other Asian Republics of the former U.S.S.R.
 Kazakhstan (Kazakh S.S.R.)
 Kyrgystan (Kirghiz S.S.R., Kyrgyz)
 Tajikistan (Tadzhik S.S.R.)
 Turkmenistan (Turkmen S.S.R.)
 Uzbekistan (Uzbek S.S.R.)
 637 Iran (Persia)
 638 Afghanistan
 639 Pakistan (West Pakistan)
- 640 Mid-East Asia, NOS
 Maldives
 641 India, Andaman Islands
 643 Nepal, Bhutan, Sikkim
 645 Bangladesh (East Pakistan)
 647 Sri Lanka (Ceylon)
 649 Myanmar (Burma)
- 650 Southeast Asia
 651 Thailand (Siam)
- 660 Indochina
 661 Laos
 663 Cambodia, Kampuchea
 665 Vietnam (Tonkin, Annam, Cochin China)
 671 Malaysia, Singapore, Brunei
 673 Indonesia (Dutch East Indies)
 675 Philippines (Philippine Islands)
- 680 East Asia
 681 China, NOS
 682 China (People's Republic of China)
 683 Hong Kong
 684 Taiwan (Formosa, Republic of China)
 685 Tibet
 686 Macao (Macau)
 691 Mongolia
 693 Japan
 695 Korea
 North Korea
 South Korea
- * Effective cases diagnosed 1/1/92.*

AUSTRALIA AND OCEANIA

- 711 Australia and Australian New Guinea
- 715 New Zealand
 - Niue
- 720 Pacific Islands
 - Oceania, NOS
 - Polynesia, NOS
- 721 Melanesian Islands
 - Solomon Islands
 - Fiji
 - Fotuna
 - New Hebrides
 - Vanuatu
 - Wallis
- 723 Micronesian Islands
- 725 Polynesian Islands
- 750 Antarctica

Except possessions of the United States.

PLACE OF BIRTH UNKNOWN

- 998 Place of Birth stated not to be in United States, but no other information available
- 999 Place of Birth unknown

References: *CIA World Factbook*, 1995. U.S. Bureau of the Census
Place of Birth Technical Documentation, 1997.

ALPHABETICAL LISTING

* *Effective cases diagnosed 1/1/92.*

A

585 Abyssinia
629 Aden
583 Afars and Issas
638 Afghanistan
500 Africa
570 Africa, East
510 Africa, North
540 Africa, South
545 Africa, South West
530 Africa, West
580 African Coastal Islands
(previously included in 540)
037 Alabama
091 Alaska
481 Albania
224 Alberta
513 Algeria
250 America, Central
260 America, North
(see also North America)
300 America, South
121 American Samoa
611 Anatolia
641 Andaman Islands
443 Andorra
543 Angola
245 Anguilla
665 Annam
750 Antarctica
245 Antigua
245 Antilles, NOS
245 Antilles, Netherlands
625 Arab Palestine
629 Arabia, Saudi
629 Arabian Peninsula
365 Argentina
087 Arizona
071 Arkansas
633 Armenia (U.S.S.R.)
611 Armenia (Turkey)
750 Antarctica
245 Aruba
600 Asia, NOS*
680 Asia, East
640 Asia, Mid-East
610 Asia Minor, NOS
610 Asia, Near-East
650 Asia, Southeast
634 Asian Republics of the former
U.S.S.R.
620 Asian Arab countries
100 Atlantic/Caribbean area,
U.S. possessions
109 Atlantic/Caribbean area,
other U.S. possessions
711 Australia
711 Australian New Guinea
436 Austria
633 Azerbaijan
633 Azerbaizhan S.S.R.

445 Azores

B

247 Bahamas
629 Bahrain
443 Balearic islands
463 Baltic Republic, NOS
463 Baltic States, NOS
645 Bangladesh
245 Barbados
245 Barbuda
431 Bavaria
545 Basutoland
545 Bechuanaland
457 Belarus
541 Belgian Congo
433 Belgium
252 Belize
539 Benin
246 Bermuda
456 Bessarabia
643 Bhutan
539 Bioko (Fernando Poo)
452 Bohemia
355 Bolivia
545 Bophuthatswana
673 Borneo
453 Bosnia-Herzegovina
545 Botswana
341 Brazil
226 British Columbia
331 British Guiana
252 British Honduras
245 British Virgin Islands
245 British West Indies, NOS
671 Brunei
454 Bulgaria
520 Burkina Faso (Upper Volta)
649 Burma
(see Myanmar)
579 Burundi
457 Byelorussian S.S.R.

C

543 Cabinda
245 Caicos Islands
097 California
663 Cambodia
539 Cameroon
220 Canada
110 Canal Zone
443 Canary islands
122 Canton islands
545 Cape Colony
445 Cape Verde islands
245 Caribbean, NOS
245 Caribbean islands, other
123 Caroline Islands
711 Cartier Islands
633 Caucasian Republics of the
former U.S.S.R.
245 Cayman Islands
500 Central Africa, NOS

539 Central African Republic
250 Central America
499 Central Europe, NOS
060 Central Midwest States
647 Ceylon
520 Chad
401 Channel Islands (British)
361 Chile
681 China
(not otherwise specified)
665 China, Cochín
682 China, People's Republic of
684 China, Republic of
723 Christmas Island
545 Ciskei
665 Cochín China
711 Cocos (Keeling) Islands
311 Colombia
083 Colorado
580 Comoros
226 Columbia, British
022 Columbia, District of
539 Congo-Brazzaville
541 Congo-Leopoldville
541 Congo, Belgian
539 Congo, French
541 Congo Kinshasa
007 Connecticut
124 Cook Islands
441 Corsica
256 Costa Rica
539 Cote d'Ivoire (Ivory Coast)
471 Crete
453 Croatia
241 Cuba
245 Curacao
495 Cyprus
517 Cyrenaica
452 Czechoslovakia
452 Czech Republic

D

539 Dahomey
453 Dalmatia
017 Delaware
425 Denmark
022 District of Columbia
583 Djibouti
449 Dobruja
245 Dominica
243 Dominican Republic
673 Dutch East Indies
332 Dutch Guiana

E

570 East Africa
680 East Asia
431 East Germany
673 East Indies, Dutch
645 East Pakistan
499 Eastern Europe, NOS
345 Ecuador

519	Egypt	539	Guinea-Bissau (Portuguese Guinea)	695	Korea
410	Eire			695	Korea, North
254	El Salvador	539	Guinea, Equatorial	695	Korea, South
125	Ellice Islands	—	Guinea, New (see New Guinea)	629	Kuwait
122	Enderbury Islands	539	Guinea, Portuguese	634	Kyrgystan
401	England	331	Guyana	634	Kyrgyz
500	Equatorial Africa, NOS				L
539	Equatorial Guinea (Spanish Guinea)	H			
585	Eritrea			221	Labrador
458	Estonia	242	Haiti	661	Laos
458	Estonian S.S.R. (Estonia)	099	Hawaii	265	Latin America, NOS
585	Ethiopia	432	Holland	420	Lapland, NOS
499	Europe, NOS*	253	Honduras	459	Latvia
470	Europe, other mainland	252	Honduras, British	459	Latvian S.S.R. (Latvia)
	F	683	Hong Kong	623	Lebanon
		475	Hungary	245	Leeward island, NOS
				545	Lesotho
425	Faroe (Faeroe) Islands	I		539	Liberia
381	Falkland Islands			517	Libya
431	Federal Republic of Germany	421	Iceland	437	Liechtenstein
539	Fernando Poo	081	Idaho	122	Line Islands, Southern
721	Fiji	061	Illinois	461	Lithuania
429	Finland	641	India	461	Lithuanian S.S.R. (Lithuania)
035	Florida	045	Indiana	073	Louisiana
684	Formosa	673	Indies, Dutch East	434	Luxembourg
721	Fotuna	660	Indochina		M
441	France	673	Indonesia		
545	Free State (Orange Free State)	053	Iowa	686	Macao
539	French Congo	637	Iran	686	Macau
333	French Guiana	627	Iraq	453	Macedonia
725	French Polynesia	620	Iraq-Saudi Arabian Neutral Zone	555	Madagascar
583	French Somaliland	410	Ireland (Eire)	445	Madeira islands
530	French West Africa, NOS	404	Ireland, Northern	002	Maine
245	French West Indies	410	Ireland, NOS	555	Malagasy Republic
	G	410	Ireland, Republic of	551	Malawi
		401	Isle of Man	671	Malay Peninsula
539	Gabon	631	Israel	671	Malaysia
345	Galapagos Islands	583	Issas	640	Maldives
539	Gambia	447	Italy	520	Mali
631	Gaza Strip	539	Ivory Coast	491	Malta
033	Georgia (U.S.A.)	J		224	Manitoba
633	Georgia (U.S.S.R.)			129	Mariana Islands
430	Germanic countries	423	Jan Mayen	221	Maritime provinces, Canada
431	German Democratic Republic	244	Jamaica	131	Marshall Islands
431	Germany	693	Japan	245	Martinique
431	Germany, East	673	Java	021	Maryland
431	Germany, Federal Republic of	401	Jersey	005	Massachusetts
431	Germany, West	631	Jewish Palestine	520	Mauritania
539	Ghana	127	Johnston Atoll	580	Mauritius
485	Gibraltar	625	Jordan	580	Mayotte
122	Gilbert Islands	453	Jugoslavia	490	Mediterranean Islands, Other
471	Greece			721	Melanesian islands
210	Greenland	K		610	Mesopotamia, NOS
245	Grenada			230	Mexico
245	Grenadines, The	539	Kameroon	041	Michigan
245	Guadaloupe	663	Kampuchea	123	Micronesian islands
126	Guam	065	Kansas	640	Mid-East Asia
251	Guatamala	634	Kazakh S.S.R.	132	Midway Islands
401	Guernsey	634	Kazakhstan	052	Minnesota
331	Guiana, British	047	Kentucky	249	Miquelon
332	Guiana, Dutch	575	Kenya	039	Mississippi
333	Guiana, French	634	Kirghiz S.S.R.	063	Missouri
539	Guinea	122	Kiribati	456	Moldavia

456	Moldavian S.S.R.	423	Norway	006	Rhode Island
456	Moldova	998	Not United States, NOS	547	Rhodesia
441	Monaco	221	Nova Scotia	549	Rhodesia, Northern
691	Mongolia	227	Nunavut	547	Rhodesia, Southern
056	Montana	551	Nyasaland	539	Rio Muni
453	Montenegro			440	Romance-language countries
245	Montserrat		O	449	Romania
452	Moravia			449	Roumania
511	Morocco	043	Ohio	577	Ruanda
080	Mountain States	075	Oklahoma	449	Rumania
553	Mozambique	629	Oman	455	Russia, NOS
629	Muscat	223	Ontario	457	Russia, White
649	Myanmar (See Burma)	545	Orange Free State	455	Russian Federation (former U.S.S.R.)
		095	Oregon	455	Russian S.F.S.R.
		403	Orkney Islands	577	Rwanda
	N		P	134	Ryukyu Islands
545	Namibia				S
133	Nampo-shoto, Southern	120	Pacific area, U.S. possessions		
545	Natal	720	Pacific islands		
723	Nauru	123	Pacific Islands, Trust Territory of the (code to specific islands if possible)	520	Sahara, Western
610	Near-East Asia			121	Samoa, American
067	Nebraska			725	Samoa, Western
643	Nepal	090	Pacific Coast States	245	St. Christopher-Nevis
432	Netherlands	639	Pakistan	580	St. Helena
245	Netherlands Antilles	645	Pakistan, East	245	St. Kitts (see St. Christopher- Nevis)
332	Netherlands Guiana	639	Pakistan, West	245	St. Lucia
085	Nevada	139	Palau (Trust Territory of the Pacific Islands)	249	St. Pierre
245	Nevis			245	St. Vincent
221	New Brunswick	625	Palestine, Arab	447	San Marino
725	New Caledonia	631	Palestine, Jewish	543	Sao Tome
001	New England	631	Palestine, NOS	447	Sardinia
673	New Guinea, except Australian and North East	631	Palestinian National Authority (PNA)	224	Saskatchewan
711	New Guinea, Australian	257	Panama	629	Saudi Arabia
711	New Guinea, North East	711	Papua New Guinea	420	Scandinavia
003	New Hampshire	371	Paraguay	403	Scotland
721	New Hebrides	014	Pennsylvania	539	Senegal
008	New Jersey	629	People's Democratic Republic of Yemen	453	Serbia
086	New Mexico			580	Seychelles
011	New York	682	People's Republic of China	403	Shetland Islands
715	New Zealand	637	Persia	651	Siam
221	Newfoundland	629	Persian Gulf States, NOS	447	Sicily
255	Nicaragua	351	Peru	539	Sierra Leone
520	Niger	675	Philippine Islands	643	Sikkim
531	Nigeria	675	Philippines	671	Singapore
715	Niue	725	Pitcairn	450	Slavic countries
711	Norfolk Island	451	Poland	453	Slavonia
671	North Borneo (Malaysia)	725	Polynesian islands	452	Slovak Republic
510	North Africa, NOS	445	Portugal	452	Slovakia
260	North America, NOS (use more specific term if possible)	539	Portuguese Guinea	453	Slovenia
240	North American islands	224	Prairie Provinces, Canada	721	Solomon Islands
025	North Carolina	221	Prince Edward Island	581	Somali Republic
040	North Central States	543	Principe	581	Somalia
054	North Dakota	101	Puerto Rico	581	Somaliland
711	North East New Guinea			583	Somaliland, French
695	North Korea		Q	540	South Africa
010	North Mid-Atlantic States	629	Qatar	545	South Africa, Republic of
499	Northern Europe, NOS	222	Quebec	545	South Africa, Union of
404	Northern Ireland			300	South America
129	Northern Mariana Islands		R	380	South American islands
050	Northern Midwest States			026	South Carolina
549	Northern Rhodesia	684	Republic of China	055	South Dakota
225	Northwest Territories (Canada)	545	Republic of South Africa	695	South Korea
		580	Reunion	020	South Mid-Atlantic States
				545	South West Africa

650	Southeast Asia		individual republics)
030	Southeastern States	629	United Arab Emirates
499	Southern Europe, NOS	519	United Arab Republic
122	Southern Line Islands	400	United Kingdom
070	Southern Midwest States	000	United States
133	Southern Nampo-shoto	102	U.S. Virgin Islands
547	Southern Rhodesia	999	Unknown
629	Southern Yemen	520	Upper Volta
—	Soviet Union (see individual republics)	375	Uruguay
443	Spain	579	Urundi
520	Spanish Sahara	084	Utah
647	Sri Lanka	634	Uzbekistan
520	Sudan (Anglo-Egyptian Sudan)	634	Uzbek S.S.R.
520	Sudanese countries		V
673	Sumatra	721	Vanuatu
332	Suriname	447	Vatican City
423	Svalbard	545	Venda
135	Swan Islands	321	Venezuela
545	Swaziland	004	Vermont
427	Sweden	665	Vietnam
435	Switzerland	102	Virgin Islands (U.S.)
621	Syria	245	Virgin Islands (British)
	T	023	Virginia
			W
634	Tadzhik S.S.R.		
684	Taiwan	137	Wake Island
634	Tajikistan	402	Wales
571	Tanzania	721	Wallis
571	Tanganyika	449	Wallachia
571	Tanzanyika	093	Washington (state)
031	Tennessee	022	Washington D.C.
077	Texas	530	West Africa, NOS
651	Thailand (Siam)	539	West African countries, other
685	Tibet	631	West Bank
245	Tobago	431	West Germany
539	Togo	245	West Indies, NOS (see also individual islands)
136	Tokelau Islands	639	West Pakistan
725	Tonga	024	West Virginia
665	Tonkin	499	Western Europe, NOS
625	Trans-Jordan	520	Western Sahara
545	Transkei	725	Western Samoa
545	Transvaal	457	White Russia
449	Transylvania	245	Windward islands
245	Trinidad	051	Wisconsin
517	Tripoli	082	Wyoming
517	Tripolitania		Y
629	Trucial States		
515	Tunisia	629	Yemen
611	Turkey	629	Yemen, People's Democratic Republic of
634	Turkmen S.S.R.	453	Yugoslavia (former Yugoslavia region)
634	Turkmenistan	225	Yukon Territory
245	Turks Islands		Z
125	Tuvalu		
	U		
573	Uganda	541	Zaire
456	Ukraine	549	Zambia
456	Ukranian S.S.R.	571	Zanzibar
404	Ulster	547	Zimbabwe
545	Union of South Africa		
—	Union of Soviet Socialist Republics (U.S.S.R.) (see		

Table Name: PEDSTAGE.DBF

1	Stage I
1A	Stage IA
1B	Stage IB
2	Stage II
2A	Stage IIA
2B	Stage IIB
2C	Stage IIC
3	Stage III
3A	Stage IIIA
3B	Stage IIIB
3C	Stage IIIC
3D	Stage IIID
3E	Stage IIIE
4	Stage IV
4A	Stage IVA
4B	Stage IVB
4S	Stage IVS
5	Stage V
A	Stage A
B	Stage B
C	Stage C
D	Stage D
DS	Stage DS
88	Not applicable (not pediatric case)
99	Unstaged, unknown

Table Name: REGID.DBF

00000200	Maine Cancer Incidence Registry	00004100	Michigan Cancer Surveillance System
00000300	New Hampshire State Cancer Registry	00004101	Michigan Cancer Foundation, CA Surveillance Detroit Metropolitan Area
00000400	Vermont Cancer Registry	00004101	Detroit Metropolitan
00000500	Massachusetts Cancer Registry	00004300	Ohio Bureau of Chronic Disease
00000580	Southeast Massachusetts Cancer Registry	00004301	Cancer Data System, Inc.
00000581	Greater Lowell Cancer Program	00004301	Ohio-Cancer Data System, Inc.
00000600	Rhode Island Cancer Registry	00004500	Indiana State Cancer Registry
00000700	Connecticut Tumor Registry	00004700	Kentucky Cancer Registry
00000800	New Jersey State Cancer Registry	00005100	Wisconsin Cancer Reporting System
00001100	New York State Cancer Registry	00005200	Minnesota Cancer Surveillance System
00001180	Rochester Regional Tumor Registry	00005300	Iowa State Health Registry
00001400	Pennsylvania Cancer Registry	00005300	State Health Registry of Iowa
00001480	Pennsylvania-Northeast Regional Cancer Ctr.	00005400	North Dakota Cancer Registry
00001480	Northeast Regional Cancer Center	00005600	Montana Central Tumor Registry
00001500	National Cancer Institute SEER Program	00006100	Illinois State Cancer Registry
00001500	SEER Program, National Cancer Institute	00006300	Missouri Cancer Registry
00001501	SEER San Francisco-Oakland SMSA	00006500	Kansas-Cancer Data Service
00001502	SEER Connecticut	00006500	Cancer Data Service
00001520	SEER Metropolitan Detroit	00006700	Nebraska Cancer Registry
00001521	SEER Hawaii	00007100	Arkansas CART I
00001522	SEER Iowa	00007300	Louisiana Tumor Registry
00001523	SEER New Mexico	00007301	New Orleans Regional Cancer Registry
00001525	SEER Seattle-Puget Sound	00007301	Louisiana Region I
00001526	SEER Utah	00007302	Baton Rouge Regional Tumor Registry
00001527	SEER Metropolitan Atlanta	00007302	Louisiana Region II
00001529	SEER Alaska Native	00007303	Southeast Louisiana Regional Cancer Registry
00001531	SEER San Jose-Monterey	00007303	Louisiana Region III
00001533	SEER Arizona Indians	00007304	Acadiana Tumor Registry
00001535	SEER Los Angeles	00007304	Louisiana Region IV
00001537	SEER Rural Georgia	00007305	Southwest Louisiana Regional Tumor Registry
00001541	SEER California except LA, SF-Oak, and San Jose/Monterey	00007305	Louisiana Region V
00001542	SEER Kentucky	00007306	Central Louisiana Regional Tumor Registry
00001543	SEER Louisiana	00007306	Louisiana Region VI
00001544	SEER New Jersey	00007307	Northwest Louisiana Regional Tumor Registry
00001551	Cherokee Nation-Oklahoma (NCI funded)	00007307	Louisiana Region VII
00001680	National Cancer Data Base	00007308	Northeast Louisiana Regional Tumor Registry
00001700	Delaware State Cancer Registry	00007308	Louisiana Region VIII
00001801	Central Brain Tumor Registry of the U.S.	00007309	New Orleans/Southeast Louisiana Reg. CA RegLouisiana's regions I and III combined
00001900	U.S. Army Central Registry (ACTUR)	00007310	North Louisiana Regional Tumor Registry; Louisiana's regions VI, VII, and VIII
00001900	Automated Central Tumor Registry (ACTUR)	00007500	Oklahoma State Department of Health
00002100	Maryland Cancer Registry	00007580	Eastern Oklahoma Regional Registry
00002200	District of Columbia Central Cancer Registry	00007580	Oklahoma-Eastern Regional Registry
00002300	Virginia Cancer Registry	00007700	Texas Cancer Incidence Reporting System
00002400	West Virginia Cancer Registry	00008100	Cancer Data Registry of Idaho
00002500	North Carolina Central Cancer Registry	00008100	Idaho Cancer Data Registry
00002600	South Carolina Central Cancer Registry	00008200	Wyoming Central Tumor Registry
00002601	Savannah River Region Cancer Registry in SC	00008300	Colorado Central Cancer Registry
00002601	South Carolina - Savannah River Region in SC	00008400	Utah Cancer Registry
00003100	Tennessee Cancer Reporting System	00008500	Nevada Statewide Cancer Registry
00003300	Georgia Center for Cancer Statistics	00008600	New Mexico Tumor Registry
00003300	Georgia Cancer Registry	00008601	Arizona Indians; data collected by New Mexico Tumor Reg.
00003301	Georgia-Metropolitan Atlanta Cancer Registry	00008700	Arizona Cancer Registry
00003301	Metropolitan Atlanta Cancer Registry	00009100	Alaska State Cancer Registry
00003302	Georgia-Rural Georgia Cancer Registry	00009101	Alaska Area Native Health Service
00003302	Rural Georgia Cancer Registry	00009300	Washington State Cancer Registry
00003303	Georgia-Savannah River Region Cancer Regsty	00009301	Cancer Surveillance System Fred Hutchinson; Seattle Puget Sound area, 13 counties
00003303	Savannah River Region Cancer Registry in GA		
00003500	Florida Cancer Data System		
00003700	Alabama State Cancer Registry		
00003900	Mississippi State Cancer Registry		

00009301 Washington-Seattle-Puget Sound
00009302 Eastern Washington State Cancer Registry
00009302 Washington - Eastern State Cancer Registry
00009380 Spokane Central Tumor Registry (multihospital)
00009380 Washington - Spokane Central Tumor Registry
(multihospital)
00009500 Oregon State Cancer Registry
00009580 Sisters of Providence Cancer Registry
00009580 Oregon-Sisters of Providence Cancer Reg.
00009700 California Cancer Registry
00009701 California Region 1
00009701 San Jose-Monterey
00009701 Greater Bay Area Cancer Registry (Region 1)
00009702 California Region 2
00009702 Cancer Registry of Central California
00009703 California Region 3
00009703 Cancer Surveillance Program, Region 3
00009704 California Region 4
00009704 Tri-Counties Regional Cancer Registry
00009705 California Region 5
00009705 Cancer Surveillance Program, Region 5
00009706 California Region 6
00009706 Cancer Registry of Northern California
00009707 California Region 7
00009707 San Diego/ Imperial Org. for Cancer Control
00009708 California Region 8
00009708 San Francisco-Oakland SMSA
00009708 Greater Bay Area Cancer Registry (Region 8)
00009709 California Region 9
00009709 Cancer Surveillance Program of Los Angeles
00009709 Los Angeles
00009710 California Region 10
00009710 Cancer Surveillance Program of Orange County
00009711 Greater Bay Area Cancer Registry; California's
regions 1 and 8 combined
00009711 California Greater Bay Area Cancer Registry
00009712 California CSPOC and SANDIOCC; California's
regions 7 and 10 combined
00009900 Hawaii Tumor Registry
10100000 Puerto Rico Central Cancer Registry
22000000 Canadian Cancer Registry
22001000 Newfoundland Cancer Treatment & Research Fnd.
22001100 Prince Edward Island Cancer Registry
22001200 Nova Scotia Cancer Registry
22001300 New Brunswick Provincial Cancer Registry
22002400 Fichier Des Tumeurs Du Quebec
22002400 Quebec Cancer Registry
22003500 Ontario Cancer Registry
22004600 Manitoba Cancer Registry
22004700 Saskatchewan Cancer Foundation
22004800 Alberta Cancer Registry
22005900 British Columbia Cancer Registry
22006000 Yukon Bureau of Statistics
22006100 Northwest Territories Department of Health

Table Name: STATE.DBF

AB	Alberta	TN	Tennessee
AK	Alaska	TT	Trust Territories
AL	Alabama	TX	Texas
AR	Arkansas	UT	Utah
AS	American Samoa	VA	Virginia
AZ	Arizona	VI	Virgin Islands
BC	British Columbia	VT	Vermont
CA	California	WA	Washington
CO	Colorado	WI	Wisconsin
CT	Connecticut	WV	West Virginia
DC	District of Columbia	WY	Wyoming
DE	Delaware	XX	Country Known, Not U.S., Not Canada
FL	Florida	YT	Yukon Territories
FM	Federated States of Micronesia	YY	Country Unknown, Not U.S., Not Canada
GA	Georgia	ZZ	U.S., NOS; Canada, NOS; Country Unknown
GU	Guam		
HI	Hawaii		
IA	Iowa		
ID	Idaho		
IL	Illinois		
IN	Indiana		
KS	Kansas		
KY	Kentucky		
LA	Louisiana		
MA	Massachusetts		
MB	Manitoba		
MD	Maryland		
ME	Maine		
MH	Marshall Islands		
MI	Michigan		
MN	Minnesota		
MO	Missouri		
MP	Northern Mariana Islands		
MS	Mississippi		
MT	Montana		
NB	New Brunswick		
NC	North Carolina		
ND	North Dakota		
NE	Nebraska		
NF	Newfoundland and Labrador		
NH	New Hampshire		
NJ	New Jersey		
NM	New Mexico		
NS	Nova Scotia		
NT	Northwest Territories		
NU	Nunavut		
NV	Nevada		
NY	New York		
OH	Ohio		
OK	Oklahoma		
ON	Ontario		
OR	Oregon		
PA	Pennsylvania		
PE	Prince Edward Island		
PR	Puerto Rico		
PW	Palau		
QC	Quebec		
RI	Rhode Island		
SC	South Carolina		
SD	South Dakota		
SK	Saskatchewan		

APPENDIX C

ABBREVIATIONS AND ACRONYMS USED

ACoS	American College of Surgeons
ACS	American Cancer Society
AJCC	American Joint Committee on Cancer
CDC	Centers for Disease Control and Prevention
CIN	Cervical intraepithelial neoplasia
CIS	Carcinoma <i>in situ</i>
CLIA	Clinical Laboratory Improvement Act
COC	Commission on Cancer (of ACoS)
CPT	Current Procedural Terminology (codes)
CRC	Cyclic redundancy code
CS	Collaborative Staging
CTR	Certified Tumor Registrar
DAM	<i>Data Acquisition Manual</i> (of ACoS)
EOD	Extent of Disease
FCDS	Florida Cancer Data System
FIPS	Federal Information Processing Standards
FORDS	<i>Facility Oncology Registry Data Standards</i> (manual of ACoS)
FTRO	<i>Fundamental Tumor Registry Operations Program</i> (of ACoS)
HCFA	Health Care Finance Administration
HIM	Health Information Management
IACR	International Association of Cancer Registrars
IARC	International Agency for Research on Cancer
ICD	International Classification of Diseases
ICD-O	<i>International Classification of Diseases for Oncology</i>
ICD-O-1	<i>International Classification of Diseases for Oncology</i> , First Edition
ICD-O-2	<i>International Classification of Diseases for Oncology</i> , Second Edition
ICD-O-3	<i>International Classification of Diseases for Oncology</i> , Third Edition
NAACCR	North American Association of Central Cancer Registries
NBCR	National Board for the Certification of Registrars
NCDB	National Cancer Data Base
NCI	National Cancer Institute
NCRA	National Cancer Registrars Association
N.d.	No date (bibliographic term: no ascertainable place of publication)
PIN	Prostatic intraepithelial neoplasia
ROADS	<i>Registry Operations and Data Standards</i> (manual of ACoS)
SEER	Surveillance, Epidemiology, and End Results Program of NCI
SIL	Squamous intraepithelial lesion
TNM	Tumor, Nodes and Metastasis: staging system of AJCC and UICC
UDSC	Uniform Data Standards Committee of NAACCR
UICC	Union Internationale Contre le Cancer (in English, International Union Against Cancer)
WHO	World Health Organization

APPENDIX D

ALTERNATE NAMES

Following the item name are other names by which the same item is called, including the name used by the standard-setter for the item. All other names are followed by the source of each name indicated with the following labels:

COC	Preferred name in the COC <i>FORDS/ROADS Manual</i> and Supplements
COC pre-96	Previously used name appearing in the COC <i>ROADS Manual</i>
COC pre-98	Previously used name appearing in the COC <i>ROADS Manual</i> before 1998
NAACCR pre-98	Previously used name appearing in NAACCR standards before 1998
SEER	Name in the SEER Program Code Manual, Third Edition (1998)
SEER pre-98	Previously used name appearing in SEER manual before 1998

Item #	Item Name	Alternate Names
70	Addr at DX--City	City or Town (PRE 96 COC) City/Town at Diagnosis (COC)
80	Addr at DX--State	State (PRE 96 COC) State at Diagnosis (COC)
90	County at DX	County (PRE 96 SEER/COC) County at Diagnosis (COC)
100	Addr at DX--Postal Code	Postal Code at Diagnosis (COC) ZIP Code (pre COC)
110	Census Tract 1970/80/90	Census Tract/Block Numbering Area (BNA) (SEER) Census Tract
120	Census Cod Sys 1970/80/90	Census Coding System (COC) Coding System for Census Tract (pre 96 SEER/COC)
130	Census Tract 2000	Census Tract--Alternate
150	Marital Status at DX	Marital Status at Diagnosis (SEER/COC) Marital Status at Initial Diagnosis (pre 96 COC)
160	Race 1	Race
190	Spanish/Hispanic Origin	Spanish Origin--All Sources (96 COC) Spanish Surname or Origin (SEER)
240	Birth Date	Date of Birth (SEER/COC)
250	Birthplace	Place of Birth (SEER/COC)
364	Census Tr Cert 1970/80/90	Census Tract Certainty
380	Sequence Number--Central	Sequence Number (pre 96 SEER)
390	Date of Diagnosis	Date of Initial Diagnosis (COC)
410	Laterality	Laterality at Diagnosis (SEER)
420	Histology (92-00) ICD-O-2	Histology (COC)
440	Grade	Grade, Differentiation, or Cell Indicator (SEER) Grade/Differentiation (COC)

Item #	Item Name	Alternate Names
540	Reporting Hospital	Institution ID Number (COC) Facility Identification Number (COC)
550	Accession Number--Hosp	Accession Number (COC)
560	Sequence Number--Hospital	Sequence Number (COC)
580	Date of 1st Contact	Date of Adm/1st Contact
590	Date of Inpatient Adm	Date of Inpatient Admission (COC)
600	Date of Inpatient Disch	Date of Inpatient Discharge (COC)
620	Year First Seen This CA	Accession Year (pre 96 COC) Year First Seen for this Primary (COC)
630	Primary Payer at DX	Primary Payer at Diagnosis (COC)
640	Inpatient/Outpt Status	Inpatient/Outpatient Status (COC)
650	Presentation at CA Conf	Presentation at Cancer Conference (COC)
660	Date of CA Conference	Date of Cancer Conference (COC)
670	RX Hosp--Surg Prim Site	Cancer-Directed Surgery at This Facility (pre 96 COC) RX Hosp--CA Dir Surgery (pre 96 NAACCR) Surgical Procedure of Primary Site
672	RX Hosp--Scope Reg LN Sur	Scope of Regional Lymph Node Surgery at this Facility (COC)
674	RX Hosp--Surg Oth Reg/Dis	Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s) at this Facility (COC) Surgical Procedure/Other Site at this Facility
676	RX Hosp--Reg LN Removed	Number of Regional Lymph Nodes Examined at This Facility (COC) RX Hosp--Reg LN Examined
690	RX Hosp--Radiation	Radiation at this Facility (COC)
700	RX Hosp--Chemo	Chemotherapy at this Facility (COC)
710	RX Hosp--Hormone	Hormone Therapy at this Facility (COC)
720	RX Hosp--BRM	Immunotherapy at this Facility (COC)
730	RX Hosp--Other	Other Treatment at this Facility (COC)
740	RX Hosp--DX/Stg Proc	Non Cancer-Directed Surgery at this Facility (COC) Surgical Diagnostic & Staging Procedure at this Facility (1996-2002)
742	RX Hosp--Screen/BX Proc1	Diagnostic and Staging Procedures (pre-2001 COC) RX Hosp--Diag/Stage Proc1 (pre-2001) Screening or Biopsy Procedures (COC)
743	RX Hosp--Screen/BX Proc2	Diagnostic and Staging Procedures (pre-2001 COC) RX Hosp--Diag/Stage Proc2 (pre-2001) Screening or Biopsy Procedures (COC)
744	RX Hosp--Screen/BX Proc3	Diagnostic and Staging Procedures (pre-2001 COC) RX Hosp--Diag/Stage Proc3 (pre-2001) Screening or Biopsy Procedures (COC)
745	RX Hosp--Screen/BX Proc4	Diagnostic and Staging Procedures ((pre-2001 COC) RX Hosp--Diag/Stage Proc4 (pre-2001) Screening or Biopsy Procedures (COC)
760	SEER Summary Stage 1977	General Summary Stage (SEER/COC)

Item #	Item Name	Alternate Names
780	EOD--Tumor Size	Size of Primary Tumor (SEER) Size of Tumor (COC)
790	EOD--Extension	Extension (pre 96 SEER/COC) Extension (SEER EOD) (96 COC)
810	EOD--Lymph Node Involv	Lymph Nodes (pre 96 SEER/COC) Lymph Nodes (SEER EOD) (96 COC)
820	Regional Nodes Positive	Number of Positive Regional Lymph Nodes (SEER) Pathologic Review of Regional Lymph Nodes (SEER)
830	Regional Nodes Examined	Number of Regional Lymph Nodes Examined (SEER) Pathologic Review of Regional Lymph Nodes (SEER)
840	EOD--Old 13 Digit	13-Digit (Expanded) Site-Specific Extent of Disease (SEER) SEER EOD (SEER)
850	EOD--Old 2 Digit	2-Digit Nonspecific and 2-Digit Site-Specific Extent of Disease (1973-1982 SEER)
860	EOD--Old 4 Digit	4-Digit Extent of Disease (1983-1987 SEER)
870	Coding System for EOD	Coding System for Extent of Disease (SEER)
880	TNM Path T	Pathologic T (COC)
890	TNM Path N	Pathologic N (COC)
900	TNM Path M	Pathologic M (COC)
910	TNM Path Stage Group	Pathologic Stage Group (COC)
920	TNM Path Descriptor	Pathologic Stage (Prefix/Suffix) Descriptor (COC)
930	TNM Path Staged By	Staged By (Pathologic Stage) (COC)
940	TNM Clin T	Clinical T (COC)
950	TNM Clin N	Clinical N (COC)
960	TNM Clin M	Clinical M (COC)
970	TNM Clin Stage Group	Clinical Stage Group (COC)
980	TNM Clin Descriptor	Clinical Stage (Prefix/Suffix) Descriptor (COC)
990	TNM Clin Staged By	Staged By (Clinical Stage) (COC)
1000	TNM Other T	Other T (COC)
1010	TNM Other N	Other N (COC)
1020	TNM Other M	Other M (COC)
1030	TNM Other Stage Group	Other Stage Group (COC)
1040	TNM Other Staged By	Staged By (Other Stage) (COC)
1050	TNM Other Descriptor	Other Stage (Prefix/Suffix) Descriptor (COC)
1080	Date of 1st Positive BX	Date of First Positive Biopsy (COC)
1090	Site of Distant Met 1	Site of Distant Metastasis #1 (COC)
1100	Site of Distant Met 2	Site of Distant Metastasis #2 (COC)
1110	Site of Distant Met 3	Site of Distant Metastasis #3 (COC)
1130	Pediatric Staging System	Type of Staging System (Pediatric) (COC)
1140	Pediatric Staged By	Staged By (Pediatric Stage) (COC)
1150	Tumor Marker 1	Tumor Marker One (COC)
1160	Tumor Marker 2	Tumor Marker Two (COC)

Item #	Item Name	Alternate Names
1170	Tumor Marker 3	Tumor Marker Three (COC)
1200	RX Date--Surgery	Date of Cancer-Directed Surgery (COC) Date of Surgery Date of First Surgical Procedure (COC)
1210	RX Date--Radiation	Date Radiation Started (COC)
1220	RX Date--Chemo	Date Chemotherapy Started (COC)
1230	RX Date--Hormone	Date Hormone Therapy Started (COC)
1240	RX Date--BRM	Date Immunotherapy Started (COC)
1250	RX Date--Other	Date Other Treatment Started (COC)
1260	Date of Initial RX--SEER	Date Therapy Initiated (SEER) Date Started (SEER)
1270	Date of 1st Crs RX--COC	Date of First Course Treatment (COC) Date Started (pre 96 COC)
1280	RX Date--DX/Stg Proc	Date of Non Cancer-Directed Surgery (COC) Date of Diagnostic, Staging or Palliative Procedures (1996-2002) Date of Surgical Diagnostic and Staging Procedure (COC)
1290	RX Summ--Surg Prim Site	Cancer-Directed Surgery (pre 96 COC) Surgery of Primary Site (SEER/COC)
1292	RX Summ--Scope Reg LN Sur	Scope of Regional Lymph Node Surgery (SEER/COC)
1294	RX Summ--Surg Oth Reg/Dis	Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Nodes (SEER/COC) Surgical Procedure/Other Site
1296	RX Summ--Reg LN Examined	Number of Regional Lymph Nodes Examined (SEER/COC) Number of Regional Lymph Nodes Removed (COC)
1310	RX Summ--Surgical Approach	Surgical Approach (COC)
1320	RX Summ--Surgical Margins	Surgical Margins (COC) Residual Primary Tumor Following Cancer-Directed Surgery (pre 96 COC)
1330	RX Summ--Reconstruct 1st	Reconstruction--First Course (SEER) Reconstruction/Restoration-First Course (COC)
1340	Reason for No Surgery	Reason for No Cancer-Directed Surgery (SEER) Reason for No CA Dir Surgery (COC) Reason for No Surgery to Primary Site
1350	RX Summ--DX/Stg Proc	Non Cancer-Directed Surgery (COC) Surgical Diagnostic and Staging Procedure (1996-2002)
1360	RX Summ--Radiation	Radiation (SEER/COC) Radiation Therapy (pre 96 COC)
1370	RX Summ--Rad to CNS	Radiation Therapy to CNS (COC) Radiation to the Brain and/or Central Nervous System (SEER)

Item #	Item Name	Alternate Names
1380	RX Summ--Surg/Rad Seq	Radiation Sequence with Surgery (pre 96 SEER/COC) Radiation/Surgery Sequence (COC)
1390	RX Summ--Chemo	Chemotherapy (SEER/COC)
1400	RX Summ--Hormone	Hormone Therapy (SEER/COC) Endocrine (Hormone/Steroid) Therapy (pre 96 SEER)
1410	RX Summ--BRM	Immunotherapy (SEER/COC) Biological Response Modifiers (pre 96 SEER)
1420	RX Summ--Other	Other Treatment (COC) Other Cancer-Directed Therapy (SEER/pre 96 COC)
1430	Reason for No Radiation	Reason for No Regional Radiation Therapy
1440	Reason for No Chemo	Reason for No Chemotherapy (COC)
1450	Reason for No Hormone	Reason for No Hormone Therapy (COC)
1470	Protocol Eligibility Stat	Protocol Eligibility Status (COC)
1490	Referral to Support Serv	Referral to Support Services (COC)
1510	Rad--Regional Dose: cGy	Regional Dose: cGy (COC)
1520	Rad--No of Treatment Vol	Number of Treatments to this Volume (COC)
1530	Rad--Elapsed RX Days	Radiation Elapsed Treatment Time (Days) (COC)
1540	Rad--Treatment Volume	Radiation Treatment Volume (COC)
1550	Rad--Location of RX	Location of Radiation Treatment (COC)
1560	Rad--Intent of Treatment	Intent of Treatment (Radiation) (COC)
1570	Rad--Regional RX Modality	Regional Treatment Modality (COC)
1580	Rad--RX Completion Status	Radiation Treatment Completion Status (COC)
1590	Rad--Local Control Status	Radiation Therapy Local Control Status (Irradiated Volume) (COC)
1640	RX Summ--Surgery Type	Site--Specific Surgery (pre 98 SEER)
1642	RX Summ--Screen/BX Proc1	Diagnostic and Staging Procedures (pre-2001 COC) RX Summ--Diag/Stage Proc1 (pre-2001) Screening or Biopsy Procedures (COC)
1643	RX Summ--Screen/BX Proc2	Diagnostic and Staging Procedures (pre-2001 COC) RX Summ--Diag/Stage Proc2 (pre-2001) Screening or Biopsy Procedures (COC)
1644	RX Summ--Screen/BX Proc3	Diagnostic and Staging Procedures (pre-2001 COC) RX Summ--Diag/Stage Proc3 (pre-2001) Screening or Biopsy Procedures (COC)
1645	RX Summ--Screen/BX Proc4	Diagnostic and Staging Procedures (pre-2001 COC) RX Summ--Diag/Stage Proc4 (pre-2001) Screening or Biopsy Procedures (COC)
1660	Subsq RX 2nd Course Date	Second Course of Therapy--Date Started (pre 96 COC)
1741	Subsq RX--Reconstruct Del	Reconstruction/Restoration--Delayed (COC)
1750	Date of Last Contact	Date of Last Contact or Death (COC) Date of Last Follow-Up or of Death (SEER)
1790	Follow-Up Source	Follow-Up Method (pre 96 COC)
1800	Next Follow-Up Source	Next Follow-Up Method (pre 96 COC)

Item #	Item Name	Alternate Names
1810	Addr Current--City	City/Town--Current (COC)
1820	Addr Current--State	State--Current (COC)
1830	Addr Current--Postal Code	Postal Code--Current (COC)
1860	Recurrence Date--1st	Date of First Recurrence (COC)
1880	Recurrence Type--1st	Type of First Recurrence (COC)
1890	Recurrence Type--1st--Oth	Other Type of First Recurrence (COC)
1910	Cause of Death	Underlying Cause of Death (SEER) Underlying Cause of Death (ICD Code) (pre 96 COC)
1920	ICD Revision Number	ICD Code Revision Used for Cause of Death (SEER)
1960	Site (73-91) ICD-O-1	Primary Site (1973-81) (SEER)
1980	ICD-O-2 Conversion Flag	Review Flag for 1973-91 Cases (SEER)
1981	Over-ride SS/NodesPos	Over-ride Summary Stage/Nodes Positive
1982	Over-ride SS/TNM-N	Over-ride Summary Stage/TNM-N
1983	Over-ride SS/TNM-M	Over-ride Summary Stage/TNM-M
1984	Over-ride SS/DisMet1	Over-ride Summary Stage/Distant Metastasis 1
1985	Over-ride Acsn/Class/Seq	Over-ride Accession/Class of Case/Sequence
1986	Over-ride HospSeq/DxConf	Over-ride Hospital Sequence/Diagnostic Confirmation
1988	Over-ride HospSeq/Site	Over-ride Hospital Sequence/Site
1990	Over-ride Age/Site/Morph	Age/Site/Histology Interfield Review (Interfield Edit 15) (SEER #3)
2000	Over-ride SeqNo/DxConf	Sequence Number/Diagnostic Confirmation Interfield Review (Interfield Edit 23) (SEER #4)
2010	Over-ride Site/Lat/SeqNo	Site/Histology/Laterality/Sequence Number Interrecord Review (Interrecord Edit 09) (SEER #5)
2020	Over-ride Surg/DxConf	Surgery/Diagnostic Confirmation Interfield Review (Interfield Edit 46) (SEER #6)
2030	Over-ride Site/Type	Site/Type Interfield Review (Interfield Edit 25) (SEER #1)
2040	Over-ride Histology	Histology/Behavior Interfield Review (Field Item Edit Morph) (SEER #2)
2050	Over-ride Report Source	Type of Reporting Source/Sequence Number Interfield Review (Interfield Edit 04) (Seer #7)
2060	Over-ride Ill-define Site	Sequence Number/Ill-defined Site Interfield Review (Interfield Edit 22) (SEER #8)
2070	Over-ride Leuk, Lymphoma	Leukemia or Lymphoma/Diagnostic Confirmation Interfield Review (Interfield Edit 48) (SEER #9)
2071	Over-ride Site/Behavior	Over-ride Flag for Site/Behavior (IF39) (SEER #11)
2072	Over-ride Site/EOD/DX Dt	Over-ride Flag for Site/EOD/Diagnosis Date (IF40) (SEER #13)
2073	Over-ride Site/Lat/EOD	Over-ride Flag for Site/Laterality/EOD (IF41) (SEER #12)
2074	Over-ride Site/Lat/Morph	Over-ride Flag for Site/Laterality/Morphology (IF42) (SEER #13)
2110	Date Case Report Exported	Date Case Transmitted (pre 98 NAACCR)

Item #	Item Name	Alternate Names
2140	COC Coding Sys--Current	Commission on Cancer Coding System-Current (COC)
2180	SEER Type of Follow-Up	Type of Follow-Up (SEER)
2190	SEER Record Number	Record Number (SEER)
2200	Diagnostic Proc 73-87	Diagnostic Procedures (1973-87 SEER)
2230	Name--Last	Last Name (COC)
2240	Name--First	First Name (COC)
2250	Name--Middle	Middle Name (COC) Middle Initial (pre 96 COC)
2260	Name--Prefix	Name Prefix (COC)
2270	Name--Suffix	Name Suffix (COC)
2280	Name--Alias	Alias (COC)
2310	Military Record No Suffix	Military Medical Record Number Suffix (COC)
2330	Addr at DX--No & Street	Patient Address (Number and Street) at Diagnosis (COC) Number and Street (pre 96 COC)
2335	Addr at DX--Supplementl	Patient Address (Number and Street) at Diagnosis--Supplemental (COC)
2350	Addr Current--No & Street	Patient Address (Number and Street)-Current (COC)
2355	Addr Current--Supplementl	Patient Address (Number and Street) Current--Supplemental (COC)
2370	DC State	Item deleted, Item number retired
2390	Name--Maiden	Maiden Name (COC)
2410	Institution Referred From	Facility Referred From
2420	Institution Referred To	Facility Referred To
2450	Reserved for Expansion	Reserved 17
2460	Physician--Managing	Managing Physician (COC) Attending Physician (pre 96 COC)
2470	Physician--Follow-Up	Following Physician (COC) Follow-Up Physician (pre 96 COC)
2480	Physician--Primary Surg	Primary Surgeon (COC)
2490	Physician 3	Physician #3 (COC) Other Physician (pre 96 COC)
2500	Physician 4	Physician #4 (COC) Other Physician (pre 96 COC)
2820	CS Tumor Size/Ext Eval	CS Tumor Size/Extension Evaluation
2830	CS Lymph Nodes	CS Lymph Nodes (SEER EOD)
2840	CS Reg Nodes Eval	CS Regional Nodes Evaluation
2850	CS Mets at DX	CS Metastasis at Diagnosis
2860	CS Mets Eval	CS Metastasis Evaluation
2940	Derived AJCC T	Derived T
2950	Derived AJCC T Descriptor	Derived T Descriptor
2960	Derived AJCC N	Derived N
2970	Derived AJCC N Descriptor	Derived N Descriptor
2980	Derived AJCC M	Derived M
2990	Derived AJCC M Descriptor	Derived M Descriptor

Item #	Item Name	Alternate Names
3000	Derived AJCC Stage Group	Derived Stage Group
3010	Derived SS1977	Derived General Summary Stage(SEER) 1977
3020	Derived SS2000	Derived SEER Summary Stage 2000
3030	Derived AJCC--Flag	AJCC Conversion Flag
3040	Derived SS1977--Flag	SS 1977 Conversion Flag
3050	Derived SS2000--Flag	SS 2000 Conversion Flag
3110	Comorbid/Complication 1	Comorbidities and Complications #1
3120	Comorbid/Complication 2	Comorbidities and Complications #2
3130	Comorbid/Complication 3	Comorbidities and Complications #3
3140	Comorbid/Complication 4	Comorbidities and Complications #4
3150	Comorbid/Complication 5	Comorbidities and Complications #5
3160	Comorbid/Complication 6	Comorbidities and Complications #6
3170	RX Date--Most Definit Surg	Date Most Definitive Surgery of Primary Site
3180	RX Date--Surgical Disch	Date of Surgical Discharge
3190	Readm Same Hosp 30 Days	Readmission to the Same Hospital Within 30 Days of Surgical Discharge
3200	Rad--Boost RX Modality	Boost Radiation Treatment Modality
3210	Rad--Boost Dose cGy	Boost Radiation Dose:cGY
3220	RX Date--Radiation Ended	Date Radiation Ended
3230	RX Date--Systemic	Date Systemic Therapy Started
3250	RX Summ--Transplnt/Endocr	Hematologic Transplant and Endocrine Procedures
3270	RX Summ--Palliative Proc	Palliative Procedure
3280	RX Hosp--Palliative Proc	Palliative Procedure at this Facility
3300	RuralUrban Continuum 1993	Beale Code
3310	RuralUrban Continuum 2000	Beale Code

APPENDIX E

GROUPED DATA ITEMS

Item Name [Item#]	Length	Column #
Extent of Disease 10-Dig [779]	12	531-542
Subfields:		
EOD--Tumor Size[780]	3	531-533
EOD--Extension [790]	2	534-535
EOD--Extension Prost Path [800]	2	536-537
EOD--Lymph Node Involv [810]	1	538-538
Regional Nodes Positive [820]	2	539-540
Regional Nodes Examined [830]	2	541-542
Morph (73-91) ICD-0-1 [1970]	6	1141-1146
Subfields:		
Histology (73-91) ICD-0-1 [1971]	4	1141-1144
Behavior (73-91) ICD-0-1 [1972]	1	1145-1145
Grade (73-91) ICD-0-1 [1973]	1	1146-1146
Morph--Type&Behav ICD-O-2 [419]	5	296-300
Subfields:		
Histology (92-00) ICD-O-2 [420]	4	296-299
Behavior (92-00) ICD-O-2 [430]	1	300-300
Morph--Type&Behav ICD-O-3 [521]	5	301-305
Subfields:		
Histologic Type ICD-O-3 [522]	4	301-304
Behavior Type ICD-O-3 [523]	1	305-305
Subsq RX 2nd Course Codes [1670]	7	996-1002
Subsq RX 2nd Course Surg [1671]	2	996-997
Subsq RX 2nd Course Rad [1672]	1	998-998
Subsq RX 2nd Course Chemo [1673]	1	999-999
Subsq RX 2nd Course Horm [1674]	1	1000-1000
Subsq RX 2nd Course BRM [1675]	1	1001-1001
Subsq RX 2nd Course Oth [1676]	1	1002-1002
Subsq RX 3rd Course Codes [1690]	7	1011-1017
Subsq RX 3rd Course Surg [1691]	2	1011-1012
Subsq RX 3rd Course Rad [1692]	1	1013-1013
Subsq RX 3rd Course Chemo [1693]	1	1014-1014
Subsq RX 3rd Course Horm [1694]	1	1015-1015
Subsq RX 3rd Course BRM [1695]	1	1016-1016
Subsq RX 3rd Course Oth [1696]	1	1017-1017

Item Name [Item#]	Length	Column #
Subsq RX 4th Course Codes [1710]	7	1026-1032
Subsq RX 4th Course Surg [1711]	2	1026-1027
Subsq RX 4th Course Rad [1712]	1	1028-1028
Subsq RX 4th Course Chemo [1713]	1	1029-1029
Subsq RX 4th Course Horm [1714]	1	1030-1030
Subsq RX 4th Course BRM [1715]	1	1031-1031
Subsq RX 4th Course Oth [1716]	1	1032-1032
Subsq RX 5th Course Codes [1730]	7	1041-1047
Subsq RX 5th Course Surg [1731]	2	1041-1042
Subsq RX 5th Course Rad [1732]	1	1043-1043
Subsq RX 5th Course Chemo [1733]	1	1044-1044
Subsq RX 5th Course Horm [1734]	1	1045-1045
Subsq RX 5th Course BRM [1735]	1	1046-1046
Subsq RX 5th Course Oth [1736]	1	1047-1047

APPENDIX F

TABLES AND DATA DICTIONARY REVISIONS

Revisions to Record Layout table in Chapter VIII:

Item #	Data Item Name	Note
37	Reserved 00	Revised
40	Registry ID	Revised
110	Census Tract 1970/80/90	Revised
120	Census Cod Sys 1970/80/90	Revised
130	Census Tract 2000	Revised
364	Census Tr Cert 1970/80/90	Revised
365	Census Tr Certainty 2000	New
370	Reserved 01	Revised
530	Reserved 02	Revised
540	Reporting Hospital	Revised
680	Reserved 03	Revised
700	RX Hosp--Chemo	Revised
710	RX Hosp--Hormone	Revised
720	RX Hosp--BRM	Revised
740	RX Hosp--DX/Stg Proc	Revised
750	Reserved 04	Revised
1060	TNM Edition Number	Revised
1180	Reserved 05	Revised
1190	Reserved 06	Revised
1280	RX Date--DX/Stg Proc	Revised
1300	Reserved 07	Revised
1350	RX Summ--DX/Stg Proc	Revised
1390	RX Summ--Chemo	Revised
1400	RX Summ--Hormone	Revised
1410	RX Summ--BRM	Revised
1460	RX Coding System--Current	Revised
1650	Reserved 08	Revised
1740	Reserved 09	Revised
1835	Reserved 10	Revised
1900	Reserved 11	Revised
1950	Reserved 12	Revised
2140	COC Coding Sys--Current	Revised
2150	COC Coding Sys--Original	Revised
2210	Reserved for Expansion	Revised
2330	Addr at DX--No & Street	Revised
2335	Addr at DX--Supplementl	New
2350	Addr Current--No & Street	Revised
2352	Latitude	New
2354	Longitude	New

Item #	Data Item Name	Note
2355	Addr Current--Supplementl	New
2392	Follow-Up Contact--No&St	Revised
2393	Follow-Up Contact--Suppl	New
2410	Institution Referred From	Revised
2420	Institution Referred To	Revised
2430	Last Follow-Up Hospital	Revised
2440	Following Registry	Revised
2700	Reserved 19	Revised
2800	CS Tumor Size	New
2810	CS Extension	New
2820	CS Tumor Size/Ext Eval	New
2830	CS Lymph Nodes	New
2840	CS Reg Nodes Eval	New
2850	CS Mets at DX	New
2860	CS Mets Eval	New
2880	CS Site-Specific Factor 1	New
2890	CS Site-Specific Factor 2	New
2900	CS Site-Specific Factor 3	New
2910	CS Site-Specific Factor 4	New
2920	CS Site-Specific Factor 5	New
2930	CS Site-Specific Factor 6	New
2940	Derived AJCC T	New
2950	Derived AJCC T Descriptor	New
2960	Derived AJCC N	New
2970	Derived AJCC N Descriptor	New
2980	Derived AJCC M	New
2990	Derived AJCC M Descriptor	New
3000	Derived AJCC Stage Group	New
3010	Derived SS1977	New
3020	Derived SS2000	New
3030	Derived AJCC--Flag	New
3040	Derived SS1977--Flag	New
3050	Derived SS2000--Flag	New
3100	Archive FIN	New
3110	Comorbid/Complication 1	New
3120	Comorbid/Complication 2	New
3130	Comorbid/Complication 3	New
3140	Comorbid/Complication 4	New
3150	Comorbid/Complication 5	New
3160	Comorbid/Complication 6	New
3170	RX Date--Most Defin Surg	New
3180	RX Date--Surgical Disch	New
3190	Readm Same Hosp 30 Days	New
3200	Rad--Boost RX Modality	New
3210	Rad--Boost Dose cGy	New
3220	RX Date--Radiation Ended	New

Item #	Data Item Name	Note
3230	RX Date--Systemic	New
3250	RX Summ--Transplnt/Endocr	New
3260	Pain Assessment	New
3270	RX Summ--Palliative Proc	New
3280	RX Hosp--Palliative Proc	New
3300	RuralUrban Continuum 1993	New
3310	RuralUrban Continuum 2000	New

Revisions to Required Status table in Chapter IX:

Item #	Data Item Name	Note
10	Record Type	Revised
50	NAACCR Record Version	Revised
70	Addr at DX--City	Revised
80	Addr at DX--State	Revised
100	Addr at DX--Postal Code	Revised
110	Census Tract 1970/80/90	Revised
120	Census Cod Sys 1970/80/90	Revised
130	Census Tract 2000	Revised
150	Marital Status at DX	Revised
170	Race Coding Sys--Current	Revised
180	Race Coding Sys--Original	Revised
230	Age at Diagnosis	Revised
250	Birthplace	Revised
310	Text--Usual Occupation	Revised
320	Text--Usual Industry	Revised
340	Tobacco History	Revised
350	Alcohol History	Revised
360	Family History of Cancer	Revised
364	Census Tr Cert 1970/80/90	Revised
365	Census Tr Certainty 2000	New
420	Histology (92-00) ICD-O-2	Revised
430	Behavior (92-00) ICD-O-2	Revised
450	Site Coding Sys--Current	Revised
460	Site Coding Sys--Original	Revised
470	Morph Coding Sys--Current	Revised
480	Morph Coding Sys--Originl	Revised
500	Type of Reporting Source	Revised
510	Screening Date	Revised
520	Screening Result	Revised
538	Reporting Hospital FAN	Revised
540	Reporting Hospital	Revised
550	Accession Number--Hosp	Revised
560	Sequence Number--Hospital	Revised
570	Abstracted By	Revised

Item #	Data Item Name	Note
580	Date of 1st Contact	Revised
590	Date of Inpatient Adm	Revised
600	Date of Inpatient Disch	Revised
610	Class of Case	Revised
620	Year First Seen This CA	Revised
640	Inpatient/Outpt Status	Revised
650	Presentation at CA Conf	Revised
660	Date of CA Conference	Revised
670	RX Hosp--Surg Prim Site	Revised
672	RX Hosp--Scope Reg LN Sur	Revised
674	RX Hosp--Surg Oth Reg/Dis	Revised
676	RX Hosp--Reg LN Removed	Revised
690	RX Hosp--Radiation	Revised
700	RX Hosp--Chemo	Revised
710	RX Hosp--Hormone	Revised
720	RX Hosp--BRM	Revised
730	RX Hosp--Other	Revised
740	RX Hosp--DX/Stg Proc	Revised
759	SEER Summary Stage 2000	Revised
760	SEER Summary Stage 1977	Revised
780	EOD--Tumor Size	Revised
790	EOD--Extension	Revised
800	EOD--Extension Prost Path	Revised
810	EOD--Lymph Node Involv	Revised
840	EOD--Old 13 Digit	Revised
850	EOD--Old 2 Digit	Revised
860	EOD--Old 4 Digit	Revised
920	TNM Path Descriptor	Revised
980	TNM Clin Descriptor	Revised
1000	TNM Other T	Revised
1010	TNM Other N	Revised
1020	TNM Other M	Revised
1030	TNM Other Stage Group	Revised
1040	TNM Other Staged By	Revised
1050	TNM Other Descriptor	Revised
1070	Other Staging System	Revised
1080	Date of 1st Positive BX	Revised
1090	Site of Distant Met 1	Revised
1100	Site of Distant Met 2	Revised
1110	Site of Distant Met 3	Revised
1120	Pediatric Stage	Revised
1130	Pediatric Staging System	Revised
1140	Pediatric Staged By	Revised
1150	Tumor Marker 1	Revised
1160	Tumor Marker 2	Revised
1170	Tumor Marker 3	Revised

Item #	Data Item Name	Note
1220	RX Date--Chemo	Revised
1230	RX Date--Hormone	Revised
1240	RX Date--BRM	Revised
1296	RX Summ--Reg LN Examined	Revised
1310	RX Summ--Surgical Approch	Revised
1330	RX Summ--Reconstruct 1st	Revised
1340	Reason for No Surgery	Revised
1360	RX Summ--Radiation	Revised
1370	RX Summ--Rad to CNS	Revised
1380	RX Summ--Surg/Rad Seq	Revised
1430	Reason for No Radiation	Revised
1440	Reason for No Chemo	Revised
1450	Reason for No Hormone	Revised
1460	RX Coding System--Current	Revised
1470	Protocol Eligibility Stat	Revised
1480	Protocol Participation	Revised
1490	Referral to Support Serv	Revised
1510	Rad--Regional Dose: cGy	Revised
1520	Rad--No of Treatment Vol	Revised
1530	Rad--Elapsed RX Days	Revised
1540	Rad--Treatment Volume	Revised
1550	Rad--Location of RX	Revised
1560	Rad--Intent of Treatment	Revised
1570	Rad--Regional RX Modality	Revised
1580	Rad--RX Completion Status	Revised
1590	Rad--Local Control Status	Revised
1600	Chemotherapy Field 1	Revised
1610	Chemotherapy Field 2	Revised
1620	Chemotherapy Field 3	Revised
1630	Chemotherapy Field 4	Revised
1640	RX Summ--Surgery Type	Revised
1642	RX Summ--Screen/BX Proc1	Revised
1643	RX Summ--Screen/BX Proc2	Revised
1644	RX Summ--Screen/BX Proc3	Revised
1645	RX Summ--Screen/BX Proc4	Revised
1660	Subsq RX 2nd Course Date	Revised
1670	Subsq RX 2nd Course Codes	Revised
1671	Subsq RX 2nd Course Surg	Revised
1672	Subsq RX 2nd Course Rad	Revised
1673	Subsq RX 2nd Course Chemo	Revised
1674	Subsq RX 2nd Course Horm	Revised
1675	Subsq RX 2nd Course BRM	Revised
1676	Subsq RX 2nd Course Oth	Revised
1677	Subsq RX 2nd--Scope LN SU	Revised
1678	Subsq RX 2nd--Surg Oth	Revised
1679	Subsq RX 2nd--Reg LN Rem	Revised

Item #	Data Item Name	Note
1680	Subsq RX 3rd Course Date	Revised
1690	Subsq RX 3rd Course Codes	Revised
1691	Subsq RX 3rd Course Surg	Revised
1692	Subsq RX 3rd Course Rad	Revised
1693	Subsq RX 3rd Course Chemo	Revised
1694	Subsq RX 3rd Course Horm	Revised
1695	Subsq RX 3rd Course BRM	Revised
1696	Subsq RX 3rd Course Oth	Revised
1697	Subsq RX 3rd--Scope LN Su	Revised
1698	Subsq RX 3rd--Surg Oth	Revised
1699	Subsq RX 3rd--Reg LN Rem	Revised
1700	Subsq RX 4th Course Date	Revised
1710	Subsq RX 4th Course Codes	Revised
1711	Subsq RX 4th Course Surg	Revised
1712	Subsq RX 4th Course Rad	Revised
1713	Subsq RX 4th Course Chemo	Revised
1714	Subsq RX 4th Course Horm	Revised
1715	Subsq RX 4th Course BRM	Revised
1716	Subsq RX 4th Course Oth	Revised
1717	Subsq RX 4th--Scope LN Su	Revised
1718	Subsq RX 4th--Surg Oth	Revised
1719	Subsq RX 4th--Reg LN Rem	Revised
1720	Subsq RX 5th Course Date	Revised
1730	Subsq RX 5th Course Codes	Revised
1731	Subsq RX 5th Course Surg	Revised
1732	Subsq RX 5th Course Rad	Revised
1733	Subsq RX 5th Course Chemo	Revised
1734	Subsq RX 5th Course Horm	Revised
1735	Subsq RX 5th Course BRM	Revised
1736	Subsq RX 5th Course Oth	Revised
1737	Subsq RX 5th--Scope LN Su	Revised
1738	Subsq RX 5th--Surg Oth	Revised
1739	Subsq RX 5th--Reg LN Rem	Revised
1741	Subsq RX--Reconstruct Del	Revised
1780	Quality of Survival	Revised
1790	Follow-Up Source	Revised
1800	Next Follow-Up Source	Revised
1810	Addr Current--City	Revised
1820	Addr Current--State	Revised
1830	Addr Current--Postal Code	Revised
1840	County--Current	Revised
1842	Follow-Up Contact--City	Revised
1844	Follow-Up Contact--State	Revised
1846	Follow-Up Contact--Postal	Revised
1850	Unusual Follow-Up Method	Revised
1860	Recurrence Date--1st	Revised

Item #	Data Item Name	Note
1871	Recurrence Distant Site 1	Revised
1872	Recurrence Distant Site 2	Revised
1873	Recurrence Distant Site 3	Revised
1880	Recurrence Type--1st	Revised
1890	Recurrence Type--1st--Oth	Revised
1910	Cause of Death	Revised
1920	ICD Revision Number	Revised
1930	Autopsy	Revised
1960	Site (73-91) ICD-O-1	Revised
1971	Histology (73-91) ICD-O-1	Revised
1972	Behavior (73-91) ICD-O-1	Revised
1973	Grade (73-91) ICD-O-1	Revised
1980	ICD-O-2 Conversion Flag	Revised
1985	Over-ride Acsn/Class/Seq	Revised
1986	Over-ride HospSeq/DxConf	Revised
1987	Over-ride COC-Site/Type	Revised
1988	Over-ride HospSeq/Site	Revised
1989	Over-ride Site/TNM-StgGrp	Revised
1990	Over-ride Age/Site/Morph	Revised
2020	Over-ride Surg/DxConf	Revised
2030	Over-ride Site/Type	Revised
2040	Over-ride Histology	Revised
2070	Over-ride Leuk, Lymphoma	Revised
2071	Over-ride Site/Behavior	Revised
2074	Over-ride Site/Lat/Morph	Revised
2110	Date Case Report Exported	Revised
2140	COC Coding Sys--Current	Revised
2150	COC Coding Sys--Original	Revised
2170	Vendor Name	Revised
2200	Diagnostic Proc 73-87	Revised
2230	Name--Last	Revised
2240	Name--First	Revised
2250	Name--Middle	Revised
2260	Name--Prefix	Revised
2270	Name--Suffix	Revised
2280	Name--Alias	Revised
2300	Medical Record Number	Revised
2320	Social Security Number	Revised
2330	Addr at DX--No & Street	Revised
2335	Addr at DX--Supplementl	New
2350	Addr Current--No & Street	Revised
2352	Latitude	New
2354	Longitude	New
2355	Addr Current--Supplementl	New
2360	Telephone	Revised
2390	Name--Maiden	Revised

Item #	Data Item Name	Note
2392	Follow-Up Contact--No&St	Revised
2393	Follow-Up Contact--Suppl	New
2394	Follow-Up Contact--Name	Revised
2410	Institution Referred From	Revised
2420	Institution Referred To	Revised
2440	Following Registry	Revised
2460	Physician--Managing	Revised
2490	Physician 3	Revised
2500	Physician 4	Revised
2520	Text--DX Proc--PE	Revised
2530	Text--DX Proc--X-ray/scan	Revised
2540	Text--DX Proc--Scopes	Revised
2550	Text--DX Proc--Lab Tests	Revised
2560	Text--DX Proc--Op	Revised
2570	Text--DX Proc--Path	Revised
2580	Text--Primary Site Title	Revised
2590	Text--Histology Title	Revised
2600	Text--Staging	Revised
2610	RX Text--Surgery	Revised
2620	RX Text--Radiation (Beam)	Revised
2630	RX Text--Radiation Other	Revised
2640	RX Text--Chemo	Revised
2650	RX Text--Hormone	Revised
2660	RX Text--BRM	Revised
2670	RX Text--Other	Revised
2680	Text--Remarks	Revised
2800	CS Tumor Size	New
2810	CS Extension	New
2820	CS Tumor Size/Ext Eval	New
2830	CS Lymph Nodes	New
2840	CS Reg Nodes Eval	New
2850	CS Mets at DX	New
2860	CS Mets Eval	New
2880	CS Site-Specific Factor 1	New
2890	CS Site-Specific Factor 2	New
2900	CS Site-Specific Factor 3	New
2910	CS Site-Specific Factor 4	New
2920	CS Site-Specific Factor 5	New
2930	CS Site-Specific Factor 6	New
2940	Derived AJCC T	New
2950	Derived AJCC T Descriptor	New
2960	Derived AJCC N	New
2970	Derived AJCC N Descriptor	New
2980	Derived AJCC M	New
2990	Derived AJCC M Descriptor	New
3000	Derived AJCC Stage Group	New

Item #	Data Item Name	Note
3010	Derived SS1977	New
3020	Derived SS2000	New
3030	Derived AJCC--Flag	New
3040	Derived SS1977--Flag	New
3050	Derived SS2000--Flag	New
3100	Archive FIN	New
3110	Comorbid/Complication 1	New
3120	Comorbid/Complication 2	New
3130	Comorbid/Complication 3	New
3140	Comorbid/Complication 4	New
3150	Comorbid/Complication 5	New
3160	Comorbid/Complication 6	New
3170	RX Date--Most Defin Surg	New
3180	RX Date--Surgical Disch	New
3190	Readm Same Hosp 30 Days	New
3200	Rad--Boost RX Modality	New
3210	Rad--Boost Dose cGy	New
3220	RX Date--Radiation Ended	New
3230	RX Date--Systemic	New
3250	RX Summ--Transplnt/Endocr	New
3260	Pain Assessment	New
3270	RX Summ--Palliative Proc	New
3280	RX Hosp--Palliative Proc	New
3300	RuralUrban Continuum 1993	New
3310	RuralUrban Continuum 2000	New

Revisions to Data Descriptor table in Chapter X:

Item #	Data Item Name	Note
10	Record Type	Revised
35	FIN Coding System	Revised
40	Registry ID	Revised
50	NAACCR Record Version	Revised
110	Census Tract 1970/80/90	Revised
120	Census Cod Sys 1970/80/90	Revised
130	Census Tract 2000	Revised
364	Census Tr Cert 1970/80/90	Revised
365	Census Tr Certainty 2000	New
380	Sequence Number--Central	Revised
540	Reporting Hospital	Revised
560	Sequence Number--Hospital	Revised
610	Class of Case	Revised
630	Primary Payer at DX	Revised
670	RX Hosp--Surg Prim Site	Revised
672	RX Hosp--Scope Reg LN Sur	Revised

Item #	Data Item Name	Note
674	RX Hosp--Surg Oth Reg/Dis	Revised
700	RX Hosp--Chemo	Revised
710	RX Hosp--Hormone	Revised
720	RX Hosp--BRM	Revised
730	RX Hosp--Other	Revised
740	RX Hosp--DX/Stg Proc	Revised
880	TNM Path T	Revised
890	TNM Path N	Revised
900	TNM Path M	Revised
910	TNM Path Stage Group	Revised
930	TNM Path Staged By	Revised
940	TNM Clin T	Revised
950	TNM Clin N	Revised
960	TNM Clin M	Revised
970	TNM Clin Stage Group	Revised
990	TNM Clin Staged By	Revised
1060	TNM Edition Number	Revised
1280	RX Date--DX/Stg Proc	Revised
1290	RX Summ--Surg Prim Site	Revised
1292	RX Summ--Scope Reg LN Sur	Revised
1294	RX Summ--Surg Oth Reg/Dis	Revised
1320	RX Summ--Surgical Margins	Revised
1340	Reason for No Surgery	Revised
1350	RX Summ--DX/Stg Proc	Revised
1390	RX Summ--Chemo	Revised
1400	RX Summ--Hormone	Revised
1410	RX Summ--BRM	Revised
1420	RX Summ--Other	Revised
1430	Reason for No Radiation	Revised
1460	RX Coding System--Current	Revised
1540	Rad--Treatment Volume	Revised
1570	Rad--Regional RX Modality	Revised
1880	Recurrence Type--1st	Revised
2120	SEER Coding Sys--Current	Revised
2130	SEER Coding Sys--Original	Revised
2140	COC Coding Sys--Current	Revised
2150	COC Coding Sys--Original	Revised
2330	Addr at DX--No & Street	Revised
2335	Addr at DX--Supplementl	New
2350	Addr Current--No & Street	Revised
2352	Latitude	New
2354	Longitude	New
2355	Addr Current--Supplementl	New
2392	Follow-Up Contact--No&St	Revised
2393	Follow-Up Contact--Suppl	New
2410	Institution Referred From	Revised

Item #	Data Item Name	Note
2420	Institution Referred To	Revised
2430	Last Follow-Up Hospital	Revised
2440	Following Registry	Revised
2800	CS Tumor Size	New
2810	CS Extension	New
2820	CS Tumor Size/Ext Eval	New
2830	CS Lymph Nodes	New
2840	CS Reg Nodes Eval	New
2850	CS Mets at DX	New
2860	CS Mets Eval	New
2880	CS Site-Specific Factor 1	New
2890	CS Site-Specific Factor 2	New
2900	CS Site-Specific Factor 3	New
2910	CS Site-Specific Factor 4	New
2920	CS Site-Specific Factor 5	New
2930	CS Site-Specific Factor 6	New
2940	Derived AJCC T	New
2950	Derived AJCC T Descriptor	New
2960	Derived AJCC N	New
2970	Derived AJCC N Descriptor	New
2980	Derived AJCC M	New
2990	Derived AJCC M Descriptor	New
3000	Derived AJCC Stage Group	New
3010	Derived SS1977	New
3020	Derived SS2000	New
3030	Derived AJCC--Flag	New
3040	Derived SS1977--Flag	New
3050	Derived SS2000--Flag	New
3100	Archive FIN	New
3110	Comorbid/Complication 1	New
3120	Comorbid/Complication 2	New
3130	Comorbid/Complication 3	New
3140	Comorbid/Complication 4	New
3150	Comorbid/Complication 5	New
3160	Comorbid/Complication 6	New
3170	RX Date--Most Defin Surg	New
3180	RX Date--Surgical Disch	New
3190	Readm Same Hosp 30 Days	New
3200	Rad--Boost RX Modality	New
3210	Rad--Boost Dose cGy	New
3220	RX Date--Radiation Ended	New
3230	RX Date--Systemic	New
3250	RX Summ--Transplnt/Endocr	New
3260	Pain Assessment	New
3270	RX Summ--Palliative Proc	New
3280	RX Hosp--Palliative Proc	New

Item #	Data Item Name	Note
3300	RuralUrban Continuum 1993	New
3310	RuralUrban Continuum 2000	New

Revisions to Data Dictionary in Chapter XI:

Data Item Name	Item #	Note
Addr at DX--No & Street	2330	Revised
Addr at DX--Supplementl	2335	New
Addr Current--No & Street	2350	Revised
Addr Current--Supplementl	2355	New
Archive FIN	3100	New
Census Cod Sys 1970/80/90	120	Revised
Census Tr Cert 1970/80/90	364	Revised
Census Tr Certainty 2000	365	New
Census Tract 1970/80/90	110	Revised
Census Tract 2000	130	Revised
Class of Case	610	Revised
COC Coding Sys--Current	2140	Revised
COC Coding Sys--Original	2150	Revised
Comorbid/Complication 1	3110	New
Comorbid/Complication 2	3120	New
Comorbid/Complication 3	3130	New
Comorbid/Complication 4	3140	New
Comorbid/Complication 5	3150	New
Comorbid/Complication 6	3160	New
CS Extension	2810	New
CS Lymph Nodes	2830	New
CS Mets at DX	2850	New
CS Mets Eval	2860	New
CS Reg Nodes Eval	2840	New
CS Site-Specific Factor 1	2880	New
CS Site-Specific Factor 2	2890	New
CS Site-Specific Factor 3	2900	New
CS Site-Specific Factor 4	2910	New
CS Site-Specific Factor 5	2920	New
CS Site-Specific Factor 6	2930	New
CS Tumor Size	2800	New
CS Tumor Size/Ext Eval	2820	New
Derived AJCC M	2980	New
Derived AJCC M Descriptor	2990	New
Derived AJCC N	2960	New
Derived AJCC N Descriptor	2970	New
Derived AJCC Stage Group	3000	New
Derived AJCC T	2940	New
Derived AJCC T Descriptor	2950	New

Data Item Name	Item #	Note
Derived AJCC--Flag	3030	New
Derived SS1977	3010	New
Derived SS1977--Flag	3040	New
Derived SS2000	3020	New
Derived SS2000--Flag	3050	New
FIN Coding System	35	Revised
Following Registry	2440	Revised
Follow-Up Contact--No&St	2392	Revised
Follow-Up Contact--Suppl	2393	New
Institution Referred From	2410	Revised
Institution Referred To	2420	Revised
Last Follow-Up Hospital	2430	Revised
Latitude	2352	New
Longitude	2354	New
NAACCR Record Version	50	Revised
Pain Assessment	3260	New
Primary Payer at DX	630	Revised
Rad--Boost Dose cGy	3210	New
Rad--Boost RX Modality	3200	New
Rad--Regional RX Modality	1570	Revised
Rad--Treatment Volume	1540	Revised
Readm Same Hosp 30 Days	3190	New
Reason for No Radiation	1430	Revised
Reason for No Surgery	1340	Revised
Record Type	10	Revised
Recurrence Type--1st	1880	Revised
Registry ID	40	Revised
Reporting Hospital	540	Revised
RuralUrban Continuum 1993	3300	New
RuralUrban Continuum 2000	3310	New
RX Coding System--Current	1460	Revised
RX Date--DX/Stg Proc	1280	Revised
RX Date--Most Defin Surg	3170	New
RX Date--Radiation Ended	3220	New
RX Date--Surgical Disch	3180	New
RX Date--Systemic	3230	New
RX Hosp--BRM	720	Revised
RX Hosp--Chemo	700	Revised
RX Hosp--DX/Stg Proc	740	Revised
RX Hosp--Hormone	710	Revised
RX Hosp--Other	730	Revised
RX Hosp--Palliative Proc	3280	New
RX Hosp--Scope Reg LN Sur	672	Revised
RX Hosp--Surg Oth Reg/Dis	674	Revised
RX Hosp--Surg Prim Site	670	Revised
RX Summ--BRM	1410	Revised

Data Item Name	Item #	Note
RX Summ--Chemo	1390	Revised
RX Summ--DX/Stg Proc	1350	Revised
RX Summ--Hormone	1400	Revised
RX Summ--Other	1420	Revised
RX Summ--Palliative Proc	3270	New
RX Summ--Scope Reg LN Sur	1292	Revised
RX Summ--Surg Oth Reg/Dis	1294	Revised
RX Summ--Surg Prim Site	1290	Revised
RX Summ--Surgical Margins	1320	Revised
RX Summ--Transplnt/Endocr	3250	New
SEER Coding Sys--Current	2120	Revised
SEER Coding Sys--Original	2130	Revised
Sequence Number--Central	380	Revised
Sequence Number--Hospital	560	Revised
TNM Clin M	960	Revised
TNM Clin N	950	Revised
TNM Clin Stage Group	970	Revised
TNM Clin Staged By	990	Revised
TNM Clin T	940	Revised
TNM Edition Number	1060	Revised
TNM Path M	900	Revised
TNM Path N	890	Revised
TNM Path Stage Group	910	Revised
TNM Path Staged By	930	Revised
TNM Path T	880	Revised

INDEX

- 13-Digit (Expanded) Site-Specific Extent of Disease (SEER), 206
- 1990 Census of Population and Housing, Alphabetical Index of Industries and Occupations, 93
- 2-Digit Nonspecific and 2-Digit Site-Specific Extent of Disease (1973-1982 SEER), 206
- 4-Digit Extent of Disease (1983-1987 SEER), 206
- Abstracted By, 138
- Accession Number (COC), 138
- Accession Number--Hosp, 138
- Accession Year (pre-96 COC), 397
- ACoS. See American College of Surgeons
- ACS. See American Cancer Society
- Addr at DX--City, 138
- Addr at DX--No & Street, 139
- Addr at DX--Postal Code, 140
- Addr at DX--State, 140
- Addr Current--City, 142
- Addr Current--No & Street, 146
- Addr Current--Postal Code, 144
- Addr Current--State, 145, 155
- Addr--City, 41
- Addr--No & Street, 41
- Addr--Postal Code, 42
- Addr--State, 42
- Age at Diagnosis, 147
- Age/Site/Histology Interfield Review (Interfield Edit 15) (SEER #3), 241
- AJCC Cancer Staging Manual, 203, 205, 207, 290, 291, 378, 379, 381, 383, 384, 385, 387, 389, 390, 392
- AJCC Staging System, 377-91
- Alcohol History, 147
- Alias (COC), 234
- Alternate Names, 431
- American Cancer Society, v, vii, xiii, 1, 4, 7, 429
- American College of Surgeons, v, xiii, 1, 7, 8, 91, 93, 107, 429
- American Joint Committee on Cancer, v, xiii, 7, 8, 16, 18, 27, 91, 119, 204, 259, 429
- Armed Forces Institute of Pathology, 8
- Attending Physician (pre-96 COC), 260
- Autopsy, 148, 396
- Behavior (73-91) ICD-O-1, 149, 231
- Behavior (92-00) ICD-O-2, 149, 150, 217, 218, 233, 439
- Behavior Code ICD-O-3, 149, 150, 217, 218, 233
- Behavior Type ICD-O-3, 439
- Bethesda System, 17
- Biological Response Modifiers (pre-96 SEER), 320
- Birth Date, 43, 150
- Birthplace, 151
- BPLACE.DBF, 168, 415
- Canadian Cancer Registry, 13
- Canadian Council of Cancer Registries, 13
- Data Quality Committee, 13
- Canadian Postal Code. See Addr at DX--Postal Code
- Cancer Program Manual, 11, 161
- Cancer Program Standards, 15, 93
- Cancer Registration: Principles and Methods, 94
- Cancer Registries Amendment Act, 8, 26, 94
- Cancer Registry Management Principles & Practice, 8
- Cancer Staging Manual, 91, 204
- Cancer Status, 151
- Cancer-Directed Surgery (pre-96 COC), 334
- Cancer-Directed Surgery at This Facility (pre-96 COC), 319
- Carcinoma in situ of the cervix, 16, 17, 18
- Case Inclusion, 23
- Cause of Death, 152
- Census Coding System (COC), 153
- Census Tract, 153, 156, 157
- Census Tract Block Group, 158
- Census Tract Certainty, 154
- Census Tract Cod Sys--Alt, 158
- Census Tract/Block Numbering Area (BNA) (SEER), 156
- Census Tract--Alternate, 157, 158
- Centers for Disease Control and Prevention, v, xiii, 1, 2, 4, 8, 12, 26, 92, 93, 94, 107, 429
- Centers for Medicare & Medicaid Services, 37
- Central Cancer Registries: Design, Management, and Use, 93
- Certified Tumor Registrars, 8, 429
- Chemotherapy (SEER/COC), 321
- Chemotherapy at this Facility (COC), 307
- Chemotherapy Field 1, 158
- Chemotherapy Field 2, 159
- Chemotherapy Field 3, 159
- Chemotherapy Field 4, 159
- City or Town, 41
- City or Town (pre-96 COC), 138
- City/Town at Diagnosis (COC), 138
- City/Town--Current (COC), 142
- Class of Case, 160
- Clinical Laboratory Improvement Act, 37, 64
- Clinical M (COC), 378
- Clinical N (COC), 378
- Clinical Stage (Prefix/Suffix) Descriptor (COC), 377
- Clinical Stage Group (COC), 379
- Clinical T (COC), 381
- COC, 431-38. See Commission on Cancer
- COC Coding Sys--Current, 161
- COC Coding Sys--Original, 161
- COC pre-96, 431-38
- COC pre-96
- Alternate Names, 431-38
- COC pre-98, 431-38
- COC pre-98
- Alternate Names, 431-38
- Code manual references, 91
- Codes and Coding Instructions. See SEER Extent of Disease

- Coding Rules, 6
- Coding System for Census Tract, 153
- Coding System for EOD, 162
- Coding System for Extent of Disease (SEER), 162
- College of American Pathologists, 37
- Commission on Cancer, 1, 4, 15, 18, 107
 - Alternate Names, 431–38
 - Comparison of Reportable Cancers, 18
 - Required Status Table, 108–19
- Commission on Cancer Coding System-Current (COC), 161
- Comparative Staging Guide for Cancer, 10, 28, 91, 203, 204, 205, 207, 227, 290, 291
- Comparison of Reportable Cancers, 18
- Computed Ethnicity, 166, 354
- Computed Ethnicity Source, 26, 166, 167
- County (pre-96 SEER/COC), 168
- County at Diagnosis (COC), 168
- County at DX, 25, 168
- County--Current, 169
- CPT Codes, 43
- CRC CHECKSUM, 169
- CTR. See Certified Tumor Registrars
- DAM. See Data Acquisition Manual
- Data Acquisition Manual, 12, 161, 429
- Data Dictionary, 138–397
- Data edits, 19
- Data Evaluation and Publications Committee, 1
- Data Exchange Committee, 2
- Data exchange standards, 4
- Data Exchange Standards and Record Description, vii, 2
- Date Case Completed, 182
- Date Case Last Changed, 183
- Date Case Report Exported, 183
- Date Case Report Loaded, 183
- Date Case Report Received, 184
- Date Case Transmitted (pre-98 NAACCR), 183
- Date Chemotherapy Started (COC), 301
- Date Hormone Therapy Started (COC), 302
- Date Immunotherapy Started (COC), 300
- Date of 1st Contact, 184
- Date of 1st Crs RX--COC, 185, 186
- Date of 1st Positive BX, 185
- Date of Birth, 43
- Date Of Birth, 70
- Date of Birth (SEER/COC), 150
- Date of CA Conference, 186, 262
- Date of Cancer Conference (COC), 186
- Date of Cancer-Directed Surgery (COC), 304
- Date of Diagnosis, 186
- Date of First Course Treatment (COC), 185
- Date of First Positive Biopsy (COC), 185
- Date of First Recurrence (COC), 285
- Date of Initial Diagnosis (COC), 186
- Date of Initial RX--SEER, 185, 186
- Date of Inpatient Adm, 187
- Date of Inpatient Admission (COC), 187
- Date of Inpatient Disch, 187
- Date of Inpatient Discharge (COC), 187
- Date of Last Contact, 151, 188, 397
- Date of Last Contact or Death (COC), 188
- Date of Last Follow-Up or of Death (SEER), 188
- Date Other Treatment Started (COC), 303
- Date Radiation Started (COC), 303
- Date Started (pre-96 COC), 185
- Date Started (SEER), 186
- Date Therapy Initiated (SEER), 186
- Date Transmitted, 43
- Date Transmitted/Date Case Transmitted, 72
- Date Tumor Record Availbl, 148, 163, 164, 165, 171, 172, 173, 174, 175, 177, 178, 179, 180, 181, 182, 188, 189, 191, 193, 197, 198, 199, 200, 201, 257, 273, 278, 281, 298, 299, 302, 304, 305, 311, 326, 337
- DC State, 188
- DC State File Number, 189
- Diagnostic and Staging Procedures (pre-2001 COC), 315, 316, 317, 332, 333
- Diagnostic Confirmation, 202
- Diagnostic Proc 73-87, 202
- Diagnostic Procedures (1973-87 SEER), 202
- Disease Classification references, 92
- EDITS Language, 21
- EDITS project, 20
 - EDITS Language, 21
- Edits, data
 - Interfield edits, 19
 - Interrecord edits, 19
 - Item edits, 19
 - multi-field edits, 19
 - multi-record edits, 19
 - single field edits, 19
- Endocrine (Hormone/Steroid) Therapy (pre-96 SEER), 323
- EOD. See SEER Extent of Disease
- EOD--Extension, 203, 208
- EOD--Extension Prost Path, 204, 208
- EOD--Lymph Node Involv, 205, 208
- EOD--Old 13 Digit, 206
- EOD--Old 2 Digit, 206
- EOD--Old 4 Digit, 206
- EOD--Tumor Size, 207, 208, 439
- Extension (pre-96 SEER/COC), 203
- Extension (SEER EOD) (96 COC), 203
- Extent of Disease 10-Dig, 439
- Family History of Cancer, 208
- FCDS. See Florida Cancer Data System
- Federal Information Processing Standards, 429
- FIN Coding System, 209, 210, 222, 223, 224, 292, 294
- FIPS. See Federal Information Processing Standards
- First Course Calc Method, 210
- First Name (COC), 234
- Florida Cancer Data System, ix, xi, 425, 429
- Following Physician (COC), 260
- Following Registry, 209, 210
- Follow-Up Contact--City, 211, 214
- Follow-Up Contact--Name, 211
- Follow-Up Contact--No&St, 211, 214
- Follow-Up Contact--Postal, 212

- Follow-Up Contact--State, 213
- Follow-Up Method (pre-96 COC), 215
- Follow-Up Physician (pre-96 COC), 260
- Follow-Up Source, 215
- FTRO. See Fundamental Tumor Registry Operations Program
- Fundamental Tumor Registry Operations Program, 429
- Future Use Timeliness 1, 215
- Future Use Timeliness 2, 216
- General Summary Stage (SEER/COC), 344
- Grade, 216, 439
- Grade (73-91) ICD-O-1, 217, 231
- Grade, Differentiation, or Cell Indicator (SEER), 216
- Grade/Differentiation (COC), 216
- Grouped Data Items, 439
 - Extent of Disease 10-Dig, 439
 - Morph (73-91) ICD-O-1, 439
 - Morph--Type&Behav ICD-O-2, 439
 - Subsq RX 2nd Course Codes, 439
 - Subsq RX 3rd Course Codes, 439
 - Subsq RX 4th Course Codes, 440
 - Subsq RX 5th Course Codes, 440
- Guidelines for Reporting Occupation and Industry on Death Certificates, 93
- Health Care Financing Administration, 37
- Health Information Management, 230, 429
- Health Level 7, 35, 36, 37, 38, 39, 48, 70, 73, 84
 - Addendum, 37
 - formatting paramters, 37
- Health Level 7 Addendum, 73
- HIM. See Health Information Management
- Hispanic/Spanish Origin, 25, 26, 166, 266, 267, 268, 269, 271, 354
- Histologic (92-00) ICD-O-2, 149, 150, 217, 218
- Histologic Type ICD-O-3, 149, 150, 217, 218, 233, 439
- Histology (73-91) ICD-O-1, 218, 231
- Histology (92-00) ICD-O-2, 233, 439
- Histology/Behavior Interfield Review (Field Item Edit Morph) (SEER #2), 243
- HL-7. See Health Level 7
- Hormone Therapy (SEER/COC), 323
- Hormone Therapy at this Facility (COC), 309
- IACR. See International Association of Cancer Registrars
- IARC. See International Agency for Research on Cancer
- ICD. See International Classification of Diseases
- ICD Code Revision Used for Cause of Death (SEER), 219
- ICD Revision Number, 219
- ICD-10, 11, 92
- ICD-9, 10, 11, 92
- ICD-O, 8, 11, 12
- ICD-O-2 Conversion Flag, 219
- ICD-O-3 Conversion Flag, 220
- Immunotherapy (SEER/COC), 320
- Immunotherapy at this Facility (COC), 306
- Industry Code--Census, 220
- Industry Source, 221
- Inpatient/Outpatient Status (COC), 221, 225
- Inpatient/Outpt Status, 221
- Institution ID Number, 64
- Institution ID Number (COC), 294
- Institution Referred From, 209, 222
- Institution Referred To, 209, 223
- Instructional Manual Part 19: Industry and Occupation Coding for Death Certificates, 92
- Intent of Treatment (Radiation) (COC), 275
- International Agency for Research on Cancer, 16, 94, 429
- International Association of Cancer Registrars, 16, 429
- International Classification of Diseases, 10, 15, 16, 18, 92, 429
- International Classification of Diseases for Oncology, 11, 92, 429
- International Classification of Diseases for Oncology, Morphology, 92
- International Statistical Classification of Diseases and Related Health Problems, 11, 92
- Inter-Related Items, Fields, and Subfields, 5
- Laboratory Codes Version Control Table, 44
- Last Follow-Up Hospital, 209, 224
- Last Name (COC), 235
- Laterality, 225
- Length, 5
- Leukemia or Lymphoma/Diagnostic Confirmation Interfield Review (Interfield Edit 48) (SEER #9), 246
- Loc/Reg/Distant Stage, 227
- Location of Radiation Treatment (COC), 276
- Lymph Nodes (pre-96-SEER/COC), 205
- Lymph Nodes (SEER EOD) (96 COC), 205
- Maiden Name (COC), 235
- Managing Physician (COC), 260
- Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death, 92
- Marital Status at Diagnosis (SEER/COC), 229
- Marital Status at DX, 229
- Marital Status at Initial Diagnosis, 229
- Medical Record Number, 45, 70, 230
- Middle Initial (pre-96 COC), 236
- Middle Name (COC), 236
- Military Medical Record Number Suffix (COC), 231
- Military Record No Suffix, 231
- Morph (73-91), 231
- Morph (73-91) ICD-O-1, 439
- Morph Coding Sys--Current, 232
- Morph Coding Sys--Originl, 232
- Morph--Type&Behav ICD-O-2, 439
- Morph--Type&Behav ICD-O-3, 439
- Multiple Primary Rules, 18, 23
- NAACCR. See North American Association of Central Cancer Registries
- NAACCR Board of Directors, vii
- NAACCR Exc, 107
- NAACCR Full, 107
- NAACCR Inc, 107
- NAACCR pre-98, 431-38
- NAACCR pre-98
 - Alternate Names, 431-38
- NAACCR Record Version, 233
- NAACCR Standard Edits, 21

- Name Prefix (COC), 236
Name Suffix (COC), 237
Name--Alias, 234
Name--First, 45, 234
Name--Last, 26, 46, 166, 235, 354
Name--Maiden, 26, 166, 235, 354
Name--Middle, 46, 236
Name--Prefix, 236
Name--Spouse/Parent, 236
Name--Suffix, 237
Narrative Diagnosis, 72
National Board for the Certification of Registrars, 8, 429
National Cancer Data Base, 1, 2, 425, 429
National Cancer Institute, v, xiii, 1, 4, 8, 9, 91, 93, 107, 429
National Cancer Registrars Association, v, xiii, 8, 429
National Center for Health Statistics, 8, 92, 93
National Coordinating Council for Cancer Surveillance, 8
National Institutes of Health, 91
National Program of Cancer Registries, xiii, 8, 15, 18, 93, 94, 107
 Comparison of Reportable Cancers, 18
 Required Status Table, 108–19
NBCR, 8. See National Board for the Certification of Registrars
NCCCS. See National Coordinating Council for Cancer Surveillance
NCDB. See National Cancer Data Base
NCI. See National Cancer Institute
Next Follow-Up Method (pre-96 COC), 237
Next Follow-Up Source, 237
Non Cancer-Directed Surgery (COC), 322
Non Cancer-Directed Surgery at this Facility (COC), 308
North American Association of Central Cancer Registries, xiii, 1, 4, 8, 9, 33, 93, 429
 Alternate Names, 431
 Required Status Table
 NAACCR Exc, 108–19
 NAACCR Full, 108–19
 NAACCR Inc, 108–19
Number of Positive Regional Lymph Nodes (SEER), 291
Number of Regional Lymph Nodes Examined (SEER), 290
Number of Regional Lymph Nodes Examined (SEER/COC), 330
Number of Regional Lymph Nodes Examined at This Facility (COC), 313
Number of Treatments to this Volume (COC), 277
Occup/Ind Coding System, 238
Occupation and Industry Classification and Coding references, 92
Occupation Code--Census, 239
Occupation Source, 240
Ordering Client/Physician, 47
Ordering Client/Physician Addr--City, 47
Ordering Client/Physician Addr--No & Street, 48
Ordering Client/Physician Addr--Postal Code, 48
Ordering Client/Physician Addr--State, 49
Ordering Client/Physician Work Facility Addr--City, 51
Ordering Client/Physician Work Facility Addr--No & Street, 51
Ordering Client/Physician Work Facility Addr--Postal Code, 52
Ordering Client/Physician Work Facility Addr--State, 52
Ordering Client/Physician Work Facility--Telephone, 53
Ordering Client/Physician--License Number, 49
Ordering Client/Physician--Name, 50
Ordering Client/Physician--Telephone, 50
Other M (COC), 383
Other N (COC), 384
Other Physician (pre-96 COC), 259, 260
Other Stage (Prefix/Suffix) Descriptor (COC), 382
Other Stage Group (COC), 385
Other Staging System, 240
Other T (COC), 387
Other Treatment at this Facility (COC), 310
Other Type of First Recurrence (COC), 289
Over-Ride Accession/Class of Case/Sequence, 241
Over-ride Acsn/Class/Seq, 241
Over-ride Age/Site/Morph, 241
Over-ride COC-Site/Type, 242
Override Flag for Site/Behavior (IF39) (SEER #11), 249
Override Flag for Site/EOD/Diagnosis Date (IF40) (SEER #13), 250
Override Flag for Site/Laterality/EOD (IF41) (SEER #12), 251
Override Flag for Site/Laterality/Morphology (IF42) (SEER #13), 252
Over-ride Histology, 243
Over-Ride Hospital Sequence/Diagnostic Confirmation, 244
Over-Ride Hospital Sequence/Site, 244
Over-ride HospSeq/DxConf, 244
Over-ride HospSeq/Site, 244
Over-ride Ill-defined Site, 245
Over-ride Leuk, Lymphoma, 246
Over-ride Report Source, 247
Over-ride SeqNo/DxConf, 248
Over-ride Site/Behavior, 249
Over-ride Site/EOD/DX Dt, 250
Over-ride Site/Lat/EOD, 251
Over-ride Site/Lat/Morph, 252
Over-ride Site/Lat/SeqNo, 253
Over-ride Site/TNM-StgGrp, 253
Over-ride Site/Type, 254
Over-ride SS/DisMet1, 254
Over-ride SS/NodesPos, 255
Over-ride SS/TNM-M, 255
Over-ride SS/TNM-N, 256
Over-Ride Summary Stage/Distant Metastasis 1, 254
Over-Ride Summary Stage/Nodes Positive, 255
Over-Ride Summary Stage/TNM-N, 255, 256
Over-ride Surg/DxConf, 256
Path Facility ID Number, 70
 City, 70
 Laboratory Name, 70
 State/Province, 70

- Street, 70
- Telephone Number, 70
- Zip Code/Postal Code, 70
- Path Ordering Client/Physician, 70
 - City, 71
 - First Name, 70
 - Last Name, 70
 - License Number/Physician, 70
 - Middle Name, 70
 - Path--Work Facility ID Number, 71
 - State/Province, 71
 - Street, 70
 - Telephone Number, 71
 - Zip/Postal Code, 71
- Path Version Number, 70
- Path--Age At Specimen, 70
- Path--Clinical History, 53, 72
- Path--Comment Section, 53, 72
- Path--CPT Code, 71
- Path--CPT Code Version Control, 71
- Path--Date of Specimen Collection, 54
- Path--Date Of Specimen Collection, 71
- Path--Final Diagnosis, 54, 72
- Path--Gross Pathology, 54, 72
- Path--ICD Code, 71
- Path--ICD Revision Number Code Version Control, 71
- Path--ICD Version Number, 55
- Path--ICD-CM-Code, 55
- Path--Microscopic Pathology, 56, 72
- Path--Nature of Specimen, 56
- Path--Nature Of Specimen, 72
- Pathologic M (COC), 389
- Pathologic N (COC), 389
- Pathologic Stage (Prefix/Suffix) Descriptor (COC), 388
- Pathologic Stage Group (COC), 390
- Pathologic T (COC), 392
- Pathology Review of Regional Lymph Nodes (SEER), 290, 291
- Path--Ordering Client/Physician, 56
- Path--Pathologist License Number, 57, 71
- Path--Pathologist State Licensur, 71
- Path--Pathologist State Licensure, 57
- Path--Patient Age At Specimen, 58
- Path--Report Type, 58, 72
- Path--Reporting Pathologist First Name, 59, 71
- Path--Reporting Pathologist Last Name, 59, 71
- Path--Reporting Pathologist Middle Name, 60, 71
- Path--Reporting Pathologist Suffix, 60, 71
- Path--Slide Report Number, 61
- Path--Slide/ Pathology Report Number, 70
- Path--SNOMED Code(s), 61, 71
- Path--SNOMED Version Control, 71
- Path--Staging Parameters, 72
- Path--Status Individual Result, 62, 71
- Path--Supplemental Reports and/or Addenda, 62
- Path--Supplemental Reports And/Or Addenda, 72
- Path--Text Diagnosis, 63
- Path--Text-Diagnosis, 72
- Path--Version Number, 63
- Patient Address, 70
 - City/Town, 70
 - State/Province, 70
 - Street, 70
 - Zip Code/Postal Code, 70
- Patient Address (Number and Street) at Diagnosis (COC), 139
- Patient Address (Number and Street)-Current (COC), 143, 146, 226, 228
- Patient ID Number, 257
- Patient Name, 70
 - First Name, 70
 - Last Name, 70
 - Middle Name, 70
- Patient Telephone Number, 70
- Patient's First Name, 45
- Patient's Last Name, 46
- Patient's middle name, 46
- Patient's Street Address, 41
- Pediatric Stage, 258, 259
- Pediatric Staged By, 258
- Pediatric Staging System, 259
- PEDSTAGE.DBF, 424
- Physician #3 (COC), 259
- Physician #4 (COC), 260
- Physician 3, 259
- Physician 4, 260
- Physician--Follow-Up, 260
- Physician--Managing, 260
- Physician--Primary Surg, 261
- Place of Birth (SEER/COC), 151
- Place of Death, 188, 189, 261
- Place of Diagnosis, 261
- Postal Code at Diagnosis (COC), 140
- Postal Code--Current (COC), 144
- Presentation at CA Conf, 186, 262
- Presentation at Cancer Conference (COC), 262
- Primary Payer at Diagnosis (COC), 263
- Primary Payer at DX, 263
- Primary Site, 19, 264
- Primary Site (1973-81) (SEER), 350
- Primary Surgeon (COC), 261
- Protocol Eligibility Stat, 264
- Protocol Eligibility Status (COC), 264
- Protocol Participation, 265
- Public Law 102-515, 8
- Quality of Survival, 265
- Race, 266
 - Race 1, 266
 - Race 2, 267, 272, 273
 - Race 3, 268, 272, 273
 - Race 4, 269, 272, 273
 - Race 5, 271, 272, 273
- Race Coding Sys--Current, 272
- Race Coding Sys--Original, 273
- Rad--Elapsed RX Days, 5, 275
- Radiation (SEER/COC), 328
- Radiation at this Facility (COC), 312

- Radiation Elapsed Treatment Time (Days) (COC), 275
- Radiation Sequence with Surgery (pre-96 SEER/COC), 335
- Radiation therapy (pre-96 COC), 328
- Radiation Therapy Local Control Status (Irradiated Volume) (COC), 276
- Radiation Therapy to CNS (COC), 327
- Radiation to the Brain and/or Central Nervous System (SEER), 327
- Radiation Treatment Completion Status (COC), 279
- Radiation Treatment Volume (COC), 280
- Radiation/Surgery Sequence (COC), 335
- Rad--Intent of Treatment, 275
- Rad--Local Control Status, 276
- Rad--Location of RX, 276
- Rad--No of Treatment Vol, 5, 277
- Rad--Regional Dose:cGy, 277
- Rad--RX Completion Status, 279
- Reason for No CA Dir Surg, 284
- Reason for No Cancer-Directed Surgery (SEER), 284
- Reason for No Chemo, 282
- Reason for No Chemotherapy (COC), 282
- Reason for No Hormone, 282, 324
- Reason for No Hormone Therapy (COC), 282
- Reason for No Radiation, 283, 328
- Reason for No Surgery (COC), 284
- Recommendations for Occupation and Industry Data Items, 92
- Reconstruction/Restoration-First Course (COC), 329
- Reconstruction--First Course (SEER), 329
- Record layout references, 91
- Record Layout Table, 96–106
- Record Number (SEER), 343
- Record Type, 64, 70, 285
- Recurrence Date--1st, 285
- Recurrence Distant Site 1, 286, 287
- Recurrence Distant Site 2, 286, 287
- Recurrence Distant Site 3, 287
- Recurrence Distant Sites, 287
- Recurrence Type--1st, 288, 289
- Recurrence Type--1st--Oth, 289
- References
 - Code manuals, 91
 - Disease Classifications, 92
 - Occupation and Industry Classification and Coding, 92
 - Record layouts, 91
 - Stage and Extent of Disease Manuals, 91
- Referral to Support Serv, 290
- Referral to Support Services (COC), 290
- REGID.DBF, 425
- Regional Nodes Examined, 205, 207, 208, 290, 439
- Regional Nodes Positive, 205, 207, 208, 291, 439
- Registry ID, 209, 257, 292
- Registry Operations and Data Standards, 7, 15, 16, 25, 26, 91, 161, 169, 185, 186, 205, 207, 216, 230, 234, 258, 261, 273, 290, 291, 300, 306, 307, 308, 309, 314, 318, 319, 321, 322, 324, 325, 331, 332, 333, 334, 335, 336, 337, 350, 369, 378, 379, 381, 383, 384, 385, 387, 389, 390, 392, 393, 394, 395, 429, 431
- Registry staffing manual, 94
- Registry Type, 209, 293
- Religion, 293
- Reportability, 23
- Reportability standards, 4, 15
 - In Situ/Invasive, 16
 - Multiple Primary Rules, 16
 - residency, 15
- Reporting Facility, 64
- Reporting Facility Addr--City, 65
- Reporting Facility Addr--No & Street, 65
- Reporting Facility Addr--Postal Code, 66
- Reporting Facility Addr--State, 66
- Reporting Facility Name, 67
- Reporting Facility--Phone Number, 67
- Reporting Hospital, 209, 294
- Reporting Hospital FAN, 295
- Required Status Table, 108–19
- Reserved for Expansion, 297
- Residual Primary Tumor Following Cancer-Directed Surgery (pre-96 COC), 336
- Review Flag for 1973-91 Cases (SEER), 219
- RX Coding System--Current, 300
- RX Date--BRM, 300
- RX Date--Chemo, 301
- RX Date--DX/Stg/Pall Proc, 301
- RX Date--Hormone, 302
- RX Date--Other, 303
- RX Date--Radiation, 303
- RX Date--Surgery, 304
- RX Hosp--BRM, 306
- RX Hosp--CA Dir Surgery (pre-96 NAACCR), 319
- RX Hosp--Chemo, 307
- RX Hosp--DX/Stg/Pall Proc, 308
- RX Hosp--Hormone, 309
- RX Hosp--Other, 310
- RX Hosp--Radiation, 312
- RX Hosp--Reg LN Examined, 313
- RX Hosp--Scope Reg LN Sur, 314
- RX Hosp--Screen/BX Proc1, 315
- RX Hosp--Screen/BX Proc2, 316
- RX Hosp--Screen/BX Proc3, 316
- RX Hosp--Screen/BX Proc4, 317
- RX Hosp--Surg Oth Reg/Dis, 318
- RX Hosp--Surg Prim Site, 308, 319
- RX Summ--Chemo, 282, 321
- RX Summ--DX/Stg/Pall Proc, 322
- RX Summ--Hormone, 282, 323
- RX Summ--Rad to CNS, 26, 327
- RX Summ--Radiation, 26, 283, 327, 328
- RX Summ--Reconstruct 1st, 322, 329, 369
- RX Summ--Reg LN Examined, 330
- RX Summ--Scope Reg LN Sur, 331
- RX Summ--Screen/BX Proc1, 332
- RX Summ--Screen/BX Proc2, 332
- RX Summ--Screen/BX Proc4, 333
- RX Summ--Surg Oth Reg/Dis, 334
- RX Summ--Surg Prim Site, 322, 334

- RX Summ--Surg/Rad Seq, 335
- RX Summ--Surgery Type, 322, 329, 335, 369
- RX Summ--Surgical Approach, 335
- RX Summ--Surgical Margins, 336
- RX Text--BRM, 338
- RX Text--Chemo, 338
- RX Text--Hormone, 339
- RX Text--Other, 339
- RX Text--Radiation (Beam), 340
- RX Text--Radiation Other, 340
- RX Text--Surgery, 341
- Scope of Regional Lymph Node Surgery (SEER/COC), 331
- Scope of Regional Lymph Node Surgery at this Facility (COC), 314
- Screening Date, 341, 342
- Screening Result, 342
- Second Course of Therapy-Date Started (pre-96 COC), 356
- SEER, 431–38
- SEER
 - GEOCODES for Coding Place of Birth, 415
- SEER Coding Sys--Original, 343
- SEER Edit Documentation, 93
- SEER EEOD (SEER), 206
- SEER Extent of Disease, 10, 27, 203, 204, 205, 206, 207, 290, 291, 429
 - Codes and Coding Instructions, 10, 91, 203, 204, 205, 206, 207, 290, 291
- SEER Historic Stage, 27, 28, 227
- SEER pre-98, 431–38
- SEER pre-98
 - Alternate Names, 431–38
- SEER Program, xiii, 9, 10, 11, 15, 16, 26, 28, 31, 94, 107
- SEER Program Code Manual, 10, 12, 15, 16, 91, 151, 152, 186, 202, 261, 308, 309, 322, 334, 393, 394, 395, 431
- SEER Record Number, 343
- SEER Summary Stage 1977, 27, 344, 345
- SEER Summary Stage 2000, 27, 345
- SEER Summary Stage Guide 1977, 27, 344, 345
- SEER Summary Stage Guide 2000, 27
- SEER Summary Staging Manual 2000, 10, 91
- SEER Type of Follow-Up, 346
- Self-Instructional Manual for Cancer Registrars, 94
- Sequence Number (COC), 348
- Sequence Number/Diagnostic Confirmation Interfield Review (Interfield Edit 23) (SEER #4), 248
- Sequence Number/Ill-defined Site Interfield Review (Interfield Edit 22) (SEER #8), 245
- Sequence Number--Central, 348
- Sequence Number--Hospital, 346, 348
- Sex, 4, 5, 19, 68, 70, 350
- Site (73-91) ICD-O-1, 350
- Site Coding Sys--Current, 351
- Site Coding Sys--Original, 351
- Site of Distant Met 1, 352
- Site of Distant Met 2, 352
- Site of Distant Met 3, 353
- Site of Distant Metastasis #1 (COC), 352
- Site of Distant Metastasis #2 (COC), 352
- Site of Distant Metastasis #3 (COC), 353
- Site/Histology/Laterality/Sequence Number Interrecord Review (Interrecord Edit 09) (SEER #5), 253
- Site/Type Interfield Review (Interfield Edit 25) (SEER #1), 254
- Site--Specific Surgery (pre-98 SEER), 335
- Size of Primary Tumor (SEER), 207
- Size of Tumor (COC), 207
- SNOMED codes, 37, 38, 73
- Social Security Number, 68, 70, 353
- Spanish Origin--All Sources (96 COC), 354
- Spanish Surname or Origin (SEER), 354
- Spanish/Hispanic Origin, 25, 26, 166, 266, 267, 268, 269, 271, 354
- Stage and Extent of Disease Manual References, 91
- Staged By (Clinical Stage) (COC), 380
- Staged By (Other Stage) (COC), 386
- Staged By (Pathologic Stage) (COC), 391
- Staged By (Pediatric Stage) (COC), 258
- Staging Parameters, 69
- Standard Data Edits, vii, 3
- Standards for Completeness, Quality, Analysis, and Management of Data, vii, 3, 93
- State (pre-96 COC), 140
- State at Diagnosis (COC), 140
- STATE.DBF, 427
- State/Requestor Items, 355
- State--Current (COC), 145, 155
- Statistics Canada, vii, 13
- Subseq Report for Primary, 368
- Subseq RX--Reconstruct Del, 329
- Subsequent Treatment
 - Subsq RX 2nd Course Codes, 439
 - Subsq RX 3rd Course Codes, 439
 - Subsq RX 4th Course Codes, 440
 - Subsq RX 5th Course Codes, 440
- Subsq RX 2nd Course BRM, 355, 356, 439
- Subsq RX 2nd Course Chemo, 356, 439
- Subsq RX 2nd Course Codes, 356, 439
- Subsq RX 2nd Course Date, 356
- Subsq RX 2nd Course Horm, 356, 357, 439
- Subsq RX 2nd Course Oth, 356, 357, 439
- Subsq RX 2nd Course Rad, 356, 357, 439
- Subsq RX 2nd Course Surg, 356, 358, 439
- Subsq RX 2nd--Reg LN Rem, 358
- Subsq RX 2nd--Scope LN SU, 358
- Subsq RX 2nd--Surg Oth, 359
- Subsq RX 3rd Course BRM, 359, 360, 439
- Subsq RX 3rd Course Chemo, 359, 360, 439
- Subsq RX 3rd Course Codes, 439
- Subsq RX 3rd Course Date, 360
- Subsq RX 3rd Course Horm, 360, 439
- Subsq RX 3rd Course Oth, 360, 361, 439
- Subsq RX 3rd Course Rad, 360, 361, 439
- Subsq RX 3rd Course Surg, 360, 361, 439
- Subsq RX 3rd--Reg LN Rem, 361
- Subsq RX 3rd--Scope LN Su, 362
- Subsq RX 3rd--Surg Oth, 362

- Subsq RX 4th Course BRM, 362, 363, 440
- Subsq RX 4th Course Chemo, 362, 363, 440
- Subsq RX 4th Course Codes, 363, 440
- Subsq RX 4th Course Date, 363
- Subsq RX 4th Course Horm, 363, 440
- Subsq RX 4th Course Oth, 363, 364, 440
- Subsq RX 4th Course Rad, 363, 364, 366, 440
- Subsq RX 4th Course Surg, 363, 364, 366, 440
- Subsq RX 4th--Reg LN Rem, 364
- Subsq RX 4th--Scope LN Su, 365
- Subsq RX 4th--Surg Oth, 365
- Subsq RX 5th Course BRM, 365, 366, 440
- Subsq RX 5th Course Chemo, 365, 366, 440
- Subsq RX 5th Course Codes, 366, 440
- Subsq RX 5th Course Date, 366
- Subsq RX 5th Course Horm, 366, 440
- Subsq RX 5th Course Oth, 366, 367, 440
- Subsq RX 5th Course Rad, 367, 440
- Subsq RX 5th Course Surg, 367, 440
- Subsq RX 5th--Reg LN Rem, 367
- Subsq RX 5th--Scope LN Su, 368
- Subsq RX 5th--Surg Oth, 368
- Subsq RX--Reconstruct Del, 369
- Summary Stage, 344
- Summary Staging Guide for the Cancer SEER Reporting program, 91
- Supplement on the Tumor Registry, 11
- Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Nodes (SEER/COC), 334
- Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s) at this Facility (COC), 318
- Surgery of Primary Site (SEER/COC), 334
- Surgery/Diagnostic Confirmation Interfield Review (Interfield Edit 46) (SEER #6), 256
- Surgical Approach (COC), 335
- Surgical Margins (COC), 336
- Surveillance, Epidemiology and End Results, 8, 18, 91, 107, 429
 - Alternate Names, 431–38
 - Comparison of Reportable Cancers, 18
 - Required Status Table, 108–19
- Surveillance, Epidemiology, and End Results Program, 91
- Telephone, 69, 369
- Text--DX Proc--Lab Tests, 370
- Text--DX Proc--Op, 370
- Text--DX Proc--Path, 371
- Text--DX Proc--PE, 371
- Text--DX Proc--Scopes, 372
- Text--DX Proc--X-ray/scan, 372
- Text--Histology Title, 373
- Text--Primary Site Title, 373
- Text--Remarks, 374
- Text--Staging, 374
- Text--Usual Industry, 375
- Text--Usual Occupation, 376
- TNM, 429
- TNM Clin Descriptor, 377
- TNM Clin M, 378
- TNM Clin N, 378
- TNM Clin Staged By, 380
- TNM Clin T, 381
- TNM Edition Number, 381
- TNM Other Descriptor, 382
- TNM Other M, 383
- TNM Other N, 384
- TNM Other Stage Group, 385
- TNM Other Staged By, 386
- TNM Other T, 387
- TNM Path Descriptor, 388
- TNM Path M, 389
- TNM Path N, 389
- TNM Path Stage Group, 390
- TNM Path Staged By, 391
- TNM Path T, 392
- Tobacco History, 392
- Tumor Marker 1, 393
- Tumor Marker 2, 394
- Tumor Marker 3, 395
- Tumor Marker One (COC), 393
- Tumor Marker Three (COC), 395
- Tumor Marker Two (COC), 394
- Tumor Record Number, 343, 395
- Type of First Recurrence (COC), 288
- Type of Follow-Up (SEER), 346
- Type of Reporting Source, 31, 396
- Type of Reporting Source/Sequence Number Interfield Review (Interfield Edit 04) (Seer #7), 247
- Type of Staging System (Pediatric) (COC), 259
- UDSC. See Uniform Data Standards Committee
- UICC. See Union Internationale Contre le Cancer
- Underlying Cause of Death (ICD Code), 152
- Underlying Cause of Death (SEER), 152
- Uniform Data Standards Committee, xi, 2, 12, 16, 23, 25, 26, 31, 92, 429
- Union Internationale Contre le Cancer, 429
- Unresolved Issues
 - County at DX, 25
 - Name--Maiden, 26
 - Occupation and Industry, 26
 - RX Summ--Rad to CNS, 26
- Unusual Follow-Up Method, 396
- Vendor Name, 397
- Vital Status, 31, 397
- WHO. See World Health Organization
- Working group on pre-invasive cervical neoplasia and population-based cancer registries, 93
- World Health Organization, 10, 92, 429
- Year First Seen for this Primary (COC), 397
- Year First Seen This CA, 397
- Zip Code, 42. See Addr at DX--Postal Code
- Zip Code (pre-CoC), 140

